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Summary 
Over the past three decades α-galactosylceramide (α-GalCer), a synthetic glycosphingolipid derived 
from marine sponges extracts, became the archetypal invariant natural killer T (iNKT) cell ligand. 
When bound to CD1d, a protein present on antigen presenting cells, the CD1d/α-GalCer complex is 
recognized by the T cell receptor (TCR) of iNKT cells after which large amounts of both pro-
inflammatory T-helper 1 (Th1) and anti-inflammatory Th2 cytokines are secreted. While Th1 
cytokines mediate protective immune functions like tumor rejection, antiviral and antibacterial 
effects, the secreted Th2 cytokines mediate regulatory immune functions and ameliorate 
autoimmune diseases. However, the concomitant release of both cytokine types, which have 
opposing roles in vivo, is believed to limit the clinical outcome of α-GalCer therapy. Consequently, 
potent analogues able to skew the cytokine response towards either Th1 or Th2 are of great interest. 
In order to achieve this goal, a plethora of α-GalCer analogues altered at various parts of the 
glycolipid, i.e. the phytosphingosine, the acyl moiety and the galactose sugar, have been investigated 
thus far. An overview of the current structure activity relationship is presented in chapter 1. 
Hitherto, the growing library of α-GalCer analogues mainly consists of glycolipids with an altered 
fatty acid chain and/or carbohydrate part. However, analogues with modifications in the 
phytosphingosine chain remain relatively scarce, due to the more challenging syntheses required to 
access these analogues. Intrigued by this gap in current α-GalCer literature, we developed a 
divergent synthetic approach that allows late-stage diversification of the phytosphingosine chain, 
allowing us to introduce variations via amide coupling. Our employed methodology is disserted in 
chapter 4 together with the biological evaluation of an initial series of galactosylsphingamides. 
Modeling studies indicated that the incorporated amide moiety may form an additional hydrogen 
bond within the CD1d binding groove, in tandem, the selected amide substituents were aimed at 
strengthening the interactions (e.g., by π-π-stacking) with aromatic residues lining the F’-pocket. 
Reinforcing the CD1d/glycolipid complex stability is generally associated with potent iNKT cell 
stimulation. Unfortunately, all galactosylsphingamides showed poor antigenic properties in vivo. 
Further investigation revealed that the galactosylsphingamide/CD1d complexes have a relatively 
high affinity for the TCR of iNKT cells, but this strong interaction does not result in iNKT cell 
activation in vivo. On the molecular level, the studied galactosylsphingamides display an altered 
binding mode in the context of CD1d, where the galactose sugar is less intimately contacted. 
However, in the ternary complex the TCR of iNKT cells molds the sugar in its conserved position and 
the associated conformational change of the glycolipid, results in an additional H-bond between the 
amide carbonyl and tyrosine-71 from within the CD1d binding groove. 
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Chapter 5 is dedicated to the synthesis of C6”-modified α-C-GalCer derivatives. Inspired by the 
potent Th1 biased response of certain C6”-modified α-GalCer analogues previously prepared in our 
laboratory and the well-established Th1 response of the C-glycoside of α-GalCer, we envisioned the 
combination of these modifications in a hybrid structure. A first group consists of four C-glycosides 
that combine a naphthylurea or pyridinecarbamate functionality at C6” with an E-alkene or 
saturated C-glycosidic linkage. Remarkably, not only did all C-glycoside analogues outperformed α-C-
GalCer in mice, more importantly the whole series was able to stimulate human iNKT cells. This 
finding denotes that the appended C6”-substituents have the ability to restore the antigenic potency 
of α-C-GalCer, which lacks activity on human iNKT cells. 
As mentioned earlier, enhancing the CD1d/glycolipid complex stability is a widely accepted strategy 
to obtain potent iNKT cell agonists. Therefore, in chapter 6 the ability to form a covalent bond 
between glycolipid antigen and CD1d was examined. The incorporation of a photoactivatable 
arylazide functionality in the fatty acid chain was successfully accomplished. And indeed, irradiation 
with light of the appropriate wavelength led to the formation of the envisaged covalent bond, albeit 
a low cross-linking efficiency was observed. A second generation, acyl elongated, arylazide species 
was designed and prepared in an attempt to address the low cross-linking behavior of the initial 
glycolipid. Of interest, the prepared photoactivatable α-GalCer analogues are more potent human 
iNKT cell activators as compared to α-GalCer, at least when no UV-irradiation is applied. Further 
investigation on the cross-linking performance of the second generation compound and the cytokine 
secretion of these compounds after applying irradiation is highly awaited. 
In addition to α-linked glycolipids, chapter 7 describes the preparation of the naturally occurring 
endogenous glycosphingolipids sulfatide and lysosulfatide, both β-galactosylsphingosine derivatives 
featuring a sulfate group at the C3”-hydroxy group of the galactose. The series was elaborated with a 
lysosulfatide derivative that contains a terminal phenyl ring in its sphingosine chain. Biological 
evaluation of the final compounds, led to the unexpected finding that sulfatide is able to activate 
human but not mice iNKT cells, and thus likely plays a crucial role in the physiology of human iNKT 
cells. Up to now, sulfatides were generally thought to be type II NKT cell antigens unable to stimulate 
their invariant counterparts. 
Finally, chapter 8 critically evaluates the content of this manuscript in a broader context and 
discusses the relevance and potential of iNKT cell therapy in the immunomodulatory revolution 
currently ongoing in oncology research. To conclude, future perspectives and ideas are shared on 
the design of new glycolipid antigens for the stimulation of iNKT cells. 
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Samenvatting 
De laatste drie decennia is α-galactosylceramide (α-GalCer), een synthetisch glycosfingolipide 
afgeleid uit extracten van de zeespons Agelas mauritianus, uitgegroeid tot het prototype invariant 
natural killer T (iNKT) cel ligand. Na binding met CD1d, een eiwit aanwezig op het oppervlak van 
antigen presenterende cellen, wordt het CD1d/α-GalCer complex herkent door de T cel receptor 
(TCR) van iNKT cellen. Vervolgens worden door de iNKT cellen grote hoeveelheden van zowel pro-
inflammatoire T-helper (Th) 1 en anti-inflammatoire Th2 cytokines gesecreteerd. Th1 cytokines 
induceren antivirale, antimicrobiële en antitumorale immuun effecten, terwijl Th2 cytokines 
aanleiding geven tot immuunregulatie en tot positieve evolutie van autoimmuun ziekten. Echter, de 
gelijktijdige vrijstelling van beide cytokine types, die in vivo elkaars biologisch effect tegenwerken, 
wordt gezien als de belangrijkste reden voor de beperkte klinische successen van α-GalCer therapie . 
Bijgevolg is het verlangen groot naar analogen die in staat zijn om de cytokinerespons te sturen naar 
een selectieve Th1 of Th2 respons. Om die reden zijn er reeds een groot aantal α-GalCer analogen 
bestudeerd waar in de drie structurele onderdelen van α-GalCer, met name het galactosegedeelte, 
de vetzuurketen en de fytosfingosineketen, wijzigingen zijn aangebracht. Hoofdstuk 1 geeft een 
overzicht van de huidige structuur-activiteitsrelatie van α-GalCer analogen. 
Tot op heden bevat de groeiende reeks α-GalCer analogen voornamelijk glycolipiden waarin het 
galactosedeel en/of de acylketen zijn gewijzigd. Daarentegen zijn derivaten die modificaties dragen 
in de fytosfingosineketen relatief zeldzaam en dit door de meer uitdagende syntheseroutes nodig 
voor het vervaardigen van deze verbindingen. Deze lacune in de bestaande α-GalCer literatuur 
inspireerde ons tot de ontwikkeling van een divergente synthetische methodologie dat diversificatie 
van de fytosfingosineketen toelaat in een ver gevorderd stadium en toelaat variaties in te bouwen 
via een amide binding. De ontwikkelde synthese strategie is beschreven in hoofdstuk 4 samen met 
de biologische evaluatie van een initiële reeks galactosylsfingamiden. 
Modelleringsstudies tonen aan dat de geïncorporeerde amide binding mogelijks een nieuwe 
waterstofbrug met CD1d kan aangaan, tegelijkertijd zijn de amide substituenten geselecteerd met 
als doel om interactie met aromatische aminozuren in de F’-bindingsgroeve  te verstevigen (door bv. 
π-π stacking). Een verhoogde stabiliteit van het CD1d/glycolipide complex is over het algemeen 
geassocieerd met krachtige iNKT cel stimulatie maar helaas vertonen alle galactosylsfingamiden 
zwakke antigene eigenschappen in vivo. Verder onderzoek bracht aan het licht dat de 
galactosylsfingamide/CD1d complexen een relatief hoge affiniteit hebben voor de TCR van iNKT 
cellen, maar kennelijk resulteert deze intense interactie niet tot iNKT cel activatie in vivo. Op het 
moleculaire niveau binden de galactosylceramiden onconventioneel aan CD1d. Het binaire 
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CD1d/glycolipide complex vertoont minder innige contacten tussen het galactosesuiker en het 
polaire deel van de CD1d bindingsgroeve. In het ternaire CD1d/glycolipide/TCR complex 
daarentegen, neemt het glycolipide zijn gebruikelijke positie in omdat de TCR van de iNKT cel het 
glycolipide op de juiste plaats duwt. De geassocieerde conformationele verandering resulteert in een 
additionale waterstofbrug tussen de carbonyl functionaliteit van het amide en tyrosine-71 vanuit 
CD1d.   
Hoofdstuk 5 is toegewijd aan de synthese van C6”-gemodificeerde α-C-GalCer derivaten. 
Geïnspireerd door de sterk sturende Th1 respons van enkele in ons labo gesynthetiseerde C6”- 
carbamaten en ureum derivaten en de befaamde Th1 respons van het C-glycoside van α-GalCer, 
combineerden we beide modificaties in een hybride glycolipide structuur. Een aanvankelijke reeks 
derivaten omvat vier C-glycosiden die een C6”-naftyl ureum of pyridine carbamaat functionaliteit 
combineren met een E-alkeen onverzadigde of een verzadigde C-glycosidische binding. Niet alleen 
presteren alle geconstrueerde C-glycoside analogen beter ten opzichte van α-C-GalCer, maar nog 
belangrijker, is de reeks in staat om humane iNKT cellen te stimuleren. Dit resultaat geeft aan dat de 
C6”-substituenten het antigeen potentieel van α-C-GalCer, dat zelf inactief is in een humane setting, 
kunnen hertstellen. 
Zoals eerder aangegeven is het verhogen van de stabiliteit van het CD1d/glycolipide complex een 
algemeen aanvaarde strategie voor het bekomen van sterke iNKT cel agonisten. Bijgevolg werd in 
hoofdstuk 6 de mogelijkheid tot het vormen van een covalente binding tussen glycolipide en CD1d 
onderzocht. Hiertoe werd een fotoactiveerbaar arylazide succesvol ingebouwd in de vetzuurketen 
van α-GalCer. Irradiatie met licht van de correcte golflengte leidt inderdaad tot de beoogde 
covalente binding, hoewel een lage fotocrosslinking efficiëntie wordt bekomen. In een poging de 
efficiëntie te verhogen werd een tweede generatie arylazide analoog gesynthetiseerd met een iets 
uitgebreidere acylketen. Opmerkelijk is dat de arylazide derivaten krachtigere humane iNKT cel 
agonisten zijn in vergelijking met α-GalCer, tenminste wanneer geen UV straling wordt toegepast. 
Veel wordt verwacht van de resultaten van deze verbindingen na UV-irradiatie en de 
fotocrosslinking efficiëntie van het tweede generatie analoog. 
Naast α-glycolipiden beschrijft hoofdstuk 7 de synthese van de endogene glycosfingolipiden sulfatide 
en lysosulfatide. Deze β-galactosylsfingosine derivaten dragen beiden een sulfaatgroep aan de C3” 
hydroxyl groep van het galactosesuiker. De initiële reeks werd uitgebreid met een lysosulfatide 
derivaat waarvan de sfingosineketen is uitgerust met een eindstandige fenyl ring. Biologische 
evaluatie van de eindverbindingen leidde tot de onverwachte ontdekking dat sulfatide in staat is om 
humane iNKT cellen te stimuleren en waarschijnlijk een cruciale rol speelt in de fysiologie van 
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humane iNKT cellen. Tot dusver werden sulfatiden voornamelijk gezien als type II NKT cel antigenen 
die niet in staat zijn om invariante NKT cellen te activeren. 
Tot slot volgt er in hoofdstuk 8 een kritische evaluatie van de inhoud van dit manuscript in een brede 
internationale context en wordt het potentieel en de relevantie van iNKT cel therapie geschetst in 
het licht van de huidige immunomodulatoire revolutie die momenteel plaatsvindt in oncologisch 
onderzoek. Verder worden toekomstige perspectieven en ideeën uiteengezet voor de ontwikkeling 
van nieuwe glycolipe antigenen voor iNKT cel stimulatie.  
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1 Introduction 
 
The role of the immune system is to protect an organism against foreign invaders and to maintain 
homeostasis. When an altered homeostatic state is detected (microbial infection, hypoxia, heat 
stress,…) specific cellular repair mechanisms get activated to remove the aggressor and/or allow the 
cells to return in their basal state. However when the stress applied is too severe, the cells will evolve 
to a necrotic or apoptotic phase to deal with the stressor. The immune system carefully monitors 
these processes and coordinates an appropriate response, called inflammation. Inflammation starts 
when a receptor detects signs of harmful stimuli and this leads to the production of inflammatory 
regulators such as cytokines. In turn, these cytokines will activate immune effector cells, which will 
counter the initial inducer of the inflammation pathway. 
Our immune system consists of an innate and an adaptive part, which have the same goal, but 
achieve it by different means. Whereas the innate immune system acts as a first-line defense 
recognizing patterns that are associated with a broad range of harmful stimuli, the adaptive immune 
system detects very specific molecular footprints found in bacteria, viruses, etc. Another striking 
difference is the speed at which both systems react to harmful stimuli. While innate responses are 
very fast but short-lasting, adaptive immunity activates slower but lasts longer and leads to memory, 
a hallmark of adaptive immunity. The immune effects are mediated through a range of molecules 
and immune cells, which often have roles in both immune systems. 
Several surface barriers such as the skin and epithelial cells lining the respiratory, gastrointestinal and 
urogenital tract, protect our body from harmful aggressors. Nonetheless infectious agents are able to 
penetrate into our tissues and when detected by our innate immune system, an inflammatory 
response is generated. Phagocytes like dendritic cells (DCs), macrophages and neutrophils, are 
characterized by the expression of pattern recognition receptors, which recognize not only alarm 
signals send out by damaged cells but also components that are conserved among a broad range of 
microorganisms. For example, the Toll like receptor (TLR) family detects molecules that are broadly 
shared by pathogens such as lipopolysaccharides, which are a constituent of the outer membrane of 
Gram-negative bacteria. Identification of these so-called pathogen or danger associated molecular 
patterns (PAMP/DAMP) triggers various effector mechanisms leading to the elimination of the 
threat. 
Cell mediated immunity mainly rests on the phagocyte cell types capable of engulfing and digesting 
pathogens or particles. Moreover, macrophages and DCs act as antigen presenting cells (APC) 
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initiating adaptive immune responses at a later stage. In addition, the innate immunity’s arsenal 
includes mast cells, basophils and eosinophils, which mainly secrete chemical mediators of 
inflammation. Finally, natural killer cells (NK cells) destroy compromised host cells rather than 
attacking foreign pathogens. They recognize cells by a condition known as missing self, describing 
low levels of major histocompatibility complex one (MHC-I) molecules. Accordingly, they kill the 
modified cells through the release of lytic granules. The major humoral component of the innate arm 
consists of the complement system, which enhances the clearance of pathogens by phagocytes and 
antibodies. It is composed of a number of small soluble proteins that upon activation result in 
massive and rapid killing. The complement cascade not only results in direct lysis of the 
microorganisms’ cell membrane, but also leads to an increased vascular permeability, additional 
recruitment of immune cells and opsonization of the pathogen. 
Whenever the innate immune system fails to eliminate the threat, an adaptive response is initiated 
by specialized leucocytes, termed lymphocytes. Adaptive immunity allows a stronger and more 
focused immune response, thereby limiting negative side effects, and leads to an immunological 
memory. The basis of the adaptive immune response is the recognition of specific non-self-antigens 
during a process called antigen presentation. Highly-specific antigen receptors are expressed on B- 
and T-lymphocytes, which following exposure to specific peptide antigens, are characterized by 
clonal expansion and differentiation into effector cells. A portion of these proliferating cells 
differentiate into memory cells that quickly eliminate pathogens upon re-challenge. This memory 
function of the adaptive immune system forms the basis for vaccination strategies. 
The T lymphocytes or T cells can be divided into two major subtypes, cluster of differentiation 4 
positive (CD4+) and CD8+ T cells. The T cell receptor (TCR) of T cells recognizes peptide antigens in the 
context of MHC-I or MHC-II molecules. MHC-II molecules are mainly expressed on DCs, macrophages 
and B-cells and present antigens derived from extracellular proteins to CD4+ T cells. Upon activation, 
the latter differentiate towards either T-helper 1 (Th1) or Th2 cells, which assist other immune cells 
in immunologic processes. Th1 cells secrete pro-inflammatory cytokines like interferon-γ (IFN-γ) and 
tumor necrosis factor (TNF) leading to activation of cytotoxic T (Tc) cells, NK cells and macrophages. 
In contrast, Th2 cells, which release anti-inflammatory cytokines such as interleukine-4 (IL-4) and IL-
10, induce maturation of B cells into plasma cells and memory B cells. 
CD8+ T cells on the other hand are activated by peptide antigens associated with MHC-I molecules 
displaying fragments of non-self-proteins from within the cell. Following activation, the CD8+ T cells 
differentiate into Tc cells and destroy viral-infected or tumorous cells through perforine and 
granzyme secretion. 
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Whereas T cells are responsible for the cellular immune response, B cells function in the humoral 
compartment of the adoptive immune system. The expression of B cell receptors (BCRs) on their cell 
membrane allows them to bind and recognize soluble proteins. Next, the BCR is internalized dragging 
along the foreign protein to be processed into smaller fragments, which in turn are presented on the 
surface of B cells in MHC-II molecules. Following TCR/MHC-II/peptide binding costimulatory signals 
promote B-cell proliferation and maturation to antibody-secreting plasma cells and memory B cells. 
(Figure 1.1) 
 
Figure 1.1 T-cell help the differentiation of B-cells to plasma cells and memory B cells (adapted from 
Immunodeficiency, ISBN 978-953-51-0791-0), Ag: antigen, TGF-β: transforming growth factor beta 
Dividing innate and adaptive immunity is somewhat artificial, as some lymphocyte subtypes like 
gamma delta T cells (γδ T cells) and natural killer T cells (NKT cells) straddle the border between 
innate and adaptive immunity. NKT cells account for an important lymphocyte population that is able 
to orchestrate various immune responses. Whereas the conventional lymphocytes recognize peptide 
antigens in the context of MHC I or II molecules, most NKT cells react to lipid and glycolipid antigens 
presented by members of the CD1 family. They lack the ability to form immunologic memory but 
activation leads to extremely fast cytokine secretion, features usually associated with innate 
immunity. The past decades the important function of NKT cells in microbial infections, tumor 
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immunity and autoimmune diseases has become apparent, largely due to the discovery of α-
galactosylceramide (α-GalCer) as prototypical antigen for these cells. 
1.1 NKT cells 
NKT cells were discovered in 1987 and were initially identified as a population of T lymphocytes 
characterized by the coexpression of an αβTCR and NK1.1 (CD161) on the cell surface.1,2,3 In mice NKT 
cells are estimated to constitute 1-3% of the total T cell pool and are most frequent in the liver (10%-
30% of the T cell pool), spleen (0,2%-0,5% of the T lymphocytes),  bone marrow, thymus, lymph 
nodes and blood (0,01-0,5% of the T lymphocytes).4 In humans, however, NKT cells are apparently 
not as numerous as in mice (approximately 4% of the hepatic T cells compared to 50% in mice).5 
Additionally these numbers are highly variable between individuals. The original definition that NKT 
cells are NK1.1+ T cells is inaccurate as some conventional T cells upregulate this marker upon 
stimulation and not all NKT cells do express NK1.1. Therefore, the precise definition of an NKT cell 
remains problematic and to avoid oversimplification four distinct subcategories were introduced 
based on their CD1d restriction and TCR phenotype.6,7 (Table 1.1) 
1.1.1 Classification 
Type I NKT cells express an invariant Vα14Jα18 TCR α-chain in mice and Vα24Jα18 in humans, paired 
with a limited repertoire of TCR β-chains (Vβ8, Vβ7, Vβ2 in mice and exclusively Vβ11 in humans).8 
Therefore, type I NKT cells are often referred to as invariant natural killer T cells (iNKT cells). They 
exhibit a highly autoreactive/memory phenotype, expressing high levels of activation markers, which 
enables them to rapidly react upon antigen recognition. They show high affinity for the 
glycosphingolipid α-GalCer, presented by CD1d on antigen presenting cells. The ability to track 
type I NKT cells in vivo with fluorescent CD1d/α-GalCer tetramers9 together with the use of mice 
that are deficient in CD1d (lacking type I and type II NKT cells)10 or selectively deficient in type I 
NKT cells (Jα18−/−)11, has allowed the elucidation of many functions of iNKT cells in vivo. Several 
functionally distinct type I NKT cells have been described based on the differential expression of 
surface markers, transcription factors and cytokines. In humans type I NKT cells expressing CD4 
produce Th2 type cytokines, while both CD4+ and CD4- subsets can generate Th1-cytokines and 
secrete cytotoxic molecules like perforin and granzyme. In addition CD8+ type I NKT cells are 
present in humans and CD4-CD8- or double negative (DN) subsets have been observed in both 
human and murine tissues.12,13 In mice, the majority of type I NKT cells in the liver and spleen are 
characterized by Th1-associated markers, mostly expressing NK1.1 and the IL-12 receptor. Their 
pronounced production of IFN-γ plays an important role during various immune responses, 
including anti-tumor immunity.13,14 Th2-like iNKT cells on the other hand are enriched in the 
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lungs and intestine of mice, mainly secreting IL-4, IL-9 and IL-10 and nurse Th2-mediated 
diseases.15,16 In addition a distinct subset of type I NKT cells can produce  Th17 related cytokines 
such as IL-17 and IL-22. These so-called iNKT17 cells are primarily found in the skin, peripheral 
lymph nodes and lungs. Th-17 cells induce auto-inflammatory and auto-immune responses and 
are currently an important research topic towards the treatment of immune disorders like 
psoriasis, Chron’s disease, multiple sclerosis and ankylosing spondylitis.17,18,19,20 Finally, a small 
number of type I NKT cells share features of follicular helper (FH) cells secreting IL-21 to support 
germinal center formation.21,22,23 
 Type I NKT cells Vα24− (h) and Vα10+ (m)  
NKT cells 
Type II NKT cells γδ and δ/αβ T cells 
 
TCR repertoire m: invariant (i)Vα14Jα18, 
Vβ8, Vβ7 or Vβ2 
h: iVα24Jα18, Vβ11 
m: iVα10Jα50, Vβ8 
h: limited α chains (Vα10, 
Vα2 or Vα3), Vβ11 





h: Vδ1+, Vδ3+ 
α-GalCer 
reactivity 
All All No Some 
Sulfatide 
reactivity 
No No Some Some 






Mammalian β-GSL and  
β-GlcSph 
Mammalian and microbial 
phospholipids (PG, DPG, PI) 
Mammalian 
lysophospholipids (LPC, 
LSM, LPE, β-GlcSph) 
Mammalian and pollen 
phospholipids (PE, PC, 
DPG) 
Function NKT1 (IFN-γ, IL-2) 
NKT2 (IL-4, IL-9, IL-10, IL-
13) 
NKT17 (IL-17A, IL-21, IL-22) 





TH2-like (IL-4, IL-13) 
TH17-like (IL-17) 
TH1-like (IFN-γ, IL-2)  













α-GSL, α-glycosphingolipid; α-GDAG, α-glyco(Gal/Glc)diacylglycerol; β-GlcSph,β-glucosylsphingosine; DPG, diphosphatidylglycerol; h, human; 
LPC, lyso phosphatidylcholine; LPE, lysophosphatidylethanolamine; LSM, lysosphingomyelin; m, mouse; PG, phosphatidylglycerol 
Table 1.1 Classification of CD1d-restricted T cells (Macho-Fernandez et al., 2015, Front Immunol ) 
The ability to recognize α-GalCer was thought to be highly correlated with the expression of the 
Vα14Jα18 or Vα24Jα18 TCR α-chains. However, CD1d-restricted NKT cells, which are activated by α-
GalCer but use different TCR α-chains have been described. In humans these Vα24-negative T cell 
populations have TCRs composed of Vα10, Vα2, or Vα3 joined to Jα18 and paired with Vβ11.24 
Similarly, in mice, α-GalCer reactive NKT cells lacking the Vα14Jα18 α-chain have also been found and 
predominantly express an invariant Vα10-Jα50 TCR α-chain paired with a Vβ8 TCR β-chain. In 
addition to binding α-GalCer, these NKT cells preferentially recognize glucose-based glycolipids25 but 
so far, data on the function of these NKT cells is limited.  
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While type II NKT cells do not recognize α-GalCer, they are CD1d restricted and some are activated by 
the endogenous glycolipid sulfatide. In contrast to type I NKT cells they display a diverse TCR usage 
and are often referred to as diverse NKT cells (dNKT).26 Most of our understanding considering the 
function of type II NKT cells stems from comparing immune responses between Jα18−/− mice (lacking 
only type I NKT cells) and CD1d−/− mice (lacking both type I and type II NKT cells). Identifying type II 
NKT cells can also be accomplished by using antigen-loaded CD1d tetramer reagents, similar to the 
use of α-GalCer/CD1d tetramers that are used to detect type I NKT cells. It is the use of 
sulfatide/CD1d tetramers that initially revealed an oligoclonal TCR repertoire among sulfatide 
reactive dNKT cells. However, sulfatide/CD1d tetramers appear to be more difficult to use compared 
to α-GalCer/CD1d tetramers, likely due to difficulties in loading the antigen and/or greater instability 
of sulfatide/CD1d complexes and, moreover, not all type II NKT cells recognize sulfatide.26,27 
Microbial antigens,28 β-glycosylceramide (β-GlcCer) or -glucosylsphingosine (β-Glc-Sph)29 and 
phospholipids30 all succeed in activating subsets of type II NKT cells demonstrating the 
heterogeneous group of ligands activating these cells. 
Finally, CD1d restricted γδ T cells have been described both in humans and mice.31 However, 
compared with αβ T cells, the types of antigens recognized by γδ T cells and the role and function of 
antigen presentation is much less clear.  
With the exception of the final chapter, the glycolipids synthesized in this work are aimed at 
targeting type I NKT cells. Consequently from this point on, we will only consider these cells. 
 
1.2 Cluster of differentiation 1d (CD1d) 
The CD1 gene family counts five members in humans (CD1a-e), whereas mice have two orthologous 
CD1d genes.32,33 Based on sequence similarity CD1a, CD1b and CD1c are categorized into group I CD1 
molecules, while the more distantly related CD1d is classified in group II. Both group I and II CD1 
molecules form the third family of antigen presenting molecules, while CD1e does not present 
antigens on the cell surface, but facilitates antigen loading in endolysosomal compartments.34  
There is a striking resemblance between CD1d and the MHC-I molecule. Both are composed of a 
heavy chain with three extracellular domains (α1-α3) that are non-covalently associated with β2-
microglobulin (β2m). (Figure 1.2) In both molecules the antigen binding region is formed by the α1 
and α2 chains adopting the shape of two anti-parallel α-helices that sit atop a central β-sheet 
platform. While MHC-I molecules present peptide antigens to the TCR of conventional T cells, CD1d 
presents lipid and glycolipid antigens. Conversely, the binding groove of CD1d is deeper and 
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narrower in comparison with MHC-I and forms two hydrophobic pockets termed A’ and F’ in mice 
and A’ and C’ in humans. In comparison the A’ pocket is larger, donut shaped and more deeply buried 
than the F’ pocket, which is more accessible to the solvent. However, both pockets are lined with 
almost exclusively hydrophobic amino acid residues, making CD1d well suited to accommodate lipid 
and glycolipid antigens. It is only at the conjunction of both pockets and deep down the bottom of 
the A’ pocket that polar amino acids are situated. 35 
 
 
Figure 1.2 Crystal structures of mCD1d (green) and the MHC-I molecule (grey) both in conjunction 
with their respective antigens (adapted from Borg et al., 2007, Nature) 
 
The ability of CD1d to present different lipids and glycolipids at the cell surface of APCs involves 
different steps. First, CD1d is assembled in the endoplasmatic reticulum (ER) and is loaded with 
endogenous lipids to stabilize the architecture of the binding groove, before travelling to the cell 
surface. When expressed on the surface the CD1d molecule can either directly bind lipid antigens or 
undergo re-internalization towards endosomal and lysosomal compartments. There, lipid transfer 
proteins such as saponins extract the bound lipids and replace them with other intracellular lipids. 




Figure 1.3 CD1d assembly and intracellular trafficking (Major et al., 2006, Trends Mol Med) 
MTP: microsomal triglyceride transfer protein, Sap: saposins, ApoE: apolipoprotein E, (V)LDL: (very) 
low-density lipoprotein, GM2A: GM2 ganglioside activator 
The CD1d tetramers used to stain iNKT cells are composed of four CD1d monomers lacking both the 
transmembrane segment and intracytoplasmic domains. Instead, CD1d is engineered to possess a 
substrate for E. coli biotin ligase (BirA) site-specific biotinylation at the COOH terminus.37 After BirA 
enzymatic biotinylation of CD1d, the monomers are mixed with a fluorescent streptavidin core 
furnishing the CD1d-tetramers.38(Figure 1.4) CD1d tetramers circumvent the problem of high TCR 
dissociation rate for CD1d monomers, since with tetramers multiple CD1d molecules can bind the 
same iNKT cell at a time and display an enhanced binding avidity. 
 
Figure 1.4 Schematic representation of a CD1d tetramer, the blow up shows a CD1d monomer 
loaded with α-GalCer. Red squares represent α-GalCer, while CD1d is shown in blue and the light 
blue square depicts β2-microglobulin. 
1.3 The immunological role of iNKT cells 
iNKT cells are associated with a plethora of diseases including various tumors,39 microbial infections40 
and auto-immune conditions.41 The secretion of vast amounts of cytokines upon antigen recognition 
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forms the cornerstone of their immunologic function. The nature of the secreted cytokines is twofold 
as both pro-inflammatory Th1 cytokines like IFN-γ, TNF-α and IL-12, as well as anti-inflammatory Th2 
cytokines like IL-4 and IL-10 are secreted.42,43 In addition, the cytokine release happens rapidly, 
between one and two hours after TCR ligation. The ability of iNKT cells to produce such high levels of 
cytokines in a short timeframe is attributed to the presence of massive amounts of mRNA’s encoding 
for IFN-γ and IL-4 in resting iNKT cells.44 The burst of cytokines secreted by iNKT cells activates other 
immune cells such as conventional B- and T-cells from the adaptive immune system, but also 
activates neutrophils, NK cells, macrophages and DCs belonging to the innate immunity. This bridging 
of innate and adaptive immunity makes iNKT cells attractive targets for immune therapy, as they 
have the potential to orchestrate complex immune responses. (Figure 1.5) Furthermore, iNKT cells 
show cytotoxic behavior due to granzyme and perforin expression upon Fas-FasL interaction. 
Simultaneously with their cytokine secretion, iNKT cells undergo rapid clonal expansion and receptor 
down-regulation upon stimulation, returning to their basal numbers usually after two to three 
days.45,46  
 
Figure 1.5 Interactions between iNKT cells and other immune effector cells (Brennan et al, 2013, Nat. 
Rev. Immunol.) GM-CSF: Granulocyte macrophage colony-stimulating factor, CXCL2: Chemokine (C-X-
C motif) ligand 2 
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As described above, iNKT cells are capable of secreting both Th1 and Th2 cytokines, which have 
distinct roles in vivo. Th1 cytokines promote immune responses mediated by cellular immunity, and 
are involved in tumor surveillance and in the protection against various infectious agents like viruses, 
bacteria and parasites.36,47,48 In contrast, Th2 cytokines mediate humoral immunity by raising 
antibody titers and elicit immunosuppressive responses that prevent autoimmune diseases.49 A loss 
of control in the Th1/Th2 balance is observed in many pathologic conditions. Conversely, iNKT cell 
defects and low levels of iNKT cells are correlated with the susceptibility of developing cancers and 
autoimmune diseases.50,51 Hence, iNKT cells are attractive as potential therapeutic agents or as 
biomarkers. 
To date, the mechanisms underlying the outcome of iNKT cell activation are poorly understood. The 
versatility of iNKT cells during various immune responses can at least be partly explained by the 
existence of functionally distinct subsets. As discussed above, several reports suggest that CD4+ iNKT 
cells are able to produce both Th1 and Th2 cytokines, while CD4- subsets mainly exhibit a Th1-
profile.52 Additionally, organ-specific functions and the distribution of the various subsets of iNKT 
cells has not been adequately investigated. To complicate things further, closely related antigens are 
known to induce distinct immunologic responses through the same iNKT cell subset (vide infra). 
1.4 Modes of iNKT cell activation 
A peculiar feature of iNKT cells is that they can be activated in various ways. There is the CD1d 
dependent pathway, which is extensively studied, but recently a less understood CD1d independent 
activation has been reported by at least three separate reports. 
1.4.1 CD1d-dependent pathway 
iNKT cells are able to recognize a whole range of lipid and glycolipid antigens presented by CD1d 
molecules. α-GalCer functions as the prototypical antigen for CD1d-dependent iNKT cell activation 
and huge advances in the field can be attributed to the discovery of α-GalCer. Over the past three 
decades an array of antigens have emerged including synthetic, endogenous as well as microbial 
lipids and glycolipids.  
1.4.1.1 α-GalCer 
Evaluation of marine natural products for anti-tumor activity led to the discovery of a new class of 
glycolipids, termed agelasphins, isolated from the sponge Agelas mauritianus.53 The agelasphin 
structure consists of a ceramide moiety, which is α-anomericly linked to a galactose sugar. Early 
structure-activity relationship (SAR) studies revealed that the hydroxyl group at C2’ of the acyl moiety 
does not influence anti-tumor activity and can be omitted, in strong contrast, deletion of the C3-OH 
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is detrimental for the activity. Straightening of the phytosphingosine chain combined with the 
extension of the acyl chain in agelasphin 9b by two carbons yielded KRN7000 or α-GalCer.54 (Figure 
1.6) 
 
Figure 1.6 Structures of the agelasphins and α-GalCer 
A series of in vitro and in vivo studies suggest that the activation of iNKT cells by strong antigens such 
as α-GalCer, occurs in three distinct steps.55,56 The first step involves ligation of the CD1d/α-GalCer 
complex with the TCR of the iNKT cell. In tandem with interaction of CD28 on the surface of NKT cells 
with CD80 or CD86 expressed on DCs, the secretion of IL-4 is triggered together with the secretion of 
a small amount of IFN-γ and upregulation of CD40 ligand. In the second step, CD40-CD40L 
interactions together with the secreted IFN-γ upregulate the expression of IL-12 receptor (IL-12R) on 
the iNKT cell and causes maturation of the DC. Finally, the matured DC produces IL-12, which upon 
binding to the IL-12R stimulates the iNKT cell to secrete a second, more important wave of IFN-γ. 
Concomitantly the secreted IL-12 activates NK cells to produce IFN-γ and become cytotoxic. This last 
step of iNKT cell activation is required for maximal release of IFN-γ. (Figure 1.7) 
 




1.4.1.2 Endogenous lipid antigens 
In a variety of contexts, iNKT cells display CD1-dependent activation even in the absence of synthetic 
and microbial antigens. Accordingly, a high level of self-reactivity is observed and it was reasoned 
that a single or several closely related self-antigens exist that can activate the invariant TCR.57 
Although this hypothesis remains unproven, several types of self-glycolipids and non-glycolipid self-
antigens have been identified.58 However, there is little consensus in the field about the nature of 
these self-antigens. Chemical analysis of lipids bound to CD1d identified phosphatidylcholine, 
phosphatidyl inositol and their respective lyso-isoforms, lacking one of the fatty acid chains, as 
possible self-antigens.59,60 Phosphatidyl inositol was the first self-derived lipid that showed 
stimulatory effect on an iNKT cell hybridoma.61 However, since the same hybridoma failed to 
recognize α-GalCer, it was apparently not representative for the whole iNKT cell population. Similarly 
disialoganglioside GD362 and β-glucosylceramide58 have been proposed as self-antigens, but both 
were unable to stimulate the majority of iNKT cells. 
 
Figure 1.8 Structures of proposed self-antigens 
The finding that β-hexosaminidase-b-deficient mice have a profound reduction in iNKT cells led to 
the proposal of isoglobotrihexosyl ceramide (iGB3) as a self-antigen, not only for iNKT cell 
differentiation in the thymus but also for peripheral stimulation.63,64 Indeed, iGB3 is a mammalian 
glycolipid that consists of a ceramide that is β-linked to three sequential glycosides, and is able to 
stimulate iNKT cells. However, the conclusion that iGB3 is the main thymic iNKT cell-selecting ligand 
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has been challenged in different ways. For example, iGB3 synthase deficient mice (iGB3S-/-) display no 
difference in the number or phenotype of iNKT cells. Moreover, the iNKT cells of these mice respond 
normally to α-GalCer.65,66 Recently lyso-phosphatidylcholine (lyso-PC) was found to stimulate the 
majority of human iNKT cell clones in a CD1d dependent manner. Yet, it was unable to activate 
mouse iNKT cells59,67 indicating that self-antigens for mice and humans could be different. Finally, the 
presence of small quantities of α-glycosylceramides in mammalian immune cells, identified the latter 
as main endogenous antigens.68 Surprisingly, this class of glycolipids was thought absent from 
mammalian cells for multiple decades, as the only two glycosylceramide synthases were thought to 
be inverting glycosyltransferases which transfer α-glucose and α-galactose from uridine diphosphate-
sugar moieties in a β-anomeric linkage on the ceramide.69 (Figure 1.8) 
1.4.1.3 Microbial lipids 
The mammalian immune system did not evolve to protect against marine sponges, therefore it is 
unlikely that α-GalCer or the agelasphins are important natural antigens for iNKT cells. Isolated lipids 
from Mycobacterium bovis were the first reported microbial antigens inducing CD1d-dependant iNKT 
cell stimulation.70 Indeed phosphatidylinositoldimannoside (PIM2)-loaded CD1d-tetramers stained 
both mouse and human iNKT cell populations, although the number of stained iNKT cells is lower 
compared to α-GalCer-loaded tetramer. In contrast, glycosphingolipids from Sphingomonas species 
could activate essentially the entire iNKT cell population in mice and humans.64,71,72 The 
Sphingomonas lipids α-glucuronosylceramide (GSL-1) and α-galacturonosylceramide (GSL-1’) highly 
resemble the α-GalCer structure, with a ceramide part α-anomerically linked to the polar headgroup. 
But whereas a galactose unit is present in α-GalCer, GSL-1 and GSL-1’ use glucuronic acid and 
galacturonic acid, respectively. Noteworthy, the fatty acid tale of both GSL-1 and GSL-1’ displays a 
hydroxyl group at C2’, a characteristic shared with the original agelasphins. Based on this structural 
similarity and the presence of Sphingomonas bacteria in sea water, the isolated agelasphins could 
well be a component of Spingomonas-like bacteria associated with Agelas mauritianus.73 Compared 
to α-GalCer, the antigenic potency of these compounds is inferior, but this might be a strategy by 
which these microorganisms try to evade iNKT cell mediated immune responses.  
A second microorganism possessing glycolipid antigens that activate most iNKT cells is Borrelia 
burgdorferia, the spirochete causing Lyme disease. Infected mice lacking CD1d develop increased 
pathology, elevated pathogen burden and a decrease in pathogen-specific antibodies, indicating that 
CD1d is required to control Borrelia infections.74,75 The diacylglycerol-based lipids isolated from this 
species are referred to as B. burgdorferia glycolipid 2 (BbGL-II) and show a diacylglyceride moiety 
that is identical to that found in phosphatidyl inositol. The fatty acid chains vary from 14 to 18 
carbons and strikingly an α-glycosidic bond links the diacylglycerol to a galactose moiety. When eight 
Chapter 1 
16 
synthetic versions of BbGL-II were analyzed, only one of these, i.e. BbGL-IIc, was highly antigenetic 
for iNKT cells.76 Other iNKT cell stimulating antigens are likely present in a lot more microorganisms 
and the identification of new antigens is progressing at a steady pace.77,78 (Figure 1.9) 
 
Figure 1.9 Structures of microbial iNKT cell antigens 
Two iNKT cell activation pathways have been described for microorganisms. In the direct pathway 
glycolipids from the microorganism are loaded on CD1d and activate iNKT cells upon TCR ligation. 
This is similar to adaptive immune responses as instead of peptides, a glycolipid derived from the 
bacteria is presented and recognition results in very specific clearance of the pathogen. This pathway 
is only feasible if the microbial derived antigens are able to induce strong TCR signaling. A second 
indirect pathway does not require TCR-mediated recognition of the bacterial antigens. Instead, a TLR 
mediated signal stimulates the DC to secrete sufficient IL-12 to activate iNKT cells recognizing low-
affinity microbial or self-lipid antigens.79 (Figure 1.10) 
 
Figure 1.10 Microbial activation of iNKT cells Left: direct pathway, right: indirect pathway (Brennan et 
al, 2013, Nat. Rev. Immunol.), PRR: pattern recognition receptor 
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1.4.2 CD1d-independent pathway 
CD1d expression may not always be required for iNKT cell stimulation as it was demonstrated that IL-
12 and IL-18 production by DC’s induced by an E. coli lipopolysaccharide suffice for the stimulation of 
iNKT cells to subsequently produce IFN-γ.80 Furthermore, a similar conclusion was drawn from assays 
using the mouse cytomegalovirus model, also showing that IL-18 and IL-12 could potently induce IFN-
γ secretion through iNKT cell activation.81,82 
1.5 Regulation of tumor immunity by iNKT cells 
As mentioned above, a number of patients with a variety of tumors showed fewer iNKT cells than 
healthy volunteers.83,84,85,86 This together with the finding that Jα18-deficient mice display an 
enhanced susceptibility toward tumor metastases,87 illustrates that iNKT cells play a crucial role in 
immunosurveillance. 
iNKT cells display antitumoral activity against CD1d+ tumors through three distinct mechanisms. First, 
due to the expression of perforin and Fas ligand on the surface, activated iNKT cells can act as 
cytotoxic T cells directly killing tumor cells. A second mechanism is based on the ability of iNKT cells 
to transactivate other immune cells like NK cells and tumor-specific CD8+ Tc, mainly due to IFN-γ 
secretion. Finally, iNKT cells can induce maturation and differentiation of DCs and by doing so 
upregulate adaptive immune responses against the tumor.88 (Figure 1.11) 
 




In contrast to the mechanisms underlying tumor immunity in CD1d+ tumors, it is still a matter of 
debate how iNKT cells protect against CD1d- tumors. A possible mechanism involves the cytolysis of 
CD1d+ tumor associated monocytes/macrophages (TAMs). Tumor cells secrete chemokines that 
induce the differentiation of monocytes to TAMs, which promote the proliferation of tumor cells 
through the secretion of IL-6 and promote STAT3-mediated immune suppression.89,90,91 
1.6 Structural basis of lipid antigen recognition 
Important insights on the structural basis of the antigen recognition could directly be derived from 
high-resolution crystal structures of the CD1d/α-GalCer complex, with and without the TCR of iNKT 
cells.92,93,94,95 The two hydrophobic pockets in the CD1d binding groove, each accommodate the 
hydrocarbon chains of the lipid. In contrast to the F’/C’ pocket, which is more or less linear and binds 
the phytosphingosine chain of α-GalCer, the bigger and more deeply buried A’ pocket binds the fatty 
acid part of the molecule. In order to accommodate the 26-carbon long acyl chain, it must wind 
around a central pole formed by amino acids Cys12 and Phe70 and depending on the bound antigen, 
this can occur in both clockwise and anti-clockwise direction. While anchoring of the lipid moiety is 
mainly governed by hydrophobic interactions, the positioning of the galactose sugar parallel to the 
top of CD1d is dominated by polar interactions. In humans, three hydrogen bonds have been 
observed for α-GalCer, first the 3-OH of the phytosphingosine interacts with Asp80 of the α1 helix, 
additionally the 2”-OH of the galactose forms contacts with Asp151 (Asp 153 in mice) and finally the 
glycosidic oxygen accepts a hydrogen bond from Thr154 (Thr156 in mice). Additional contacts 
between Asp153 and the galactose 3”-OH, Thr156 and the amide bond as well as a hydrogen bond 
between Asp80 and the 4-OH of the phytosphingosine chain have been observed in mice. (Figure 
1.12) 
 
Figure 1.12 Presentation of α-GalCer: Left panel shows binding of α-GalCer in mCD1d with the lipid 
chains accommodated in the A’ and F’ pocket. Right panel shows hydrogen bonds with mCD1d and α-
GalCer (Joyce et al, 2011, J. Immunol. and Zajonc et al, 2005, Nat. Immunol.) 
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A hallmark of α-GalCer binding is the induction of conformational changes in the F’ pocket of CD1d. 
Indeed, upon binding Leu84 and Leu150 are reoriented thereby closing the F’ pocket, resulting in 
tighter binding of the glycolipid due to additional Van der Waals interactions. While the F’ roof is 
observed in most ternary complexes after TCR engagement, it is pre-formed in the case of α-GalCer. 
Furthermore the F’ roof leads to repositioning of other amino acid residues such as Arg79, which is 
known to be important for recognition by the TCR. The closing of the F’ roof not only results in 
tighter binding but also allows the swift recognition of the CD1d/α-GalCer complex contributing to 
the exceptional potency of α-GalCer. (Figure 1.13) 
 
Figure 1.13 Closing of the F’ roof. Left: empty mCD1d. Right: A closely related α-GalCer analogue 
differing in acyl chain length (C8 vs C26) bound to mCD1d (Zajonc et al, 2005, Nat. Immunol.) 
Interestingly, mouse and human CD1d are very similar in structure and in their binding to α-GalCer. 
Consequently, a degree of reciprocal cross-species reactivity of mouse and human iNKT TCR has been 
observed.96 Nevertheless, an important difference between human and mouse CD1d occurs around 
the 6”-OH group of α-GalCer where a tryptophan at position 153 in the human isoform, is replaced 
by a much smaller glycine (Gly155) in mCD1d. The result is that in hCD1d Trp153 causes a tilt in the 
galactose headgroup and slightly raises the glycolipid out of CD1d97, causing the dissimilarity of polar 
interactions described above. Despite this difference, crystal structures of both human and mice 
TCRs complexed with α-GalCer loaded CD1d show a highly conserved lock-and-key binding mode. 
The TCR binds approximately parallel of the CD1d binding groove directly above the F’ pocket, in 
sharp contrast to the ‘diagonal’ footprints observed for MHC class I restricted TCRs and the 
orthogonal binding above the A’ pocket for type II NKT cell TCRs.98 Furthermore, this conserved TCR 
footprint between humans and mice is independent of the used Vβ chain and the antigen complexed 




Figure 1.14 Docking mode of the TCR in a type I NKT-cell TCR/lipid/CD1d complex, a type II NKT 
TCR/lipid/CD1d complex and a TCR/peptide/MHC complex (Rossjohn et al, 2012, Nat. Rev. Immunol.) 
At the interface between the TCR and the CD1d/α-GalCer complex, the CDR1α loop solely interacts 
with α-GalCer, whereas the Jα-encoded CDR3α contacts both CD1d as α-GalCer. In particular, 
hydrogen bonds are formed between the 2”, 3” and 4” hydroxyl groups of the galactose with Gly96 
from the CDR3α loop and Phe29 and Ser30 from the CDR1α loop respectively. In addition, the 3-OH 
group of the phytosphingosine moiety interacts with Arg95 from the CDR3α loop.92,93 On the other 
hand, the contacts between CD1d and the TCR, are mainly governed by the TCR-β chains, with two 
residues (Tyr48 and Tyr50) within the CDR2β loop in particular, contacting residues above the F’ 
pocket. Furthermore the hydrogen bond network between residues of the α1 and α2 chains of CD1d, 
and amino acids within the CDR3α loop of the TCR, is important for proper binding. Noteworthy, 
Leu99 from the CDR3α loop seems to have a crucial role in modifying the CD1d interface as it is 
inserted into the F’ pocket resulting in the formation of the F’ roof (if not pre-formed), which is 
important for NKT TCR binding.99,100 Interestingly, the amino acids within the CDR3α, 1α and 2β 
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mentioned above, are germline-encoded and form a ‘hot spot’ that doesn’t shift in the recognition of 
structurally diverse glycolipids. Suggesting that the invariant TCR functions as a pattern-recognition 
receptor, permitting the innate-like response of iNKT cells.101 (Figure 1.15) 
 
Figure 1.15 Hydrogen bond interactions between the TCR and the CD1d/α-GalCer complex: A) H-
bonds with α-GalCer, B) and C) H-bonds with CD1d (Borg et al, 2007, Nature) 
Structural comparison of α-GalCer to the borrelial antigen BbGl-2c bound to mCD1d, with and 
without TCR, shed further light on the mechanisms underlying antigen recognition. In the TCR 
unbound CD1d/glycolipid complex for BbGl-2c, the sugar is rotated approximately 60° 
counterclockwise from the optimal position as compared to α-GalCer, and the F’ roof is not closed. 
However, upon TCR engagement the ternary complex is similar to the ternary α-GalCer-complex. 
Hence, binding of the TCR not only induces conformational changes above the F’ pocket but can also 
mold the sugar in its correct position.102 This repositioning of the sugar in BbGl-2c, however, is 
probably the reason for the nearly 500-fold lower binding-affinity of the CD1d/glycolipid complex for 
the TCR. Thus, although the lipid portion of glycolipids is buried beneath the surface of CD1d and is 
not directly involved in the TCR recognition, the lipid chains can modulate the CD1d/glycolipid/TCR 
interface and govern the potency of the different antigens. 
1.7 Clinical trials with α-GalCer in advanced cancer 
To date boosting the immune system of cancer patients in order to eradicate tumors that escaped 
immunosurveillance, has had limited clinical success. Hence, there’s an urgent need to introduce 
more effective, knowledge-based therapeutic strategies. The ability of iNKT cells to exhibit a long-
lasting pro-inflammatory antitumor immune response in a variety of tumor-metastasis models 
suggests a broad clinical applicability. 
1.7.1 Pre-clinical background  
In mice inoculated with B16 melanoma or EL-4 lymphoma, α-GalCer was found to prolong survival to 
a greater extent than typical chemotherapeutics like mitomycin C. 103,104 Furthermore, these mice 
showed resistance to subsequent tumor challenge, suggesting the emergence of a tumor-specific 
immune memory. Both intravenous (i.v.) as intraperitoneal (i.p.) administration of α-GalCer induces 
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antitumor activity against various tumor types (melanoma, lung carcinoma, sarcoma, lymphoma) 
including spontaneous tumor models.105,106,107,108 Importantly, no side effects are reported in mice, 
rats and monkeys with doses of α-GalCer up to 220, 440 and 660 µg/kg/day, respectively, receiving 
28 days of treatment. Only a transient increase in alanine aminotransferase was seen in mice 
receiving 100 µg/kg/day. 
1.7.2 Clinical trials  
A first-in-man clinical phase 1 study was performed in patients with refractory solid tumors.109 A total 
of 24 patients were treated with i.v. administration of α-GalCer to identify the maximum tolerated 
dose (MTD) and the optimal biologically active dose (OBAD) as major endpoints. Toxicity was 
evaluated to be minimal and included a case 3 fever with headache, vomiting, chills and malaise 
following administration, transient flush and sneezing. Importantly, no signs of liver toxicity were 
observed, in contrast to data in mice. The MTD could not be reached in a few patients as the 
available formulation did not allow further dose escalation, additionally the OBAD could not be 
determined as none of the immunologic parameters tested showed clear dose-dependent effects. 
Unfortunately, no tumor responses (even not partial) were observed during this trial, yet disease 
stabilization was observed in seven patients. 
Preclinical data indicated that i.v. administration of α-GalCer-pulsed DCs exerted greater antitumor 
activity than i.v. administration of α-GalCer alone, and led to the evaluation of this approach in 
clinical trials. Treatment of 12 patients with metastatic malignancy generated striking reproducible 
immune responses upon administration of pulsed CD1d-expressing immature monocyte-derived 
(mo)DCs. The serum levels of IFN-γ and IL-12 significantly increased in most patients, albeit in a 
transient fashion. In several patients extensive tumor necrosis and sustained decrease of tumor 
markers was observed.110 A similar trial using mature moDCs, which provide more potent immune 
responses as compared to their immature counterparts, resulted in a sustained increase in iNKT cell 
numbers up to 6 months after administration. Moreover, an increase in cytomegalovirus specific 
memory cytotoxic T cells was observed indicating that this approach significantly boosts adaptive 
responses in vivo.111 
In conclusion, although clinical responses have been observed using α-GalCer-pulsed DCs, these are 
not sufficiently consistent and predictable to allow widespread application. The poor clinical 
outcome of α-GalCer therapy is inter alia attributed to the antagonizing nature of the simultaneous 
secreted Th1 and Th2 cytokines, which have opposing roles in vivo. Therefore, α-GalCer derivatives 
with the ability to induce a biased cytokine response are highly awaited and are believed to surpass 
the clinical effectiveness of α-GalCer. 
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1.8 Adjuvant activity of α-GalCer 
Since activation of iNKT cells with α-GalCer induces DC maturation, immunization strategies to boost 
the generation of tumor- or pathogen-specific T cells with simultaneous administration of glycolipid 
derivatives, are currently under investigation. It seems that for effective adjuvant activity, glycolipid 
and protein antigen should preferably be presented by the same APC, requiring concomitant 
administration of both vaccine components.112,113  
Recently, Tsuji et al. evaluated the adjuvant activity of a potent Th1 biasing glycolipid, 7DW8-5 
(structure depicted in section 1.8.2), in the context of a human viral vector malaria vaccine in rhesus 
macaques.114 Strikingly, 7DW8-5 potently enhanced malaria-specific T cell responses induced by the 
malaria vaccine and resulted in long lasting antimalarial T cell responses. These results are promising 
as no single adjuvant known to date, is able to potently enhance a vaccine induced CD8+ T-cell 
response or enhance the immunogenicity of viral-vectored vaccines. 
Furthermore B cell help provided by iNKT cell activation can induce B cell maturation, resulting in 
higher antibody titers and expansion of the B cell memory pool.115,116 Specific targeting of B cells can 
be achieved by binding the antigen and glycolipid agonist to particles117 or by covalently joining α-
GalCer with B cell antigens. 118 
1.9 Structure-activity relationship studies 
For over two decades major research effort has been focused on the development of synthetic α-
GalCer analogues that are able to induce a biased cytokine response. The current library of α-GalCer 
analogues can be divided into four types of modifications, i.e. variation and substitution of the 
galactose sugar, modification of the ceramide, alteration of the stereochemistry and nature of the 
glycosidic bond and finally, polymodified analogues that combine two or more of the above 
mentioned alterations. 
1.9.1 Variation and substitution of the galactose sugar 
While α-D-glucosylceramide is still active, albeit less potent, the substitution of the galactose unit for  
α-D-mannose results in complete abolishment of the activity. Furthermore, 2”-methoxy-α-GalCer,119 
2’’-deoxy-α-GalCer,120 2’’-NH2-α-GalCer,
121 2’’-F-α-GalCer and 2’’-acetamido-α-GalCer122 do not 
activate iNKT cells. Today, these results are not surprising since the crystal structure shows that the 
2”-OH is highly involved in a hydrogen bond network, stabilizing both the binary and ternary 
complex. More flexibility is observed for positions 3” and 4” since both the 3”- and 4”-deoxy and -
fluorogalactosyl derivatives still stimulate some iNKT cell hybridomas.123 Sulfation of the 3”-OH gives 
comparable iNKT cell stimulation as α-GalCer by keeping the H-bond network in place and showing 
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enough contacts with the TCR.124 Although the addition of some arylalkyl chains to the C4”-OH 
resulted in compounds with comparable to better activities,125 to date such 4”-modifications have 
not been explored to great extent. Furthermore, no loss in activity is noted when the galactose 
moiety is substituted with other sugars at C2”, C4” and C6”,126,127,128 due to in vivo cleavage of the 
disaccharides by the APC, except in the case of disaccharides in position 6” which can be 
accommodated by the TCR without cellular processing. Interaction with the TCR seems to tolerate 
small substituents at this position. Indeed, crystal data of the ternary complex, reveals there is space 
to accommodate small groups between the CDR1α and CDR3α loops of the TCR. Accordingly, a whole 
set of C6”-derivatives have been synthesized. 
 
Figure 1.16 Schematic overview of the SAR of the galactose sugar 
Substitution of the 6”-OH for an acetamide group gave a compound with comparable activity to α-
GalCer showing increased solubility in both aqueous and organic solvents.129 In addition a series of 
6”-fluorophores and biotinylated α-GalCer were found to retain iNKT stimulating properties and are 
used to study interactions and loading of glycolipids in CD1d.130 A water-soluble 6”-pegylated 
analogue of α-GalCer showed increased biological activity skewed towards a Th2 response.131 On the 
other hand, Th1 biased responses are observed with 6”-OMe and an α-D-fucopyranosyl analogue, 
both inducing superior IFN-γ secretion in mice.132 Our group reported a series of 6”-urea derivatives 
that retain or even surpass the antigenic potency of α-GalCer, while displaying a profound Th1 bias in 
vivo.133 Among them, NU-α-GalCer bearing a naphthylurea functionality at C6”, shows promising 
antitumor effects in the B16 melanoma mouse model.134 Guided by these results, a second 
generation of C6”-carbamates was recently investigated, yielding PyrC-α-GalCer, which is superior to 
NU-α-GalCer in mediating a Th1-cytokine response and in the prevention of tumor metastases.135 
(Figure 1.16) 
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Apart from the countless analogues modified at one of the glycosidic hydroxyl groups, several non-
glycosidic derivatives have been studied. In order to evaluate the role of the intracyclic oxygen of the 
sugar, carbosugars and inositol derivatives were synthesized.136 While both induced Th1 biased 
cytokine production, the response for inositol analogues proved less potent. Finally, compounds 
presenting a non-cyclic headgroup like threitolceramide can activate iNKT cells. 137 With regard to the 
antigen-specific B and T cell response observed upon coinjection with OVA, this acyclic glycolipid is 
considered as a promising adjuvant in vaccination strategies. Moreover, due to the weaker TCR 
affinity, iNKT cell overstimulation and the associated anergy is reduced. (Figure 1.17) 
 
Figure 1.17 Structures of non-glycosidic α-GalCer analogues 
1.9.2 Modification of the ceramide 
While deletion of both hydroxyls at C3 and C4 is detrimental for the activity,138 sphinganine 
analogues lacking only the 4-OH are nearly as active as α-GalCer.139 Knowing the involvement of the 
3-OH in the recognition by the TCR, this result is not surprising. Furthermore, Park et al. evaluated 
several stereoisomers of α-GalCer revealing the crucial importance of the S configuration of both the 
amide and the 3-hydroxyl, for antigenic activity, while changing the stereochemistry at C4 merely 
altered cytokine production.140 These results contradict an earlier report by our group, showing that 
the configuration at C4 is more important than that of C3.141 Replacement of the hydroxyl functions 
at C3 and C4 for amine groups also gave a substantial drop in cytokine production.142 
Interesting results in terms of skewed cytokine responses have been observed with truncation and 
functionalization of the α-GalCer lipid chains. OCH was the first analogue able to significantly alter 
the response of iNKT cells and is composed of a slightly trimmed acyl chain (C23 versus C26 in α-
GalCer) combined with a phytosphingosine chain comprising only nine carbon atoms. When 
administered to mice, OCH gives a weak immune response with predominantly Th2 cytokine 
secretion.143 More general, truncation of the lipid chains gives compounds with comparable activities 
as OCH.144 The low potency associated with the shortened lipid chains can be restored by the 
introduction of Z-insaturations into the fatty acid chain. Conversely, C20:2 is a much stronger Th2 
biasing iNKT cell agonist as compared to OCH.145 
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Given the abundance of aromatic amino acids lining both pockets of the CD1d binding groove, 
incorporation of aromatic moieties into the lipid chains of α-GalCer has been a popular strategy. A 
comparison of the activity of derivatives with a terminal phenyl ring in the phytosphingosine, 
highlights the importance of the positioning of the aryl moiety. The addition of a few methylene units 
can shift the cytokine response from Th2 to Th1 as well as modify the antigenic potency.146,147 A 
similar strategy for the acyl chain, has generated a series of aromatic analogues which show highly 
relevant Th1 cytokine responses.148 Expansion of this series led to the discovery of the earlier 
mentioned 7DW8-5,149 which is identified as lead candidate with superior adjuvant activity for 
malaria and HIV vaccines in mice.150 
 
Figure 1.18 Structures of ceramide modified α-GalCer analogues 
Isosteric replacement of the amide for a triazole or a sulfonamide group both resulted in a Th2 
biased cytokine secretion.151,152 Furthermore, replacement to an ester or ether group results in weak 
Th2 responses or the inability to activate iNKT cells, respectively.153 Recently, α-GalCer analogues in 
which the acyl chain is connected through a thioamide, urea or carbamate linker were evaluated. 
Both thioamide and carbamate derivatives showed potent Th1 cytokine profiles, whereas the urea 
linked α-GalCer analogue proved weakly stimulating.154 (Figure 1.18) 
1.9.3 Modifications of the glycosidic bond 
The requirement of an α-glycosidic bond to elicit iNKT cell stimulation is in line with crystal structure 
data, as proper positioning of the sugar is impaired in β-glycosides. Consequently, weak activation 
was observed with β-GalCer155 and several β-glycosides in a study of fluorescent analogues.156 In 
order to limit in vivo degradation of α-GalCer by glycosidases, the glycosidic bond was converted to a 
methylene unit, yielding the C-glycoside analogue α-C-GalCer. Original biological evaluation showed a 
strong Th1 response compared to α-GalCer against B16 melanoma.157 More recently, the ability of α-
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C-GalCer to protect against lung metastases and malaria in mice was evaluated, showing hundred 
and thousand times more potency than the O-glycoside, respectively.158 Unfortunately, α-C-GalCer is 
unable to induce significant levels of cytokines from human iNKT cells.159 However, α-GalCer 
analogues that link the ceramide moiety to the galactose sugar by means of an E-alkene linker retain 
strong biological activity against human iNKT cells, inducing a potent Th1 biased immunologic 
response.159 The importance of the linker region is further highlighted by the weak stimulatory 
properties of α-C-GalCer derivatives with increased or truncated linker lengths.160,161 
In addition thiogalactoside,162 selenoglycoside163 and oxime analogues164 have been synthesized. 
Whereas no biological data is available on α-Se-GalCer and the oxime analogues, the thiogalactoside 
shows no activation of iNKT cells in vitro nor in vivo.165 (Figure 1.19) 
Figure 1.19 Structures of glycosidic bond modified α-GalCer analogues 
1.9.4 Polymodified analogues 
Combining known Th1 or Th2 biasing modifications to further enhance the cytokine profile seems 
obvious but often leads to unexpected results. Confirming this idea, several analogues with terminal 
aromatic rings on both acyl chain and phytosphingosine, surprisingly failed to show any iNKT cell 
activation.166 A series of derivatives with different substituted aromatic moieties both on the acyl 
chain and the galactosyl 6”-position were synthesized by Wong. Among them, a C6”-naphthylurea 
compound with an 11-(3,4-difluorophenyl)undecanoyl acyl chain was able to retain or even surpass 
the Th1 bias of the parent compounds, however the antigenic potency was significantly decreased.167 
Furthermore, out of a small library of 40 derivatives sharing the same aromatic moieties at the C6” 
position as well as on the acyl chain, only the double 4-butylbenzamido modified analogue was able 




Figure 1.20 Structures of polymodified α-GalCer analogues 
In order to enhance the Th2 polarizing properties of OCH, a series of phytosphingosine modified OCH 
derivatives were prepared, including aromatic, ethereal and aliphatic groups.169 Close to slightly 
reduced Th2 profiles were observed as compared to OCH, indicating no clear benefit of these 
variations. Moreover, the C-glycoside analogue of OCH was synthesized to minimize degradation in 
vivo. Surprisingly, this molecule is unable to activate iNKT cells in vitro nor in vivo.170 A striking loss in 
activity is also observed by altering the galactose unit in C20:2 into a α-L-fucosyl head.171 These 
examples demonstrate that combining two or more favorable modifications does not necessarily 
result in compounds eliciting enhanced biological profiles. (Figure 1.20) 
1.10 Polarization mechanism hypotheses 
While the panel of α-GalCer analogues that are able to induce a biased cytokine response is growing, 
the precise mechanisms governing the selective activation, are not clearly understood. Hence, 
because specific applications require different cytokine responses, the rational development of 
optimized iNKT cell activators is clearly in its infancy. However, several discoveries led to a number of 
possible explanations including differences in cellular loading site, binding affinities and 
pharmacokinetics as well as the nature of the APC. 
1.10.1 Ternary complex stability 
After in vivo administration of α-GalCer, peak levels of Th2 cytokines like IL-4 occur around 4h, while 
levels of the Th1 cytokine IFN-γ peak at 16h. These observations suggest that the secretion of both 
cytokine types is at least partially separated in time and led to the hypothesis that stable 
CD1d/glycolipid/TCR complexes are crucial for Th1 cytokine secretion. Owing to its short lipid chains 
the affinity of OCH for CD1d was estimated low as the hydrophobic pockets in CD1d would not be 
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fully occupied. Indeed, a study comparing truncated derivatives of α-GalCer, including OCH, nicely 
showed a correlation between the half-life of the CD1d/glycolipid complex and the length of the 
phytosphingosine chain.172 Furthermore, longer phytosphingosine chains induced proportionally 
increased IFN-γ secretion, while the secretion of IL-4 was unaffected. According to the authors, 
transcriptional activation of IFN-γ, but not IL-4, requires de novo protein synthesis, which is regulated 
by TCR-signal transduction and thus requires longer TCR stimulation.  
A similar study concluded that while the length of both the acyl chain and the phytosphingosine 
affects lipid dissociation from hCD1d, TCR binding affinity is controlled by the phytosphingosine part 
of the ceramide.173 Since the TCR binds parallel over the F’ pocket, conformational changes induced 
upon binding of the phytosphingosine chain are likely to cause alterations in TCR recognition. Indeed, 
when comparing TCR binding affinities for α-GalCer and OCH9, which is an OCH derivative with a 
cerotic acid acyl chain, substantial higher affinity is observed for α-GalCer (Kd of 1.6 µM versus 122 
µM respectively). These experiments illustrate that the reduced duration of the TCR signaling for 
OCH is caused by a rapid dissociation from CD1d combined with a low affinity for the TCR. 
 
Figure 1.21 Ternary complex stability in relation to the induced cytokine profile. (Adapted from 
Berkers and Ovaa, 2005, Trends Pharmacol Sci) 
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On the other hand, the Th1 polarizing 7DW8-5 displays a much stronger binding to CD1d, originating 
from increased contacts between the aromatic moiety and the A’ pocket. In addition to the long half-
life, the CD1d/glycolipid complex shows a near 16-fold increase in TCR affinity.174 Accordingly, 
antigens leading to long-lasting TCR signaling like 7DW8-5 have the tendency to induce Th1 polarized 
responses, whereas α-GalCer analogues like OCH showing a reduced ternary complex stability result 
in a Th2 bias. (Figure 1.21) 
In agreement with this hypothesis the 6”-modified α-GalCer analogues PyrC-α-GalCer and NU-α-
GalCer generate long-lived ternary complexes owing to increased interactions with the TCR or with 
CD1d, respectively. Crystal data of the ternary CD1d/PyrC-α-GalCer/TCR complex demonstrate 
increased Van der Waals contacts between the pyridine ring and Gln52 of the TCR.135 On the other 
hand, the naphthyl moiety of NU-α-GalCer creates a small hydrophobic cavity on top of the A’ pocket 
via induced fit, thereby enhancing the CD1d-affinity.134 (Figure 1.22) 
 
Figure 1.22 Ternary complexes of PyrC-α-GalCer (left pane) and NU-α-GalCer (yellow, right pane) 
However, this theory does not hold for Th2 biasing derivatives like C20:2 which shows both a higher 
CD1d and TCR-affinity as compared to α-GalCer.175 Furthermore, the prototypical Th1 polarizing 
antigen α-C-GalCer forms an even shorter-lived complex with CD1d than OCH and exhibits weaker 
binding to the TCR.176 Thus, mechanisms other than or in addition to variations in ternary complex 
stability must underlie the altered cytokine responses stimulated by certain α-GalCer derivatives. 
In the case of α-C-GalCer, long-lived functional complexes exist on the surface of APCs in vivo due to 
the metabolic stability of the C-glycosidic bond. Conversely, the in vivo stability of iNKT cell antigens 
may play a critical role in the induction of a polarized cytokine response. 
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1.10.2 Cellular loading site 
An alternative mechanism relates to how glycolipid compounds become associated with CD1d in 
APCs. Th2 biasing glycolipids have the tendency to contain features that are likely to increase their 
aqueous solubility. This enhanced solubility may account for the ability of Th2 biasing ligands to 
directly load onto CD1d molecules at the surface of APCs, without the aid of lipid transfer proteins.177 
In contrast, α-GalCer requires the help of lysosomal lipid exchange proteins to load into CD1d and 
lysosomal trafficking accounts for the higher degree of α-GalCer loaded CD1d molecules in lipid raft 
domains. These lipid-rafts are cholesterol-rich microdomains in the plasma membrane, which are 
enriched in signal transduction proteins and are believed to act as signaling platforms. Generally, 
when CD1d-glycolipid complexes show strong localization in lipid rafts the resulting iNKT cell 
activation tends to be biased towards a Th1 response. 
While surface loaded CD1d-glycolipid complexes undergo endosomal recycling, the acidic lysosomal 
environment together with the presence of free endogenous lipids, results in a rapid dissociation of 
Th2-type glycolipids. Not surprisingly, neutralization of the endocytic pH increases the cell surface 
levels of CD1d complexes containing Th2-biasing glycolipids.178,179 Additionally, an increased 
accumulation in plasma membrane lipid raft microdomains was observed, resulting in Th1 cell-type 
responses induced by antigens known as Th2 polarizers. (Figure 1.23) 
 
Figure 1.23 CD1d loading and intracellular processing affects the iNKT cell response (Venkataswamy 
and Porcelli, 2010, Sem. Immunol.), GMCSF: Granulocyte-macrophage colony-stimulating factor, 




Strikingly, such lipid-raft-dependent alternative activation strategy has previously been described for 
MHC class II molecules. In analogy, peptide antigens loaded on MHC class II molecules in intracellular 
compartments, mainly localize in lipid-rafts and favor Th1 cell-type responses by conventional CD4+ T 
cells, while Th2 cell-type responses are observed with peptides loaded at the cell surface outside of 
rafts.180 
1.10.3 The nature of the APC 
Finally, a third possible mechanism implies that the different cytokine production of α-GalCer 
analogues in vivo emerges from presentation by different types of APCs. This hypothesis relies on the 
observation that forced presentation of α-GalCer by B cells skew iNKT cell responses towards a Th2 
bias.181  
Furthermore, the fact that iNKT cell stimulation with α-GalCer is impaired in mice lacking CD1d on 
dendritic cells selectively, suggests that α-GalCer requires DC for antigen presentation. In contrast, 
these mice do respond to Th2 biasing ligands, suggesting that the presentation of Th2 compounds is 
promiscuous and mostly carried out by non-DC cell types that do not produce IL-12. This implies that 
for Th2 biasing ligands the great burst of IFN-γ secreted by NK cells induced upon IL-12 is absent. This 
IL-12/NK/IFN-γ feedback loop is critical for transactivation of bystander immune cells and to generate 
a sustained IFN-γ secretion.182  
To complicate things further, recent reports suggest that a single subset of DC is the key APC for a 
range of structurally different glycolipids. The differential upregulation of costimulatory and 
coinhibitory molecules induced by Th1 and Th2 ligands was shown to control the iNKT cell response. 
However, the details of the signaling processes through which the DC function is modulated, remain 
to be determined.183 
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2 Objectives 
In line with the well-established polarization hypothesis advancing that the duration of the iNKT cell 
TCR interaction determines the cytokine response, the aim of this thesis is to explore various affinity 
enhancing modifications that are likely to yield more stable ternary CD1d/glycolipid/TCR complexes. 
By incorporating deliberate modifications in different parts of the α-GalCer structure (Figure 2.1), we 
aim to gain further insights in the relative importance of both lipid chains and the sugar, in driving 
the biological outcome of iNKT cell activation. 
 
Figure 2.1 Schematic representation of the envisioned strategies to stabilize the ternary complex. 
A study by McCarthy et al. indicated that although both the acyl chain and phytosphingosine 
contribute to the stability of the CD1d/glycolipid complex, it is the phytosphingosine chain that 
controls TCR binding and iNKT-cel activation.
1
 Strikingly, examples of α-GalCer analogues with a 
modified phytosphingosine are relatively scarce, and established synthetic strategies often rely on 
tedious linear reaction sequences to furnish the desired compounds. Therefore, in chapter 4 we aim 
to develop a divergent synthetic approach that allows late-stage diversification of the 
phytosphingosine chain, endeavoring to reinforce the interaction (e.g., by π-π stacking) with amino 
acids lining the F’ pocket by introducing aromatic moieties at different distances from the anomeric 
position. 
This approach will be applied for the synthesis of 4.1a - 4.1h (Figure 2.2) containing an amide bond 
within the phytosphingosine chain. To ensure acceptable solubility of these so termed α-
galactosylsphingamides, an octanoyl acyl chain will be installed, as Goff et al. demonstrated that this 
fatty acid chain may retain most of the antigenic properties.2 




Figure 2.2 Structures of the envisioned α-galactosylsphingamides. 
Given that the C-glycoside of α-GalCer forms short-lived complexes with CD1d and exhibits weaker 
binding to the TCR as compared to α-GalCer,3 the Th1 cytokine profile exhibited by this C-glycoside is 
probably a reflection of it’s enhanced in vivo stability. In chapter 5 we therefore aim to investigate if 
the promising iNKT-cell mediated responses induced by the C6”-derivatised α-GalCer analogues PyrC-
α-GalCer and NU-α-GalCer, may be reinforced by preparing the corresponding C-glycoside 
derivatives. Additionally, we pursued the synthesis of the corresponding E-alkenes, as in contrast to 
α-C-GalCer, E-alkene C-glycosides have shown potent human iNKT cell activation.4 (Figure 2.3) 
Additionally, such compounds could provide detailed insights in the polarization mechanisms as they 
allow evaluating a number of possible hypotheses. Firstly, modifications of the galactose sugar at 
position 6” are known to increase the affinity for the TCR and/or to enhance the CD1d/glycolipid 
complex stability.5,6 Comparing the effect of α-C-GalCer to the envisioned sugar-modified C-
glycosides will give a direct estimate of the contribution of a higher ternary complex stability. 
Secondly, evaluation of PyrC-α-GalCer and NU-α-GalCer to their C-glycoside counterparts, will 
highlight the importance of the metabolic stability for in vivo iNKT cell antigenic activity. 
 
Figure 2.3 Structures of C6”-modified α-C-GalCer derivatives. 
The ultimate strategy to strengthen the stability of the CD1d/glycolipid complex would be through 
irreversible binding. Inspired by the structure of the potent Th1 polarizer 7DW8-5, containing a 
terminal p-fluorophenyl moiety in the fatty acid chain that is well accommodated in the A’ pocket, in 
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chapter 6 we intend the synthesis of a 7DW8-5 analogue in which the fluoride atom is replaced by an 
azide group. (Figure 2.4) Upon UV-irradiation arylazide species give rise to reactive nitrene species, 
which can react with various amino acid residues within the A’ pocket to establish a covalent bond 
between CD1d and the glycolipid. 
 
Figure 2.4 Structures of the known glycolipid 7DW8-5 and the envisaged photo-affinity crosslinker. 
In chapter 7, several reagents to study type II NKT cells will be prepared. In recent years, type II NKT 
cells have gained increasing attention as in humans, they appear to be much more frequent than 
their iNKT cell counterparts.7,8 In general type II NKT cells are involved in immune suppressive roles 
and thus counteract the immunological response generated by iNKT cells. Consequently, antitumor 
immunotherapy strategies will have a higher chance of success if we extent our understanding of 
type II NKT cells and find ways to overcome their immunosuppressive properties. Unfortunately, in 
contrast to iNKT cells, which can be stained by α-GalCer loaded CD1d-tetramers, to date no direct 
and specific tools are available to identify the entire type II NKT cell population in vivo. While CD1d-
tetramer reagents exist for type II NKT cells, difficulties in loading and the lower stability of 
CD1d/type II antigen complexes hamper further discoveries. Additionally, commercially available 
type II NKT cell antigens, like sulfatide and lysosulfatide, frequently suffer from poor quality and are 
often contaminated with small amounts of α-anomer, leading to unwanted staining of iNKT cells. 
To circumvent the issues with commercial sulfatide and lysosulfatide, which are extracts from natural 
sources, we plan the synthesis of these well-known type II NKT cell ligands. In addition, we aim at 
enhancing the CD1d-tetramer stability by preparing a lysosulfatide analogue containing a terminal 
phenyl ring within the phytosphingosine chain. Finally, as the envisioned synthetic strategy involves 
the azide versions of lysosulfatide and the aforementioned aromatic variant, these intermediates will 
also be included in the biological evaluation. (Figure 2.5) 
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Figure 2.5 Structures of the aimed type II NKT cell ligands. 
The focus of this work is on the chemical synthesis of the aforementioned glycosphingolipids. The 
biological evaluation of the final compounds will be conducted in collaboration with the following 
partners: 
- Department of Internal Medicine, Faculty of Medicine and Health Sciences at Ghent 
University: the research group of Prof. D. Elewaut will perform the in vivo cytokine secretion 
assays in mice and recorded in vitro cytokine data for human iNKT cells. 
 
- Aaron Diamond AIDS Research Center, Affiliate of The Rockefeller University, New York, USA: 
T. Moriya and coworkers will assist in gathering both in vivo cytokine secretion data for mice 
and measuring in vitro cytokine data for human iNKT cells. 
 
- Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, USA: 
The crystal structures of the CD1d/glycolipid and CD1d/glycolipid/TCR complexes will be 
determined in the research group of D. M. Zajonc. In addition, the group will determine 
binding affinity data via Surface Plasmon Resonance (SPR) and in vitro cytokine data. 
 
- Department of Pathology and Laboratory Medicine, University of British Columbia, 
Vancouver, Canada: The biological evaluation of the type II NKT cell antigens will be 
performed by the group of P. van den Elzen. 
  
Chapter 2: Objectives 
 




 McCarthy, C.; Shepherd, D.; Fleire, S.; Stronge, V. S.; Koch, M.; Illarionov, P. A.; Bossi, G.; Salio, M.; Denkberg, 
G.; Reddington, F.; Tarlton, A.; Reddy, B. G.; Schmidt, R. R.; Reiter, Y.; Griffiths, G. M.; van der Merwe, P. A.; 
Besra, G. S.; Jones, E. Y.; Batista, F. D.; Cerundolo, V. J. Exp. Med., 2007, 204, 1131-1144. 
2
 Goff, R. D.; Gao, Y.; Mattner, J.; Zhou, D.; Yin, N.; Cantu III, C.; Teyton, L.; Bendelac, A.; Savage, P. B. J. Am. 
Chem. Soc., 2004, 126, 13602-13603. 
3
 Sullivan, B. A.; Nagarajan, N. A.; Wingender, G.; Wang, J.; Scott, I.; Tsuji, M.; Franck, R. W.; Porcelli, S. A.; 
Zajonc, D. M.; Kronenberg, M. J. Immunol., 2010, 184, 141-153. 
4
 Li, X.; Chen, G.; Garcia-Navarro, R.; Franck, R. W.; Tsuji, M. Immunology, 2009, 127, 216–225. 
5
 Aspeslagh, S.; Nemčovič, M.; Pauwels, N.; Venken, K.; Wang, J.; Van Calenbergh, S.; Zajonc, D. M.; Elewaut, D. 
J. Immunol., 2013, 191, 2916-2925. 
6
 Aspeslagh, S.; Yali, L.; Yu, E. D.; Pauwels, N.; Trappeniers, M.; Girardi, E.; Decruy, T.; Van Beneden, K.; Venken, 
K.; Drennan, M.; Leybaert, L.; Wang, J.; Van Calenbergh, S.; Zajong, D.; Elewaut, D. EMBO J., 2011, 11, 2294-
2305. 
7
 Exley, M.A.; Tahir, S.M.; Cheng, O.; Shaulov, A.; Joyce, R.; Avigan, D.; Sackstein, R.; Balk, S.P. J. Immunol., 2001, 
167, 5531–5534. 
8
 Chang, D.H.; Deng, H.; Matthews, P.; Krasovsky, J.; Ragupathi, G.; Spisek, R.; Mazumder, A.; Vesole, D.H.; 















  51 
3 Chemical glycosylation 
3.1 Introduction 
In glycolipid synthesis, glycosylation is arguably the most important, though challenging step. 
Glycosidic bond formation is generally achieved by reacting a glycosyl acceptor with a protected 
glycosyl donor that has a suitable leaving group at its anomeric center. Upon activation by a 
promoter, the departure of the anomeric leaving group results in the formation of a glycosyl cation, 
which is stabilized through an oxacarbenium intermediate. Nucleophilic attack by the glycosyl 
acceptor can occur both from the top and bottom of the flattened carbohydrate ring, resulting in 
either 1,2-trans or 1,2-cis glycosides. The protecting group strategy of the glycosyl donor plays a 
critical role in the stereoselective outcome of the glycosylation reaction, with the substituent at C2 
being most crucial.  
Acyl-type protecting groups at C2 stabilize the oxacarbenium ion via neighboring group participation, 
ultimately leading to an acyloxonium ion intermediate, which dominates the course of the reaction. 
As the bottom face of the pyranose ring is blocked, the glycosyl acceptor attacks the anomeric 
position from the opposite, top face, resulting in a 1,2-trans glycoside. While neighboring-group 
participation is the most reliable method for the preparation of 1,2-trans-glycosidic linkages, it is of ill 
value for the synthesis of α-linked galactosyl ceramides, like α-GalCer, that exhibit a 1,2-cis linkage. 
(Figure 3.1) 
 




Construction of 1,2-cis glycosidic bonds requires the presence of a non-participating protecting group 
at C2, but this alone does not ensure the stereoselectivity. Although the anomeric effect favors α-
glycosides, often poor reaction yields and unfavorable α/β ratios are observed. Hence, the synthesis 
of 1,2-cis glycosides is typically much more challenging and requires different modes of 
stereocontrol. Nevertheless, several approaches to construct 1,2-cis glycosides have emerged and 
will be discussed hereafter. (Figure 3.2) 
 
Figure 3.2 Glycosylation mechanism with a non-participating group at C2 
3.2 The preparation of 1,2-cis glycosidic bonds 
3.2.1 In situ anomerisation 
While most glycosylation reactions proceed via the oxacarbenium intermediate and follow a 
unimolecular SN1 displacement mechanism, occasionally some glycosylations follow a SN2-like 
mechanism, inverting the configuration at the anomeric center. Exploiting this, Lemieux and co-
workers1 described an in situ anomerisation protocol that allows the stereoselective formation of 
1,2-cis linkages. 
A rapid equilibrium can be established between α- and β-halides by the addition of tetra-n-butyl 
ammonium iodide. Since the β-iodide is less stable due to the absence of the anomeric effect and 
thus more reactive towards nucleophilic attack, glycosylation takes place on the β-intermediate in a 
SN2 fashion, to give mainly α-glycosides. (Scheme 3.1) Although the in situ anomerisation strategy has 
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been applied to α-GalCer chemistry,2 experience has taught us that this strategy often needs 
extensive optimization. 
 
Scheme 3.1 In situ anomerisation protocol 
3.2.2 Conformation-restraining cyclic protecting groups 
Cyclic protecting groups induce torsional strain and can strongly affect the stereoselectivity of the 
glycosylation reaction. The robust glycosylation protocol described by Schmidt uses a 4,6-
benzylidene acetal protected galactose building block, which upon reaction with the glycosyl 
acceptor, displays almost exclusively the 1,2-cis glycosylated product.3 The high stereoselectivity can 
be explained by the conformational preference of the oxacarbenium intermediate, which can adopt 
two half-chair conformations. (Figure 3.3) 
 
Figure 3.3 The two half-chair conformations of the intermediate oxacarbenium ion during the 
Schmidt glycosylation protocol 
The 4H3 structure contains one pseudo-axial substituent at C4, whereas the 
3H4 half chair has three at 
C2, C3 and C5, biasing the conformational equilibrium towards the 4H3 conformer. Additionally, 
hyperconjugation occurs between the C-H bond at C2 and the double bond in this half-chair 
conformation. Finally, in 4H3 the phenyl group of the benzylidene acetal adopts an equatorial position 
on the acetal chair-conformation, whereas in 3H4 it occupies an axial position and causes sterical 
hindrance with the pseudo-axial substituent on C3. 
Also, axial attack from the nucleophile in the 4H3 conformer happens from the bottom face, forming 




state. Hence, in the 4H3 conformer the nucleophile does not experience steric hindrance from the 
pseudo-equatorial substituent on C2. Diversely, the nucleophile in the 3H4 conformation approaches 
from the top face and is hindered by the pseudo-axial group on C3.  
In analogy, bulky 4,6-di-tert-butylsilylene galactosyl donors have been successfully applied for α-
selective glycoysylations in the preparation of α-GalCer and human ABO histo-blood group type 2 
antigens.4 
3.2.3 Effect of the reaction conditions 
The nature of the reaction solvent can markedly influence the stereoselective outcome of 
glycosylation reactions. Typically, solvents of low polarity are likely to increase the α-selectivity, as 
these facilitate in situ anomerisation and suppress the formation of oxacarbeniums ions. 
Interestingly, ether type reaction solvents form complexes with the oxacarbenium intermediate, 
adopting a β-configuration due to the reverse anomeric effect. Consequently, nucleophilic 
displacement inverts the anomeric configuration resulting in 1,2-cis glycosides. (Figure 3.4) 
 
Figure 3.4 The participating effect of diethyl ether in glycosylation reactions. 
Whereas the promoter usually only effectuates the departure of the anomeric leaving group, it may, 
in tandem with other additives orchestrate the anomeric outcome of the glycosylation reaction. The 
use of stannous chloride (SnCl2) and silver perchlorate (AgClO4) as promoter system for glycosyl 
fluorides was first introduced by Mukaiyama and yields good stereoselectivity.5 The vacant orbital of 
tin accepts a lone pair of the fluorine atom, resulting in the cleavage of the C-F bond and generation 
of the oxacarbenium intermediate. Next, the perchlorate anion forms an ion pair with the 
oxacarbenium ion and is positioned at the more accessible β-face of the galactose sugar, ensuring 
nucleophilic attack to occur from the bottom and furnishing α-glycosides. (Figure 3.5) 
 
Figure 3.5 Mechanism of the Mukaiyama glycosylation with SnCl2 and AgClO4 
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3.2.4 Miscellaneous methods 
Remote participating acyl-type protecting groups, have in some cases been harnessed for the 
construction of 1,2-cis glycosides. More in particular, the stereoselective formation of α-galactosides 
is enhanced when a participating moiety is present at C4.6 Recently, a different stereodirecting effect 
was discovered for remote picoloyl and picolinyl substituents. The picolinyl nitrogen forms a 
hydrogen bond with the incoming glycosyl acceptor and as a result, a high facial selectivity , always 
syn in respect to the picolinyl substituent, is observed.7 (Figure 3.6) Although these strategies show 
great potential, to date they have not been applied for the synthesis of α-GalCer analogues. 
 
Figure 3.6 Remote protecting group effects 
Due to great advances in the area of chemical glycosylation we are now able to synthesize various 
glycosidic linkages with promising yields and stereoselectivity. Nonetheless, the glycosylation 
reaction often remains the critical step in many syntheses. The variety of factors, conditions, and 
driving forces that can influence the yield and stereoselectivity, makes glycosylation reactions very 
complex and hard to control. 
3.3 C-glycosylation 
Carbohydrate derivatives where the anomeric oxygen is replaced by a methylene unit are called C-
glycosides and the synthesis of the latter has become an active subfield of carbohydrate chemistry 
for over three decades. The general idea is that C-glycosides, while retaining general recognition and 
binding properties, are resistant to glycosidase enzymes and display a higher metabolic stability. The 
apparent isosterism flows from the chemical and structural similarities between O- and C-glycosides 





 O-Glycosides C-glycosides 
Bond Lenght O-C = 1.43 Å C-C = 1.54 Å 
VdW radius O = 1.52 Å CH2 = 2.00 Å 
Electronegativity O = 3.51 C = 2.35 
Dipole Moment C-O = 0.74 D C-C = 0.3 D 
H-bonding Two None 
Anomeric effect Yes No 
Exoanomeric effect Yes No 
Stability Cleaved by acid and enzymes Stable to acid and enzymes 
Conformation C1’-C2’ antiperiplanar to O1-C1 C1’-C2’ antiperiplanar to C1-C2 
Table 3.1 Physical properties of O- and C-glycosides. (Adapted from Daniel et al., The Chemistry of C-
glycosides, 1995) 
A major difference is the deletion of the anomeric effect, which is an important factor regarding the 
stereoselective outcome in O-glycosylations. An axial O-glycoside stabilizes the 4C1 chair 
conformation by approximately 2 kcal/mmol as compared to the equatorial counterpart, in contrast 
axial alkyl substituents destabilize the 4C1 chair by an equal amount. Furthermore, transfer of 
electron density from a lone pair of the exocyclic oxygen to the antibonding orbital of the endocyclic 
C-O bond is not achievable for the methylene unit, thereby losing the exoanomeric effect 
stabilization.  
Due to the absence of the anomeric effect, the stereoselective outcome of C-glycosides is completely 
dictated by stereoelectronic effects. In addition, neighboring group participation is much less 
important as in the preparation of O-glycosidic linkages. Hence, axially substituted C-glycosides or α-
glycosides in the case of galactose sugars, are more accessible versus the equatorial isomers. (Figure 
3.7) 
Figure 3.7 Conformational and steric effects govern α-selectivity in C-galactosylation reactions 
Although several strategies exist for the preparation of C-glycosides, electrophilic C-glysosyl donors 
are identical as those used in O-glycosylation reactions, while the glycosyl acceptors are generally 
organometallic nucleophiles such as organosilanes, Grignard reagents or stannanes. The 
conformational preference of the oxacarbenium ion and steric interactions occurring during 
nucleophilic attack will govern the α-selectivity even though axial alkyl substituents are disfavored.  
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Due to the interesting biological effects of the C-glycoside analogue of α-GalCer, several synthetic 
strategies towards α-C-GalCer have been described and will be discussed in the next section. 
3.4 Syntheses of α-C-GalCer 
The first synthetic scheme reported for the preparation of α-C-GalCer relied on Wittig olefination 
between D-galactosyl triphenylphosphonium bromide 3.1 and aldehyde 3.2 derived from 
phytosphingosine.8 In addition to the low yields associated with this approach, epimerization at C2 
can occur and leads to inseparable mixtures of amide-epimers.9 (Scheme 3.3) 
 
Scheme 3.3 First reported synthetic strategy for α-C-GalCer. 
In 2003 Franck et al. exploited the Ramberg-Backlund reaction of sulfone 3.6 as key step in 
establishing the C-glycosidic linkage. In order to generate the desired stereochemistry, an 
intramolecular hydride transfer from a silyl group at C4” to an intermediate carbocation was 
performed. However, extensive protecting group manipulations were required to allow this 
transfer.10 Moreover, the Ramberg-Backlund step requires C2Br2F4, which is no longer commercially 
available as it depletes the ozone layer. (Scheme 3.4) 
 




Both methods described above require a large number of synthetic steps and accordingly, two 
concise syntheses were developed. The first scheme is based on an olefin cross-methatesis between 
vinylated phytosphingosine 3.11 and easily prepared α-1-C-propenylgalactose 3.10 in the presence of 
ethylene gas.11 Despite the straightforward derivatization towards α-C-GalCer and its alkene analogs, 
more care should be addressed to the vinylated phytosphingosine, which stems from a precursor 
aldehyde which is susceptible to epimerization as described above. The second concise synthesis 
links formyl-C galactoside 3.13 and phytosphingosine sulfone 3.14 via Julia-Kocienski olefination and 
affords alkene 3.15 without epimerization or elimination of the aldehyde building block.12 (Scheme 
3.5) 
Scheme 3.5 Concise syntheses of α-C-GalCer 
Additionally, during the last decade several linear approaches have surfaced allowing the preparation 
of a small number of α-C-GalCer derivatives. A Sonogashira cross-coupling between vinyl iodide 3.17 
and α-C-ethynylgalactoside 3.16, afforded enyne 3.18 in good yield. Epoxidation of the double bond 
and guided introduction of the amine functionality through cyclization of an 
epoxytrichloroacetimidate intermediate, paved the way to α-C-GalCer and the acetylene-linked 
derivative.13 (Scheme 3.6) 
 
Scheme 3.6 Synthetic scheme relying on Sonogashira reaction 
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Aldehyde 3.20 serves as common starting material for two linear synthetic strategies. Conversion to 
epoxide 3.21, followed by azide-mediated ring-opening introduces the amine functionality, which is 
subsequently protected prior to oxidation of the primary alcohol. Next, organometallic chemistry 
affords a mixture of isomers, which eventually leads to α-C-GalCer and its C5 epimer.14 On the other 
hand, aldehyde 3.20 allows access to sulfinimine 3.25 that is amenable for organometallic chemistry 
yielding precursor 3.26 which is easily transformed to the C-glycoside.15 (Scheme 3.7) 
 
 
Scheme 3.7 Linear syntheses of α-C-GalCer allowing modification of the phytosphingosine chain. 
 
An interesting approach was developed by Haudrechy et al. providing ester analogues of α-C-GalCer. 
The key transformation is the condensation of a galactose derived acyclic epoxide/aldehyde 
intermediate 3.27 with arabinose derived alkyne 3.28. Using a ribose-derived alkyne in the 
condensation reaction would offer entry to standard C-glycosides after inversion of the alcohol with 





Scheme 3.8 Synthesis of ester analogues of α-C-GalCer 
Finally, a C-H oxidation strategy allowed the preparation of enol 3.30, which was subjected to a 
cross-metathesis reaction to obtain alkene 3.32. Introduction of the nitrogen at C3 was accomplished 
via an allyl cyanate to isocyanate rearrangement and ultimately led to 5-deoxy-6”-methoxy α-C-
GalCer derivatives 3.34.17 (Scheme 3.9) 
 
Scheme 3.9 Synthesis of 5-deoxy-6”-methoxy α-C-GalCer derivatives 
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4 Galactosylsphingamides: new α-GalCer analogues to probe the F’-pocket of 
CD1d 
4.1 Introduction 
Whereas modifications of the galactose moiety and the fatty acid chain are omnipresent in literature, 
only a limited number of phytosphingosine modified α-GalCer derivatives have been synthesized to 
date. A plausible explanation for this tendency is that, in contrast to the anomeric linkage, the 
carbohydrate part or the C-2 amine group, the aliphatic phytosphingosine chain offers no direct 
diversifying motif, rendering such analogues synthetically more challenging. Previously established 
strategies are rather limited in their scope and often require long linear reaction sequences to furnish 
the desired α-GalCer-analogues. 
For example, methods using L-Garner’s aldehyde as chiral building block1 rely on Wittig olefination 
followed by stereoselective dihydroxylation of the Z-double bond, to obtain the required D-ribo 
stereochemistry. Although high stereoselectivity has been observed this approach inevitably leads to 
minor unwanted isomers thereby lowering the overall yield and forcing demanding purification steps 
ahead in the synthesis. An additional inconvenience is the Boc protecting group, which due to 
internal hydrogen bond formation, decreases the nucleophilicity of the primary alcohol, resulting in 
sloppy glycosylation. Protecting group manipulations to circumvent this issue lengthen the synthetic 
routes. The synthetic strategy by Toba et al.2 utilizes known epoxide C holding the proper 
stereochemistry to introduce various substituents via alkylation. However, several protecting group 
manipulations are needed to obtain an appropriate glycosyl acceptor, thereby increasing the amount 
of linear steps towards the final structures. (Scheme 4.1) 
Scheme 4.1 Top: Garner’s aldehyde strategy, bottom: method applied by Toba et al. 
The disaccharide approach by Michieletti et al.3 which uses a common precursor obtained after 




optimal use of the chiral pool. Allyl cleavage to the hemi-acetal allows Wittig olefination, but due to 
the possible 1,3-dipolar cycloaddition reaction upon introduction of an azide at C-2, the double bond 
needs to be saturated with care, leaving the benzyl ethers unharmed. An additional disadvantage is 
the heterogeneous protecting group strategy rendering this scheme rather lengthy as well. On the 
other hand reduction of the hemi-acetal offers the possibility to synthesize analogues bearing an 
extra oxygen. 
 
In an effort to obtain a more divergent strategy, glycoside J was synthesized.4 Oxidation to the 
aldehyde followed by enantioselective Careira alkynylation leads to the wanted anti configuration 
and introduces the envisioned substituent. (Scheme 4.2) 
Scheme 4.2 Top: strategy used by Michieletti et al., bottom: synthesis of phytosphingosine modified 
analogues by Matto et al. 
 
Late stage diversification was also accomplished by N-alkylation of the pyrazole moiety in P,5 allowing 
systematic migration of a phenyl moiety in the phytosphingosine backbone. Glycoside P was 
obtained after Vilsmeier-Haack formylation of enol ether M and cyclization with hydrazine. The 
pyrazole ring can potentially lead to increased hydrophobic interactions, but is detrimental for the 
flexibility of the phytosphingosine chain. (Scheme 4.3) 
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Scheme 4.3 Synthesis of pyrazole containing phytosphingosine modified analogues by Kim et al. 
The above mentioned synthetic strategies are far from ideal as they each suffer from one or the 
other inconvenience. However, they delivered a handful of useful α-GalCer derivatives allowing 
structure activity relationship studies summarized in table 4.1. The first α-GalCer derivative that 
significantly changed the cytokine response of iNKT cells was called OCH, a glycolipid with a 
truncated phytosphingosine chain and a slightly trimmed fatty acid. It rapidly became the 
prototypical Th2 polarizing iNKT cell ligand showing increased suppression of EAE and superior 
protection against diabetes and collagen-induced arthritis in mice as compared to α-GalCer.6 In 
general, truncation of either the acyl or phytosphingosine chain results in analogues with similar 
activities as OCH. 
Non-linear isopropyl and cyclopentyl phytosphingosine-modified derivatives (entry 6-7) decrease the 
antigenic potency of the glycolipids, although the loss in activity might also stem from the 
concomitant truncation of the acyl chain. The cytokine response of analogues bearing a terminal 
phenyl moiety is highly dependent on the positioning of the aromatic ring. While the presence of 2 or 
4 methylene units between the 4-OH and the phenyl ring gives rise to potent Th1-responses, a one-
carbon spacer (entry 8) results in a Th2-biasing derivative. Furthermore, combining terminal aromatic 
moieties in both hydrophobic parts of α-GalCer (entries 12-14) seems to hamper iNKT cel activation. 
Additionally, ether bonds within the phytosphingosine chain lead to compromised iNKT cel 
activation. Interestingly, however, an ethylene glycol analogue gave comparable iNKT-cell activation 
as α-GalCer (entry 16). Finally, the α-GalCer analogues containing a pyrazole moiety paired with a 
migrating phenyl group, all show a distinct Th2-profile, while the antigenic potency varies with the 
positioning of the phenyl ring. These examples demonstrate that alterations of the sphingosine chain 





Table 4.1 Overview of known phytosphingosine modified α-GalCer analogues (Adapted from 
Banchet-Cadeddu et al., 2011, Org. Biomol. Chem.) 
 
 
entry R1 R2 Activity 
1 nC2H5 nC23H47 TH2 (~↗) 
2 nC5H11 nC23H47 TH2 , weak iNKT 
stimulation 
3 nC5H11 nC19H39 to nC24H49 TH2 (~→) 




6 (CH2)3CH(CH3)2 nC21H43 TH1 (↘) 
7 
 
nC23H47 TH2 (→) 
8 CH2Ph nC23H47 TH2 (→) 
9 (CH2)2Ph nC25H51 TH1 (↗↗) 
10 (CH2)3Ph nC21H43 TH1 (↘) 
11 (CH2)3Ph nC25H51 TH1 (→) 
12 (CH2)3Ph (CH2)5Ph No iNKT cell activation 
13 (CH2)3Ph (CH2)7Ph No iNKT cell activation 
14 (CH2)3Ph (CH2)9Ph No iNKT cell activation 
15 (CH2)4Ph nC25H51 TH1 (↗) 
16 
 
nC25H51 iNKT cell activation (→) 
17 
 
nC25H51 iNKT cell activation (~↘) 
18 
 
nC25H51 iNKT cell activation (~↘) 
19 
 
nC25H51 iNKT cell activation (~↘) 
20 
 
nC25H51 TH2 (↘) 
TH2 (→) if R = CH2-Ph-C6H13 
↘ Less potent than KRN 7000 or OCH according to TH1 or TH2 induced response; ↗ more potent 
than KRN 7000 or OCH according to TH1 or TH2 induced response;→ similar activity compared to 
KRN7000 or OCH according toTH1 or TH2 induced response; ~↗or ~↘ slight increasing/decreasing 
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Up to now, the mechanism of cytokine polarization is poorly understood, although there is ample of 
evidence suggesting that the stability of the CD1d/glycolipid/TCR-complex is an important 
contributing factor.7 The potent Th1-response observed for α-GalCer derivatives featuring aromatic 
moieties in the acyl chain, is attributed to the formation of additional Van der Waals interactions 
with amino acid residues lining the A’-pocket.8 Consequently these glycolipids exhibit an enhanced 
affinity for CD1d resulting in the observed cytokine bias. In analogy, the potent Th1-polarizing sugar-
modified galactosylceramides previously synthesized in our lab, also feature a greater CD1d-affinity 
due to the formation of an extra binding pocket in CD1d via induced-fit. 9 
A study by McCarthy et al. indicates that although both the acyl chain and phytosphingosine 
contribute to the stability of the glycolipid/CD1d-complex, it is the phytosphingosine chain that 
controls TCR-binding and iNKT-cell activation, since ligand-induced conformational changes of the F’-
pocket allosterically influence the CD1d/glycolipid footprint.10 The aforementioned arguments 
excited us to explore a synthetic strategy for the preparation of phytosphingosine modified α-GalCer 
analogues, allowing us to introduce variations in the later stages of the synthesis via amide coupling. 
Molecular modeling studies indicate that the amide moiety, when placed at the right position, can 
potentially form a hydrogen bond with Tyr73 in the CD1d-binding groove and may consequently 
enhance the glycolipid/CD1d-complex stability (Figure 4.1). The selected amide substituents are 
aimed at reinforcing the interactions (e.g., by π-π-stacking) with aromatic residues lining the F’-
pocket. 
 
Figure 4.1 Binding model of an α-GalCer analogue featuring an amide moiety in the phytosphingosine 
chain (green) with CD1d (blue and grey). A possible hydrogen bond with the amide oxygen atom and 




To ensure acceptable solubility of the envisioned analogues, which were named α-
galactosylsphingamides, we opted to equip these initially with an octanoyl moiety, which was shown 
to retain most of the antigenic properties when replacing the N-hexacosanoyl group of α-GalCer.11 
An overview of the synthesized α-galactosylsphingamides is shown in Table 4.2. 
 
 








 = C7H15 R
2
 = C11H23 R
2
 = C15H31 R
2
 = C19H39 R
2
 = C25H51 
C9H19 4.1a     
 (CH2)2Ph 4.1b     
 (CH2)4Ph 4.1c     
 (CH2)6Ph 4.1d 4.2d 4.3d 4.4d 4.5d 
 (CH2)8Ph 4.1e     
Ph-m-C5H11 4.1f    4.5f 
Ph-p-C5H11 4.1g     
((CH2)2O)2C2H5 4.1h     
Table 4.2 Overview of the synthesized α-galactosylsphingamides. 
 
4.2 Synthesis 
As shown in the retrosynthetic analysis (Scheme 4.4), the α-galactosylsphingamides (4.1a-h, 4.2-4.5d 
and 4.5f) can be accessed from methyl ester 4.14, which is obtained through Lewis acid catalyzed 
glycosylation of glycosyl acceptor 4.12. The latter would be obtained by conversion of alcohol 4.10 to 
an azide with an inversion of stereochemistry at the carbon centre, followed by selective benzyl 
ether cleavage to afford the primary alcohol. The 2-deoxygalactose intermediate 4.8, prepared from 
commercially available tri-O-acetyl-D-galactal (4.6), would serve as a substrate for a Wittig olefination 
with phosphonium ylid 4.17. 
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Scheme 4.4 Retrosynthesis of the target α-galactosylsphingamides. 
The synthetic route towards glycosyl acceptor 4.12 is outlined in Scheme 4.5. It was decided to start 
from commercially available tri-O-acetyl-D-galactal (4.6), which was readily converted into the 3,4,6-
tri-O-benzyl-protected derivative 4.7.12 Hydrolysis of the enol ether was achieved upon treatment 
with 4M sulfuric acid, furnishing 2-deoxygalactose intermediate 4.8.13 Next, the Wittig reaction on 4.8 
with methyl(triphenylphosphoranylidene)acetate was investigated. When the reaction was carried 
out in THF, α,β-unsaturated ester 4.9 was obtained exclusively as the E-isomer in moderate yield 
(64%). Performing the reaction in refluxing toluene increased the yield to 79%, while also providing 
solely the E-isomer. 
To avoid Michael type side reactions and to eliminate the possibility for a 1,3-dipolar cycloaddition 
upon introduction of the azide, saturation of the double bond was accomplished by conjugate 
reduction with nickel(II) chloride and sodium borohydride. Mitsunobu reaction with diphenyl 
phosphoryl azide (DPPA) converts the C2-OH to an azido group with the appropriate stereochemistry 
(4.11). Next, selective deprotection of the primary hydroxyl was achieved by treatment of 4.11 with 
zinc chloride in acetic anhydride followed by Zemplén deacetylation of the intermediate acetate to 




Scheme 4.5 Reagents and conditions: a) (i) Et3N, H2O, MeOH, RT, 4d; (ii) NaH, BnBr, DMF, RT, 
overnight, 94% (over 2 steps); b) 4M H2SO4, DMF, 0 °C  RT, overnight, 85%; c) methyl 
(triphenylphosphoranylidene)acetate, toluene, 85 °C, 6 h, 79%; d) NiCl2∙6 H2O, NaBH4, MeOH/THF, 0 
°C, 1h, 94%; e) PPh3, diethylazodicarboxylate, diphenylphosphorylazide, THF, -20 °C  RT, 7h, 95%; f) 
(i) ZnCl2, AcOH/Ac2O, 3.5h, RT; (ii) MeOH, NaOMe, pH 10, RT, overnight, 67% over 2 steps. 
Next, TMSOTf-promoted glycosylation of acceptor 4.12 with galactosyl trichloroacetimidate 4.1314 
afforded α-galactoside 4.14 in good yield and without notable formation of the β-glycoside. The 
ability to diversify the methyl ester after glycosylation is convenient as it reduces the number of 
linear steps towards the target α-GalCer analogues. A Lewis acid-catalyzed amidation with the 
appropriate amines gave intermediates 4.15a-h. 
Next, the azido group was subjected to Staudinger reduction with trimethylphosphine and the 
resulting amine was coupled with octanoic acid using EDC. (Scheme 4.6) Finally, catalytic 
hydrogenolysis afforded the desired compounds 4.1a-h. Analogues 4.2-4.5d and 4.5f with alternative 
acyl moieties were synthesized according to similar procedures. 
Scheme 4.6 a) TMSOTf, THF, -30 °C, 2h, 67%; b) AlMe3, amine, CH2Cl2, reflux, overnight, 56%-85%; c) 
(i) PMe3, H2O, THF, RT, 7h; (ii) EDC, octanoic acid, CH2Cl2, RT, overnight, 51%-69% over 2 steps; d) H2, 
Pd black, MeOH, CHCl3, RT, overnight, 37%-58%. 
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4.3 Biological evaluation 
To assess the biological activity of the α-galactosylsphingamides, we analyzed the IFN-γ- and IL-4-
levels after intraperitoneal injection of 5 µg of the galactosylsphingamides 4.1a-h in C57BL/6 mice 
(Figure 4.2).  
 
Figure 4.2 IL-4 and IFN-γ secretion, measured at respectively 4 h and 16 h, after intraperitoneal 
injection of 5 µg of the glycolipids in mice. Data for one individual experiment using 8 mice for each 
glycolipid. Bars represent means + SEM. 
The marginal cytokine release induced by this series indicates that the introduction of an amide 
moiety in the phytosphingosine chain compromises the antigenic potency. Unexpectedly however, 
reference glycolipid PBS-25, an α-GalCer analogue that also features an octanoic acid residue, was 
also inactive in the in vivo cytokine secretion assay. The lack of in vivo antigenic properties of PBS-
2515 was confirmed in a follow-up experiment, suggesting that the octanoyl acyl chain might 
negatively impact the iNKT cell activation in vivo.16 
In an effort to explain the poor antigenicity of galactosylsphingamides 4.1a-h, we tested the binding 
of the Vα14Vβ8.2 TCR of the murine iNKT-cell hybridoma 2C12 to mCD1d presenting ligands 4.1d and 
4.1e using surface plasmon resonance (SPR) and compared it with the binding of PBS-25. To further 
evaluate whether the low antigenicity of 4.1d is resulting from the amide functionality in the 
phytosphingosine chain, we synthesized glycolipid 4.17 (Figure 4.3), which is the amide-deleted 
counterpart of α- galactosylsphingamides 4.1d and 4.1e. 
 




Surprisingly, all ligands were bound with similarly high TCR affinities (KD=38-50 nM). Therefore, the 
TCR binding kinetics cannot explain the inability of the galactosylsphingamides to induce robust 
cytokine production in vivo. In addition, the maximal response (RU 120-220) observed for the 
individual sensorgrams of the α-galactosylsphingamides are comparable between the individual 
CD1d-ligand complexes, which were immobilized at similar levels, suggesting a similar CD1d ligand 
binding efficiency in vitro. (Figure 4.4) A possible explanation for the lack in activity of α-GalCer 
analogues bearing octanoyl acyl chains might result from their increased solubility and accompanied 
rapid clearance from the body. 
 
Figure 4.4 Real-time TCR-binding kinetics to mCD1d-presented ligands. Each curve represents the 
TCR binding sensorgram to CD1d-glycolipid complexes at a different TCR concentration after 
reference substraction (binding response to CD1d without added glycolipid). Sensorgrams (top) 
indicate similar lipid loading levels for 4.1d and 4.1e. Single cycle TCR kinetics were measured for 
PBS-25 and 4.17. Here, TCR with increasing concentrations (3-fold) was sequentially added to CD1d-
glycolipid with a final dissociation step of 10 min. Colored curves represent actual binding responses 
and black curves the fitted data. Kinetic values derived from the sensorgrams are listed in the table 
below. 
Since the current galactosylsphingamides are based on a C8 fatty acid, the short acyl chain will not 
fully occupy the A’ pocket of CD1d. Likely similar to PBS-25,15 free fatty acid will be recruited to fill 
the remainder of the pocket. To assess whether these spacer lipids can potentially influence the 
ligand potency, we synthesized ligands based on 4.1d that contained longer acyl chains of 12, 16, 20, 
and 26 carbon atoms (4.2d-4.5d). Since the acyl chain is introduced at the final stages of the 
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synthesis, the elongated fatty acid chains could easily be introduced, demonstrating the versatility of 
our synthetic approach. We next analyzed antigenicity by measuring IFN-γ- and IL-4-levels after 
intraperitoneal injection of 5 µg of the acyl-elongated galactosylsphingamides 4.2-4.5d in mice 
(Figure 4.5). Surprisingly, cytokine levels are still inferior to those observed for α-GalCer but increase 
slightly upon elongating the acyl chain. Overall, the introduction of an amide functionality in the 
phytosphingosine chain appears to result in poor iNKT-cell stimulation. The recruitment of spacer 
lipids occupying the A’ pocket was observed for 4.2-4.5d, but the spacer lipid had no impact on the 
antigenic potency of the galactosylsphingamides since the antigenic potency of 4.4d and 4.5d, which 
have no space to fit a spacer lipid, was also poor.  
  
Figure 4.5 IFN-γ and IL-4 secretion, measured at 16 h and 4 h respectively, after intraperitoneal 
injection of 5 µg of the glycolipids in mice. Data for one individual experiment using 8 mice for each 
glycolipid. Bars represent means + SEM. 
4.4 Structural data 
To gain insights into the poor antigenic potency of the glycolipids but high affinity TCR binding, we 
determined the crystal structure of the CD1d/4.1d-complex as well as that of the complex of CD1d 
with compound 4.17, which resembles 4.1d but lacks the amide group. As expected, 4.17 gives rise 
to well-defined electron density and is rigidly presented using the conserved H-bond network 
involving CD1d-residues Asp80 and the 3’- and 4’-OH of phytosphingosine, as well as CD1d Thr156 
and the glycosidic oxygen, and most importantly, CD1d-residue Asp153 and the 2”-, and 3”-OH of the 
galactose (Figure 4.6). Surprisingly, galactosylsphingamide 4.1d is presented less well ordered by 
CD1d, as judged by the less contoured electron density. 
This slight disorder of the galactose presentation correlates well with the increase in the H-bond 
distance between CD1d and 4.1d. Especially the 2”-OH interaction with CD1d Asp153 is increased 
compared to 4.17 (3.0 vs. 2.6 Å, Figure 4.6 C, D), while the 3’-OH of phytosphingosine is also less 




between the amide oxygen and Tyr73 was not observed in the recorded glycolipid/CD1d complexes. 
When looking down into the binding groove of CD1d (TCR view), we noticed lack of the F’-roof 
closure by 4.1d, while 4.17 induced the F’-roof formation (Figure 4.6 E, F). This is likely the result of 
the amide group perturbing the hydrophobic nature of the F’-pocket in general. Based on our 
previous work on microbial glycolipids, we postulated that the TCR-dissociation rate is increased for 
glycolipids that do not close the F’-roof before TCR-binding.17 
However, since we have not observed any differences in the binding kinetics, especially the 
dissociation rate, we speculated that a compensatory mechanism will stabilize the TCR-interaction 
and this could likely be driven by the amide group and a novel interaction within the F’-pocket of 
CD1d. 
 
Figure 4.6 (A-B) Electron density map of 4.1d and 4.17 with CD1d. Spacer lipid (palmitic acid) is 
depicted in orange. (C-D) H-bond interactions between 4.1d and 4.17 (yellow) with CD1d (grey). (E-F) 
Glycolipid ligand presentation shown in “TCR view” from top with molecular surface of CD1d in grey 
and ligands as yellow sticks. 
We next compared the precise presentation of both ligand headgroups by CD1d. As suggested by the 
changes in hydrogen bond distances, the galactose of 4.1d is slightly elevated compared to 4.17, 
correlating with the increased distance in H-bonding interactions with CD1d. (Figure 4.7). 
This slightly flexible presentation of 4.1d is reminiscent to the presentation of the microbial 
glycosphingolipid GalA-GSL, which was also slightly shifted in the binding groove of CD1d compared 
to PBS-25 but had comparable TCR association rates.18 Therefore, the fine presentation of the 
galactose is likely not the reason for the biological inactivity of these galactosylsphingamides. 
 
Galactosylsphingamides: new α-GalCer analogues to probe the F’-pocket of CD1d 
 
  77 
 
Figure 4.7 Comparison between 4.1d (green) and 4.17 (grey) presented by CD1d. 
Since the only difference between both glycolipids is the presence (4.1d) or absence (4.17) of the 
amide group, this indicates that the amide is indeed responsible for the slight elevation of the 
galactose but more importantly for the failure in closure of the F’ roof in the binary complex, the 
latter of which is likely the main reason for the low antigenicity of the α-galactosylsphingamides. 
As stated above, the inability to close the F’-roof is generally associated with an increased TCR-
dissociation rate, which is not observed for the presented α-galactosylsphingamides. We 
hypothesized that there is mechanism that compensates for the inability to close the F’-roof, 
resulting in stabilized TCR-interaction. 
Indeed, the crystal structure of the ternary CD1d/4.1d/TCR complex shows that upon binding, the 
NKT TCR induces a structural change in the α-galactosylsphingamides. This structural change moves 
the headgroup of 4.1d back into the conserved position found in PBS-25 (which is also conserved 
with α-GalCer), resulting in the same conserved interactions compared to other known α-GalCer 
derivatives. The ability of the TCR to push the sugar head group was previously observed for iGB3 
where the trisaccharide headgroup is squashed over the α-2 helix molding the proximal sugar to bind 
in a highly similar position as compared to α-GalCer.19 Furthermore, the recognition of the borrelial 
α-galactosyl diacylglycerolipids is also hypothesized to occur after TCR molding. However, this 
induced fit mechanism is associated with an entropic penalty, resulting in lower TCR-affinities for 
iGB3 and the borrelial lipids (Kd=718 nm and 6.2 µM respectively). Surprisingly only a slight reduction 
of TCR-affinity is perceived for the α-galactosylsphingamides, as compared to PBS-25. 
The TCR-stabilizing effect is probably the result of a novel hydrogen-bond, which is formed between 




observed for any glycolipid for which crystal structures exist, regardless whether the complex 
contained the TCR or not. (Figure 4.8) 
 
Figure 4.8 Crystal structure of the ternary CD1d/4.1d/TCR complex. 
4.5 Conclusion 
In summary, a series of α-GalCer analogues featuring an amide bond in the phytosphingosine were 
synthesized. The presented synthesis allows to alter an advanced methyl ester precursor after 
glycosylation, thereby reducing the number of linear steps towards the aimed α-GalCer analogues. 
Furthermore, the ability to diversify the acyl moiety in the penultimate step of the synthesis adds to 
the versatility of the presented synthesis route. Also, methyl ester 4.14 is an interesting intermediate 
for alternative derivatization of the phytosphingosine chain. 
Biological evaluation revealed that the novel α-galactosylsphingamides are weak iNKT-cell antigens 
and that the main compromising factor is the implemented amide functionality. While extending the 
acyl chain offered partial restoration of the antigenic effect, overall iNKT-cell stimulation remained 
poor. 
Crystal structure analysis revealed a flexible presentation of the α-galactosylsphingamides to CD1d, 
where the sugar head group is slightly shifted in the CD1d binding groove. A similar binding has been 
observed for the microbial glycosphingolipid GalA-GSL, but never for known α-GalCer analogues.18 
These crystal structures support the hypothesis that although both the acyl chain and 
phytosphingosine contribute to the stability of the CD1d/glycolipid complex, it is the 
phytosphingosine chain that controls the CD1d/glycolipid footprint. 
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The amide group affects the biological activity of these compounds and its presence seems to 
compensate for the lack of the pre-formed F’ roof formation upon TCR binding. Indeed, a 
unprecedented hydrogen bond was discovered between the amide moiety and Tyr73 in the 
CD1d/galactosylsphingamide/TCR structures. 
The poor antigenicity of the α-galactosylsphingamides combined with their high TCR-affinity might 
identify the presented glycolipids as antagonist of the iNKT-CD1d immune response. Hence, we are 
currently investigating the antagonizing potential of the α-galactosylsphingamides in mice. 
 
4.6 Experimental part 
General 
Precoated Macherey-Nagel SIL G/UV254 plates were used for TLC, and spots were examined under 
UV light at 254 nm and further visualized by sulfuric acid-anisaldehyde spray or by spraying with a 
solution of (NH4)6Mo7O24.4 H2O (25 g/L) and (NH4)4Ce(SO4)4.2 H2O (10 g/L) in H2SO4 (10%) followed by 
charring. Column chromatography was performed on Biosolve silica gel (32 – 63 µm, 60 Å). NMR 
spectra were obtained with a Varian Mercury 300 Spectrometer. Chemical shifts are given in ppm (δ) 
relative to the residual solvent signals, in the case of CDCl3: δ= 7.26 ppm for 
1H and δ = 77.4 ppm for 
13C and in the case of pyridine-d5: δ = 8.74, 7.58 and 7.22 ppm for 
1H and δ = 149.9, 135.5 and 123.5 
ppm for 13C. Exact mass measurements were performed on a Waters LCT Premier XE TOF equipped 
with an electrospray ionization interface and coupled to a Waters Alliance HPLC system. Samples 
were infused in a CH3CN/HCOOH (1000:1) mixture at 100 µL/min. LC-MS analyses were carried out 
on a Waters Alliance 2695 XE separation Module by using a Phenomenex Kinetex EVO C18, 5um 
100x2.1mm column and a gradient system of TFA in H2O (0.05 %, v/v) / TFA in MeOH (0.05 %, v/v) at 
a flow rate of 0.6 mLmin-1, 95:05 to 00:100 (05 to 100 % MeOH) in 9 minutes. High-resolution 
spectra were recorded on a Waters LCT Premier XE Mass spectrometer. 
3,4,6-tri-O-benzyl-D-galactal (4.7) 
3,4,6-Tri-O-acetyl-D-galactal (22.05 g, 81 mmol) was dissolved in MeOH (250 mL), Et3N (67 mL) and 
H2O (8 mL) and the reaction mixture was stirred for 5 days at room temperature. After completion of 
the reaction the solvent was removed under reduced pressure. The crude product was dried by 
making an azeotropic mixture with toluene to afford pure D-galactal in quantitative yield. This 
material was dissolved in dry DMF (250 mL), cooled to 0 °C and sodium hydride (60% dispersion, 13 g, 
324 mmol) was added portionwise over a period of 15 min. After 30 minutes benzyl bromide (38.8 




the temperature to rise to room temperature. Upon completion of the reaction, the reaction mixture 
was quenched with MeOH at 0 °C. The mixture was extracted with EtOAc (4 x 200 mL) and the 
combined organic layers were washed with brine, dried over anhydrous Na2SO4 and the solvents 
were evaporated under reduced pressure. The crude was purified by silica gel chromatography 
(hexane/EtOAc: 9/1) furnishing 3,4,6-tri-O-benzyl-D-galactal 4.7 (31.67 g, 94%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ 3.65 (dd, J = 10.1 and 5.1 Hz, 1 H, Ha-6) 3.78 (dd, J = 10.1 and 7.2 
Hz, 1 H, Hb-6) 3.92 – 3.96 (m, 1 H, H-4) 4.15 – 4.21 (m, 2 H, H-3 and H-5) 4.41 (d, J = 12.2, 1 H, CH2Ph) 
4.50 (d, J = 12.2, 1 H, CH2Ph) 4.57 – 4.68 (m, 3 H, H-2, CH2Ph) 4.82 – 4.90 (m, 2 H, H-2, CH2Ph) 6.36 (d, 
J = 6.4 Hz, 1 H, H-1) 7.24 – 7.36 (m, 15 H, arom. H). 
13C-NMR (75 MHz, CDCl3): δ 68.38, 70.70, 70.82, 71.21, 73.26, 73.35, 75.63, 99.90, 127.37, 
127.48, 127.62, 127.83, 128.08, 128.24, 128.32, 137.94, 138.30, 138.44, 144.12. 
Exact mass (ESI-MS) for C27H28NaO4 [M+Na]
+ found, 439.1878; calcd, 439.1880. 
2-Deoxy-3,4,6-tri-O-benzyl-D-galactose (4.8) 
To a solution of 3,4,6-tri-O-benzyl-D-galactal (31.7 g, 76 mmol) in DMF (250 mL) maintained at 0 °C,  
H2SO4 (80 mL, 4.0M) was added dropwise. The reaction mixture was allowed to rise to room 
temperature and was stirred for 16 h. Upon completion of the reaction, the mixture was neutralized 
with NaHCO3  (400 mL, sat. aq.) and extracted with Et2O (3 x 200 mL). The combined organic layers 
were washed with brine, dried over MgSO4, filtered and evaporated. The crude residue was purified 
by silica gel chromatography (hexane/EtOAc: 85/15) furnishing 4.8 (28.13 g, 85%) as a white solid. 
1H-NMR (α-anomer) (300 MHz, CDCl3): δ 1.90 – 2.09 (m, 1 H, Ha-2) 2.23 (td, J = 12.4 and 3.6 
Hz, 1 H, Hb-2) 3.41 – 3.73 (m, 2 H, CH2-6) 3.73 – 3.92 (m, 1 H, H-5) 4.00 (ddd, J = 12.0, 4.6 and 2.5 Hz, 
1 H, H-3) 4.14 (t, J = 6.5 Hz, 1 H, H-4) 4.44 (d, J = 12.0 Hz, 1 H, CH2Ph) 4.52 (d, J = 12.0 Hz, 1 H, CH2Ph) 
4.59 – 4.66 (m, 3 H, CH2Ph) 4.94 (d, J = 11.8 Hz, 1 H, CH2Ph) 5.47 (d, J = 3.1 Hz, 1 H, H-1) 7.20 – 7.43 
(m, 15 H, arom. H). 
13C-NMR (75 MHz, CDCl3): δ 30.92, 34.24, 69.0, 69.79, 70.08, 70.31, 71.65, 72.97, 73.29, 
73.99, 74.19, 92.39, 94.54, 127.16, 127.40, 127.44, 127.53, 127.61, 128.02, 128.08, 128.22, 128.27, 
137.67, 138.36, 138.45. 
Exact mass (ESI-MS) for C27H30NaO5 [M+Na]
+ found, 457.1987; calcd, 457.1985. 
Data consistent with literature.20 
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(5R,6S,7R,E)-methyl 5,6,8- tri-O-benzyl-7-hydroxyoct-2-enoate (4.9) 
2-Deoxy-3,4,6-tri-O-benzyl-D-galactose 4.8 (3.7 g, 8.52 mmol) and methyl(triphenylphosphor 
anylidene)acetate (5.68 g, 17.04 mmol) were dissolved in anhydrous toluene (150 mL) and stirred for 
6 h at 85 °C. The reaction mixture was evaporated under reduced pressure, and the residue was 
purified by silica gel chromatography (hexane/EtOAc: 8/2) to give 4.9 (3.29 g, 79%) as a slightly 
yellow oil. 
 1H-NMR (300 MHz, CDCl3): δ 2.58 (ddd, J = 7.2, 5.7 and 1.3 Hz, 2 H, H-4) 3.48 – 3.60 (m, 2 H, 
H-8) 3.62 – 3.70 (m, 1 H, H-6) 3.73 (s, 3 H, OCH3) 3.76 – 3.84 (m, 1 H, H-5) 3.96 – 4.05 (m, 1 H, H-7) 
4.49 – 4.52 (m, 2 H, CH2Ph) 4.55 – 4.57 (m, 3 H, CH2Ph) 4.67 (d, J = 11.4 Hz, 1 H, CH2Ph) 5.88 (dt, J = 
15.7 and 1.3 Hz, 1 H, H-2) 7.01 (dt, J = 15.7 and 7.4 Hz, 1 H, H-3) 7.23 – 7.40 (m, 15 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 33.81, 51.44, 69.66, 71.08, 72.56, 73.44, 74.06,78.48, 79.00, 
123.21, 127.77, 127.86, 127.90, 127.94, 127.99, 128.07, 128.42, 128.45, 137.68, 137.75, 137.87, 
145.57, 166.64. 
 Exact mass (ESI-MS) for C30H35O6 [M+H]
+ found, 491.2427; Calcd., 491.2428. 
(5R,6S,7R)-methyl 5,6,8- tri-O-benzyl -7-hydroxyoctanoate (4.10) 
NiCl2.6 H2O (800 mg, 3.36 mmol) and NaBH4 (508 mg, 13.42 mmol) were added to a stirred solution 
of unsaturated ester 4.9 (3.29 g, 6.71 mmol) in MeOH (37 mL) and THF (3.7 mL) at 0 °C. After 1 h, the 
reaction mixture was filtered through Celite and the filter cake rinsed with Et2O. Evaporation of the 
filtrate yielded 4.10 (3.09 g, 94% yield) as a yellow oil which could be used in the next step without 
further purification. 
 1H-NMR (300 MHz CDCl3) δ 1.52 – 1.88 (m, 4 H, H-2 and H-4) 2.16 – 2.50 (m, 2 H, H-3) 3.01 
(br. s, 1 H, -OH) 3.55 (d, J = 5.8 Hz, 2 H, H-8) 3.60 – 3.73 (m, 5 H, OCH3, H-5 and H-6) 3.98 – 4.05 (m, 1 
H, H-7) 4.51 – 4.54 (m, 3 H, CH2Ph) 4.56 – 4.58 (m, 1 H, CH2Ph) 4.66 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.72 
(d, J = 11.4 Hz, 1 H, CH2Ph) 7.25 – 7.41 (m, 15 H, arom. H). 
13C NMR (75 MHz, CDCl3) δ 20.99, 30.27, 33.94, 51.48, 69.86, 71.06, 72.71, 73.42, 73.78, 
78.97, 79.41, 127.71, 127.74, 127.85, 127.89, 127.96, 128.09, 128.38, 128.41, 138.03, 138.08, 173.83. 
 Exact mass (ESI-MS) for C30H36KO6 [M+K]
+ found, 531.2151; Calcd., 531.2143. 
(5R,6S,7S)-methyl 7-azido-5,6,8- tri-O-benzyl-octanoate (4.11) 
To a solution of compound 4.10 (3.09 g, 6.27 mmol) in anhydrous THF (100 mL) were added PPh3 




azide (3.45 g, 2.71 mL, 12.54 mmol) at -20 °C. After addition, the reaction mixture was allowed to 
warm to room temperature and stirred for 7 h. The solvent was evaporated under reduced pressure 
to give an orange residue. Purification by silica gel chromatography (hexane/EtOAc: 9/1) afforded 
4.11 (3.19 g, 95% yield) as a yellow oil. 
 1H-NMR (300 MHz CDCl3) δ 1.52 – 1.86 (m, 4 H, H-2 and H-4) 2.18 – 2.39 (m, 2 H, H-3) 3.55 – 
3.83 (m, 8 H, OCH3, H-5, H-6, H-7 and H-8) 4.57 – 4.62 (m, 3 H, CH2Ph) 4.65 (d, J = 11.5 Hz, 1 H, CH2Ph) 
4.68 (d, J = 11.3 Hz, 1 H, CH2Ph) 4.78 (d, J = 11.3 Hz, 1 H, CH2Ph) 7.18 – 7.46 (m, 15 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 20.72, 29.07, 33.94, 51.47, 61.93, 70.08, 71.95, 73.34, 73.83, 
78.65, 78.74, 120.18, 120.24, 126.09, 127.66, 127.69, 127.71, 127.77, 127.91, 128.00, 128.37, 128.38, 
128.41, 130.03, 130.05, 137.81, 137.91, 138.09, 173.84. 
 Exact mass (ESI-MS) for C30H35KN3O5 [M+K]
+ found, 556.2210; Calcd., 556.2208 
(5R,6S,7S)-methyl 7-azido-5,6-di-O-benzyl-8-hydroxyoctanoate (4.12) 
Azide 4.11 (1.4 g, 2.7 mmol) and ZnCl2 (7.38 g, 54 mmol) were dissolved in Ac2O/AcOH (2:1, 21 mL). 
The reaction was allowed to stir for 3.5 h at room temperature. Next, H2O (10 mL) was added and the 
reaction mixture was extracted with CH2Cl2. The combined organic layers were washed with H2O, 
NaHCO3 (sat. aq.) and brine. Then the organic phase was dried over Na2SO4, filtered, and evaporated 
to afford 598 mg of crude acetate. The crude acetate was dissolved in MeOH (20 mL) and NaOMe 
(5.4 M solution in MeOH) was added till pH 10. After stirring overnight, Amberlite 120R (H+ form) was 
added to neutralize the reaction mixture. The mixture was diluted with MeOH (20 mL) and the 
exchange resin was filtered off and rinsed with MeOH. Evaporation of the filtrate under reduced 
pressure yielded a solid residue that was purified by silica gel chromatography (hexane/EtOAc: 7/3) 
to afford 4.12 (771 mg, 67% yield) as a colorless oil. 
 1H-NMR (300 MHz CDCl3) δ 1.56 – 1.87 (m, 4 H, H-5 and H-7) 2.25 – 2.34 (m, 2 H, H-6) 2.38 (t, 
J = 6.3 Hz, 1 H, OH) 3.58 – 3.96 (m, 8 H, OCH3, H-1, H-2, H-3 and H-4) 4.57 (d, J = 11.2 Hz, 1 H, CH2Ph) 
4.63 (d, J = 11.2 Hz, 1 H, CH2Ph) 4.67 (d, J = 11.1 Hz, 1 H, CH2Ph) 4.73 (d, J = 11.3 Hz, 1 H, CH2Ph) 7.24 
– 7.41 (m, 10 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 20.79, 29.38, 33.82, 51.51, 62.31, 63.11, 72.38, 73.71, 78.60, 
79.84, 127.88, 128.00, 128.02, 128.11, 128.46, 128.52, 137.53, 137.75, 173.77. 
 Exact mass (ESI-MS) for C23H30N3O5 [M+H]
+ found, 428.2177; Calcd., 428.2180. 
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(5R,6S,7S)-methyl-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-
galactopyranosyl)-octanoate (4.14) 
To a mixture of 4.13 (670 mg, 1.13 mmol) in THF (9 mL), a solution of 4.12 (323 mg, 0.76 mmol) in 
THF (6 mL) was added. The reaction mixture was cooled to –30 °C and TMSOTf (0.3 mL, 0.11 mmol) 
was added dropwise. After stirring for 2 h. at -30 °C, the reaction mixture was neutralized with Et3N 
and evaporated to dryness. The residue was purified by silica gel chromatography (hexane/EtOAc: 
8/2 + 1% v/v Et3N) to afford 4.14 (438 mg, 67% yield) as colorless liquid which solidified upon storage. 
 1H-NMR (300 MHz CDCl3) δ 1.46 – 1.79 (m, 4 H, CH2) 2.20 (t, J = 6.6 Hz, 2 H, CH2) 3.52 (br. s, 1 
H, H-4”) 3.56 – 3.71 (m, 7 H, H-2, H-2”, H-4, Hb-6”, OCH3) 3.84 (dd, J = 12.5 and 1.5 Hz, 1 H, H-3”) 3.93 
(dd, J = 9.8 and 2.9 Hz, 1 H, Ha-1) 3.97 – 4.06 (m, 3 H, Hb-1, H-3 and Hb-6”) 4.13 (dd, J = 3.2 and 1.0 
Hz, 1 H, H-5”) 4.43 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.50 – 4.63 (m, 4 H, CH2Ph) 4.69 (d, J = 12.3 Hz, 1 H, 
CH2Ph) 4.76 (d, J = 12.5 Hz, 1 H, CH2Ph) 4.80 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.92 (d, J = 3.2 Hz, 1 H, H-1”) 
5.41 (s, 1 H, H-8”) 7.14 – 7.36 (m, 23 H, arom. H) 7.44 – 7.48 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 20.83, 29.23, 33.89, 51.47, 61.65, 63.00, 68.31, 69.31, 71.95, 
72.00, 73.54, 73.84, 74.59, 75.41, 77.42, 78.42, 78.95, 99.14, 101.05, 126.33, 127.46, 127.50, 127.65, 
127.69, 127.79, 127.83, 127.92, 128.09, 128.22, 128.26, 128.39, 128.85, 137.82, 137.91, 138.11, 
138.73, 138.75, 173.80. 
 Exact mass (ESI-MS) for C50H56N3O10 [M+H]
+ found, 858.3948; Calcd., 858.3960. 
General procedure for AlMe3 assisted amide coupling: 
To a solution of glycoside 4.14 (500 mg, 0.58 mmol) in anhydrous CH2Cl2 (10 mL) was added the 
appropriate amine (5 eq.) and AlMe3 (2M in heptanes) (2.5 eq.). The reaction mixture was stirred 
overnight at reflux temperature. Next the reaction mixture was cooled to 0 °C and water was added. 
The mixture was extracted with CH2Cl2 and the combined organic phase was washed with H2O and 
brine, dried over Na2SO4, filtered, and evaporated. Purification by column chromatography gave the 
desired amides 4.15a (61%), 4.15b (64%), 4.15c (64%), 4.15d (52%), 4.15e (51%), 4.15f (68%), 4.15g 
(81%), 4.15h (60%). 
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
nonyloctanamide (4.15a) 
 1H-NMR (300 MHz CDCl3) δ 0.89 (t, J = 6.5 Hz, 3 H, terminal CH3) 1.23 – 1.35 (m, 12 H, CH2) 
1.45 (dt, J = 13.4 and 7.8 Hz, 2 H, CH2) 1.53 – 1.81 (m, 4 H, CH2) 2.09 (t, J = 6.6 Hz, 2 H, CH2) 3.14 – 




1 H, Ha-1) 3.98 – 4.04 (m, 1 H, Hb-6”) 4.06 (d, J = 3.2 Hz, 1 H, H-3”) 4.08 – 4.14 (m, 2 H, Hb-1 and H-
2”) 4.20 (dd, J = 3.5 and 1.2 Hz, 1 H, H-4”) 4.49 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.59 – 4.72 (m, 4 H, CH2Ph) 
4.75 (d, J = 12.3 Hz, 1 H, CH2Ph) 4.82 (d, J = 12.3 Hz, 1 H, CH2Ph) 4.88 (d, J = 12.0 Hz, 1 H, CH2Ph) 4.98 
(d, J = 3.3 Hz, 1 H, H-1”) 5.32 (t, J = 5.1 Hz, 1 H, (CO)NH) 5.48 (s, 1 H, H-8”) 7.22 – 7.43 (m, 23 H, arom. 
H) 7.51 – 7.56 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 14.10, 21.81, 22.65, 26.93, 29.25, 29.29, 29.50, 29.67, 31.84, 
36.57, 39.50, 61.55, 63.03, 68.35, 69.33, 71.96, 72.02, 73.59, 73.87, 74.58, 75.38, 75.84, 78.35, 79.20, 
99.19, 101.06, 126.34, 127.47, 127.52, 127.68, 127.71, 127.75, 127.78, 127.89, 127.98, 128.11, 
128.23, 128.27, 128.40, 128.43, 128.49, 128.87, 137.83, 137.98, 138.14, 138.74, 172.41. 
 Exact mass (ESI-MS) for C58H76N5O9 [M+NH4]
+ found, 986.5641; Calcd., 986.5638. 
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
phenethyloctanamide (4.15b) 
 1H-NMR (300 MHz CDCl3) δ 1.52 – 1.76 (m, 4 H, CH2) 2.02 – 2.07 (m, 2 H, (CO)CH2) 2.73 (t, J = 
6.9 Hz, 2 H, H-11) 3.44 (q, J = 6.8 Hz, 2 H, NHCH2) 3.56 (app. s, 1 H, H-2) 3.57 – 3.63 (m, 2 H, H-4 and 
H-3) 3.66 – 3.75 (m, 2 H, H-5” and Ha-6”) 3.88 (dd, J = 12.3 and 1.3 Hz, 1 H, H-3”) 3.95 (d, J = 3.3 Hz, 1 
H, Ha-1) 3.97 – 4.06 (m, 2 H, H-2” and Hb-6”) 4.07-4.10 (m, 1 H, Hb-1) 4.15 (d, J = 2.9 Hz, 1 H, H-4”) 
4.43 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.54 – 4.66 (m, 4 H, CH2Ph) 4.71 (d, J = 12.4 Hz, 1 H, CH2Ph) 4.78 (d, J 
= 12.4 Hz, 1 H, CH2Ph) 4.83 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.93 (d, J = 3.2 Hz, 1 H, H-1”) 5.29 (t, J = 5.6 Hz, 
1 H, (CO)NH) 5.43 (s, 1 H, H-8”) 7.12 – 7.38 (m, 28 H, arom. H) 7.48 (dd, J = 7.3 and 2.3 Hz, 2 H, arom. 
H). 
 13C NMR (75 MHz, CDCl3) δ 21.71, 29.25, 35.70, 36.49, 40.49, 61.55, 63.03, 68.34, 69.32, 
71.94, 72.01, 73.57, 73.85, 74.56, 75.37, 75.83, 77.86, 78.28, 78.35, 78.70, 79.08, 79.63, 99.17, 
101.04, 126.32, 126.49, 127.46, 127.50, 127.66, 127.69, 127.76, 127.87, 127.95, 128.09, 128.21, 
128.26, 128.38, 128.40, 128.61, 128.72, 128.85, 128.94, 128.97, 129.15, 129.23, 129.37, 129.49, 
129.54, 129.68, 129.89, 130.00, 137.81, 137.96, 138.12, 138.72, 138.87, 140.00, 172.47. 
 Exact mass (ESI-MS) for C57H62N4NaO9 [M+Na]
+ found, 969.4413; Calcd., 969.4409. 
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
(4-phenylbutyl)octanamide (4.15c) 
 1H-NMR (300 MHz CDCl3) δ 1.43 – 1.78 (m, 8 H, CH2) 2.07 (t, J = 6.8 Hz, 2 H, CH2) 2.62 (t, J = 
7.5 Hz, 2 H, CH2) 3.21 (dd, J = 13.0 and 7.3 Hz, 2 H, NHCH2) 3.56 (app. s, 1 H, H-2) 3.60 – 3.67 (m, 2 H, 
H-4 and Ha-6”) 3.69 – 3.79 (m, 2 H, H-5” and H-3) 3.91 (dd, J = 13.0 and 2.0 Hz, 1 H, Ha-1) 3.97 – 4.02 
Galactosylsphingamides: new α-GalCer analogues to probe the F’-pocket of CD1d 
 
  85 
(m, 1 H, Hb-6”) 4.04 (d, J = 2.9 Hz, 1 H, H-3”) 4.07 – 4.10 (m, 2 H, H-2” and Hb-1) 4.18 (d, J = 2.9 Hz, 1 
H, H-4”) 4.47 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.57 – 4.69 (m, 4 H, CH2Ph) 4.74 (d, J = 12.6 Hz, 1 H, CH2Ph) 
4.81 (d, J = 12.6 Hz, 1 H, CH2Ph) 4.86 (d, J = 11.9 Hz, 1 H, CH2Ph) 4.98 (d, J = 3.2 Hz, 1 H, H-1”) 5.29 (t, J 
= 5.2 Hz, 1 H, (CO)NH) 5.47 (s, 1 H, H-8”) 7.14 – 7.41 (m, 28 H, arom. H) 7.49 – 7.53 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 21.79, 28.64, 29.22, 35.44, 36.54, 39.27, 61.55, 63.03, 68.35, 
69.33, 71.95, 72.02, 73.59, 73.87, 74.57, 75.38, 75.84, 77.21, 78.32, 79.18, 99.18, 101.05, 125.82, 
126.33, 127.47, 127.52, 127.67, 127.70, 127.75, 127.77, 127.87, 127.98, 128.10, 128.22, 128.27, 
128.33, 128.37, 128.39, 128.42, 128.86, 137.81, 137.98, 138.11, 138.72, 142.05, 172.45. 
 Exact mass (ESI-MS) for C59H67N4O9 [M+H]
+ found, 975.4905; Calcd., 975.4903. 
 (5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
(6-phenylhexyl)octanamide (4.15d) 
 1H-NMR (300 MHz CDCl3) δ 1.26 – 1.48 (m, 6 H, CH2) 1.52 – 1.78 (m, 6 H, CH2) 2.08 (t, J = 6.7 
Hz, 2 H, CH2) 2.59 (t, J = 7.5 Hz, 2 H, CH2) 3.18 (dd, J = 13.4 and 7.2 Hz, 2 H, NHCH2) 3.59 (app. s, 1 H, 
H-2) 3.61 – 3.67 (m, 2 H, H-3 and H-4) 3.68 – 3.79 (m, 2 H, H-5” and Ha-6") 3.91 (dd, J = 12.7 and 1.1 
Hz, 1 H, Ha-1) 3.98 – 4.02 (m, 1 H, Hb-6”) 4.04 (d, J = 3.5 Hz, 1 H, H-3”) 4.07 – 4.12 (m, 2 H, Hb-1 and 
H-2”) 4.19 (d, J = 2.7 Hz, 1 H, H-4”) 4.47 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.57 – 4.72 (m, 4 H, CH2Ph) 4.75 
(d, J = 12.4 Hz, 1 H, CH2Ph) 4.81 (d, J = 12.4 Hz, 1 H, CH2Ph) 4.86 (d, J = 12.1 Hz, 1 H, CH2Ph) 4.97 (d, J = 
3.5 Hz, 1 H, H-1”) 5.30 (t, J = 5.4 Hz, 1 H, (CO)NH) 5.47 (s, 1 H, H-8”) 7.15 – 7.42 (m, 28 H, arom. H) 
7.50 – 7.54 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 21.80, 26.77, 28.89, 29.23, 29.58, 31.31, 35.84, 36.55, 39.43, 
61.54, 63.02, 68.34, 69.32, 71.95, 72.02, 73.57, 73.86, 74.56, 75.37, 75.83, 77.20, 78.33, 79.19, 99.17, 
101.04, 125.62, 126.32, 127.46, 127.51, 127.67, 127.70, 127.74, 127.76, 127.87, 127.96, 128.09, 
128.22, 128.24, 128.26, 128.35, 128.38, 128.42, 128.86, 137.81, 137.97, 138.11, 138.71, 142.59, 
172.42. 
 Exact mass (ESI-MS) for C61H71N4O9 [M+H]
+ found, 1003.5232; Calcd., 1003.5216. 
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
(8-phenyloctyl)octanamide (4.15e) 
 1H-NMR (300 MHz CDCl3) δ 1.23 – 1.49 (m, 10 H, CH2) 1.51 – 1.78 (m, 6 H, CH2) 2.08 (t, J = 6.0 
Hz, 2 H, CH2) 2.59 (t, J = 7.5 Hz, 2 H, CH2) 3.18 (dd, J = 13.0 and 6.5 Hz, 2 H, NHCH2) 3.59 (app. s, 1 H, 
H-2) 3.61 – 3.68 (m, 2 H, H-3 and H-4) 3.68 – 3.80 (m, 2 H, H-5” and Ha-6") 3.91 (dd, J = 12.4 and 1.4 




Hb-1) 4.19 (dd, J = 3.1 and 0.9 Hz, 1 H, H-4”) 4.47 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.56 – 4.71 (m, 4 H, 
CH2Ph) 4.75 (d, J = 12.4 Hz, 1 H, CH2Ph) 4.82 (d, J = 12.4 Hz, 1 H, CH2Ph) 4.86 (d, J = 11.8 Hz, 1 H, 
CH2Ph) 4.98 (d, J = 3.2 Hz, 1 H, H-1”) 5.31 (t, J = 5.1 Hz, 1 H, (CO)NH) 5.47 (s, 1 H, H-8”) 7.14 – 7.43 (m, 
28 H, arom. H) 7.49 – 7.54 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 21.82, 26.90, 29.22, 29.39, 29.66, 31.46, 35.95, 36.58, 39.48, 
61.55, 63.03, 68.36, 69.34, 71.96, 72.04, 73.58, 73.87, 74.59, 75.38, 75.84, 77.21, 78.34, 79.21, 99.20, 
101.06, 110.00, 125.57, 126.34, 127.48, 127.53, 127.68, 127.71, 127.76, 127.79, 127.89, 127.98, 
128.11, 128.23, 128.27, 128.40, 128.43, 128.87, 137.83, 137.98, 138.14, 138.73, 142.82, 172.42. 
 Exact mass (ESI-MS) for C63H75N4O9 [M+H]
+ found, 1031.5575; Calcd., 1031.5529. 
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
(3-pentylphenyl)octanamide (4.15f) 
 1H-NMR (300 MHz CDCl3) δ 0.88 (t, J = 6.7 Hz, 3 H, terminal CH3) 1.26 – 1.36 (m, 4 H, CH2) 1.54 
– 1.65 (m, 4 H, CH2) 1.70 – 1.87 (m, 2 H, CH2) 2.26 (t, J = 6.9 Hz, 2 H, CH2) 2.56 (t, J = 8.0 Hz, 2 H, CH2) 
3.54 – 3.59 (m, 2 H, H-2 and H-3) 3.62 – 3.69 (m, 2 H, H-4 and Ha-6”) 3.75 (dd, J = 6.7 and 3.6 Hz, 1 H, 
H-5”) 3.85 (dd, J = 12.4 and 1.2 Hz, 1 H, Ha-1) 3.93 – 4.07 (m, 4 H, H-2”, H-3”, Hb-1 and Hb-6”) 4.13 (d, 
J = 2.7 Hz, 1 H, H-4”) 4.43 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.64 – 4.52 (m, 4 H, CH2Ph) 4.68 (d, J = 12.5 Hz, 1 
H, CH2Ph) 4.75 (d, J = 12.5 Hz, 1 H, CH2Ph) 4.81 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.91 (d, J = 3.2 Hz, 1 H, H-
1”) 5.40 (s, 1 H, H-8”) 6.85 (d, J = 7.2 Hz, 1 H, arom. H) 6.99 (s, 1 H, (CO)NH) 7.08 – 7.37 (m, 26 H, 
arom. H) 7.46 (dd, J = 7.3 and 2.2 Hz, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 14.03, 21.78, 22.52, 28.95, 31.09, 31.52, 35.93, 37.45, 61.49, 
63.04, 68.27, 69.32, 71.91, 72.06, 73.61, 73.95, 74.54, 75.38, 75.84, 77.21, 78.19, 79.37, 99.17, 
101.05, 116.85, 116.95, 119.63, 124.29, 126.33, 127.48, 127.52, 127.67, 127.71, 127.79, 127.85, 
127.94, 128.10, 128.23, 128.27, 128.39, 128.50, 128.75, 128.86, 137.78, 137.82, 137.91, 138.01, 
138.72, 143.97, 170.72. 
 Exact mass (ESI-MS) for C60H68N4NaO9 [M+Na]




 1H-NMR (300 MHz CDCl3) δ 0.88 (t, J = 6.8 Hz, 3 H, terminal CH3) 1.29 – 1.31 (m, 3 H, CH2) 1.55 
– 1.67 (m, 5 H, CH2) 1.71 – 1.89 (m, 2 H, CH2) 2.26 (t, J = 6.8 Hz, 2 H, CH2) 2.57 (t, J = 7.6 Hz, 2 H, CH2) 
3.59 – 3.67 (m, 2 H, H-2 and H-5”) 3.67 – 3.77 (m, 2 H, H-4 and Ha-6”) 3.82 (dd, J = 6.8 and 3.6 Hz, 1 
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H, H-3) 3.92 (dd, J = 12.5 and 1.5 Hz, 1 H, Ha-1) 3.98 – 4.14 (m, 4 H, Hb-1, H-2”, H-3” and Hb-6”) 4.20 
(d, J = 2.5 Hz, 1 H, H-4”) 4.50 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.58 – 4.72 (m, 4 H, CH2Ph) 4.75 (d, J = 12.3 
Hz, 1 H, CH2Ph) 4.82 (d, J = 12.3 Hz, 1 H, CH2Ph) 4.88 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.98 (d, J = 3.2 Hz, 1 
H, H-1”) 5.47 (s, 1 H, H-8”) 7.04 – 7.14 (m, 3 H, arom. H) 7.22 – 7.43 (m, 25 H, (CO)NH and arom. H) 
7.51 – 7.56 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 14.02, 21.77, 22.52, 28.96, 31.18, 31.41, 35.30, 37.36, 61.50, 
63.03, 68.26, 69.32, 71.91, 72.05, 73.60, 73.93, 74.54, 75.38, 75.83, 77.20, 78.21, 79.30, 99.16, 
101.04, 119.77, 126.33, 127.48, 127.51, 127.67, 127.71, 127.78, 127.84, 127.94, 128.10, 128.22, 
128.26, 128.39, 128.49, 128.81, 128.86, 135.43, 137.82, 137.91, 138.01, 138.71, 138.91, 170.66. 
 Exact mass (ESI-MS) for C60H68N4NaO9 [M+Na]
+ found, 1011.4874; Calcd., 1011.4879. 
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
(2-(2-ethoxyethoxy)ethyl)octanamide (4.15h) 
 1H-NMR (300 MHz CDCl3) δ 1.17 (t, J = 7.0 Hz, 3 H, terminal CH3) 1.46 – 1.75 (m, 4 H, CH2) 1.99 
– 2.08 (m, 2 H, CH2) 3.39 (q, 2 H, J = 5.2 Hz, NHCH2) 3.43 – 3.62 (m, 11 H, CH2, H-2, H-3 and H-4) 3.63 – 
3.73 (m, 2 H, H-5” and Ha-6”) 3.85 (dd, J = 12.6 and 1.8 Hz, 1 H, Ha-1) 3.91 – 3.97 (m, 1 H, Hb-6”) 3.99 
(d, J = 3.0 Hz, 1 H, H-3”) 4.00 – 4.07 (m, 2 H, Hb-1 and H-2”) 4.13 (d, J = 3.0 Hz, 1 H, H-4”) 4.43 (d, J = 
11.5 Hz, 1 H, CH2Ph) 4.54 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.59 – 4.64 (m, 3 H, CH2Ph) 4.69 (d, J = 12.6 Hz, 1 
H, CH2Ph) 4.76 (d, J = 12.6 Hz, 1 H, CH2Ph) 4.81 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.92 (d, J = 3.2 Hz, 1 H, H-
1”) 5.41 (s, 1 H, H-8”) 5.86 (t, J = 5.5 Hz, 1 H, (CO)NH) 7.16 – 7.37 (m, 23 H, arom. H) 7.44 – 7.48 (m, 2 
H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 15.60, 22.06, 29.82, 36.89, 39.50, 62.02, 63.43, 67.07, 68.78, 
69.75, 70.14, 70.29, 70.71, 72.39, 72.45, 73.97, 74.26, 75.01, 75.82, 76.24, 77.63, 78.87, 79.50, 99.57, 
101.47, 126.76, 127.88, 127.93, 128.10, 128.12, 128.19, 128.33, 128.52, 128.64, 128.69, 128.81, 
128.82, 129.27, 138.25, 138.40, 138.58, 139.16, 172.98. 
 Exact mass (ESI-MS) for C55H67N4O11 [M+H]
+ found, 959.4799; Calcd., 959.4801. 
General procedure for Staudinger reduction and acylation with EDC  
To a solution of azide 4.15c (350 mg, 0.36 mmol, 1eq.) in THF (5 mL) at room temperature, PMe3 (1 
M solution in THF, 5.38 mL, 5.38 mmol, 15 eq.) was added dropwise. After stirring for 3 h at room 
temperature, H2O (2 mL) was added and the reaction mixture was allowed to stir overnight at room 
temperature. Then the solvent was removed under reduced pressure. The crude product was dried 




EDC (112 mg, 0.72 mmol, 2 eq.) and octanoic acid (78 mg, 0.09 mL, 0.54 mmol, 1.5 eq.) in CH2Cl2 (10 
mL) was stirred for 24 h at room temperature. The reaction mixture was diluted with CH2Cl2, washed 
with H2O (2 x 10 mL) and brine (1 x 10 mL), dried over Na2SO4, filtered, and evaporated to dryness. 
Purification by silica gel chromatography gave the desired the desired amides. 4.16a (74%), 4.16b 
(76%), 4.16c (82%), 4.16d (80%), 4.16e (81%), 4.16f (87%), 4.16g (87%), 4.16h (70%).  
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-
octanamido-N-nonyloctanamide (4.16a) 
 1H-NMR (300 MHz CDCl3) δ 0.85 (app. td, J = 6.7 and 2.8 Hz, 6 H, 2 x terminal CH3) 1.19 – 1.35 
(m, 18 H, CH2) 1.39 – 1.54 (m, 4 H, CH2) 1.60 – 1.83 (m, 6 H, CH2) 1.90 – 1.97 (m, 2 H, CH2) 2.02 – 2.10 
(m, 2 H, CH2) 3.17 (dd, J = 12.9 and 6.9 Hz, 2 H, NHCH2) 3.44 (m, 1 H, H-4) 3.52 (app. s, 1 H, H-5”) 3.74 
(dd, J = 7.0 and 2.0 Hz, 1 H, H-3) 3.82 (d, J = 4.8 Hz, 2 H, H-1) 3.89 – 3.96 (m, 2 H, H-4” and Ha-6”) 4.04 
(d, J = 3.6 Hz, 1 H, H-2”) 4.07-4.14 (m, 2 H, H-2 and Hb-6”) 4.18 (d, J = 3.2 Hz, 1 H, H-3”) 4.39 (d, J = 
11.6 Hz, 1 H, CH2Ph) 4.47 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.55 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.62 (d, J = 11.8 
Hz, 1 H, CH2Ph) 4.72 – 4.77 (m, 3 H, CH2Ph) 4.84 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.93 (d, J = 3.4 Hz, 1 H, H-
1”) 5.45 (s, 1 H, H-8”) 5.98 (d, J = 8.4 Hz, 1 H, NH(CO)) 6.05 (t, J = 5.7 Hz, 1 H, (CO)NH) 7.19 – 7.40 (m, 
23 H, arom. H) 7.47 – 7.52(m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 14.09, 21.84, 22.64, 25.65, 26.99, 28.82, 29.07, 29.26, 29.33, 
29.52, 29.60, 31.76, 31.84, 36.03, 36.65, 39.48, 50.02, 63.00, 68.08, 69.36, 71.52, 71.72, 73.28, 73.98, 
74.18, 75.61, 76.10, 78.88, 99.60, 101.01, 126.27, 127.57, 127.63, 127.70, 127.75, 127.86, 127.89, 
127.92, 128.11, 128.31, 128.38, 128.41, 128.88, 137.73, 138.23, 138.26, 138.39, 138.55, 172.81, 
173.01. 
 Exact mass (ESI-MS) for C66H89N2O10 [M+H]
+ found, 1069.6512; Calcd., 1069.6517. 
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-
octanamido-N-phenethyloctanamide (4.16b) 
 1H-NMR (300 MHz CDCl3) δ 0.89 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.20 – 1.33 (m, 7 H, CH2) 1.44 
– 1.82 (m, 7 H, CH2) 1.88 – 1.98 (m, 2 H, CH2) 2.02 – 2.07 (m, 2 H, CH2) 2.78 (t, J = 7.3 Hz, 2 H, CH2) 
3.40 – 3.54 (m, 4 H, H-4, H-5” and CH2) 3.75 (dd, J = 7.0 and 2.4 Hz, 1 H, H-3) 3.79 – 3.94 (m, 3 H, H-1 
and Ha-6”) 3.96 (d, J = 3.3 Hz, 1 H, H-4”) 4.07 (d, J = 3.3 Hz, 1 H, H-2”) 4.08 – 4.16 (m, 2 H, H-2 and Hb-
6”) 4.18 (d, J = 3.2 Hz, 1 H, H-3”) 4.41 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.50 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.57 
(d, J = 11.7 Hz, 1 H, CH2Ph) 4.64 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.74 – 4.79 (m, 3 H, CH2Ph) 4.86 (d, J = 
11.3 Hz, 1 H, CH2Ph) 4.96 (d, J = 3.6 Hz, 1 H, H-1”) 5.46 (s, 1 H, H-8”) 5.98 (d, J = 8.5 Hz, 1 H, NH(CO)) 
6.14 (t, J = 5.6 Hz, 1 H, (CO)NH) 7.15 – 7.42 (m, 28 H, arom. H) 7.50 – 7.54 (m, 2 H, arom. H). 
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 13C NMR (75 MHz, CDCl3) δ 14.09, 21.77, 22.63, 25.67, 28.83, 29.08, 29.32, 31.77, 35.70, 
36.00, 36.66, 40.60, 50.03, 62.99, 68.06, 69.35, 71.50, 71.73, 73.31, 74.02, 74.14, 75.64, 76.09, 76.57, 
77.20, 77.43, 78.85, 78.88, 99.56, 101.01, 126.27, 126.33, 127.59, 127.64, 127.71, 127.79, 127.85, 
127.91, 127.93, 128.11, 128.33, 128.36, 128.39, 128.42, 128.50, 128.71, 128.89, 137.73, 138.24, 
138.27, 138.36, 138.54, 139.09, 172.92, 173.08. 
 Exact mass (ESI-MS) for C65H79N2O10 [M+H]
+ found, 1047.5768; Calcd., 1047.5729. 
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-
octanamido-N-(4-phenylbutyl)octanamide (4.16c) 
 1H-NMR (300 MHz CDCl3) δ 0.86 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.17 – 1.28 (m, 9 H, CH2) 1.40 
– 1.51 (m, 4 H, CH2) 1.53 – 1.81 (m, 7 H, CH2) 1.82 – 2.08 (m, 2 H, CH2) 2.57 (t, J = 7.5 Hz, 2 H, CH2) 
3.19 (q, J = 6.6 Hz, 2 H, NHCH2) 3.43 – 3.51 (m, 2 H, H-4 and H-5”) 3.72 (dd, J = 6.8 and 1.6 Hz, 1 H, H-
3) 3.80 (d, J = 4.8 Hz, 2 H, H-1) 3.87 – 3.95 (m, 2 H, H-4” and Ha-6”) 4.04 (d, J = 3.2 Hz, 1 H, H-2”) 4.06 
– 4.14 (m, 2 H, H-2 and Hb-6”) 4.17 (d, J = 3.0 Hz, 1 H, H-3”) 4.38 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.46 (d, J 
= 11.5 Hz, 1 H, CH2Ph) 4.54 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.61 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.71 – 4.77 (m, 
3 H, CH2Ph) 4.84 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.92 (d, J = 3.4 Hz, 1 H, H-1”) 5.44 (s, 1 H, H-8”) 5.91 (d, J 
= 8.5 Hz, 1 H, NH(CO)) 6.08 (t, J = 5.4 Hz, 1 H, (CO)NH) 7.09 – 7.40 (m, 28 H, arom. H) 7.46 – 7.52 (m, 2 
H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 14.08, 21.80, 22.63, 25.65, 28.70, 28.77, 29.07, 29.18, 29.31, 
31.76, 35.49, 35.96, 36.65, 39.24, 50.03, 63.00, 68.10, 69.36, 71.51, 71.74, 73.30, 73.99, 74.16, 75.61, 
76.10, 77.20, 78.86, 99.64, 101.01, 125.72, 126.27, 127.56, 127.63, 127.72, 127.76, 127.88, 127.89, 
127.91, 128.11, 128.27, 128.32, 128.34, 128.39, 128.42, 128.89, 129.96, 137.72, 138.22, 138.24, 
138.39, 138.55, 142.18, 172.94, 173.06. 
 Exact mass (ESI-MS) for C67H83N2O10 [M+H]
+ found, 1075.6052; Calcd., 1075.6042. 
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-
octanamido-N-(6-phenylhexyl)octanamide (4.16d) 
 1H-NMR (300 MHz CDCl3) δ 0.86 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.16 – 1.37 (m, 12 H, CH2) 
1.38 – 1.83 (m, 10 H, CH2) 1.87 – 2.11 (m, 4 H, CH2) 2.56 (t, J = 7.5 Hz, 2 H, CH2) 3.16 (q, J = 7.5 Hz, 2 H, 
NHCH2) 3.44 – 3.56 (m, 2 H, H-4 and H-5”) 3.74 (dd, J = 6.8 and 2.4 Hz, 1 H, H-3) 3.82 (d, J = 4.6 Hz, 2 
H, H-1) 3.88 – 3.99 (m, 2 H, H-4” and Ha-6”) 4.05 (d, J = 3.3 Hz, 1 H, H-2”) 4.07 – 4.15 (m, 2 H, H-2 and 
Hb-6”) 4.18 (d, J = 3.2 Hz, 1 H, H-3”) 4.39 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.48 (d, J = 11.4 Hz, 1 H, CH2Ph) 




= 11.6 Hz, 1 H, CH2Ph) 4.93 (d, J = 3.5 Hz, 1 H, H-1”) 5.45 (s, 1 H, H-8”) 5.93 (d, J = 8.4 Hz, 1 H, NH(CO)) 
6.04 (t, J = 5.7 Hz, 1 H, (CO)NH) 7.11 – 7.43 (m, 28 H, arom. H) 7.48 – 7.52 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 14.08, 21.83, 22.63, 25.65, 26.82, 28.83, 28.94, 29.07, 29.31, 
29.53, 31.35, 31.75, 35.85, 36.03, 36.66, 39.42, 50.04, 63.00, 68.14, 69.36, 71.53, 71.75, 73.28, 73.96, 
74.19, 75.61, 76.11, 77.21, 78.90, 99.66, 101.01, 125.58, 126.27, 127.55, 127.62, 127.71, 127.74, 
127.88, 127.91, 128.11, 128.21, 128.32, 128.34, 128.39, 128.42, 128.89, 137.73, 138.23, 138.25, 
138.42, 138.56, 142.64, 172.82, 173.00. 
 Exact mass (ESI-MS) for C69H86N2NaO10 [M+Na]
+ found, 1125.6173; Calcd., 1125.6175. 
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-
octanamido-N-(8-phenyloctyl)octanamide (4.16e) 
 1H-NMR (300 MHz CDCl3) δ 0.87 (t, J = 6.9 Hz, 3 H, terminal CH3) 1.17 – 1.35 (m, 14 H, CH2) 
1.37 – 1.84 (m, 12 H, CH2) 1.87 – 2.00 (m, 2 H, CH2) 2.02 – 2.11 (m, 2 H, CH2) 2.58 (t, J = 7.6 Hz, 2 H, 
CH2) 3.16 (dd, J = 12.8 and 7.5 Hz, 2 H, NH-CH2) 3.45 – 3.51 (m, 1 H, H-4) 3.53 (br. s, 1 H, H-5”) 3.75 
(dd, J = 6.8 and 2.3 Hz, 1 H, H-3) 3.84 (d, J = 4.9 Hz, 2 H, H-1) 3.88 – 3.97 (m, 2 H, H-4” and Ha-6”) 4.05 
(d, J = 3.4 Hz, 1 H, H-2”) 4.07 – 4.17 (m, 2 H, H-2 and Hb-6”) 4.19 (d, J = 2.9 Hz, 1 H, H-3”) 4.42 (d, J = 
11.6 Hz, 1 H, CH2Ph) 4.50 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.58 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.65 (d, J = 11.6 
Hz, 1 H, CH2Ph) 4.75 – 4.80 (m, 3 H, CH2Ph) 4.87 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.96 (d, J = 3.5 Hz, 1 H, H-
1”) 5.48 (s, 1 H, H-8”) 5.93 (d, J = 8.5 Hz, 1 H, NH(CO)) 6.04 (t, J = 5.6 Hz, 1 H, (CO)NH) 7.14 – 7.21 (m, 
2 H, arom. H) 7.21 – 7.42 (m, 26 H, arom. H) 7.49 – 7.55 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 14.08, 21.85, 22.63, 25.65, 26.96, 28.82, 29.08, 29.25, 29.31, 
29.42, 29.60, 31.46, 31.77, 35.94, 36.04, 36.65, 39.46, 50.03, 63.00, 68.07, 69.37, 71.52, 71.73, 73.31, 
73.99, 74.18, 75.61, 76.10, 77.20, 78.88, 78.91, 99.61, 101.03, 125.54, 126.28, 127.59, 127.63, 
127.71, 127.77, 127.86, 127.91, 128.12, 128.20, 128.32, 128.35, 128.40, 128.43, 128.90, 137.74, 
138.24, 138.38, 138.56, 142.82, 172.82, 173.02. 
 Exact mass (ESI-MS) for C71H90N2NaO10 [M+Na]
+ found, 1153.6510; Calcd., 1153.6488. 
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-
octanamido-N-(3-pentylphenyl)octanamide (4.16f) 
 1H-NMR (300 MHz CDCl3) δ 0.83 – 0.88 (m, 6 H, 2 x terminal CH3) 1.22 – 1.33 (m, 12 H, CH2) 
1.47 – 1.83 (m, 7 H, CH2) 1.85 – 2.03 (m, 3 H, CH2) 2.11 – 2.25 (m, 2 H, CH2) 2.54 (t, J = 7.4 Hz, 2 H, 
CH2) 3.46 – 3.53 (m, 2 H, H-4 and H-5”) 3.73 (dd, J = 7.7 and 1.5 Hz, 1 H, H-3) 3.80 (d, J = 4.9 Hz, 2 H, 
H-1) 3.85 – 3.93 (m, 1 H, Ha-6”) 3.95 (d, J = 3.3 Hz, 1 H, H-4”) 4.05 (d, J = 3.5 Hz, 1 H, H-2”) 4.07 – 4.14 
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(m, 2 H, H-2 and Hb-6”) 4.17 (d, J = 3.3 Hz, 1 H, H-3”) 4.38 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.48 (d, J = 11.6 
Hz, 1 H, CH2Ph) 4.57 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.62 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.74 – 4.80 (m, 3 H, 
CH2Ph) 4.86 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.94 (d, J = 3.6 Hz, 1 H, H-1”) 5.44 (s, 1 H, H-8”) 6.00 (d, J = 8.6 
Hz, 1 H, NH(CO)) 6.86 (d, J = 7.6 Hz, 1 H, arom. H) 7.12 (t, J = 7.9 Hz, 1 H, arom. H) 7.21 – 7.41 (m, 24 
H, arom. H) 7.44 – 7.53 (m, 3 H, arom. H) 8.36 (s, 1 H, (CO)NH). 
 13C NMR (75 MHz, CDCl3) δ 14.03, 21.67, 22.53, 22.63, 25.70, 29.09, 29.33, 31.10, 31.54, 
31.78, 36.01, 36.72, 50.00, 63.04, 67.99, 69.32, 71.49, 71.70, 73.26, 74.02, 74.13, 75.59, 76.10, 78.63, 
99.55, 101.01, 116.86, 119.69, 123.80, 126.27, 127.56, 127.65, 127.73, 127.78, 127.82, 127.90, 
127.93, 128.00, 128.12, 128.34, 128.37, 128.41, 128.45, 128.90, 137.74, 138.10, 138.14, 138.44, 
138.56, 143.74, 171.59, 173.24. 
 Exact mass (ESI-MS) for C68H84KN2O10 [M+K]
+ found, 1127.5773; Calcd., 1127.5758. 
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-
octanamido-N-(4-pentylphenyl)octanamide (4.16g) 
 1H-NMR (300 MHz CDCl3) δ 0.86 – 0.93 (m, 6 H, 2 x terminal CH3) 1.22 – 1.38 (m, 12 H, CH2) 
1.50 – 1.84 (m, 6 H, CH2) 1.87 – 2.07 (m, 3 H, CH2) 2.09 – 2.28 (m, 2 H, CH2) 2.54 (t, J = 7.1 Hz, 2 H, 
CH2) 3.46 – 3.54 (m, 2 H, H-4 and H-5”) 3.75 (dd, J = 8.0, 1.2 Hz, 1 H, H-3) 3.79 – 3.83 (m, 2 H, H-1) 
3.89 (dd, J = 12.5 and 1.3 Hz, 1 H, Ha-6”) 3.95 (dd, J = 10.0 and 3.5 Hz, 1 H, H-4”) 4.08 (d, J = 3.5 Hz, 1 
H, H-2”) 4.09 – 4.16 (m, 2 H, H-2 and Hb-6”) 4.19 (d, J = 2.8 Hz, 1 H, H-3”) 4.39 (d, J = 11.6 Hz, 1 H, 
CH2Ph) 4.49 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.59 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.64 (d, J = 11.3 Hz, 1 H, 
CH2Ph) 4.76 – 4.83 (m, 3 H, CH2Ph) 4.88 (d, J = 11.3 Hz, 1 H, CH2Ph) 4.95 (d, J = 3.5 Hz, 1 H, H-1”) 5.46 
(s, 1 H, H-8”) 6.16 (d, J = 8.7 Hz, 1 H, NH(CO)) 7.06 (d, J = 8.5 Hz, 2 H, arom. H) 7.22 – 7.37(m, 22 H, 
arom. H) 7.38 – 7.46 (m, 3 H, arom. H) 7.49 – 7.5(m, 2 H, arom. H) 8.49 (s, 1 H, (CO)NH). 
 13C NMR (75 MHz, CDCl3) δ 14.02, 14.04, 14.08, 21.68, 22.52, 22.58, 22.63, 24.75, 25.69, 
28.11, 28.90, 29.03, 29.09, 29.34, 31.23, 31.43, 31.62, 31.78, 33.64, 35.34, 36.51, 36.70, 49.97, 63.01, 
67.87, 69.31, 71.50, 71.66, 73.27, 74.07, 74.12, 75.60, 76.07, 77.20, 78.55, 99.40, 101.01, 119.67, 
126.27, 127.59, 127.68, 127.71, 127.82, 127.90, 127.94, 127.98, 128.12, 128.35, 128.37, 128.41, 
128.44, 128.59, 128.90, 136.28, 137.72, 138.09, 138.14, 138.28, 138.35, 138.53, 171.57, 173.39. 
 Exact mass (ESI-MS) for C68H85N2O10 [M+H]








 1H-NMR (300 MHz CDCl3) δ 0.89 (t, J = 6.8 Hz, 3 H, terminal CH3) 1.18 – 1.35 (m, 12 H, CH2 and 
terminal CH3) 1.45 – 1.56 (m, 2 H, CH2) 1.60 – 1.88 (m, 3 H, CH2) 1.89 – 1.97 (m, 2 H, CH2) 2.10 (t, J = 
6.2 Hz, 2 H, CH2) 3.40 – 3.48 (m, 2 H, CH2) 3.50 – 3.62 (m, 10 H, H-4, H-5” and CH2) 3.78 (dd, J = 6.1 
and 2.4 Hz, 1 H, H-3) 3.80 – 3.99 (m, 4 H, CH2-1, H-2 and Ha-6”) 4.07 (d, J = 3.3 Hz, 1 H, H-4”) 4.10 – 
4.18 (m, 1 H, Hb-6”) 4.19 – 4.25 (m, 2 H, H-2” and H-3”) 4.46 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.51 (d, J = 
11.6 Hz, 1 H, CH2Ph) 4.59 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.65 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.73 – 4.78 (m, 3 
H, CH2Ph) 4.87 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.96 (d, J = 3.4 Hz, 1 H, H-1”) 5.48 (s, 1 H, H-8”) 5.89 (d, J = 
8.4 Hz, 1 H, NH(CO)) 6.26 (t, J = 5.3 Hz, 1 H, (CO)NH) 7.22 – 7.44 (m, 23 H, arom. H) 7.51 – 7.55 (m, 2 
H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 14.08, 15.16, 21.82, 22.63, 25.67, 29.06, 29.16, 29.31, 31.75, 
36.13, 36.68, 39.04, 50.12, 62.96, 66.61, 68.11, 69.38, 69.70, 69.81, 70.22, 71.57, 71.78, 73.30, 73.90, 
74.23, 75.64, 76.12, 77.20, 78.94, 79.16, 99.58, 101.00, 126.28, 127.56, 127.60, 127.67, 127.70, 
127.72, 127.88, 127.90, 128.09, 128.30, 128.33, 128.38, 128.41, 128.85, 137.77, 138.28, 138.30, 
138.45, 138.60, 172.91, 173.00. 
 Exact mass (ESI-MS) for C63H83N2O12 [M+H]
+ found, 1059.5945; Calcd., 1059.5941. 
General procedure for debenzylation 
A solution of the protected amide (0.06 mmol) in CHCl3 (3 mL) and EtOH (9 mL) was hydrogenated 
under atmospheric pressure in the presence of palladium black (35 mg). Upon reaction completion, 
the mixture was filtered through celite. The filter cake was rinsed with CHCl3 and EtOH and the 
filtrate was evaporated to dryness. After purification by silica gel chromatography (10%  18% 
MeOH in CH2Cl2), final compounds 4.1a (43%), 4.1b (30%), 4.1c (42%), 4.1d (56%), 4.1e (56%), 4.1f 
(78%), 4.1g (71%), 4.1h (53%) were obtained as white powders. 
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-nonyloctanamide (4.1a) 
 1H-NMR (300 MHz, pyridine-d5) δ 0.77 – 0.91 (m, 6 H, 2 x terminal CH3) 1.08 – 1.38 (m, 20 H, 
CH2) 1.59 (dt, J = 14.8 and 7.6 Hz, 2 H, CH2) 1.77 (dt, J = 14.8 and 7.6 Hz, 2 H, CH2) 1.92 – 2.04 (m, 1 H, 
CH2) 2.17 – 2.29 (m, 1 H, CH2) 2.34 – 2.60 (m, 6 H, CH2) 3.46 (dd, J = 13.0 and 6.8 Hz, 2 H, NHCH2) 4.26 
– 4.37 (m, 3 H, Ha-1, H-3 and H-4) 4.37 – 4.45 (m, 3 H, H-4” and H-6”) 4.48 (q, J = 6.2 Hz, 1 H, H-3”) 
4.55 (d, J = 2.9 Hz, 1 H, H-5”) 4.60 – 4.69 (m, 2 H, Hb-1 and H-2”) 5.19 – 5.28 (m, 1 H, H-2) 5.56 (d, J = 
3.8 Hz, 1 H, H-1”) 6.36 (br. s, 6 H, OH) 8.30 (t, J = 5.2 Hz, 1 H, NH(CO)) 8.46 (d, J = 8.6 Hz, 1 H, (CO)NH). 
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 13C NMR (75 MHz, pyridine-d5) δ 14.60, 14.65, 23.23, 23.28, 23.47, 26.71, 27.78, 29.73, 29.88, 
30.01, 30.18, 30.38, 30.66, 32.27, 32.43, 34.38, 37.14, 37.35, 40.11, 51.78, 63.03, 68.98, 70.68, 71.37, 
71.96, 72.61, 73.42, 77.19, 101.92, 173.65. 
 Exact mass (ESI-MS) for C31H61N2O10 [M+H]
+ found, 621.4347; Calcd., 621.4326; m.p.: 95-97 
°C, HPLC purity: not available (UV inactive) 
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-phenethyloctanamide (4.1b) 
 1H-NMR (300 MHz, pyridine-d5) δ 0.80 (t, J = 6.2 Hz, 3 H, terminal CH3) 1.11 – 1.35 (m, 8 H, 
CH2) 1.77 (dt, J = 14.6 and 7.3 Hz, 2 H, CH2) 1.89 – 2.04 (m, 1 H, CH2) 2.11 – 2.26 (m, 1 H, CH2) 2.31 – 
2.55 (m, 6 H, CH2) 2.93 (t, J = 7.2 Hz, 2 H, CH2Ph) 3.68 (q, J = 6.8 Hz, 2 H, NHCH2) 4.26 – 4.32 (m, 1 H, 
H-3) 4.32 – 4.54 (m, 6 H, H-4, Ha-1, H-4”, H-5” and CH2-6”) 4.56 (d, J = 2.5 Hz, 1 H, H-3”) 4.61 – 4.69 
(m, 2 H, H-2” and Hb-1) 5.20 – 5.30 (m, 1 H, H-2) 5.57 (d, J = 3.4 Hz, 1 H, H-1”) 7.24 – 7.35 (m, 3 H, 
arom. H) 8.43 – 8.54 (m, 2 H, arom. H). 
 13C NMR (75 MHz, pyridine-d5) δ 29.03, 37.66, 37.83, 41.15, 44.16, 44.44, 46.70, 48.82, 51.21, 
51.58, 51.69, 56.18, 66.16, 77.46, 83.33, 85.09, 85.81, 86.38, 87.06, 87.83, 91.60, 116.30, 141.31, 
143.62, 144.10, 155.13, 188.15, 188.27. 
 Exact mass (ESI-MS) for C30H51N2O10 [M+H]
+ found, 599.3541; Calcd., 599.3538; m.p. 56-58 °C, 
HPLC purity: 95,5% rel. area. 
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-(4-phenylbutyl)octanamide 
(4.1c) 
 1H-NMR (300 MHz, pyridine-d5) δ 0.80 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.07 – 1.42 (m, 10 H, 
CH2) 1.54 – 1.67 (m, 4 H, CH2) 1.76 (dt, J = 14.9 and 7.5 Hz, 2 H, CH2) 1.90 – 2.04 (m, 1 H, CH2) 2.12 – 
2.27 (m, 1 H, CH2) 2.30 – 2.58 (m, 6 H, CH2) 3.44 (q, J = 5.8 Hz, 2 H, NHCH2) 4.25 – 4.44 (m, 6 H, Ha-1, 
H-3, H-4, H-4” and CH2-6”) 4.48 (q, J = 5.7 Hz, 1 H, H-3”) 4.55 (d, J = 2.6 Hz, 1 H, H-5”) 4.60 – 4.68 (m, 
2 H, Hb-1 and H-2”) 5.19 – 5.28 (m, 1 H, H-2) 5.56 (d, J = 3.8 Hz, 1 H, H-1”) 6.47 (br. s, 6 H, OH) 7.17 – 
7.25 (m, 3 H, arom. H) 7.28 – 7.35 (m, 2 H, arom. H) 8.28 (t, J = 5.3 Hz, 1 H, (CO)NH) 8.46 (d, J = 8.6 
Hz, 1 H, NH(CO)). 
 13C NMR (75 MHz, pyridine-d5) δ 14.60, 23.23, 23.46, 26.72, 29.58, 29.72, 30.01, 30.21, 30.39, 
32.27, 34.41, 36.07, 37.14, 37.33, 39.79, 51.78, 63.04, 68.98, 70.68, 71.38, 71.97, 72.62, 73.43, 77.21, 
101.92, 126.46, 129.09, 129.23, 136.58, 143.22, 173.66, 173.67. 
 Exact mass (ESI-MS) for C32H55N2O10 [M+H]
+ found, 627.3860; Calcd., 627.3851; m.p. 57-59 °C, 






 1H-NMR (300 MHz, pyridine-d5) δ 0.77 – 0.87 (m, 3 H, terminal CH3) 1.09 – 1.43 (m, 13 H, CH2) 
1.54 (dt, J = 12.6 and 6.3 Hz, 3 H, CH2) 1.77 (dt, J = 14.4 and 7.1 Hz, 2 H, CH2) 1.91 – 2.05 (m, 1 H, CH2) 
2.16 – 2.31 (m, 1 H, CH2) 2.33 – 2.60 (m, 6 H, CH2) 3.03 (q, J = 7.0 Hz, 2 H, CH2) 3.43 (d, J = 5.8 Hz, 2 H, 
NHCH2) 4.27 – 4.46 (m, 6 H, Ha-1, H-3, H-4, H-4” and CH2-6”) 4.46 – 4.53 (m, 1 H, H-5”) 4.56 (app. s, 1 
H, H-3”) 4.60 – 4.69 (m, 2 H, Hb-1 and H-2”) 5.19 – 5.29 (m, 1 H, H-2) 5.56 (d, J = 2.4 Hz, 1 H, H-1”) 
6.40 (br. s, 6 H, OH) 7.19 – 7.29 (m, 3 H, arom. H) 7.30 – 7.39 (m, 2 H, arom. H) 8.29 (t, J = 5.7, 1 H, 
(CO)NH) 8.49 (d, J = 8.2 Hz, 1 H, NH(CO)). 
 13C NMR (75 MHz, pyridine-d5) δ 8.91, 14.59, 23.22, 23.45, 26.70, 27.58, 29.58, 29.71, 29.99, 
30.35, 30.53, 32.08, 32.26, 34.37, 36.40, 37.13, 37.33, 40.05, 46.18, 51.78, 63.00, 68.92, 70.68, 71.34, 
71.95, 72.56, 73.39, 77.17, 101.89, 126.41, 129.07, 129.21, 143.51, 173.66, 173.68. 
 Exact mass (ESI-MS) for C34H59N2O10 [M+H]
+ found, 655.4161; Calcd., 655.4164; m.p. 135-137 
°C, HPLC purity: 95,5% rel. area. 
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-(8-phenyloctyl)octanamide 
(4.1e) 
 1H-NMR (300 MHz, pyridine-d5) δ 0.80 (t, J = 6.3 Hz, 3 H, terminal CH3) 1.09 – 1.36 (m, 16 H, 
CH2) 1.47 – 1.64 (m, 4 H, CH2) 1.69 – 1.83 (m, 2 H, CH2) 1.91 – 2.05 (m, 1 H, CH2) 2.14 – 2.30 (m, 1 H, 
CH2) 2.34 – 2.60 (m, 8 H, CH2) 3.45 (dd, J = 13.1 and 6.8 Hz, 2 H, NHCH2) 4.26 – 4.45 (m, 6 H, Ha-1, H-
3, H-4, H-4” and CH2-6”) 4.49 (q, J = 6.0 Hz, 1 H, H-5”) 4.56 (d, J = 3.0 Hz, 1 H, H-3”) 4.61 – 4.69 (m, 2 
H, Hb-1 and H-2”) 5.19 – 5.29 (m, 1 H, H-2) 5.57 (d, J = 3.5 Hz, 1 H, H-1”) 6.56 (br. s, 6 H, OH) 7.21 – 
7.29 (m, 3 H, arom. H) 7.33 – 7.40 (m, 2 H, arom. H) 8.30 (t, J = 5.4, 1 H, (CO)NH) 8.48 (d, J = 8.5 Hz, 1 
H, NH(CO)). 
 13C NMR (75 MHz, pyridine-d5) δ 8.91, 14.58, 23.21, 23.45, 26.69, 27.73, 29.71, 29.80, 29.89, 
29.99, 30.03, 30.61, 32.15, 32.26, 34.37, 36.47, 37.12, 37.33, 40.08, 46.18, 51.78, 63.00, 68.93, 70.67, 
71.34, 71.95, 72.58, 73.40, 77.17, 101.88, 126.42, 129.09, 129.24, 143.59, 173.66. 
 Exact mass (ESI-MS) for C36H63N2O10 [M+H]
+ found, 683.4477; Calcd., 683.4477; m.p. 128-130 
°C, HPLC purity: 95,5% rel. area. 
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(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-(3-pentylphenyl)octanamide 
(4.1f) 
 1H-NMR (300 MHz, pyridine-d5) δ 0.81 (t, J = 6.5 Hz, 6 H, 2 x terminal CH3) 1.11 – 1.34 (m, 14 
H, CH2) 1.55 (dt, J = 14.8 and 7.4 Hz, 2 H, CH2) 1.77 (dt, J = 14.8 and 7.4 Hz, 2 H, CH2) 1.90 – 2.03 (m, 1 
H, CH2) 2.17 – 2.31 (m, 1 H, CH2) 2.41 (t, J = 7.6 Hz, 2 H, CH2) 2.55 (t, J = 7.6 Hz, 2 H, CH2) 2.68 (dd, J = 
14.2 and 7.0 Hz, 2 H, CH2) 4.24 – 4.31 (m, 1 H, H-3) 4.31 – 4.45 (m, 5 H, H-4, Ha-1, H-4” and H-6”) 4.48 
(q, J = 5.4 Hz, 1 H, H-3”) 4.55 (d, J = 2.4 Hz, 1 H, H-5”) 4.60 – 4.69 (m, 2 H, H-2” and Hb-1) 5.20 – 5.29 
(m, 1 H, H-2) 5.57 (d, J = 3.4 Hz, 1 H, H-1”) 6.48 (br. s., 6 H, OH) 6.99 (d, J = 7.5 Hz, 1 H, arom. H) 7.32 
(t, J = 7.7 Hz, 1 H, arom. H) 7.88 (d, J = 8.0 Hz, 1 H, arom. H) 7.98 (s, 1 H, arom. H) 8.47 (d, J = 8.7 Hz, 1 
H, NH(CO)) 10.60 (s, 1 H, (CO)NH). 
 13C NMR (75 MHz, pyridine-d5) δ 14.51, 14.57, 23.10, 23.21, 23.41, 26.70, 29.70, 29.98, 31.76, 
31.98, 32.25, 34.30, 36.57, 37.11, 38.21, 51.65, 63.02, 68.80, 70.63, 71.37, 71.93, 72.61, 73.40, 77.15, 
101.82, 117.89, 120.54, 124.09, 129.41, 141.00, 144.22, 172.70, 173.69. 
 Exact mass (ESI-MS) for C33H57N2O10 [M+H]
+ found, 641.4001; Calcd., 641.4008; m.p. 165-167 
°C, HPLC purity: 97,0% rel. area. 
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-(4-pentylphenyl)octanamide 
(4.1g) 
 1H-NMR (300 MHz, pyridine-d5) δ 0.81 (dt, J = 9.1 and 7.0 Hz, 6 H, 2 x terminal CH3) 1.12 – 
1.34 (m, 14 H, CH2) 1.55 (dt, J = 14.8 and 7.4 Hz, 2 H, CH2) 1.77 (dt, J = 14.9 and 7.5 Hz, 2 H, CH2) 1.89 
– 2.05 (m, 1 H, CH2) 2.17 – 2.33 (m, 1 H, CH2) 2.42 (t, J = 7.8 Hz, 2 H, CH2) 2.53 (t, J = 7.8 Hz, 2 H, CH2) 
2.61 – 2.71 (m, 2 H, CH2) 4.24 – 4.45 (m, 6 H, H-3, H-4, H-4”, H-6” and Ha-1 ) 4.49 (q, J = 5.9 Hz, 1 H, 
H-3”) 4.56 (d, J = 2.9 Hz, 1 H, H-5”) 4.61 – 4.69 (m, 2 H, Hb-1 and H-2”) 5.20 – 5.29 (m, 1 H, H-2) 5.57 
(d, J = 3.7 Hz, 1 H, H-1”) 6.41 (br. s, 6 H, OH) 7.23 (app. s, 2 H, arom. H) 8.01 (d, J = 8.4 Hz, 2 H, arom. 
H) 8.48 (d, J = 8.7 Hz, 1 H, NH(CO)) 10.63 (s, 1 H, (CO)NH). 
 13C NMR (75 MHz, pyridine-d5) δ 14.55, 14.58, 23.14, 23.22, 23.42, 26.70, 29.71, 29.99, 31.95, 
32.26, 34.31, 35.86, 37.13, 38.14, 51.66, 63.04, 68.81, 70.66, 71.38, 71.95, 72.62, 73.42, 77.18, 
101.85, 120.56, 129.43, 138.26, 138.75, 172.58, 173.68. 
 Exact mass (ESI-MS) for C33H57N2O10 [M+H]
+ found, 641.4011; Calcd., 641.4008; m.p. 147-149 







 1H-NMR (300 MHz, pyridine-d5) δ 0.80 (t, J = 6.5 Hz, 3 H, terminal CH3) 1.08 – 1.22 (m, 8 H, 
terminal CH3 and CH2) 1.23 – 1.41 (m, 5 H, CH2) 1.76 (dt, J = 14.8 and 7.4 Hz, 2 H, CH2) 1.87 – 2.01 (m, 
1 H, CH2) 2.11 – 2.24 (m, 1 H, CH2) 2.31 – 2.47 (m, 4 H, CH2) 2.47 – 2.58 (m, 2 H, CH2) 3.41 (q, J = 7.0 
Hz, 2 H, CH2) 3.49 – 3.54 (m, 2 H, CH2) 3.56 – 3.61 (m, 2 H, CH2) 3.62 – 3.70 (m, 2 H, CH2) 4.22 – 4.44 
(m, 6 H, Ha-1, H-3, H-4, H-4” and CH2-6”) 4.48 (q, J = 5.8 Hz, 1 H, H-5”) 4.55 (d, J = 2.7 Hz, 1 H, H-3”) 
4.60 – 4.69 (m, 2 H, Hb-1 an H-2”d) 5.19 – 5.29 (m, 1 H, H-2) 5.56 (d, J = 3.7 Hz, 1 H, H-1”) 6.43 (br. s, 
6 H, OH) 8.43 (d, J = 8.4 Hz, 1 H, NH(CO)) 8.47 – 8.52 (m, 1 H, (CO)NH). 
 13C NMR (75 MHz, pyridine-d5) δ 14.59, 15.84, 23.23, 23.39, 26.71, 29.72, 30.00, 30.37, 32.27, 
34.46, 37.14, 37.21, 40.14, 51.74, 63.03, 66.84, 68.93, 70.50, 70.67, 70.85, 71.01, 71.38, 71.96, 72.64, 
73.42, 77.21, 101.90, 173.64, 173.86. 
 Exact mass (ESI-MS) for C28H55N2O12 [M+H]
+ found, 611.3750; Calcd., 611.3750; m.p. could 
not be determined due to hygroscopicity, HPLC purity: decomposed on column. 
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-undecanamino-N-(6-phenylhexyl)octanamide 
(4.2d) 
 1H-NMR (300 MHz, pyridine-d5) δ 0.87 (t, J =6.6 Hz, 3 H, terminal CH3) 1.13 – 1.41 (m, 20 H, 
CH2) 1.45 – 1.61 (m, 4 H, CH2) 1.73 – 1.87 (m, 2 H, CH2) 1.91 – 2.05 (m, 1 H, CH2) 2.18 – 2.60 (m, 9 H, 
CH2) 3.43 (q, J = 6.8 Hz, 2 H, NHCH2) 4.26 – 4.53 (m, 7 H, Ha-1, H-3, H-4, H-4”, H-5” and CH2-6”) 4.56 
(d, J = 3.1 Hz, 1 H, H-3”) 4.61 – 4.71 (m, 2 H, Hb-1 and H-2”) 5.21 – 5.31 (m, 1 H, H-2) 5.57 (d, J = 3.8 
Hz, 1 H, H-1”) 5.96 (br. s, 6 H, OH) 7.17 – 7.27 (m, 3 H, arom. H) 7.31 – 7.38 (m, 2 H, arom. H) 8.27 (t, J 
= 5.8 Hz, 1 H, (CO)NH) 8.48 (d, J = 8.7 Hz, 1 H, NH(CO)). 
 13C NMR (75 MHz, pyridine-d5) δ 14.69, 23.33, 23.47, 26.77, 27.59, 29.62, 29.99, 30.14, 30.20, 
30.26, 30.32, 30.55, 32.11, 32.51, 34.41, 36.43, 37.18, 37.34, 40.08, 51.77, 63.05, 68.96, 70.70, 71.40, 
71.98, 72.62, 73.45, 77.22, 101.93, 126.45, 129.10, 129.24, 143.53, 173.68, 173.72. 
 Exact mass (ESI-MS) for C38H67N2O10 [M+H]
+ found, 711.4781; Calcd., 711.4790; m.p. 91-93 °C. 
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-pentadecanamino-N-(6-phenylhexyl) 
octanamide (4.3d) 
 1H-NMR (300 MHz, pyridine-d5) δ 0.88 (t, J =6.7 Hz, 3 H, terminal CH3) 1.16 – 1.41 (m, 28 H, 
CH2) 1.45 – 1.61 (m, 4 H, CH2) 1.74 – 1.87 (m, 2 H, CH2) 1.91 – 2.04 (m, 1 H, CH2) 2.16 – 2.60 (m, 9 H, 
CH2) 3.43 (q, J = 6.7 Hz, 2 H, NHCH2) 4.26 – 4.53 (m, 7 H, Ha-1, H-3, H-4, H-4”, H-5” and CH2-6”) 4.56 
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(d, J = 3.2 Hz, 1 H, H-3”) 4.61 – 4.71 (m, 2 H, Hb-1 and H-2”) 5.21 – 5.30 (m, 1 H, H-2) 5.57 (d, J = 3.9 
Hz, 1 H, H-1”) 5.93 (br. s, 6 H, OH) 7.19 – 7.30 (m, 3 H, arom. H) 7.30 – 7.38 (m, 2 H, arom. H) 8.27 (t, J 
= 5.6 Hz, 1 H, (CO)NH) 8.47 (d, J = 8.6 Hz, 1 H, NH(CO)). 
 13C NMR (75 MHz, pyridine-d5) δ 14.69, 23.35, 23.47, 26.77, 27.59, 29.60, 30.02, 30.15, 30.18, 
30.25, 30.34, 30.40, 30.57, 32.11, 32.52, 34.43, 36.43, 37.18, 37.34, 40.06, 51.77, 63.07, 68.99, 70.70, 
71.40, 71.98, 72.64, 73.46, 77.25, 101.95, 126.43, 129.10, 129.24, 143.53, 173.61, 173.68. 
 Exact mass (ESI-MS) for C42H75N2O10 [M+H]




 1H-NMR (300 MHz, pyridine-d5) δ 0.88 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.14 – 1.40 (m, 36 H, 
CH2) 1.45 – 1.61 (m, 4 H, CH2) 1.70 – 1.88 (m, 2 H, CH2) 1.90 – 2.05 (m, 1 H, CH2) 2.18 – 2.58 (m, 9 H, 
CH2) 3.44 (q, J = 6.7 Hz, 2 H, NHCH2) 4.23 – 4.54 (m, 7 H, Ha-1, H-3, H-4, H-4”, H-5” and CH2-6”) 4.57 
(d, J = 3.1 Hz, 1 H, H-3”) 4.61 – 4.72 (m, 2 H, Hb-1 and H-2”) 5.21 – 5.31 (m, 1 H, H-2) 5.57 (d, J = 3.8 
Hz, 1 H, H-1”) 5.83 (br. s, 6 H, OH) 7.20 – 7.27 (m, 3 H, arom. H) 7.31 – 7.38 (m, 2 H, arom. H) 8.28 (t, J 
= 5.6 Hz, 1 H, (CO)NH) 8.49 (d, J = 9.0 Hz, 1 H, NH(CO)). 
 13C NMR (75 MHz, pyridine-d5) δ 14.69, 23.35, 23.47, 26.78, 27.61, 29.62, 30.02, 30.20, 30.26, 
30.32, 30.43, 30.55, 32.11, 32.52, 34.41, 36.43, 37.19, 37.34, 40.08, 51.77, 63.07, 68.96, 70.68, 71.40, 
71.97, 72.64, 73.45, 77.22, 101.93, 126.43, 129.10, 129.24, 143.53, 173.66, 173.71. 
 Exact mass (ESI-MS) for C46H83N2O10 [M+H]




 1H-NMR (300 MHz, pyridine-d5) δ 0.88 (t, J = 6.4 Hz, 3 H, terminal CH3) 1.11 – 1.43 (m, 42 H, 
CH2) 1.43 – 1.62 (m, 6 H, CH2) 1.81 (quint, J = 7.3 Hz, 2 H, CH2) 1.91 – 2.07 (m, 2 H, CH2) 2.12 – 2.30 
(m, 2 H, CH2) 2.34 – 2.61 (m, 8 H, CH2) 3.03 (q, J = 7.4 Hz, 2 H, CH2) 3.43 (q, J = 6.6 Hz, 2 H, NHCH2) 
4.26 – 4.45 (m, 6 H, Ha-1, H-3, H-4, H-4” and CH2-6”) 4.49 (q, J = 5.9 Hz ,1 H, H-5”) 4.56 (d, J = 2.9 Hz, 
1 H, H-3”) 4.60 – 4.70 (m, 2 H, Hb-1 and H-2”) 5.19 – 5.30 (m, 1 H, H-2) 5.57 (d, J = 3.8 Hz, 1 H, H-1”) 
6.33 (br. s, 6 H, OH) 7.17 – 7.27 (m, 3 H, arom. H) 7.30 – 7.39 (m, 2 H, arom. H) 8.29 (t, J = 5.4 Hz, 1 H, 




 13C NMR (75 MHz, pyridine-d5) δ 8.89, 14.66, 23.32, 23.45, 26.75, 27.57, 29.59, 29.99, 30.14, 
30.17, 30.25, 30.29, 30.37, 30.41, 30.52, 32.08, 32.49, 34.37, 36.40, 37.15, 37.31, 40.05, 46.15, 51.78, 
63.00, 68.91, 70.67, 71.32, 71.95, 72.55, 73.40, 77.17, 101.87, 126.40, 129.07, 129.21, 143.50, 
173.66, 173.69. 
 Exact mass (ESI-MS) for C52H95N2O10 [M+H]




 1H-NMR (300 MHz, pyridine-d5) δ 0.80 (t, J = 6.9 Hz, 3 H, terminal CH3) 0.88 (t, J = 6.5 Hz, 3 H, 
terminal CH3) 1.14 – 1.47 (m, 48 H, CH2) 1.47 – 1.64 (m, 2 H, CH2) 1.74 – 1.89 (m, 2 H, CH2) 1.89 – 2.16 
(m, 1 H, CH2) 2.16 – 2.33 (m, 1 H, CH2) 2.33 – 2.51 (m, 4 H, CH2) 2.51 – 2.60 (m, 2 H, CH2) 2.60 – 2.74 
(m, 2 H, CH2) 4.23 – 4.46 (m, 6 H, Ha-1, H-3”, H-4, H-4” and CH2-6”) 4.46 – 4.53 (m, 1 H, H-3) 4.56 (br. 
s, 1 H, H-5”) 4.60 – 4.71 (m, 2 H, Hb-1 and H-2”) 5.20 – 5.31 (m, 1 H, H-2) 5.57 (d, J = 3.8 Hz, 1 H, H-1”) 
6.27 (d, J = 6.1 Hz, 1 H, OH) 6.32 (d, J = 3.7 Hz, 1 H, OH) 6.46 – 6.58 (m, 2 H, OH) 6.72 (br. s, 1 H, OH) 
6.97 – 7.08 (m, 2 H, arom. H and OH) 7.33 (t, J = 7.8 Hz, 1 H, arom. H) 7.88 (d, J = 7.9 Hz, 1 H, arom. H) 
7.97 (s, 1 H, arom. H) 8.46 (d, J = 8.5 Hz, 1 H, NH(CO)) 10.59 (s, 1 H, (CO)NH). 
 13C NMR (75 MHz, pyridine-d5) δ 14.54, 14.69, 23.13, 23.35, 23.44, 26.78, 30.02, 30.17, 30.20, 
30.26, 30.32, 30.40, 30.44, 31.80, 32.02, 32.52, 34.35, 36.61, 37.18, 38.24, 51.68, 63.07, 68.87, 70.68, 
71.42, 71.98, 72.65, 73.46, 77.22, 101.88, 117.91, 120.55, 124.11, 129.45, 141.05, 144.26, 172.71, 
173.68. 
 Exact mass (ESI-MS) for C51H93N2O10 [M+H]
+ found, 893.6830; Calcd., 893.6825; m.p. 127-129 
°C. 
N-((2S,3S,4R)-1-O-(α-D-galactopyranosyl)-3,4-dihydroxy-16-phenylhexadecan-2-yl)octanamide(4.17) 
Compound 4.17 was synthesized in an analogous way as described in scheme 4.5 and 4.6. A Wittig 
olefination between 4.8 and triphenyl(10-decylphenyl)phosphonium bromide was followed by 
selective reduction of the double bond. The azide moiety on C2 was installed using a Mitsunobu 
inversion with hydrazoic acid (HN3). Next, the primary hydroxyl group was selectively deprotected to 
give the corresponding acceptor, which was glycosylated with trichloroacetimidate donor 4.13. 
Staudinger reduction of the azide, followed by amide formation with octanoic acid, yielded, after 
overall deprotection, compound 4.17. 
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1H-NMR (300 MHz, pyridine-d5) δ 0.81 (t, J = 6.3 Hz, 3 H, terminal CH3) 1.11 – 2.01 (m, 32 H, 
CH2) 2.44 (t, J = 7.6 Hz, 2 H, CH2) 2.60 (t, J = 7.6 Hz, 2 H, CH2) 4.31 – 4.35 (m, 2 H, H-2” and H3) 4.38 – 
4.46 (m, 3 H, Hb1 and CH2-6”) 4.47 (m, 1 H, H-4) 4.53 (m, 1 H, H-4”) 4.57 (m, 1 H, H-5”) 4.63 – 4.72 
(m, 2 H, Ha1 and H-3”) 5.24 – 5.34 (m, 1 H, H-2) 5.60 (d, J = 3.7 Hz, 1 H, H-1”) 5.94 (br. s, 6 H, OH) 7.22 
– 7.29 (m, 3 H, arom. H) 7.31 – 7.39 (m, 2 H, arom. H) 8.49 (d, J = 8.6 Hz, 1 H, NH). 
13C NMR (75 MHz, pyridine-d5) δ 14.23, 22.89, 26.37, 26.50, 29.38, 29.56, 29.66, 29.82, 29.98, 
30.01, 30.14, 30.38, 31.89, 34.42, 36.11, 36.77, 51.64, 62.68, 68.65, 70.30, 71.03, 71.67, 71.71, 72.50, 
73.05, 76.72, 101.45, 128.73, 128.88. 
In vivo cytokine secretion assay 
Experiments were approved by and conducted according to the guidelines of the Ethical Committee of 
Laboratory Animal Welfare of Ghent University. 
The different glycolipids were dissolved in DMSO at a concentration of 1 mg/mL, heated for 
20 minutes at 80 °C and subsequently sonicated for 10 minutes at the same temperature. Next, 11 µL 
of the prepared solution was diluted with PBS in order to obtain a 10 µg/mL solution and the 
resulting solution was again warmed to 80 °C for 20 minutes followed by sonication for 10 minutes at 
this temperature. Then, 500 µL (5 µg) was injected i.p. in 8 different C57BL/6 mice and blood was 
collected 4 h (IL-4) and 16 h (IFN-γ) post injection. The levels of IL-4 and INF-γ were determined by 
ELISA (eBioscience). KRN7000 (α-GalCer) was employed as control. 
Recombinant proteins, SPR studies and crystallography 
Soluble mCD1-β2 M protein was expressed and purified from insect cells as described21. Glycolipid 
loading and SPR studies were performed as previously reported.22 In brief, increasing concentrations 
of TCR (two-fold dilutions from 500 nM to 15.625 nM) were passed over streptavidin immobilized 
CD1d using a CAP chip on a Biacore T200. A reference substraction included the TCR binding 
response to CD1d to which no lipid has been added. In addition, single cycle kinetics were carried out 
with 3-fold dilutions of TCR (900nM-11nM), without reference substraction. Running buffer 
contained no detergent in an attempt to not extract these short-acyl chain ligands during the course 
of the experiment. CD1d-ligand-TCR complex formation, purification, crystallization and structure 
determination was performed as reported previously23,24. Structure of mCD1d-5d and mCD1d-23 
have been deposited in the Protein Data Bank (http://www.rcsb.org/) under accession codes 5TW2 
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Chapter 5: Synthesis of C6''-Modified α-C-GalCer Analogues as Mouse and 
Human iNKT Cell Agonists 
5.1 Introduction 
As outlined in the general introduction, the C-glycoside of α-GalCer apparently possesses the ability 
to promote prolonged Th1-biased cytokine responses. Accordingly, α-C-GalCer exhibited a 100-fold 
more potent antimetastatic activity and a 1000-fold superior protection against malaria, as compared 
to α-GalCer.1 The observed Th1 bias seems to be a reflection of a prolonged IFN-γ production 
through trans-activation of NK cells and stable binding of α-C-GalCer to DCs.2 Strikingly, the activation 
of iNKT cells by α-C-GalCer is weaker than that of α-GalCer and is correlated with a lower TCR-
affinity. In contrast to α-GalCer, an approximate 6-fold decrease in TCR affinity was observed for the 
CD1d/α-C-GalCer complex, resulting in a shorter half-life of the ternary complex (~2,4 s versus ~35 s). 
Crystal structure analysis of the CD1d/α-C-GalCer/TCR complex revealed the basis for this affinity 
drop. In comparison to α-GalCer the ternary α-C-GalCer complex loses two hydrogen bonds. One 
between Gly96α of the TCR and Asp153 within the α2 helix of CD1d and the second between the 4”-
OH of the galactose moiety and Asn30α from the TCR. This loss of polar interactions is a result of the 
isosteric replacement of the O-glycosidic bond for a methylene unit, which is unable to accept an H-
bond from Tyr156. Consequently, the galactose is pulled less tight into the CD1d binding groove and 
a small shift occurs in the positioning of the glycon, causing the loss of the aforementioned 
interactions and in tandem the loss in affinity. (Figure 5.1)  
While showing promising results in mice, a major disadvantage of the C-glycoside is the inability to 
potently activate human iNKT cells in vitro.3 Yet, several C-glycoside analogues that contain an E-
alkene linker between the ceramide moiety and the galactose can activate both human and murine 
iNKT cells.4 Crystal data analysis shows that in the bound conformation the linker region of α-GalCer 
adopts an anti-dihedral angle of approximately 170° between the galactose and the ceramide. In the 
E-alkene derivatives this angle is fixed at 180° suggesting a better fit in the CD1d binding groove. 
However, a more recent study demonstrated that small differences in the iNKT TCR between humans 







Figure 5.1 NKT TCR-mediated interactions with mCD1d-glycolipid interface Top pane: CD1d/α-
GalCer/TCR complex Bottom pane: CD1d/α-C-GalCer/TCR complex (Adapted from Patel et al., 2011, 
J. Immunol and Birkholz et al., 2015, JBC) 
Since the first reported synthesis of α-C-GalCer in 2004, relatively few C-glycoside analogues have 
emerged in comparison to the O-glycoside series, which are omnipresent in literature. Most 
researchers have developed new synthetic strategies to prepare α-C-GalCer and have neglected the 
synthesis of derivatives. Nevertheless, a handful of C-glycoside derivatives were prepared and not 
surprisingly, most C-glycoside analogues are altered at the acyl moiety, as the nitrogen at C3 of the 
phytosphingosine chain serves as obvious diversification motif.4 Furthermore, modifications of the 
linker region have been extensively studied ranging from truncation to homologation as well as the 
preparation of unsaturated derivatives.6,7,8  
Driven by the promising results obtained with C6”-modified α-GalCer analogues prepared in our lab, 
we envisioned the challenging synthesis of the corresponding C-glycoside analogues, in an attempt to 
further enhance their biological activity. We previously demonstrated that compounds like NU-α-
GalCer and PyrC-α-GalCer, exhibit strong Th1 responses in mice and humans, resulting in superior 
protection against lung metastases in the B16 melanoma mouse model.9,10  
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5.2 Synthesis 
Initially we modified the procedure of Chen et al.8 utilizing the Julia-Kocienski olefination method to 
join the ceramide part to the sugar, as it allows the formation of both saturated and unsaturated 
derivatives. To allow swift manipulation of the C6”-position an orthogonally protected galactose 
formaldehyde was required. Treatment of perbenzylated α-methylgalactoside 5.5 with 
propargyltrimethylsilane and trimethylsilyl triflate, followed by the addition of acetic anhydride, 
furnished allene 5.6. Next, the acetate group was removed with ammonia in methanol and the 
alcohol was protected as PMB-ether. Ozonolysis of 5.7 and in situ reduction of the product with 
sodium borohydride gave primary alcohol 5.8, which was reoxidized to the desired galactose 
formaldehyde enabling Julia-Kocienski olefination. (Scheme 5.1) Unfortunately the 
ozonolysis/reduction sequence was poorly reproducible as only trace amounts of desired alcohol 5.8 
were obtained in most attempts. 
 
Scheme 5.1 Reagents and conditions: a) BnBr, TBAI, NaH, DMF, 0 °C  RT, 18h, 93%; b) i) 
propargylTMS, TMSOTf, MeCN, 0 °C, 72h; ii) Ac2O, 0 °C, 2h, 66% (over 2 steps); c) i) 7 N NH3 in 
methanol, RT, 20h; ii) PMBCl, TBAI, NaH, DMF, 0 °C  RT, 18h, 78% (over 2 steps); d) i) O3, DCM, 
MeOH, -78 °C, 2h; ii) NaBH4, 0 °C  RT, 5h, 5% - 73% 
 
With alcohol 5.8 in hand, we next prepared benzothiazole sulfone 5.14. First, diol 5.10 is prepared 
upon Boc-protection of the amine and subsequent silylation of the primary alcohol of commercially 
available phytosphingosine. Next, treatment of the 1,2-diol with 2,2-dimethoxy propane under acid 
catalysis, followed by hydrolysis of the silyl ether furnished primary alcohol 5.12. Finally, Mitsunobu 
reaction with 2-mercapto benzothiazole followed by oxidation with 3-chloroperbenzoic acid, gave 




Scheme 5.2 Reagents and conditions: a) Boc2O, EtOH, 1 M NaOH, H2O, RT, 2.5h; b) TBSCl, DMAP, 
DCM, DMF, Et3N, 0 °C, 2h, 82% (over 2 steps); c) 2,2-dimethoxy propane, PPTS, DCM, RT, 5h; d) TBAF 
(1 M in THF), THF, 0 °C, 2h, 93 % (over 2 steps); e) PPh3, DEAD, 2-mercapto benzothiazole, THF, -20 
°C RT, 18h, 81%; f) 3-chloroperbenzoic acid, NaHCO3, DCM, 0 °C  RT, 16h, 87% 
 
Next, Julia-Kocienski olefination between aldehyde 5.15 and benzothiazole 5.14 gave olefin 5.16 
showing no epimerization at the anomeric center. Subsequent deprotection of the PMB-ether was 
accomplished with ceric ammonium nitrate at low temperature and short reaction time to avoid 
unwanted acetonide cleavage. Primary alcohol 5.17 was converted to an azide by means of a 
Mitsunobu reaction with DPPA to furnish azide 5.18. Next, deprotection of the acid labile protecting 
groups with TFA and acylation of the resulting amine with the p-nitrophenyl ester of cerotic acid gave 
intermediate 5.19. Finally, Staudinger reduction followed by addition of 1-naphthyl isocyanate 
provided protected urea 5.20, which was subjected to a catalytic hydrogenolysis and concomitant 
alkene saturation using Pd-black under hydrogen atmosphere. However, the reaction proceeded 
sluggishly resulting in an inseparable mixture of products, including saturation of the naphthyl to the 
tetraline ring and incomplete double bond saturation. (Scheme 5.3)  
Noteworthy, a troublesome side reaction occurred during the TFA treatment as the released amine 
was converted to the trifluoroacetamide, significantly lowering the yield of this transformation. 
Addition of triethylsilane to suppress this side reaction did not particularly improve the reaction 
outcome.11 
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Scheme 5.3 Reagents and conditions: a) Dess-Martin periodinane, RT, 2h; b) benzothiazole sulfone 
5.14, LiHMDS, THF, -78 °C  RT, 18h, 46% (over 2 steps); c) CAN, H2O, MeCN, 0 °C, 50 min., 73%; d) 
PPh3, DEAD, DPPA, THF, -20 °C  RT, 18h, 66%; e) i) TFA, Et3SiH, DCM, RT, 5h; ii) p-nitrophenyl ester 
of cerotic acid, DMAP, THF, pyridine, RT, 48h, 60% (over 2 steps); f) i) PMe3, THF, H2O, RT, 18h; ii) 1-
naphthyl isocyanate, DMF, 0 °C  RT, 18h, quant. yield (over 2 steps); g) Pd black, H2, EtOH, CHCl3, 
6d 
 
To circumvent the unwanted saturation of the naphthyl ring, protecting group cleavage without 
hydrogenation was desirable. Considering the protection group strategy of the sulfone we opted for 
PMB-groups on the sugar aldehyde, as a single acid hydrolysis step removes all protecting groups. 
Rather than employing the allene approach, which suffers from low yields due to the unreliable 
ozonolysis/reduction step and the requirement of expensive reagents such as 
propargyltrimethylsilane, we synthesized propene 5.26. (Scheme 5.4)  
 
The synthesis of 5.26 starts with a C-glycosylation reaction with allyltrimethylsilane in presence of 
TMSOTf, resulting in a mixture of both α- and β-C-allyl glycosides in a 7:1 ratio. In order to obtain 
pure α-allyl C-glycoside 5.22, hydrolysis of the acetate moieties allowed the selective crystallization 






Figure 5.2 Comparison of the NMR spectra of the mixture of α and β anomers (black) with the 
recrystallized pure α-anomer (spectra recorded in CD3OD at 300 MHz) 
Next, the pure α-anomer was treated with acetic anhydride to furnish C-galactoside 5.22, which was 
subjected to a palladium-catalyzed isomerization reaction. Zemplén deacetylation of the obtained C-
propenyl sugar 5.23 and protection of the primary alcohol as triisopropylsilyl ether gave 
propenylgalactoside 5.25. The remaining hydroxyl functions were protected as PMB-ethers and 
propene sugar 5.26 was subjected to an osmium-catalyzed dihydroxylation to furnish vicinal diols 
5.27. (Scheme 5.4) 
 
Scheme 5.4 Reagents and conditions: a) allylTMS, TMSOTf, MeCN, 0 °C  RT, 18h, 64%; b) i) 
NaOMe, MeOH, pH=10, RT, 4h, then recrystallization ii) Ac2O, pyridine, RT, 20h, 69% (over 2 steps); c) 
Pd(PhCN)2Cl2, toluene, 90 °C, 72h, 63%; d) NaOMe, MeOH, pH=10, RT, 4h, 93%; e) TIPSCl, DMF, 
imidazole, 0 °C  RT, 16h, 84%; f) PMBCl, TBAI, NaH, DMF, 0 °C  RT, 18h, 96%; g) K2OsO4, NMO, 
H2O, MeCN, RT, 18h, 65% 
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Upon oxidation of the vicinal diol with sodium periodate C-formyl galactoside 5.28 was obtained 
amenable for Julia-Kocienski olefination with the previously used sulfone. Using the same coupling 
protocol as for 5.16, an inseparable mixture of α- and β-anomers was obtained together with side 
product 5.30 due to β-elimination. The α/β-ratio could be increased by slow addition of the aldehyde 
to the deprotonated sulfone in dilute conditions, which also reduced the formation of elimination 
product. After deprotection of the silylether with tetrabutylammonium fluoride both anomers could 
be easily purified by column chromatography to furnish alcohol 5.31 as the single α-anomer (Scheme 
5.5). 
Scheme 5.5 Reagents and conditions: a) NaIO4, THF,H2O, RT, 2h b) benzothiazole sulfone 5.14, 
LiHMDS, THF, -78 °C  RT, 16h, 46% (over 2 steps); c) TBAF (1 M in THF), THF, 0 °C  RT, 18h, 65% 
Mitsunobu reaction with hydrazoic acid to introduce an azide functionality at C6” did not furnish the 
desired product. Furthermore, the use of DPPA as azide source gave no reaction, while mesylation 
followed by sodium azide treatment gave the undesired elimination product. To our delight 
Mitsunobu reaction with phthalimide swiftly yielded 5.32 in good yield. Treatment with hydrazine 
monohydrate not only liberated the free amine but conveniently reduced the alkene via diimide 
reduction. Switching hydrazine for methylhydrazine allowed to remain the double bond intact. Next, 
treatment of the crude amines with 1-naphthyl isocyanate furnished the corresponding urea 
derivatives. To avoid trifluoroacetamide formation the acid-labile protecting groups were removed 
by dissolving intermediates 5.33 and 5.34 in a 4 M HCl in dioxane solution. An attempt to acylate the 
resulting amines by treatment with cerotoyl chloride in a biphasic mixture of THF and saturated 
sodium acetate solution12 resulted in a mixture of the desired compound and the corresponding 
acetamide, probably due to mixed anhydride formation. Addition of the p-nitrophenyl ester of 
cerotic acid in DCM gave 5.1, while acylation with cerotoyl chloride in a biphasic mixture of THF and 1 
M KOH solution gave 5.2. The low yields associated with the final acylation are likely due to the low 




Scheme 5.6 Reagents and conditions: a) Phtalimide, DEAD, PPh3, THF, -20 °C  RT, 5h, 88%; b) i) 
MeNHNH2, EtOH, 80 °C, 3h ii) 1-naphthyl isocyanate, DMF, 0 °C  RT, 16h, 60% (over 2 steps); c) i) 4 
M HCl in dioxane, RT, 2h ii) p-nitrophenyl ester of cerotic acid, DMAP, Et3N, THF, RT, 48h, 29% (over 2 
steps); d) i) NH2NH2, EtOH, 80 °C, 3h ii) 1-naphthyl isocyanate, DMF, 0 °C  RT, 16h, 77% (over 2 
steps); e) i) 4 M HCl in dioxane, RT, 2h ii) cerotoyl chloride, THF, 10% KOH, 0 °C  RT, 3h, 29% (over 2 
steps) 
 
Since 4-pyridylisocyanate is not commercially available the primary alcohol of 5.31 was first treated 
with p-nitrophenyl chloroformate and the mixed anhydride was subsequently turned into the 4-
pyridylcarbamate by addition of 4-aminopyridine. Deprotection with HCl and acylation gave 5.3. 
Obtaining the saturated carbamate through catalytic hydrogenation proved arduous since the 
pyridine nitrogen poisons the palladium catalyst. Addition of acetic acid to protonate the pyridine 
improved the conversion rate, although full saturation of the double bond could not be attained. 
Instead, we used the diimide reduction with hydrazine to saturate intermediate 5.31 and further 
derivatization following previously used reactions furnished saturated derivative 5.4. (Scheme 5.7) 
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Scheme 5.7 Reagents and conditions: a) i) p-nitrophenyl chloroformate, DCM, pyridine, RT  40 °C, 
9h ii) 4-amino pyridine, DCM, Et3N, 40 °C, 16 h, 62% (over 2 steps); b) 4 M HCl in dioxane, RT, 2h ii) p-
nitrophenyl ester of cerotic acid, DMAP, Et3N, THF, RT, 48h, 17% (over 2 steps); c) ) NH2NH2, EtOH, 80 
°C, 18h, 73%; d) i) p-nitrophenyl chloroformate, DCM, pyridine, RT  40 °C, 9h ii) 4-amino pyridine, 
DCM, Et3N, 40 °C, 16 h, 55% (over 2 steps); e) 4 M HCl in dioxane, RT, 2h ii) p-nitrophenyl ester of 
cerotic acid, DMAP, Et3N, THF, RT, 48h, 44% (over 2 steps) 
 
5.3 Biological evaluation 
To assess the antigenic potency of the final compounds, plate-bound CD1d was loaded overnight 
with varying concentration of the target glycolipids. After 16h of coculture with Vα14 iNKT 
hybridoma 1.2 (mouse iNKT cell line), IL-2 secretion was determined by ELISA. All novel C-glycoside 
analogues were less potent than α-GalCer and the corresponding parent O-glycosides PyrC-α-GalCer 
and NU-α-GalCer. (Figure 5.3) It should be noted that α-C-GalCer and all C-glycoside analogues 
known to date, also show reduced antigenic properties as compared to α-GalCer. 
In terms of relative potency, the C-glycoside series mirror the trend for the O-glycosides, identifying 
the pyridine carbamates 5.3 and 5.4 as more antigenic compared to naphthylureas 5.1 and 5.2. 
Strikingly, the nature of the linker region (E-alkene versus saturated alkane) doesn’t affect the 





Figure 5.3 IL-2 secretion after coculture of Vα14 iNKT hybridoma 1.2 with plate bound 
CD1d/glycolipid complexes 
Next, the cytokine secretion profile of the C-glycosides was evaluated upon intraperitoneal 
administration of 5 µg of the corresponding glycolipids in C57BL/6 mice. Serum levels of IFN-γ and IL-
4 were determined by ELISA, at 16h and 4h respectively. Considering the IL-2 data presented above, 
we expected that the levels of secreted cytokines would be inferior to α-GalCer. Remarkably 
however, pyridine carbamate 5.4 showed IFN-γ levels that are comparable with the levels obtained 
for α-GalCer, whilst secreting less IL-4 and thus induces a Th1 biased cytokine response. Moreover, 
5.4 shows near equal IFN-γ secretion as its parent compound PyrC-α-GalCer. (Figure 5.4) 
Interesting to note is that while the cytokine secretion induced by C-glycoside analogues 5.1, 5.2 and 
5.3 was indeed inferior to α-GalCer, they surpass the cytokine secretion induced by α-C-GalCer. 
 
Figure 5.4 IFN-γ and IL-4 secretion, measured at respective 16 h and 4 h, after intraperitoneal 
injection of 5 μg of the glycolipids in mice. Data points and SEM are depicted. 
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Since it has previously been shown that α-C-GalCer is able to induce a prolonged IFN-γ secretion1, we 
injected C57BL/6 mice with 1 µg of the prepared glycolipids, and at various time points obtained 
blood samples for IFN-γ and IL-4 quantification by means of ELISA. (Figure 5.5) Similar to the 
experiment described above, with the exception of 5.2, all synthesized C-glycoside analogues 
glycolipids show superior antigenic properties as compared to α-C-GalCer. Furthermore, carbamate 
5.4 shows significantly more IFN-γ secretion compared to α-GalCer and displays elevated levels of 
INF-γ up to 48h post injection. These results further emphasize that modification of the C6”-OH with 
a naphthylurea or pyridine carbamate, is generally beneficial for the activity of α-GalCer analogues 
and in general that the pyridine carbamate modified analogues are more potent than the 
naphthylurea derivatives. 
 
Figure 5.5 IFN-γ and IL-4 levels at different time points after injection of 1µg of the glycolipids in 
mice. Data points and SEM are depicted. 
In an attempt to rationalize the cytokine secretion pattern for the four C-glycoside analogues, we 
determined the equilibrium binding affinities of the mouse iNKT TCR towards the four CD1d-
glycolipid complexes using surface plasmon resonance (SPR). (Table 5.1) The glycolipid antigens were 
loaded onto biotinylated mouse CD1d and coated on a Biacore sensor chip. Next, increasing 
concentrations of refolded mouse iNKT TCR were passed over the chips to measure real time binding 
kinetics. 
 
The data indicates that the affinity of the TCR for all C-glycoside analogues is lower as compared to 
the parent O-glycosides. Additionally, E-alkene derivatives 5.1 and 5.3 display higher affinity for the 
TCR than the saturated derivatives. This trend can be rationalized by the observation that in the 
bound conformation of α-GalCer the angle of the linker region between the galactose sugar and 
ceramide is approximately 170°. The E-alkene analogs, which have a fixed angle of 180°, may 




TCR.4 However, the E-alkene linker forces the molecules to stretch out and as a consequence lowers 
the solubility of the final compounds. The peculiar solubility of the final compounds was not only 
experienced in the lab during the synthesis of the molecules, but also reflects in the reduced lipid 
loading efficiency of the E-alkenes (5.1 vs 5.2 and 5.3 vs 5.4) in the in vitro experiment. 
 
Table 5.1 Equilibrium binding affinity of the iNKT TCR towards the indicated glycolipid/CD1d 
complexes 
 
It should be noted that the in vitro loading efficiency should not be considered as a measure for in 
vivo loading, as in the latter case lipid transfer proteins can facilitate the loading. However, the 
cytokine secretion does seem to depend on both affinity and loading efficiency, as pyridine 
carbamate 5.4 combines the lowest binding affinity for the TCR with the highest loading efficiency. 
Overall, the affinity data for the saturated derivatives 5.2 and 5.4 does not differ much from the 
affinity reported for the parent α-C-GalCer (KD = 247 nm),
10 indicating that factors other than the 
affinity for the TCR are responsible for the differences observed in cytokine secretion. 
 
Finally, since α-C-GalCer is unable to stimulate human iNKT cells due to the presence of small 
differences between mouse and human CD1d (chapter 1), we evaluated the C-glycoside analogues in 
a human setting. For this, 5x104 human iNKT cells from healthy adult individuals were cocultured with 
5x104 glycolipid pulsed PBMCs, which were incubated overnight in the presence of the indicated C-
glycoside analogues (100 ng/ml) or DMSO. Supernatants were collected after 24h and 48h of culture 
and IL-4 and IFN-γ levels were determined by means of ELISA.13 (Figure 5.6) 
 
Lipid KD Kon Koff RU cd1 RU TCR lipid loading(%) 
5.1 32 nM 2,83E+05 0,008904 1111 38 3,42 
5.2 224 nM 1,42E+04 0,003181 1266 60 4,74 
5.3 82 nM 8,21E+04 0,006739 1419 200 14,09 
5.4 298 nM 1,35E+04 0,004011 1303 200 15,35 
PyrC-α-GalCer 8 nM 3,20E+05 0,002557 209 124 59,33 
NU-α-GalCer 24 nM 2,06E+05 0,004942 609 117 19,21 
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Figure 5.6 IFN-γ and IL-4 secretion after coculture of human iNKT cells and PBMC’s incubated 
overnight with 100 ng/mL of the corresponding glycolipids. Data points and SEM are depicted. 
We were delighted to observe that all C-glycoside analogues were able to activate human iNKT cells, 
indicating that the appended C6”-substituents have the ability to restore the antigenic potency of α-
C-GalCer in humans. As expected, α-C-GalCer failed to induce cytokine secretion from human iNKT 
cells, while in line with previous observations, the E-alkene derivative restored the activity. E-alkene 
naphthyl urea 5.1 displays interesting characteristics as it induces nearly equal amounts of IFN-γ 
compared to both α-GalCer and its parent compound NU-α-GalCer, in tandem with lowered levels of 
IL-4. To the best of our knowledge, in a human context 5.1 is the first C-glycoside analogue that is 
able to induce comparable levels of cytokine secretion as compared to α-GalCer, whilst displaying a 
Th1 profile.  
Remarkably, while E-alkene 5.1 is outperforming the saturated naphthylurea 5.2, it seems the 
saturated pyridine carbamate 5.4 is marginally more active than the unsaturated derivative 5.3. We 
hypothesized that due to the fixed angle of 180° for the linker region between the glycon and the 
ceramide, the conformational strain may hamper the pyridine ring of 5.3 to form additional van der 
Waals contacts with the TCR observed for the parent O-glycoside.9 Saturated derivative 5.4, which 
possesses more flexibility in the linker region, may therefore restore the additional contacts with the 
TCR, leading to the observed biologic activity. Crystal structures of the final compounds with human 




Surprisingly, when the final compounds were evaluated in a different human setting, where 1x104 
human iNKT cells (cell line #630B) were cocultured with 4x104 glycolipid loaded Hela-CD1d cells, 
where after 24h the IFN-γ secretion was determined by ELISA, glycolipid 5.3 showed the most 
promising activity. (Figure 5.7) However, it should be noted that at the concentration of 100 ng/mL 
(red bars), the differences in IFN-γ levels are rather small and they mirror the data from figure 5.6 for 
the 24h ELISA. The observed results could be a reflection of the solubility difference between the 
prepared C-glycoside analogues. There is a relatively big gap in solubility between a naphthyl moiety 
and a pyridine ring, the latter being more soluble due to the basic nitrogen in the ring. As a 
consequence, increasing the concentration of compounds 5.1 and 5.2 may not result in more free 
glycolipid antigen available for CD1d, whereas for the pyridine carbamates this probably increases 
the free antigen concentration to a greater extent. However, this hypothesis does not hold for E-
alkene 5.3, which is likely to be less soluble than the saturated counterpart 5.4, yet 5.3 induces 
higher levels of IFN-γ.  
Another possible explanation may be that while the Hela-CD1d cells have a more uniform CD1d 
distribution, they lack co-stimulatory molecules and therefore, the generated immune response is 
somewhat artificial. It is well documented that co-stimulatory factors are of great importance for 
iNKT cell activation. 14,15  
 
Figure 5.7 IFN-γ secretion after coculture of human iNKT cells and Hela CD1d cells with the indicated 
C-glycoside analogues. Bars represent means + SEM. 
5.4 Conclusion 
In summary, we developed a versatile synthetic strategy allowing the preparation of both saturated 
and unsaturated α-C-GalCer derivatives with variable C6”-substituents. We expanded the Julia-
Kocienski method utilized by Franck et al., and developed a scalable and reliable route for the 
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preparation of an orthogonally protected C-formyl galactoside. Key-intermediate 5.31 allows access 
to a plethora of C-glycosides including saturated and unsaturated derivatives, modifications of the 
acyl moiety and alteration of the C6”-OH.  
To our delight all of the prepared C-glycoside analogues were able to stimulate human iNKT cells in 
two independent experiments. This finding, denotes that the appended C6”-substituents have the 
ability to restore the antigenic potency of α-C-GalCer, which lacks activity on human iNKT cells. 
Further experiments are ongoing to elucidate the reason for the contrasting biological activity 
observed in both models. 
5.5 Experimental part 
Methyl 2,3,4,6-Tetra-O-benzyl-α-D-galactopyranose (5.5) 
To a solution of methyl-α-D-galactopyranose (5 g, 25.75 mmol) in anhydrous DMF (100 mL) at 0 °C, 
was added NaH (2.97g, 123.58 mmol) and the reaction mixture was stirred for 30 minutes. Next 
benzylbromide (14.78 mL, 123.58 mmol) was added dropwise and the mixture was allowed to reach 
room temperature and was stirred overnight. The mixture was then cooled to 0 °C and quenched by 
addition of H2O (50 mL). The aqueous layer was extracted with EtOAc (3 x 75 mL), the combined 
organic layers washed with H2O and brine, dried with MgSO4 and filtered. The solvent was removed 
under reduced pressure and the residue was purified by column chromatography (hexane/EtOAc: 
85/15) to furnish galactoside 5.5 (13.52g, 95%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 3.35 (s, 3 H, OCH3) 3.52 (d, J = 6.4 Hz, 2 H, CH2-6) 3.86 – 3.93 (m, 
3 H, H-3, H-4 and H-5) 4.01 – 4.07 (m, 1 H, H-2) 4.35 – 4.97 (m, 9 H, CH2Ph and H-1) 7.19 – 7.43 (m, 20 
H, CH2Ph). 
13C NMR (75 MHz, CDCl3): δ 55.33, 69.07, 69.22, 73.27, 73.46, 73.55,74.72 ,75.17, 76.45, 
76.58, 77.00, 77.21, 77.43, 79.11, 98.79, 127.46, 127.54, 127.65, 127.67, 127.73, 127.91, 128.07, 
128.19, 128.23, 128.30, 128.34, 128.36, 137.97, 138.51, 138.64, 138.82. 
Exact mass (ESI-MS) for C35H38KO6 [M+K]
+ found, 593.2315; calcd, 593.2305. 
1-allenyl-6-O-acetyl-2,3,4-tri-O-benzyl-α-D-galactopyranose (5.6) 
To a solution of 5.5 (5.7 g, 10.28 mmol) in anhydrous acetonitrile (30 mL) at 0 °C, was added 
propargyltrimethylsilane (80 – 90%, 3.85 mL, 20.55 mmol) followed by the addition of TMSOTf (1.37 
mL, 5.14 mmol). The reaction mixture was stirred for 2 days at 0 °C and upon disappearance of the 
starting material (as judged by TLC), Ac2O (15 mL) was added dropwise. The mixture was allowed to 
stir for another 30 minutes at 0 °C before addition of DCM (100 mL) and saturated NaHCO3 solution 
(50 mL) to quench the reaction. The aqueous layer was extracted with DCM (2 x 75 mL) and the 




removed under reduced pressure and the residue was purified by flash column chromatography (20 
 30% EtOAc in hexanes) to furnish allenyl-sugar 5.6 (3.49 g, 66% over 2 steps) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 2.02 (s, 3 H, CH3) 3.73 (dd, J = 8.5 and 2.8 Hz, 1 H, H-4) 3.93 (t, J = 
2.7 Hz, 1 H, H-3) 4.02 – 4.09 (m, 2 H, H-2 and H-5) 4.17 (dd, J = 11.7 and 4.1 Hz, 1 H, Ha-6) 4.27 – 4.36 
(m, 1 H, Hb-6) 4.60 – 4.89 (m, 9 H, H-1, CH2Ph, CH=C=CH2) 5.41 (td, J = 6.7 and 5.0 Hz, 1 H, CH=C=CH2) 
7.29 – 7.40 (m, 15 H, CH2Ph). 
Exact mass (ESI-MS) for C32H34NaO6 [M+Na]
+ found, 537.2245; calcd, 537.2248. 
Spectral data are consistent with the literature data.16 
1-allenyl-6-O-p-methoxybenzyl-2,3,4-tri-O-benzyl-α-D-galactopyranose (5.7) 
A solution of allene 5.6 (4.42 g, 8.6 mmol) in a 7 N NH3 in methanol solution (80 mL) was stirred for 3 
days at room temperature. Upon deacetylation the solvents were removed under reduced pressure 
and the residue was used without further purification. 
The crude sugar was dissolved in anhydrous DMF (30 mL) and cooled to 0 °C. PMBCl (1.06 mL, 7.81 
mmol) and TBAI (125 mg) were added before the addition of NaH (60% dispersion, 221 mg, 5.52 
mmol). The resulting mixture was allowed to reach room temperature and was stirred overnight. 
Upon completion, the mixture was cooled to 0 °C and H2O (100 mL) was slowly added to quench the 
reaction. The aqueous layer was extracted with EtOAc (3 x 75 mL) and the combined organics washed 
with H2O (100 mL) and brine (100 mL). The organic layer was dried over Na2SO4, filtered and 
evaporated under reduced pressure. The residue was purified by column chromatography (0  15% 
EtOAc in hexanes) yielding PMB-ether 5.7 (3,98 g, 78%) as a clear oil. 
1H NMR (300 MHz, CDCl3): δ 3.55 – 3.61 (m, 2 H, H-5 and Ha-6) 3.73 (dd, J = 9.4 and 2.8 Hz, 1 
H, H-3) 3.81 (s, 3 H, OCH3) 3.95 – 4.02 (m, 2 H, H-4 and Hb-6) 4.14 (dd, J = 9.3 and 5.5 Hz, 1 H, H-2) 
4.37 (d, J = 11.5 Hz, 1 H, CH2PhOMe) 4.45 (d, J = 11.5 Hz, 1 H, CH2PhOMe) 4.57 – 4.92 (m, 9 H, H-1, 
CH2Ph, CH=C=CH2) 5.43 (td, J = 6.6 and 5.3 Hz, 1 H, CH=C=CH2) 6.83 – 6.86 (m, 2 H, CH2PhOMe) 7.18 – 
7.24 (m, 2 H, CH2PhOMe) 7.25 – 7.37 (m, 15 H, CH2Ph). 
13C NMR (75 MHz, CDCl3): δ 55.25, 68.10, 71.76, 72.85, 72.99, 73.09, 74.35, 74.86, 76.53, 
76.70, 77.21, 78.92, 86.07, 113.74, 127.41, 127.46, 127.53, 127.56, 127.67, 128.14, 128.20, 128.28, 
128.31, 129.45, 130.19, 138.44, 138.62, 138.67, 159.20, 208.91. 
Exact mass (ESI-MS) for C38H41O6 [M+H]
+ found, 593.2900; calcd, 593.2898. 
1-hydroxymethyl-6-O-p-methoxybenzyl-2,3,4-tri-O-benzyl-α-D-galactopyranose (5.8) 
Ozone was bubbled through a solution of allene 5.7 (1.75 g, 3 mmol) in anhydrous DCM (80 mL) and 
MeOH (20 mL) at -78°C for 1h15 min. After flushing with oxygen, NaBH4 (560 mg, 14.8 mmol) was 
added at 0°C and the reaction mixture was stirred for 2h. Water was added and the aqueous phase 
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was extracted with DCM (3 x 50 ml). The combined organic layers were washed with brine, dried 
over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography (35%  
40% EtOAc in hexanes) to afford 5.8 (1.26 g, 73%) as a colorless liquid. 
1H NMR (300 MHz, CDCl3): δ 2.07 (d, J = 5.7 Hz, 1 H, OH) 3.61 (dd, J = 10.5 and 4.5 Hz, 1 H, Ha-
CH2OH) 3.65 – 3.73 (m, 1 H, Ha-6) 3.76 (dd, J = 6.8 and 2.7 Hz, 1 H, H-4) 3.80 – 3.82 (m, 4 H, Hb-
CH2OH and OCH3) 3.81 – 3.85 (m, 1 H, Hb-6) 3.85 – 3.92 (m, 1 H, H-5) 4.01 (dd, J = 3.6 and 2.9 Hz, 1 H, 
H-3) 4.04 – 4.12 (m, 2 H, H-1 and H-2) 4.39 – 4.75 (m, 8 H, CH2Ph and CH2PhOMe) 6.84 – 6.89 (m, 2 H, 
CH2PhOMe) 7.21 – 7.28 (m, 2 H, CH2PhOMe) 7.28 – 7.38 (m, 15 H, CH2Ph). 
13C NMR (75 MHz, CDCl3): δ 55.25, 60.64, 67.10, 71.44, 72.97, 73.04, 73.13, 73.28, 74.03, 
76.02, 104.74, 113.79, 127.50, 127.65, 127.70, 127.89, 127.97, 128.00, 128.32, 128.38, 128.48, 
129.42, 129.49, 129.69, 130.13, 137.78, 138.26, 138.31, 159.22. 
Exact mass (ESI-MS) for C36H40KO7 [M+K]
+ found, 623.2403; calcd, 623.2406. 
tert-butyl ((2S,3S,4R)-1-((tert-butyldimethylsilyl)oxy)-3,4-dihydroxyoctadecan-2-yl)carbamate (5.10) 
To a suspension of phytosphingosine (10 g, 31.5 mmol) in 1 M aqueous NaHCO3 (23 ml), H2O (60 mL) 
and EtOH (120 ml) was added di-tert-butyl dicarbonate (10.32 g, 47.3 mmol). The reaction mixture 
was stirred at room temperature for 3h. Upon completion of the reaction the suspension was 
quenched with saturated NH4Cl solution and extracted with EtOAc (3 x 200 mL). The combined 
organic layer was washed with brine, dried over Na2SO4, and concentrated to afford the crude triol as 
a white solid. The crude triol was dissolved in anhydrous DCM (200 ml), DMF (50 ml) and Et3N (5 mL). 
The mixture was cooled to 0 °C, followed by the addition of TBSCl (5.7 g, 37.8 mmol) and a catalytic 
amount of 4-DMAP (280 mg). After stirring for 2 h at 0 °C, the mixture was diluted with DCM (200 
mL) and washed subsequently with saturated aqueous NH4Cl (150 mL) and H2O (150 mL). The organic 
phase was dried over Na2SO4, filtered and evaporated under reduced pressure. The resulting residue 
was purified by column chromatography (hexane/EtOAc: 9/1  8/2) providing diol 5.10 (13.24 g, 
82% over 2 steps) as a pale liquid. 
1H NMR (300 MHz, CDCl3): δ 0.13 (s,6 H, 2x CH3 TBS) 0.91 (t, J = 6.8 Hz, 3 H, terminal CH3) 0.93 
(s, 9 H, tBu TBS) 1.25-1.75 (m, 26 H, CH2) 1.47 (s, 9 H, tBu Boc) 2,69 (d, J = 7.4 Hz, 1 H, OH) 3.15 (d, J = 
7.5 Hz, 1 H, OH) 3.66 – 3.59 (m, 2 H, H-3 and H-4) 3.81 – 3.77 (m, 1 H, Ha-1) 3.85 (br s, 1 H, H-2) 3.95 
(d, J = 9.2 Hz, 1 H, Hb-1) 5.19 (d, J = 7.5 Hz, 1 H, NH). 
13C NMR (75 MHz, CDCl3): δ -5.61, -5.52, 14.08, 22.74, 25.81, 25.88, 28.43, 29.31, 29.56, 
29.61, 29.64, 29.68, 31.94, 33.43, 51.67, 62.89, 73.42, 76.01. 
Exact mass (ESI-MS) for C29H62NO5Si [M+H]






To a solution of diol 5.10 (13.24 g, 25.8 mmol) in anhydrous DCM (250 ml) and 2,2- 
dimethoxypropane (25 mL, 200 mmol) at room temperature was added a catalytic amount of 
pyridinium p-toluenesulfonate (200 mg). The reaction mixture was stirred for 5 h at room 
temperature. Next the reaction mixture was diluted with DCM and quenched with saturated aqueous 
NaHCO3 solution. The aqueous layer was extracted with DCM (3 x 150 mL) and the combined organic 
layers were washed with brine, dried over Na2SO4, and concentrated to afford the crude acetonide. 
This crude was used without further purification in the desilylation reaction. To an ice cooled solution 
of the crude acetonide in THF (250 ml) was added tetrabutylammonium fluoride (1.0 M in THF, 34 ml, 
34 mmol). After stirring for 2 h at 0 °C, saturated aqueous NH4Cl solution was added to quench the 
reaction. The aqueous layer was extracted with DCM (3 x 150 mL) and the combined organic layers 
were washed with saturated aqueous NaHCO3 solution and brine. The organics were dried over 
Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column 
chromatography (hexanes/EtOAc: 7/3) to provide alcohol 5.12 (10.68 g, 93 % over 2 steps) as a white 
solid. 
1H NMR (300 MHz, CDCl3): δ 0.88 (t, J = 6.9 Hz, 3 H, terminal CH3) 1.21-1.39 (m, 22 H, CH2) 
1.32 (s, 3 H, CH3) 1.45 (s, 9 H, tBu) 1.46 (s, 3 H, CH3) 1.50-1.66 (m, 4H, CH2) 2.29 (br. s, 1 H, OH) 3.66 – 
3.91 (m, 3 H, H-2 and CH2-1) 4.05 – 4.13 (m, 1 H, H-4) 4.12 – 4.23 (m, 1 H, H-3) 4.95 (d, J = 8.5 Hz, 1 H, 
NH). 
13C NMR (75 MHz, CDCl3): δ 14.11, 22.67, 25.32, 26.71, 27.59, 28.36, 29.22, 29.34, 29.45, 
29.58, 29.61, 29.73, 31.88, 51.14, 63.89, 77.92, 78.33. 
Exact mass (ESI-MS) for C26H52NO5 [M+H]
+ found, 458.3833; calcd, 458.3840. 
tert-butyl((R)-2-(benzo[d]thiazol-2-ylthio)-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-1,3-dioxolan-4-
yl)ethyl)carbamate (5.13) 
To a solution of alcohol 5.12 (10.68 g, 23.34 mmol) in anhydrous THF (530 mL) at -20°C was added 
PPh3 (6.71 g, 25.67 mmol), DEAD (40% DEAD in toluene, 11.65 mL, 25.67 mmol) and 2-mercapto 
benzothiazole (4.30 g, 25.67 mmol) in this order. The resulting mixture was allowed to reach room 
temperature and was stirred for 18h. Upon complete consumption of the starting material the 
solvents were removed under reduced pressure and the resulting residue was taken in EtOAc (250 
mL). The organic layer was washed with 1 M NaOH (2 x 100 mL), 1 M HCl (100 mL) and saturated 
NaHCO3 solution (100 mL). Next the organic phase was dried over Na2SO4, filtered and evaporated 
under reduced pressure. The resulting residue was purified by column chromatography 
(hexane/EtOAc: 9/1) affording pure thioether 5.13 (11.44 g, 81%) as a white solid 
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1H NMR (300 MHz, CDCl3): δ 0.89 (t, J = 6.6 Hz, 3H, terminal CH3) 1.21 – 1.35 (m, 31 H, tBu, 
CH2) 1.35 (s, 3H, CH3) 1.50 (s, 3H, CH3) 1.50 – 1.71 (m, 4 H, CH2) 3.59 (dd, J = 14.2 and 7.4 Hz, 1 H, Ha-
1) 3.68 – 3.79 (m, 1 H, Hb-1) 3.94 – 4.23 (m, 3 H, H-2, H-3 and H-4) 5.22 (d, J = 7.6 Hz, 1 H, NH) 7.27 – 
7.33 (m, 1 H, arom. H) 7.38 – 7.45 (m, 1 H, arom. H) 7.75 (ddd, J = 8.0, 0.7 and 0.5 Hz, 1 H, arom. H) 
7.86 (d, J = 8.1 Hz, 1 H, arom. H). 
13C NMR (75 MHz, CDCl3): δ 14.11, 22.69, 25.51, 26.69, 27.76, 28.14, 28.99, 29.34, 29.50, 
29.54, 29.62, 29.65, 29.68, 31.91, 36.65, 50.65, 77.90, 78.62, 79.38, 108.16, 120.93, 121.36, 124.49, 
126.14, 135.14, 155.17. 
Exact mass (ESI-MS) for C33H54N2NaO4S2 [M+Na]
+ found, 607.3593; calcd, 607.3598. 
tert-butyl((R)-2-(benzo[d]thiazol-2-ylsulfonyl)-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-1,3-dioxolan-4-
yl)ethyl)carbamate (5.14) 
To a solution of thioether 5.13 (11.44 g, 18.84 mmol) in DCM (210 mL) at 0° C was added solid 
NaHCO3 (7.92 g, 94.2 mmol) and 3-chloroperbenzoic acid (70% pure, 11.61 g, 47.10 mmol). The 
resulting suspension was stirred overnight at room temperature. The reaction mixture was then 
cooled to 0 °C and H2O (150 mL) was added to quench the reaction. The aqueous layer was extracted 
with DCM ( 2 x 150 mL) and the combined organic layer was washed with saturated NaHCO3 solution 
(100 mL) and brine (100 mL). The organic phase was then dried over Na2SO4, filtered and evaporated 
under reduced pressure. The residue was purified by column chromatography (hexane/ EtOAc: 8/2) 
affording sulfone 5.14 (10.48 g, 87%) as a white solid. 
1H NMR (300 MHz, CDCl3): δ 0.88 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.15 – 1.35 (m, 34 H, tBu, 
CH3, CH2) 1.38 (s, 3H, CH3) 1.45 – 1.58 (m, 4 H, CH2) 3.85 – 4.05 (m, 2 H, CH2-1) 4.08 – 4.32 (m, 3 H, H-
2, H-3 and H-4) 4.85 (d, J = 8.8 Hz, 1 H, NH) 7.61 (quint d, J = 7.4 and 1.5 Hz, 2 H, arom. H) 7.97 – 8.02 
(m, 1 H, arom. H) 8.18 – 8.23 (m, 1 H, arom. H). 
13C NMR (75 MHz, CDCl3): δ 14.11, 22.69, 25.10, 26.79, 27.31, 28.01, 28.55, 29.36, 29.45, 
29.48, 29.57, 29.63, 29.68, 30.18, 31.92, 47.32, 48.96, 55.75, 77.20, 77.61, 79.95, 108.25, 122.31, 
125.50, 127.57, 127.98, 128.24, 129.79, 130.21, 133.63, 152.67, 154.29, 166.62, 168.35. 
Exact mass (ESI-MS) for C33H55N2O6S2 [M+H]
+ found, 639.3492; calcd, 639.3496. 
 (3S,4S,5R)-1-(2’,3’,4’-tri-O-benzyl-6’-O-p-methoxybenzyl-α-C-D-galactopyranosyl)-3-
tertbutyloxycarbonylamino-4,5-Di-O-isopropylidene-1-nonadecene-4,5-diol (5.16) 
To a solution of alcohol 5.8 (538 mg, 0.92 mmol) in DCM (20 ml) was added Dess-Martin periodinane 
(468 mg, 1.1 mmol) and the reaction mixture was stirred at room temperature for 2h. Upon 
disappearance of the starting material as judged by TLC, saturated NaHCO3 solution (10 mL) was 




combined organic phases were dried over Na2SO4, filtered and concentrated to afford the crude 
aldehyde which was used without further purification in the next step. 
Lithium bis(trimethylsilyl)amide (1 M in THF, 1.84 mL, 1.84 mmol) was slowly added to a solution of 
sulfone 5.14 (538 mg, 0.92 mmol) in anhydrous THF (15 mL) at -78°C. After 1h, the above prepared 
crude aldehyde in THF (20 mL) was added dropwise over a period of 45 minutes. The mixture was 
allowed to warm to room temperature and stirred overnight. The reaction was quenched with water 
(20 mL) and extracted with Et2O (3 x 20 mL). The combined organic phases were washed with water 
and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column 
chromatography (toluene/EtOAc: 95/5) to afford alkene 5.16 (428 mg, 46%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 0.89 (t, J = 6.8 Hz, 3 H, terminal CH3) 1.17 – 1.34 (m, 25 H, CH3 
and CH2) 1.39 (s, 3 H, CH3) 1.43 (s, 9 H, tBu) 1.48 – 1.71 (m, 4 H, CH2) 3.51 – 3.67 (m, 3 H, H-4” and 
CH2-6”) 3.80 (s, 3 H, OCH3) 3.93 – 4.10 (m, 4 H, H-4, H-2”, H-3” and H-5”) 4.10 – 4.20 (m, 1 H, H-5) 
4.28 – 4.74 (m, 10 H, CH2Ph, CH2PhOMe, NH, H-3 and H-1”) 4.79 – 4.95 (m, 1 H, CH2Ph) 5.90 (dd, J = 
16.1 and 3.2 Hz, 1 H, H-1) 5.98 (dd, J = 16.4 and 4.0 Hz, 1 H, H-2) 6.82 – 6.89 (m, 2 H, CH2PhOMe) 7.09 
– 7.43 (m, 17 H, CH2Ph and CH2PhOMe). 
13C NMR (75 MHz, CDCl3): δ 14.12, 22.69, 25.44, 26.86, 27.31, 28.18, 28.36, 28.96, 29.36, 
29.58, 29.64, 29.66, 29.70, 31.92, 52.22, 55.23, 67.91, 71.65, 72.58, 72.90, 72.92, 73.24, 74.05, 74.96, 
76.78, 77.21, 77.75, 79.47, 79.57, 107.98, 111.33, 113.70, 113.84, 122.63, 123.22, 123.95, 126.10, 
126.43, 127.33, 127.42, 127.48, 127.53, 127.79, 128.04, 128.18, 128.25, 128.30, 128.57, 129.38, 
129.71, 130.35, 131.38, 135.00, 138.54, 138.66, 138.69, 154.95, 159.13, 171.73. 
Exact mass (ESI-MS) for C62H87NNaO10 [M+Na]
+ found, 1028.6207; calcd, 1028.6222. 
 (3S, 4S, 5R)-1-(2’,3’,4’-tri-O-benzyl-6’-hydroxy-α-C-D-galactopyranosyl)-3-tertbutyloxycarbonylamino-
4,5-Di-O-isopropylidene-1-nonadecene-4,5-diol (5.17) 
To a solution of PMB-ether 5.16 (428 mg, 0.43 mmol) in acetonitrile (14 ml) and H2O (2 ml) was 
added CAN (581 mg, 1.06 mmol) at 0°C. The mixture was stirred for 50 minutes at 0 °C and was 
quenched with saturated NaHCO3 solution (10 ml). The aqueous layer was extracted with EtOAc (3 x 
10 ml) and the combined organic phases washed with saturated NaHCO3 solution and brine, dried 
over Na2SO4, filtered through a patch of celite and concentrated. The residue was purified by flash 
chromatography (hexane/EtOAc: 85/15) to afford alcohol 5.17 (197 mg, 73% based on starting 
material recovery), recovered starting material (123 mg) and acetonide cleaved product (20 mg). 
1H NMR (300 MHz, CDCl3): δ 0.89 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.20 – 1.36 (m, 25 H, CH3 
and CH2) 1.40 (s, 3 H, CH3) 1.44 (s, 9 H, tBu) 1.48 – 1.77 (m, 4 H, CH2) 1.95 (d, J = 6.8 Hz, 1 H, OH) 3.53 
– 3.65 (m, 1 H, Ha-6”) 3.64 (dd, J = 8.2 and 2.8 Hz, 1 H, H-3”) 3.82 – 4.05 (m, 5 H, H-4, H-2”, H-4”, H-5” 
and Hb-6”) 4.10 – 4.20 (m, 1 H, H-5) 4.27 – 4.37 (m, 1 H, H-3) 4.58 – 4.75 (m, 7 H, CH2Ph, NH and H-
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1”) 4.49 (d, J = 11.6 Hz, 1 H, CH2Ph) 5.87 (dd, J = 16.1 and 3.3 Hz, 1 H, H-1) 5.96 (dd, J = 16.5 and 4.2 
Hz, 1 H, H-2) 7.21 – 7.39 (m, 15 H, CH2Ph). 
13C NMR (75 MHz, CDCl3): δ 14.11, 22.67, 25.39, 26.85, 27.20, 28.36, 28.82, 29.35, 29.54, 
29.61, 29.64, 29.66, 29.68, 31.91, 52.18, 61.84, 72.10, 73.00, 73.29, 73.33, 73.56, 74.71, 76.86, 77.21, 
77.71, 78.49, 79.51, 79.57, 108.02, 125.39, 126.20, 127.48, 127.55, 127.62, 127.66, 127.76, 127.86, 
127.88, 127.94, 127.99, 128.06, 128.18, 128.25, 128.31, 128.39, 128.43, 128.51, 128.60, 128.67, 
129.74, 129.81, 129.98, 131.50, 133.26, 137.46, 137.86, 138.12, 138.33, 138.42, 154.86, 154.90, 
165.78. 
Exact mass (ESI-MS) for C54H83N2O9 [M+NH4]
+ found, 903.6096; calcd, 903.6093. 
(3S,4S,5R)-1-(6’-azido-2’,3’,4’-tri-O-benzyl-α-C-D-galactopyranosyl)-3-tertbutyloxycarbonylamino-4,5-
Di-O-isopropylidene-1-nonadecene-4,5-diol (5.18) 
To a solution of alcohol 5.17 (197 mg, 0.22 mmol) in anhydrous THF (15 ml) were added PPh3 (231 
mg, 0.88 mmol), DEAD (153 mg, 0.88 mmol) and DPPA (242 mg, 0.88 mmol) at -20°C. The mixture 
was allowed to warm to room temperature and stirred overnight. The solvent was evaporated under 
reduced pressure, and the residue was purified by flash chromatography (hexane/EtOAc: 9/1) to 
afford azide 5.18 (133 mg, 66%) as a white solid. 
1H NMR (300 MHz, CDCl3): δ 0.89 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.20 – 1.36 (m, 25 H, CH3 
and CH2) 1.40 (s, 3 H, CH3) 1.44 (s, 9 H, tBu) 1.48 – 1.77 (m, 4 H, CH2) 3.12 (dd, J = 12.9 and 4.3 Hz,1 H, 
Ha-6”) 3.63 (dd, J = 8.0 and 2.6 Hz, 1 H, H-4”) 3.73 (dd, J = 12.9 and 8.6 Hz, 1 H, Hb-6”) 3.86 (t, J = 2.9 
Hz, 1 H, H-3”) 3.91 – 4.07 (m, 3 H, H-4, H-2”, H-5”) 4.11 – 4.27 (m, 1 H, H-5) 4.27 – 4.40 (m, 1 H, H-3) 
4.53 – 4.74 (m, 7 H, CH2Ph, NH and H-1”) 4.83 (d, J = 11.6 Hz, 1 H, CH2Ph) 5.86 (dd, J = 16.2 and 3.8 
Hz, 1 H, H-1) 5.99 (dd, J = 16.5 and 4.2 Hz, 1 H, H-2) 7.23 – 7.42 (m, 15 H, CH2Ph). 
13C NMR (75 MHz, CDCl3): δ 14.12, 22.69, 25.41, 26.91, 27.23, 28.36, 28.95, 29.36, 29.40, 
29.46, 29.55, 29.62, 29.65, 29.67, 29.69, 31.92, 50.33, 52.21, 71.63, 72.23, 73.30, 73.35, 73.56, 74.60, 
77.21, 77.73, 78.17, 79.48, 79.61, 108.03, 120.04, 120.08, 120.11, 120.15, 120.18, 120.25, 125.71, 
127.49, 127.66, 127.71, 127.84, 127.88, 128.15, 128.34, 128.38, 128.41, 129.73, 129.83, 129.84, 
130.04, 130.05, 131.72, 138.09, 138.26, 138.39, 154.96. 
Exact mass (ESI-MS) for C54H78N4NaO8 [M+Na]
+ found, 933.5705; calcd, 933.5712. 
(3S,4S,5R)-1-(6’-azido-2’,3’,4’-tri-O-benzyl-α-C-D-galactopyranosyl)-3-hexacosylamino-1-nonadecene-
4,5-diol (5.19) 
To a solution of azide 5.18 (75 mg, 0.08 mmol) in DCM (4.5 mL) was added TFA (0.5 mL) and 
triethylsilane (0.25 mL). The resulting mixture was stirred 5h at room temperature and upon 
complete consumption of the starting material the solvents were evaporated under reduced 




amine was suspended in THF (5 mL) and a catalytic amount of 4-DMAP was added. Next p-
nitrophenyl hexacosanoate (63 mg, 0.12 mmol) was added followed by addition of pyridine (5 mL). 
The resulting mixture was stirred for 3 days at room temperature. Evaporation of the solvents and 
purification of the resulting residue by means of column chromatography (hexane/EtOAc: 7/3) 
yielded 5.19 (55 mg, 60%) as a white solid.  
1H NMR (300 MHz, CDCl3): δ 0.89 (t, J = 6.5 Hz, 6 H, 2 x terminal CH3) 1.16 – 1.38 (m, 67 H, 
CH2) 1.38 – 1.79 (m, 6 H, CH2) 2.19 (t, J = 7.2 Hz, 2 H, CH2) 3.87 (d, J = 6.6 Hz, 1 H, OH) 3.10 (dd, J = 
13.5 and 3.2 Hz, 1 H, Hb-6”) 3.47 – 3.59 (m, 2 H, H-4, H-2”, H-5 and H-3”) 3.66 (dd, J = 6.7 and 2.7 Hz, 
1 H, H-4) 3.79 – 3.94 (m, 3 H, H-3, H-4” and Hb-6”) 4.03 – 4.11 (m, 1 H, H-5”) 4.47 – 4.77 (m, 8 H, 
CH2Ph, NH and H-1”) 5.84 (dd, J = 15.9 and 4.0 Hz, 1 H, H-1) 5.92 – 6.02 (m, 2 H, H-2 and NH(CO)) 7.23 
– 7.39 (m, 15 H, CH2Ph). 
13C NMR (75 MHz, CDCl3): δ 14.12, 22.69, 25.75, 29.32, 29.36, 29.51, 29.60, 29.63, 29.66, 
29.70, 31.92, 33.77, 36.88, 49.34, 53.51, 70.05, 72.86, 73.12, 73.25, 73.32, 73.85, 76.30, 76.76, 77.20, 
115.63, 126.13, 127.60, 127.80, 127.91, 127.97, 128.25, 128.45, 129.28, 137.88, 137.91, 138.13, 
141.08, 162.44, 173.30. 
Exact mass (ESI-MS) for C77H122N5O7 [M+pyridine+H]
+ found, 1228.9360; calcd, 1228.9339. 
(3S,4S,5R)-1-(2’,3’,4’-tri-O-benzyl-6’-naphthureido-6’-deoxy-α-C-D-galactopyranosyl)-3-
hexacosylamino-1-nonadecene-4,5-diol (5.20) 
To a solution of azide 5.19 (89 mg, 0.08 mmol) in THF (3 mL) at room temperature, a 1 M solution of 
PMe3 in THF (2.31 ml, 2.31 mmol) was added dropwise. After stirring for 4h at room temperature, 
H2O (0.5 mL) was added and the reaction mixture was allowed to stir overnight at room temperature. 
Then the solvent was removed under reduced pressure. The crude product was dried by making 
azeotropic mixture with toluene to afford the crude amine. The crude amine was dissolved in 
anhydrous DMF (3 mL) and cooled to 0 °C. Next 1-naphthyl isocyanate (11 µL, 0.08 mmol) was added, 
the mixture was allowed to reach room temperature and was stirred overnight. Upon completion, 
the solvent was removed under reduced pressure and the residue purified by column 
chromatography (hexane/EtOAc: 5/5) to afford urea 5.20 (100 mg, quantitative yield) as a waxy solid. 
1H NMR (300 MHz, pyridine-d5): δ 0.88 (t, J = 6.5 Hz, 6 H, 2 x terminal CH3) 1.16 – 1.44 (m, 66 
H, CH2) 1.60 – 1.77 (m, 1 H, CH2) 1.77 – 1.98 (m, 4 H, CH2) 2.20 – 2.34 (m, 1 H, CH2) 2.46 (t, J = 8.2 Hz, 
2 H, CH2) 3.91 – 4.03 (m, 2 H, H-4” and Ha-6”) 4.06 – 4.18 (m, 2 H, H-3” and Hb-6”) 4.20 – 4.29 (m, 2 
H, H-4 and H-5) 4.36 (dd, J = 8.2 and 5.5 Hz, 1 H, H-5”) 4.48 – 4.56 (m, 1 H, H-2”) 4.68 – 4.84 (m, 5 H, 
CH2Ph) 4.90 – 5.06 (m, 3 H, H-1”, CH2Ph and OH) 5.86 (t, J = 7.5 Hz, 1 H, H-3) 6.21 (br. s, 1 H, OH) 6.51 
(br. s, 1 H, NH) 6.63 (dd, J = 15.7 and 4.1 Hz, 1 H, H-1) 6.85 (dd, J = 15.7 and 6.4 Hz, 1 H, H-2) 7.17 – 
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7.60 (m, 18 H, naphthyl and CH2Ph) 7.63 – 7.70 (m, 1 H, naphthyl) 7.87 – 7.94 (m, 1 H, naphthyl) 8.27 
– 8.33 (m, 1 H, naphthyl) 8.48 – 8.56 (m, 2 H, naphthyl and NH(CO)) 9.36 (s, 1 H, NH). 
13C NMR (75 MHz, pyridine-d5): δ 14.71, 23.36, 26.74, 26.91, 30.03, 30.05, 30.24, 30.30, 
30.34, 30.36, 30.44, 30.47, 30.57, 30.81, 32.54, 32.56, 35.06, 37.37, 41.65, 54.17, 72.82, 73.14, 73.53, 
73.65, 73.80, 74.84, 77.04, 77.95, 78.46, 119.98, 122.80, 123.20, 124.57, 124.80, 126.28, 126.50, 
126.99, 127.41, 128.19, 128.24, 128.27, 128.54, 128.81, 129.03, 129.05, 129.17, 129.28, 132.68, 
135.27, 136.53, 139.80, 139.85, 139.99, 149.41, 151.01, 157.85, 172.97. 
Exact mass (ESI-MS) for C83H126N3O8 [M+H]
+ found, 1292.9557; calcd, 1292.9539. 
1-allyl-2,3,4,6-tetra-O-acetyl-α-D-galactopyranose (5.22) 
To a solution of galactose pentaacetate (9 g, 23.06 mmol) in anhydrous acetonitrile (90 mL) at 0 °C, 
was added allylTMS (7.35 mL, 46.12 mmol) followed by dropwise addition of TMSOTf (4.17 mL, 46.12 
mmol). The reaction mixture was stirred overnight at 0 °C. Upon disappearance of the starting 
material the mixture was quenched by slow addition of a saturated NaHCO3 solution. The aqueous 
layer was extracted with DCM (3 x 100 mL) and the combined organic layers washed with H2O (150 
mL) and brine (150 mL). The organics were dried over MgSO4, filtered and evaporated under reduced 
pressure. The resulting residue was subjected to column chromatography (hexanes/EtOAc : 7/3) 
furnishing a mixture of both α and β anomers 5.21 in a 7:1 ratio.  
To a solution of the α:β mixture (5.52 g, 14.8 mmol) in methanol (55 mL) was added sodium 
methoxide (5.4 M solution in MeOH) till pH 10. The reaction was stirred 4 hours at room 
temperature, next the reaction mixture was diluted with methanol and neutralized with amberlyte 
IR120 H+-form. The resin was filtered off and the filtrate was concentrated under reduced pressure. 
The residue was crystallized from methanol/diethyl ether by dissolution in minimum boiling 
methanol with addition of ether until the cloud point, followed by slow cooling to -20 °C. Pure alpha 
anomer crystals were collected by filtration and were reacetylated by treatment with 15 mL of acetic 
anhydride and 15 mL of pyridine followed by stirring overnight at room temperature. The reaction 
was slowly poured into ice water (200 mL) and then extracted with EtOAc (3 x 200 mL). The organic 
layer was washed with saturated NaHCO3 solution until the evolution of gasses ceased (2 x 200 mL), 
and then washed with H2O (200 mL), and brine (200 mL). The organic phase was dried over MgSO4, 
filtered and concentrated under reduced pressure yielding pure α-anomer 5.22 (3.83 g, 44% over 3 
steps) as a white solid. 
1H NMR (300 MHz, CDCl3): δ 2.03 (s, 3 H, CH3) 2.04 (s, 3 H, CH3) 2.07 (s, 3 H, CH3) 2.12 (s, 3 H, 
CH3) 2.23 – 2.34 (m, 1 H, CH=CH2a) 2.41 – 2.54 (m, 1 H, CH=CH2b) 4.05 – 4.13 (m, 2 H, CH2-6) 4.16 – 




(dd, J = 9.3 and 3.2 Hz, 1 H, H-5) 5.28 (dd, J = 9.3 and 4.8 Hz, 1 H, H-4) 5.40 – 5.44 (m, 1 H, H-3) 5.68 – 
5.83 (m, 1 H, CH=CH2). 
13C NMR (75 MHz, CDCl3): δ 20.71, 20.77, 20.83, 30.93, 61.52, 67.65, 67.93, 68.25, 68.27, 
71.47, 117.69, 133.42, 169.85, 169.96, 170.13, 170.57. 
Exact mass (ESI-MS) for C17H25O9 [M+H]
+ found, 373.1498; calcd, 373.1493. 
1-propenyl-2,3,4,6-tetra-O-acetyl-α-D-galactopyranose (5.23) 
To a solution of allylsugar 5.22 (6.96 g, 18.69 mmol) in toluene (1 L) was added bis(benzonitrile) 
palladium(II) chloride (717 mg, 1.87 mmol) and the mixture was heated to 90 °C and stirred for 3 
days. The reaction was monitored by NMR and upon completion the reaction mixture was filtered 
through a patch of celite and evaporated under reduced pressure. The residue was purified by flash 
column chromatography ( 0  30 % EtOAc in hexanes) to afford a mixture of E and Z-alkene sugars 
5.23 (4.38 g, 63%) as a yellow oil. 
1H NMR (300 MHz, CDCl3): δ 1.78 (dt, J = 6.4 and 1.5 Hz, 3H, terminal CH3) 2.01 (s, 3 H, CH3) 
2.04 (s, 3 H, CH3) 2.04 (s, 3 H, CH3) 2.14 (s, 3 H, CH3) 4.03 – 4.19 (m, 3 H, CH2-6 and H-5) 4.74 (tt, J = 
5.9 and 1.5 Hz, 1 H, H-1) 5.01 – 5.34 (m, 2 H, H-3 and H-2) 5.41 (dd, J = 4.8 and 3.2 Hz, 1 H, H-4) 5.56 – 
5.70 (m, 1 H, CH=CHCH3) 5.82 – 5.98 (m, 1 H, CH=CHCH3). 
13C NMR (75 MHz, CDCl3): δ 18.31, 20.67, 20.70, 20.78, 61.82, 68.02, 68.08, 68.33, 73.15, 
122.58, 133.20, 169.94, 170.09, 170.22, 170.54. 
Exact mass (ESI-MS) for C17H25O9 [M+H]
+ found, 373.1496; calcd, 373.1493. 
1-propenyl-α-D-galactopyranose (5.24) 
To a solution of 5.23 (1.72 g, 4.62 mmol) in methanol (30 mL) was added sodium methoxide (5.4M 
NaOMe in MeOH) till pH 10. The reaction was allowed to stir overnight at room temperature. 
Subsequently, the mixture was neutralized with Amberlite IR 120 (H+ form) and diluted with 
methanol. After filtration and rinsing with methanol, the filtrate was concentrated under reduced 
pressure. The residue was purified by flash column chromatography (0  20% MeOH in DCM) 
affording sugar 5.24 (874 mg, 93%) as a white solid. 
1H NMR (300 MHz, MeOD3): δ 1.74 – 1.78 (m, 3H, terminal CH3) 3.58 (dd, J = 9.7 and 3.2 Hz, 1 
H, H-3) 3.63 – 3.86 (m, 3H, H-5 and CH2-6) 3.89 (dd, J = 3.2 and 1.7 Hz, 1 H, H-2) 3.94 (dd, J = 9.7 and 
5.8 Hz, 1 H, H-4) 4.41 (tt, J = 5.7 and 1.2 Hz, 1 H, H-1) 5.73 – 5.94 (m, 2 H, CH=CH). 
13C NMR (75 MHz MeOD3): δ 18.57, 62.57, 69.73, 70.67, 72.06, 73.56, 76.96, 125.44, 132.13. 
Exact mass (ESI-MS) for C9H17O5 [M+H]
+ found, 205,1059; calcd, 205.1071. 
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1-propenyl-6-O-triisopropylsilyl-α-D-galactopyranose (5.25) 
To a solution of 5.24 (2.14 g, 10.46 mmol) in anhydrous DMF (45 mL) at 0 °C was added imidazole 
(1.42 g, 20.92 mmol) and TIPSCl (2.9 mL, 13.60 mmol). The reaction mixture was allowed to reach 
room temperature and was stirred overnight. Upon completion of the reaction H2O (100 mL) was 
added and the aqueous layer was extracted with Et2O (3 x 75 mL). The combined organic layer was 
dried over MgSO4, filtered and evaporated under reduced pressure. The residue was purified by flash 
column chromatography (45  75% EtOAc in hexanes) affording silylether 5.25 (3.19 g, 84%) as a 
colorless liquid. 
1H NMR (300 MHz, CDCl3): δ 1.02 – 1.11 (m, 21 H, i-prop) 1.77 (dt, J = 6.4 and 1.5 Hz, 3 H, 
terminal CH3) 2.36 – 2.37 (br. s, 3H, 3 x OH) 3.63 (dd, J = 9.7 and 3.4 Hz, 1 H, H-3) 3.75 – 4.00 (m, 3H, 
H-5 and CH2-6) 4.06 (dd, J = 9.6 and 6.0 Hz, 1 H, H-2) 4.13 (dd, J = 3.4 and 1.6 Hz, 1 H, H-4) 4.53 (t, J = 
6.0 Hz, 1 H, H-1) 5.67 – 5.77 (m, 1 H, CH=CHCH3) 5.85 – 5.99 (m, 1 H, CH=CHCH3). 
13C NMR (75 MHz, CDCl3): δ 11.80, 17.88, 18.25, 63.66, 63.89, 69.34, 69.95, 70.08, 71.23, 
71.32, 71.76, 75.78, 77.20, 123.56, 132.47. 
Exact mass (ESI-MS) for C18H37O5Si [M+H]
+ found, 361.2407; calcd, 361.2405. 
2,3,4-tri-O-(4-methoxybenzyl)-1-propenyl-6-O-triisopropylsilyl-α-D-galactopyranose (5.26) 
Sugar 5.25 (3.19 g, 8.83 mmol) was dissolved in anhydrous DMF (100 mL) and cooled to 0 °C. PMBCl 
(6.0 mL, 44.15 mmol) and TBAI (500 mg) were added before the addition of NaH (60% dispersion, 
1.77 g, 44.15 mmol). The resulting mixture was heated to 40 °C and stirred overnight. Upon 
completion, the mixture was cooled to 0 °C and H2O (300 mL) was slowly added to quench the 
reaction. The aqueous layer was extracted with EtOAc (3 x 200 mL) and the combined organics 
washed with H2O (200 mL) and brine (200 mL). The organic layer was dried over Na2SO4, filtered and 
evaporated under reduced pressure. The residue was purified by column chromatography 
(hexane/EtOAc: 9/1) yielding alkene 5.26 (6.12 g, 96%) as a clear oil. 
1H NMR (300 MHz, CDCl3): δ 0.98 – 1.06 (m, 21 H, i-prop) 1.70 – 1.76 (m, 3 H, terminal CH3) 
3.47 – 3.74 (m, 4 H, H-3, H-5 and CH2-6) 3.76 – 3.83 (m, 9 H, 3 x OCH3) 3.88 – 3.92 (m, 1 H, H-4) 4.06 
(dd, 1 H, J = 9.5 and 5.9 Hz, H-2) 4.36 – 4.85 (m, 7 H, H-1 and 3 x CH2PhOMe) 5.65 – 5.91 (m, 2 H, 
CH=CH) 6.79 – 6.89 (m, 6 H, arom. H) 7.17 – 7.31 (m, 6H, arom. H). 
13C NMR (75 MHz, CDCl3): δ 11.88, 12.52, 17.97, 18.08, 18.12, 18.18, 55.22, 55.25, 62.21, 
67.95, 70.65, 71.92, 72.34, 72.50, 72.57, 72.65, 72.94, 73.12, 73.34, 73.63, 74.02, 74.22, 74.53, 74.76, 
77.20, 79.49, 110.00, 113.54, 113.67, 113.73, 124.84, 125.91, 128.96, 128.99, 129.39, 129.45, 129.62, 
129.68, 129.77, 129.92, 130.46, 130.82, 130.85, 131.11, 131.14, 159.02, 159.09. 
Exact mass (ESI-MS) for C42H60NaO8Si [M+Na]






To a solution of 5.26 (2 g, 2.77 mmol) in THF (8.5 mL) and H2O (1.3 mL) was added NMO (976 mg, 
8.33 mmol) and K2OsO4 (50 mg, 0.14 mmol). The reaction was allowed to stir overnight at room 
temperature and was then quenched with a saturated Na2SO3 solution (10 mL). After 30 minutes of 
stirring H2O (50 mL) was added and the aqueous layer was extracted with EtOAc (3 x 40 mL). The 
combined organic layers were washed successively with 0.6 M HCl solution (40 mL), saturated 
NaHCO3 solution (40 mL) and brine (40 mL). The organic phase was dried over Na2SO4, filtered and 
evaporated under reduced pressure. The residue was purified by flash column chromatography (10 
 30% EtOAc in hexanes) yielding diol 5.27 (1.37 g, 65%) as a yellowish oil. 
1H NMR (300 MHz, CDCl3) (isomers): δ 0.92 – 1.11 (m, 21 H, i-prop) 1.16 – 1.24 (m, 3 H, 
terminal CH3) 1.99 (br. s, 1 H, OH) 2.20 (br. s, 1 H, OH) 3.46 – 3.76 (m, 3 H, H-1’, H-3 and Ha-6) 3.77 – 
3.83 (m, 9 H, 3 x OCH3) 3.83 – 4.03 (m, 3 H, H-2, H-4 and H-5) 4.03 – 4.25 (m, 2 H, H-1 and H-2’) 4.27 – 
4.40 (m, 1 H, Hb-6) 4.40 – 4.71 (m, 6 H, 3 x CH2PhOMe) 6.81 – 6.90 (m, 6 H, arom. H) 7.12 – 7.26 (m, 6 
H, arom. H). 
13C NMR (75 MHz, CDCl3) (isomers): δ 11.94, 12.57, 17.94, 18.08, 55.28, 59.80, 65.31, 66.50, 
66.91, 68.79, 69.14, 69.35, 71.44, 71.58, 71.83, 71.93, 72.39, 72.51, 72.56, 72.89, 73.17, 73.35, 75.00, 
75.38, 113.68, 113.73, 113.77, 113.86, 114.31, 129.21, 129.34, 129.37, 129.59, 129.77, 129.94, 
129.98, 130.23, 130.32, 130.46, 131.98, 159.20, 159.29, 159.46. 
Exact mass (ESI-MS) for C42H62KO10Si [M+K]
+ found, 793.3746; calcd, 793.3744. 
(3S,4S,5R)-1-(2’,3’,4’-tri-O-(4-methoxybenzyl)-6’-O-triisopropylsilyl-α-C-D-galactopyranosyl)-3-
tertbutyloxycarbonylamino-4,5-Di-O-isopropylidene-1-nonadecene-4,5-diol (5.29) 
To a solution of diol 5.27 (930 mg, 1.23 mmol) in THF (16 ml) and H2O (8 mL) was added NaIO4 (1.32 
g, 6.15 mmol) portionwise over a period of 1h. The reaction mixture was stirred at room temperature 
for 2h30’. Upon disappearance of the starting material (as judged by TLC), the mixture was diluted 
with Et2O (30 ml) and the aqueous layer was extracted with Et2O (3 x 30 ml). The combined organic 
phases were washed with saturated NaHCO3 solution (100 mL), dried over Na2SO4, filtered and 
concentrated at 30 °C to afford crude aldehyde which was used without further purification in the 
next step. 
Lithium bis(trimethylsilyl)amide (1 M in THF, 2.46 mL, 2.46 mmol) was slowly added to a solution of 
sulfone 5.14 (786 mg, 1.23 mmol) in anhydrous THF (40 mL) at -78°C. After 1h30’, the above 
prepared crude aldehyde in THF (40 mL) was added dropwise over a period of 2h. The mixture was 
allowed to warm to room temperature and stirred overnight. The reaction was quenched with water 
(50 mL) and extracted with Et2O (3x 50 mL). The combined organic phases were washed with H2O 
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and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash 
chromatography (5  25% EtOAc in hexanes) to afford a mixture of α and β alkenes 5.29 (640 mg, 
46%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) (mixture of anomers): δ 0.89 (t, J = 6.3 Hz, 3 H, terminal CH3) 0.99 – 
1.11 (m, 21 H, i-prop) 1.20 – 1.35 (m, 25 H, CH2 and CH3 ) 1.36 – 1.46 (m, 12 H, tBu and CH3 ) 1.49 – 
1.70 (m, 4 H, CH2) 3.56 (dd, J = 9.2 and 2.5 Hz, 1 H, H-3) 3.71 – 3.78 (m, 3 H, H-3’ and CH2-6) 3.78 – 
3.83 (m, 10 H, 3 x OCH3 and H-5’) 3.84 – 4.02 (m, 2 H, H-4 and H-5) 4.02 – 4.20 (m, 2 H, H-4’ and H-2) 
4.25 – 4.75 (m, 7 H, CH2PhOMe, H-1 and NH) 4.82 (d, J = 10.8 Hz, 1 H, CH2PhOMe) 5.87 – 6.01 (m, 2 H, 
CH=CH) 6.77 – 6.90 (m, 6 H, arom. H) 7.15 – 7.30 (m, 6 H, arom. H). 
13C NMR (75 MHz, CDCl3): δ 11.91, 12.49, 14.11, 18.06, 18.12, 22.69, 25.53, 26.79, 27.53, 
28.35, 29.02, 29.36, 29.60, 29.65, 29.69, 31.92, 52.21, 55.23, 61.81, 72.62, 72.80, 72.95, 73.98, 74.82, 
79.47, 80.56, 107.97, 113.54, 113.65, 113.68, 125.76, 128.92, 129.02, 129.36, 129.66, 129.71, 130.85, 
131.05, 131.18, 154.90, 159.00, 159.08. 
Exact mass (ESI-MS) for C66H106NO12Si [M+H]
+ found, 1132.7462; calcd, 1132.7479. 
(3S,4S,5R)-1-(6’-hydroxy-2’,3’,4’-tri-O-(4-methoxybenzyl)-α-C-D-galactopyranosyl)-3-
tertbutyloxycarbonylamino-4,5-Di-O-isopropylidene-1-nonadecene-4,5-diol (5.31) 
A solution of 5.29 (2.3 g, 2.03 mmol) in THF (20 mL) was cooled to 0 °C and tetrabutylammonium 
fluoride (1 M in THF, 4.06 mL, 4.06 mmol) was added dropwise. The reaction mixture was allowed to 
reach room temperature and was stirred overnight. The reaction mixture was diluted with DCM (150 
mL) and washed with saturated aqueous NH4Cl solution (75 mL) and H2O (75 mL). The aqueous layer 
was back extracted with DCM (2 x 50 mL) and the combined organic layers were washed with brine 
(100 mL). The organics were dried over Na2SO4, filtered and concentrated under reduced pressure 
and the residue was purified by flash column chromatography (0  30% EtOAc in hexanes) to 
provide α-glycoside 5.31 (1.28 g, 65 %) as a colorless oil together with the corresponding β-glycoside 
(362 mg, 18%). 
1H NMR (300 MHz, CDCl3): δ 0.89 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.31 (s, 3 H, CH3) 1.22 – 1.34 
(m, 22 H, CH2) 1.40 (s, 3 H, CH3) 1.44 (s, 9 H, tBu) 1.48 – 1.71 (m, 4 H, CH2) 2.02 (br. s, 1 H, OH) 3.51 – 
3.62 (m, 2 H, H-5 and Ha-6’) 3.81 (s, 3 H, OCH3) 3.82 (s, 3 H, OCH3) 3.82 (s, 3 H, OCH3) 3.79 – 4.01 (m, 
5 H, H-2, H-4, H-4’, H-5’ and Hb-6’) 4.10 – 4.19 (m, 1 H, H-3) 4.25 – 4.36 (m, 1 H, H-3’) 4.49 – 4.70 (m, 
7 H, CH2PhOMe, H-1 and NH) 4.74 (d, J = 11.6 Hz, 1 H, CH2PhOMe) 5.84 (dd, J = 16.3 and 3.7 Hz, 1 H, 
CH-1=CH) 5.93 (dd, J = 16.3 and 4.4 Hz, 1 H, CH=CH-2) 6.83 – 6.90 (m, 6 H, arom. H) 7.19 – 7.27 (m, 6 
H, arom. H). 
13C NMR (75 MHz, CDCl3): δ 14.11, 22.69, 25.40, 26.85, 27.21, 28.37, 28.81, 29.36, 29.56, 




79.50, 79.61, 108.02, 113.71, 113.77, 113.82, 126.38, 129.13, 129.53, 129.88, 130.26, 130.50, 130.61, 
131.43, 154.90, 159.17, 159.23, 159.35. 
Exact mass (ESI-MS) for C57H86NO12 [M+H]
+ found, 976.6146; calcd, 976.6145. 
(3S,4S,5R)-1-(2’,3’,4’-tri-O-(4-methoxybenzyl)-6’-phtalimidoyl-6’-deoxy-α-C-D-galactopyranosyl)-3-
tertbutyloxycarbonylamino-4,5-Di-O-isopropylidene-1-nonadecene-4,5-diol (5.32) 
To a solution of alcohol 5.31 (100 mg, 0.1 mmol) in anhydrous THF (2 mL) at -20°C was added PPh3 
(79 mg, 0.3 mmol), DEAD (40% DEAD in toluene, 0.09 mL, 0.3 mmol) and phtalimide (44 mg, 0.3 
mmol) in this order. The resulting mixture was allowed to reach room temperature and was stirred 
for 5h. Upon complete consumption of the starting material the solvents were removed under 
reduced pressure and the resulting residue was purified by flash column chromatography (10  30% 
EtOAc in hexanes) giving phtalimide 5.32 (100 mg, 88%) as a white waxy solid. 
1H NMR (300 MHz, CDCl3): δ 0.89 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.20 – 1.35 (m, 26 H, CH3 
and CH2) 1.35 (s, 3 H, CH3) 1.42 (s, 9 H, tBu) 1.46 – 1.66 (m, 3 H, CH2) 3.50 – 3.60 (m, 1 H, H-5’) 3.69 – 
3.74 (m, 1 H, H-4’) 3.80 – 3.81 (m, 2 H, CH2-6’) 3.82 (s, 4 H, H-5 and OCH3) 3.82 (s, 3 H, OCH3) 3.83 (s, 
3 H, OCH3) 3.98 (dd, J = 5.0 and 2.9 Hz, 1H, H-4) 4.04 – 4.13 (m, 1 H, H-3’) 4.19 – 4.77 (m, 10 H, H-1’, 
H-2’, H-3, CH2PhOMe and NH) 5.67 (dd, J = 15.8 and 6.2 Hz, 1 H, CH-1=CH) 5.91 (dd, J = 15.7 and 4.0 
Hz, 1 H, CH=CH-2) 6.82 – 6.93 (m, 6 H, arom. H) 7.10 – 7.17 (m, 2 H, arom. H) 7.22 – 7.27 (m, 2 H, 
arom. H) 7.32 – 7.38 (m, 2 H, arom. H) 7.66 – 7.70 (m, 2 H, Phtal) 7.79 – 7.83 (m, 2 H, Phtal). 
13C NMR (75 MHz, CDCl3): δ 14.12, 22.69, 25.47, 26.99, 27.22, 28.40, 29.36, 29.59, 29.69, 
31.92, 51.72, 55.28, 71.52, 72.63, 72.85, 76.79, 77.21, 77.82, 79.30, 79.72, 107.85, 113.73, 113.76, 
123.10, 123.25, 123.59, 127.01, 129.19, 122.22, 129.50, 129.59, 129.80, 130.21, 130.38, 130.50, 
130.64, 131.91, 132.08, 132.34, 133.60, 133.92, 134.30, 154.81, 159.13, 159.32, 168.30, 168.73. 
Exact mass (ESI-MS) for C65H88N2NaO13 [M+Na]
+ found, 1127.6172; calcd, 1127.6179. 
(3S,4S,5R)-1-(2’,3’,4’-tri-O-(4-methoxybenzyl)-6’-naphthureido-6’-deoxy-α-C-D-galactopyranosyl)-3-
tertbutyloxycarbonylamino-4,5-Di-O-isopropylidene-1-nonadecene-4,5-diol (5.33) 
To a solution of alkene 5.32 (243 mg, 0.22 mmol) in degassed EtOH (3 mL) was added 
methylhydrazine (46 µL, 0.88 mmol). The resulting mixture was heated till reflux and stirred for 18h 
under nitrogen atmosphere. Upon completion of the reaction, DCM (20 mL) was added and the 
organic layer was washed with 1 M NaOH solution (20 mL). The aqueous layer was back extracted 
with DCM (2 x 20 mL) and the combined organic phase was washed with H2O (50 mL). The organics 
were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude amine was 
used in the next step without further purification. The amine was dissolved in DMF (5 mL) and cooled 
to 0 °C. Next 1-naphthyl isocyanate (82 µL, 0.57 mmol) was added and the mixture was stirred 
overnight at room temperature. The solvents were removed under reduced pressure and the residue 
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was purified by flash column chromatography (10  30% EtOAc in hexanes) to furnish urea 5.33 (152 
mg, 60% over 2 steps) as a light brown solid. 
1H NMR (300 MHz, CDCl3): δ 0.89 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.19 – 1.32 (m, 27 H, CH3 
and CH2) 1.39 (s, 3 H, CH3) 1.44 (s, 9 H, tBu) 1.48 – 1.71 (m, 2 H, CH2) 3.40 – 3.59 (m, 3 H, H-3’and CH2-
6’) 3.77 (s, 3 H, OCH3) 3.78 – 3.81 (m, 1 H, H-5) 3.81 (s, 3 H, OCH3) 3.82 (s, 3 H, OCH3) 3.84 – 3.98 (m, 3 
H, H-4, H-4’ and H-5’) 4.09 – 4.19 (m, 1 H, H-2’) 4.24 – 4.34 (m, 1 H, H-3) 4.44 – 4.67 (m, 7 H, H-1’, 
CH2PhOMe and NH) 4.70 (d, J = 10.9 Hz, 1 H, CH2PhOMe)5.07 (br. s, 1 H, NH) 5.78 (dd, J = 16.4 and 
3.9 Hz, 1 H, CH-1=CH) 5.88 (dd, J = 16.4 and 4.0 Hz, 1 H, CH=CH-2) 6.78 – 6.91 (m, 6 H, arom. H) 7.15 – 
7.27 (m, 6 H, arom. H) 7.41 – 7.53 (m, 3 H, naphthyl) 7.69 (d, J = 7.9 Hz, 2 H, naphthyl) 7.83 – 7.88 (m, 
1 H, naphthyl) 7.95 – 8.00 (m, 1 H, naphthyl). 
13C NMR (75 MHz, CDCl3): δ 14.11, 22.67, 25.51, 25.69, 26.76, 28.37, 28.41, 28.67, 29.34, 
29.53, 29.60, 29.65, 29.69, 30.90, 31.91, 40.87, 55.23, 72.91, 72.97, 73.43, 74.13, 74.88, 76.22, 77.20, 
77.85, 79.50, 108.13, 113.68, 113.71, 113.76, 113.79, 121.80, 125.80, 125.91, 126.12, 126.50, 126.76, 
126.96, 128.47, 128.55, 129.10, 129.15, 129.39, 129.50, 129.79, 130.06, 130.32, 130.43, 130.47, 
130.53, 130.64, 130.75, 133.56, 134.30, 134.43, 154.88, 155.43, 159.16, 159.23. 
Exact mass (ESI-MS) for C68H94N3O12 [M+H]
+ found, 1144.6827; calcd, 1144.6832. 
(3S,4S,5R)-1-(2’,3’,4’-tri-O-(4-methoxybenzyl)-6’-naphthureido-6’-deoxy-α-C-D-galactopyranosyl)-3-
tertbutyloxycarbonylamino-4,5-Di-O-isopropylidene-nonadecane-4,5-diol (5.34) 
A solution of alkene 5.32 (100 mg, 0.09 mmol) in EtOH (4 mL) and hydrazine monohydrate (0.4 mL) 
was heated till reflux and stirred for 18h. Upon completion of the reaction, DCM (20 mL) was added 
and the organic layer was washed with 1 M NaOH solution (20 mL). The aqueous layer was back 
extracted with DCM (2 x 20 mL) and the combined organic phase was washed with H2O (50 mL). The 
organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude 
amine was used in the next step without further purification. The amine was dissolved in DMF (2 mL) 
and cooled to 0 °C. Next 1-naphthyl isocyanate (34 µL, 0.23 mmol) was added and the mixture was 
stirred overnight at room temperature. The solvents were removed under reduced pressure and the 
residue was purified by flash column chromatography (10  30% EtOAc in hexanes) to furnish urea 
5.34 (80 mg, 77% over 2 steps) as a light brown solid. 
1H NMR (300 MHz, CDCl3): δ 0.89 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.15 – 1.32 (m, 27 H, CH3 
and CH2) 1.38 (s, 3 H, CH3) 1.42 (s, 9 H, tBu) 1.46 – 1.78 (m, 6 H, CH2) 3.43 – 3.56 (m, 1 H, H-4) 3.64 – 
3.75 (m, 3 H, H-5, CH2-6’) 3.79 (s, 3 H, OCH3) 3.82 (s, 3 H, OCH3) 3.82 (s, 3 H, OCH3) 3.86 – 3.99 (m, 4 
H, H-3, H-2’, H-4’ and H-5’) 4.02 – 4.10 (m, 1 H, H-3’) 4.37 (d, J = 12.4 Hz, 1 H, CH2PhOMe) 4.41 – 4.68 




arom. H) 7.41 – 7.53 (m, 4 H, naphthyl and NH) 7.60 – 7.73 (m, 1 H, naphthyl) 7.82 – 7.88 (m, 2 H, 
naphthyl) 7.98 – 8.06 (m, 1 H, naphthyl). 
13C NMR (75 MHz, CDCl3): δ 14.12, 22.69, 25.39, 25.77, 26.76, 27.11, 28.43, 28.92, 29.37, 
29.43, 29.57, 29.66, 29.71, 30.92, 31.92, 50.21, 55.25, 72.02, 72.53, 72.83, 73.53, 73.76, 77.20, 77.75, 
79.82, 107.85, 113.74, 120.37, 121.62, 124.50, 125.80, 126.02, 128.46, 129.31, 129.47, 129.63, 
129.73, 130.20, 130.37, 130.64, 134.11, 134.24, 155.87, 156.44, 156.96, 159.19, 159.34. 
Exact mass (ESI-MS) for C68H96N3O12 [M+H]
+ found, 1146.6990; calcd, 1146.6989. 
(3S,4S,5R)-1-(2’,3’,4’-tri-O-(4-methoxybenzyl)-6’-O-(4-pyridinylcarbamoyl)-α-C-D-galactopyranosyl)-3-
tertbutyloxycarbonylamino-4,5-Di-O-isopropylidene-1-nonadecene-4,5-diol (5.35) 
To a solution of alcohol 5.31 (187 mg, 0.19 mmol) in anhydrous DCM (8 mL) was added p-nitrophenyl 
chloroformate (57 mg, 0.29 mmol) and pyridine (31 µL, 0.38 mmol). The mixture was heated to 40 °C 
for 8h. After complete disappearance of the starting material the mixture was diluted with DCM (30 
mL) and washed successively with saturated NaHCO3 solution (20 mL), H2O (20 mL) and brine (20 
mL). Next the aqueous layer was extracted with DCM (2 x 50 mL) and the combined organic layer was 
dried over Na2SO4, filtered and concentrated under reduced pressure. The crude p-
nitrophenylcarbonate was used without further purification in the next reaction.  
The crude carbonate was dissolved in anhydrous DCM (5 mL) followed by addition of 4-
aminopyridine (89 mg, 0.95 mmol) and Et3N (53 µL, 0.38 mmol). The reaction mixture was heated to 
reflux temperature and was stirred overnight. The mixture was diluted with DCM (30 mL) and 
washed successively with saturated NaHCO3 solution (20 mL), H2O (20 mL) and brine (20 mL). Next 
the aqueous layer was extracted with DCM (2 x 50 mL) and the combined organic layer was dried 
over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash 
column chromatography (0  50% EtOAc in hexanes) to provide carbamate 5.35 (129 mg, 62 %) as a 
white foam. 
1H NMR (300 MHz, CDCl3): δ 0.88 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.13 – 1.34 (m, 24 H, CH3 
and CH2) 1.34 – 1.50 (m, 14 H, tBu, CH2 and CH3) 1.59 – 1.75 (m, 2 H, CH2) 1.74 – 1.87 (m, 1 H, CH2) 
3.54 (dd, J = 9.0 and 2.2 Hz, 1 H, H-3”) 3.71 – 3.79 (m, 1 H, H-4”) 3.81 (s, 3 H, OCH3) 3.81 (s, 3 H, OCH3) 
3.83 (s, 3 H, OCH3) 3.90 (d, J = 11.2 Hz, 1 H, Ha-6”) 3.99 (d, J = 9.0 Hz, 1 H, H-5”) 4.04 – 4.21 (m, 2 H, 
H-5, H-2”) 4.31 – 4.42 (m, 2 H, H-3, H-4) 4.48 – 4.73 (m, 7 H, H-1”, Hb-6, CH2PhOMe and NH) 4.77 – 
4.88 (m, 2 H, CH2PhOMe) 5.89 (dt, J = 16.5 and 2.0 Hz, 1 H, CH-2=CH) 6.03 (dt, J = 16.5 and 2.2 Hz, 1 
H, CH=CH-1) 6.82 – 6.94 (m, 6 H, arom. H) 7.20 – 7.31 (m, 6 H, arom. H) 7.53 (d, J = 5.6 Hz, 2 H, 
pyridine) 8.44 (d, J = 6.2 Hz, 2 H, pyridine) 8.55 (s, 1 H, NHC(O)O). 
13C NMR (75 MHz, CDCl3): δ 14.11, 22.67, 25.60, 26.32, 27.19, 28.37, 28.88, 29.34, 29.48, 
29.56, 29.63, 31.91, 51.60, 55.26, 66.19, 70.45, 72.74, 73.03, 73.18, 74.08, 76.28, 77.20, 77.98, 79.76, 
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80.43, 108.61, 112.43, 113.74, 113.80, 115.74, 125.36, 126.15, 129.10, 129.44, 129.88, 130.12, 
130.47, 130.60, 147.98, 152.61, 155.46, 159.20, 159.35, 163.58. 
Exact mass (ESI-MS) for C63H90N3O13 [M+H]
+ found, 1096.6450; calcd, 1096.6468. 
(3S,4S,5R)-1-(6’-hydroxy-2’,3’,4’-tri-O-(4-methoxybenzyl)-α-C-D-galactopyranosyl)-3-
tertbutyloxycarbonylamino-4,5-Di-O-isopropylidene-nonadecane-4,5-diol (5.36) 
A solution of alkene 5.31 (121 mg, 0.12 mmol) in EtOH (5 mL) and hydrazine monohydrate (0.5 mL) 
was heated till reflux and stirred for 18h. Upon completion of the reaction, DCM (20 mL) was added 
and the organic layer was washed with 1 M NaOH solution (20 mL). The aqueous layer was back 
extracted with DCM (2 x 20 mL) and the combined organic phase was washed with H2O (50 mL). The 
organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (0  50% EtOAc in hexanes) to provide saturated glycoside 
5.36 (88 mg, 73 %) as a yellowish oil. 
1H NMR (300 MHz, CDCl3): δ 0.88 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.31 (s, 3 H, CH3) 1.20 – 1.33 
(m, 24 H, CH2) 1.39 (s, 3 H, CH3) 1.42 (s, 9 H, tBu) 1.47 – 1.78 (m, 6 H, CH2) 2.56 (br. s, 1 H, OH) 3.53 – 
3.73 (m, 4 H, H-2’, H-3’, H-4’ and Ha-6’) 3.81 (s, 3 H, OCH3) 3.81 (s, 3 H, OCH3) 3.81 (s, 3 H, OCH3) 3.86 
– 4.00 (m, 4 H, H-2, H-3, H-4 and H-5) 4.03 – 4.14 (m, 2 H, H-1 and Hb-6’) 4.41 (d, J = 11.7 Hz, 1H, 
CH2PhOMe) 4.45 – 4.67 (m, 6 H, CH2PhOMe and NH) 6.82 – 6.91 (m, 6 H, arom. H) 7.13 – 7.28 (m, 6 
H, arom. H). 
13C NMR (75 MHz, CDCl3): δ 14.08, 22.64, 23.88, 25.50, 26.70, 27.37, 28.32, 28.63, 28.90, 
29.31, 29.51, 29.57, 29.65, 31.88, 50.21, 55.20, 60.32, 72.12, 72.50, 72.83, 73.73, 73.93, 75.02, 76.24, 
77.82, 79.47, 79.81, 107.74, 113.71, 113.74, 129.22, 129.31, 129.48, 129.60, 130.29, 130.52, 155.26, 
159.16, 159.25. 
Exact mass (ESI-MS) for C57H88NO12 [M+H]
+ found, 978.6314; calcd, 978.6301. 
(3S,4S,5R)-1-(2’,3’,4’-tri-O-(4-methoxybenzyl)-6’-O-(4-pyridinylcarbamoyl)-α-C-D-galactopyranosyl)-3-
tertbutyloxycarbonylamino-4,5-Di-O-isopropylidene-nonadecane-4,5-diol (5.37) 
To a solution of alcohol 5.36 (324 mg, 0.33 mmol) in anhydrous DCM (12 mL) was added p-
nitrophenyl chloroformate (100 mg, 0.5 mmol) and pyridine (53 µL, 0.66 mmol). The mixture was 
heated to 40 °C for 8h. After complete disappearance of the starting material the mixture was diluted 
with DCM (30 mL) and washed successively with saturated NaHCO3 solution (20 mL), H2O (20 mL) and 
brine (20 mL). Next the aqueous layer was extracted with DCM (2 x 50 mL) and the combined organic 
layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The crude p-
nitrophenylcarbonate was used without further purification in the next reaction.  
The crude carbonate was dissolved in anhydrous DCM (8 mL) followed by addition of 4-




reflux temperature and was stirred overnight. The mixture was diluted with DCM (30 mL) and 
washed successively with saturated NaHCO3 solution (20 mL), H2O (20 mL) and brine (20 mL). Next 
the aqueous layer was extracted with DCM (2 x 50 mL) and the combined organic layer was dried 
over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash 
column chromatography (0  50% EtOAc in hexanes) to provide carbamate 5.37 (200 mg, 55 %) as a 
white foam. 
1H NMR (300 MHz, CDCl3): δ 0.88 (t, J = 6.5 Hz, 3 H, terminal CH3) 1.14 – 1.36 (m, 24 H, CH3 
and CH2) 1.36 – 1.51 (m, 16 H, tBu, CH2 and CH3) 1.57 – 1.71 (m, 4 H, CH2) 1.74 – 1.87 (m, 1 H, CH2) 
3.56 – 3.73 (m, 2 H, H-3’ and H-5’) 3.81 (s, 3 H, OCH3) 3.82 (s, 3 H, OCH3) 3.83 (s, 3 H, OCH3) 3.84 – 
3.97 (m, 4 H, H-3, H-4, H-5 and H-4’) 4.04 – 4.15 (m, 1 H, Ha-6’) 4.15 (dd, J = 6.6 and 3.3 Hz, 1H, H-2) 
4.27 (q, J = 6.3 Hz, 1 H, H-1) 4.44 – 4.67 (m, 7 H, Hb-6’, CH2PhOMe and NH) 4.72 (d, J = 11.4 Hz, 1H, 
CH2PhOMe) 6.82 – 6.92 (m, 6 H, arom. H) 7.16 – 7.30 (m, 6 H, arom. H) 7.55 (d, J = 6.2 Hz, 2 H, 
pyridine) 8.44 (d, J = 6.4 Hz, 2 H, pyridine) 8.66 (s, 1 H, NHC(O)O). 
13C NMR (75 MHz, CDCl3): δ 14.12, 22.69, 25.54, 26.35, 27.18, 27.92, 28.43, 28.73, 29.36, 
29.43, 29.51, 29.66, 29.69, 31.92, 51.17, 55.29, 70.34, 72.88, 73.11, 73.84, 77.95, 79.56, 79.87, 
108.14, 112.46, 113.74, 113.80, 129.24, 129.48, 129.74, 130.11, 130.41, 130.53, 147.91, 152.67, 
155.66, 159.25, 159.37. 
Exact mass (ESI-MS) for C63H92N3O13 [M+H]
+ found, 1098.6619; calcd, 1098.6625.  
(3S,4S,5R)-1-(6”-naphthureido-6”-deoxy-α-C-D-galactopyranosyl)-3-hexacosylamino-1-nonadecene-
4,5-diol (5.1) 
A solution of 5.33 (125 mg, 0.11 mmol) in 4 M HCl in dioxane (5 mL) was stirred 3h at room 
temperature. The reaction was monitored with mass spectrometry and upon completion the solvents 
were evaporated under reduced pressure. The crude amine thus obtained was used without further 
purification in the next step. The amine was suspended in THF (2 mL) and a catalytic amount of 4-
DMAP was added. Next p-nitrophenyl hexacosanoate (85 mg, 0.17 mmol) was added followed by 
addition of Et3N (1 mL). The resulting mixture was stirred for 3 days at room temperature. 
Evaporation of the solvents and purification of the resulting residue by means of column 
chromatography (2  12% MeOH in DCM) yielded 5.1 (32 mg, 29%) as a white solid. 
1H NMR (300 MHz, pyridine-d5): δ 0.89 (t, J = 6.6 Hz, 6 H, terminal CH3) 1.00 – 1.49 (m, 64 H, 
CH2) 1.49 – 1.96 (m, 5 H, CH2) 2.20 – 2.38 (m, 2 H, CH2) 2.47 (t, J = 7.4 Hz, 2H, CH2) 3.22 (app t, J = 5.6 
Hz, 1 H, CH2) 4.16 (t, J = 5.5 Hz, 2 H, CH2-6”) 4.19 – 4.34 (m, 3 H, H-4, H-5 and H-3”) 4.34 – 4.38 (m, 1 
H, H-5”) 4.59 (t, J = 6.2 Hz, 1 H, H-4”) 4.79 (dd, J = 9.7 and 6.2 Hz, 1 H, H-2”) 5.03 – 5.09 (m, 1 H, H-1”) 
5.85 – 5.93 (m, 1 H, H-3) 6.08 (br. s, 5 H, OH) 6.84 (dd, J = 16.2 and 3.8 Hz, 1 H, CH-1=CH) 6.94 (dd, J = 
16.2 and 6.0 Hz, 1 H, CH=CH-2) 7.43 – 7.54 (m, 2 H, naphthyl) 7.61 – 7.72 (m, 2 H, naphthyl) 7.84 – 
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7.91 (m, 1 H, naphthyl) 8.52 (dd, J = 7.6 and 1.1 Hz, 1 H, naphthyl) 8.57 – 8.62 (m, 1 H, naphthyl) 8.68 
(d, J = 9.0 Hz, 1 H, NH) 9.69 (s, 1 H, NHC(O)NH). 
13C NMR (75 MHz, pyridine-d5): δ 14.69, 23.35, 26.72, 26.87, 30.02, 30.20, 30.23, 30.29, 
30.32, 30.41, 30.46, 30.55, 30.80, 32.54, 35.05, 37.37, 42.35, 44.63, 46.24, 54.46, 70.27, 71.54, 72.71, 
73.00, 76.93, 78.91, 119.65, 123.26, 124.45, 126.25, 126.43, 126.87, 127.73, 128.19, 129.13, 132.28, 
135.24, 136.70, 158.30, 173.08. 
Exact mass (ESI-MS) for C62H108N3O8 [M+H]




A solution of 5.34 (150 mg, 0.13 mmol) in 4 M HCl in dioxane (6 mL) was stirred 2h30’ at room 
temperature. The reaction was monitored with mass spectrometry and upon completion the solvents 
were evaporated under reduced pressure. The crude amine was used without further purification in 
the next step and was dissolved in THF (5 mL) and 10% aqueous KOH solution (2.5 mL) and cooled to 
0 °C. In a separate flask cerotic acid (199 mg, 0.5 mmol) was refluxed for 2h in oxalylchloride (5 mL) 
and the crude acid chloride was obtained after evaporation of the solvent by a stream of nitrogen 
and subsequent drying on high-vacuum. The crude acid chloride was dissolved in THF (5 mL) to 
obtain a 0.1 M solution of acid chloride in THF and was subsequently added dropwise (2 mL, 0.2 
mmol) to the biphasic mixture. The reaction mixture was stirred for 3h at 0 °C and TLC showed 
complete conversion of the starting material. Next the aqueous layer was extracted with THF (3 x 15 
mL) and the combined organic layer was dried over Na2SO4, filtered and evaporated. 
The resulting residue was purified by column chromatography (2  12% MeOH in DCM) followed by 
trituration with MeOH and yielded 5.2 (38 mg, 29%) as a white solid. 
1H NMR (500 MHz, pyridine-d5): δ 0.92 (t, J = 6.1 Hz, 6 H, 2 x terminal CH3) 1.18 – 1.51 (m, 67 
H, CH2) 1.62 – 1.98 (m, 4 H, CH2) 2.21 – 2.32 (m, 3 H, CH2) 2.42 – 2.63 (m, 4 H, CH2) 4.20 – 4.39 (m, 6 
H, H-4, H-5, H-3”, H-5” and CH2-6”) 4.48 (br. s, 1 H, H-4”) 4.60 – 4.66 (m, 2 H, H-1” and H-2”) 5.09 – 
5.16 (m, 1 H, H-3) 7.48 – 7.57 (m, 4 H, naphthyl) 7.65 (d, J = 7.9 Hz, 1 H, naphthyl) 7.92 (d, J = 7.3 Hz, 1 
H, naphthyl) 8.43 (d, J = 8.6 Hz, 1 H, NH) 8.59 (t, J = 7.3 Hz, 2 H, naphthyl and NH) 9.38 (s, 1 H, NH). 
13 C NMR (125 MHz, pyridine-d5): δ 14.68, 23.38, 23.58, 26.15, 27.02, 27.10, 27.76, 30.05, 
30.06, 30.18, 30.23, 30.29, 30.36, 30.38, 30.44, 30.46, 30.49, 30.56, 30.83, 32.59, 32.60, 35.11, 37.68, 
41.67, 52.90, 70.43, 71.31, 72.79, 73.75, 73.86, 75.86, 78.23, 119.32, 123.13, 123.64, 124.22, 126.17, 
126.41, 127.00, 128.14, 129.30, 135.40, 136.20, 137.04, 150.72, 157.90, 174.67. 
Exact mass (ESI-MS) for C62H110N3O8 [M+H]







A solution of 5.35 (180 mg, 0.16 mmol) in 4 M HCl in dioxane (6 mL) was stirred 3h at room 
temperature. The reaction was monitored with mass spectrometry and upon completion the solvents 
were evaporated under reduced pressure. The crude amine thus obtained was used without further 
purification in the next step. The amine was suspended in THF (3 mL) and a catalytic amount of 4-
DMAP was added. Next p-nitrophenyl hexacosanoate (125 mg, 0.24 mmol) was added followed by 
addition of Et3N (0.5 mL). The resulting mixture was stirred for 2 days at room temperature. 
Evaporation of the solvents and purification of the resulting residue by means of column 
chromatography (4  18% MeOH in DCM) yielded 5.3 (27 mg, 17%) as a white solid. 
1H NMR (300 MHz, pyridine-d5): δ 0.89 (t, J = 5.6 Hz, 6 H, terminal CH3) 1.01 – 1.60 (m, 60 H, 
CH2) 1.60 – 2.05 (m, 8 H, CH2) 2.05 – 2.40 (m, 6 H, CH2) 2.40 – 2.84 (m, 4 H, CH2) 4.20 – 4.43 (m, 4 H, 
H-4, H-5, H-2” and H-5”) 4.43 – 4.62 (m, 2 H, H-3”, H-4”) 4.63 – 4.76 (m, 1 H, H-1”) 4.85 (d, J = 10.2 
Hz, 1H, Ha-6”) 5.00 – 5.17 (m, 1 H, H-3) 5.24 (dd, J = 10.2 and 8.9 Hz, 1 H, Hb-6”) 7.92 (d, J = 5.3 Hz, 2 
H, pyridine) 8.53 (d, J = 8.5 Hz, 1 H, NH) 8.68 (d, J = 5.6 Hz, 2 H, pyridine) 10.89 (s, 1 H, NHC(O)O). 
13C NMR (75 MHz, pyridine-d5): δ 14.69, 23.35, 26.77, 26.93, 27.06, 27.91, 30.02, 30.20, 
30.23, 30.29, 30.32, 30.43, 30.58, 30.78, 32.54, 34.49, 37.41, 52.67, 66.26, 70.36, 70.82, 72.39, 72.61, 
73.45, 75.93, 77.87, 113.61, 115.68, 131.30, 144.52, 147.73, 151.36, 154.84, 173.87. 
Exact mass (ESI-MS) for C57H106N3O9 [M+H]




A solution of 5.37 (180 mg, 0.16 mmol) in 4 M HCl in dioxane (6 mL) was stirred 3h at room 
temperature. The reaction was monitored with mass spectrometry and upon completion the solvents 
were evaporated under reduced pressure. The crude amine thus obtained was used without further 
purification in the next step. The amine was suspended in THF (3 mL) and a catalytic amount of 4-
DMAP was added. Next p-nitrophenyl hexacosanoate (125 mg, 0.24 mmol) was added followed by 
addition of Et3N (0.5 mL). The resulting mixture was stirred for 2 days at room temperature. 
Evaporation of the solvents and purification of the resulting residue by means of column 
chromatography (4  18% MeOH in DCM) yielded 5.4 (27 mg, 17%) as a white solid. 
1H NMR (300 MHz, pyridine-d5): δ 0.89 (t, J = 5.6 Hz, 6 H, terminal CH3) 1.01 – 1.60 (m, 60 H, 
CH2) 1.60 – 2.05 (m, 8 H, CH2) 2.05 – 2.40 (m, 6 H, CH2) 2.40 – 2.84 (m, 4 H, CH2) 4.20 – 4.43 (m, 4 H, 
H-4, H-5, H-2” and H-5”) 4.43 – 4.62 (m, 2 H, H-3”, H-4”) 4.63 – 4.76 (m, 1 H, H-1”) 4.85 (d, J = 10.2 
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Hz, 1H, Ha-6”) 5.00 – 5.17 (m, 1 H, H-3) 5.24 (dd, J = 10.2 and 8.9 Hz, 1 H, Hb-6”) 7.92 (d, J = 5.3 Hz, 2 
H, pyridine) 8.53 (d, J = 8.5 Hz, 1 H, NH) 8.68 (d, J = 5.6 Hz, 2 H, pyridine) 10.89 (s, 1 H, NHC(O)O). 
13C NMR (75 MHz, pyridine-d5): δ 14.69, 23.35, 26.77, 26.93, 27.06, 27.91, 30.02, 30.20, 
30.23, 30.29, 30.32, 30.43, 30.58, 30.78, 32.54, 34.49, 37.41, 52.67, 66.26, 70.36, 70.82, 72.39, 72.61, 
73.45, 75.93, 77.87, 113.61, 115.68, 131.30, 144.52, 147.73, 151.36, 154.84, 173.87. 
Exact mass (ESI-MS) for C57H106N3O9 [M+H]
+ found, 976.7925; calcd, 976.7924; m.p. 177-179 
°C. 
IL-2 plate assay 
100 µl of soluble mCD1d protein (10 ug/ml in 1X PBS) is coated on a 96-well flat bottom plate by 1 h 
incubation at 37˚C. Subsequently, the plates are washed 4 times with 200 µl 1X PBS and non-specific 
binding blocked by addition of 200 µl of 1X PBS-10% FBS for 1 h.Next, the blocking solution is 
discarded and 100µl of the glycolipid of interest is added to the well and incubated for 2-24 h at 37˚C 
Due to the relative insolubility of most glycolipids, it is recommended that the compounds are 
sonicated for 15 min in warm water (37 °C) bath before adding the glycolipid to the plates. The 
compounds are diluted in a vehicle containing 0.5% polysorbate-20 and 0.9% NaCl. 
The plates are then washed 3 times with 1X PBS and twice with complete media (RPMI 1640 
supplemented with 10%FBS, Penicillin-Streptomycin (100x dilution from Gibco stock solution)and 
55µM 2-ME). 5x104 hybridoma cells in 200µl completed media are then immediately added to each 
well and the cells are grown at 37˚C for 16 hours in a CO2 incubator. 
Finally, IL-2 release in the supernatant is measured after 16 h of culture in a sandwich ELISA using a 
pair of rat anti-mouse IL-2 mAbs for capture (cat. #554424) and detection (cat. #554426) and a 
recombinant IL-2 standard (cat. #550069) (BD BioSciences, PharMingen). 
In vivo cytokine secretion assay (mice) 
Experiments were approved by and conducted according to the guidelines of the Ethical Committee of 
Laboratory Animal Welfare of Ghent University. 
The different glycolipids were dissolved in DMSO at a concentration of 1 mg/mL, heated for 
20 minutes at 80 °C and subsequently sonicated for 10 minutes at the same temperature. Next, 11 µL 
of the prepared solution was diluted with PBS in order to obtain a 10 µg/mL solution and the 
resulting solution was again warmed to 80 °C for 20 minutes followed by sonication for 10 minutes at 
this temperature. Then, 500 µL (5 µg) was injected i.p. in 8 different C57BL/6 mice and blood was 
collected 4 h (IL-4) and 16 h (IFN-γ) post injection. The levels of IL-4 and INF-γ were determined by 




α-GalCer and light- and darkgreen triangles for NU-α-GalCer represent 2 distinct batches of the 
glycolipids. 
Extended time in vivo cytokine assay 
A similar experimental setup as above was employed but rather than injecting 5µg of the lipids 1 µg 
of the different lipids was injected. Next, blood was collected at 2, 6, 12, 24 and 48 h post injection 
and the levels of IL-4 and INF-γ were determined by ELISA (eBioscience). 
Human iNKT cultures (figure 5.6)  
Human iNKT cells from healthy adult individuals were FACS-sorted and expanded as described 
previously.17 Peripheral blood mononuclear cells (PBMC) were isolated by means of density 
centrifugation and T cell-depleted by negative selection with CD2 Pan T Dynabeads (Dynal). T cell 
depleted PBMC were incubated overnight in the presence of indicated glycolipids (100 ng/ml) or 
DMSO and used as lipid antigen presenting cells (APC). Subsequently, 5x104 iNKT cells were 
cocultured with 5x104 glycolipid pulsed APC in RPMI 1640 media supplemented with 10% FBS, 1% 
sodium pyruvate, 1% nonessential amino acids and 1% penicillin/streptomycin (all from Thermofisher 
Scientific) and 1U/ml IL-2 (Roche). Supernatants were collected after 24hr and 48hrs of culture and 
IL-4 and IFN-γ levels were determined by means of ELISA (eBioscience). 
Co-culture of human iNKT cells and Hela-CD1d cells 
1 x 104 Human iNKT cells (cell line #630B) were co-cultured with 4 x 104 HeLa-CD1d cells that are 
incubated overnight in the presence of the indicated glycolipids (1μg/mL, 0.1μg/mL or 0.01μg/mL 
respecyively). After 24h of co-culture at 37 °C, supernatant was collected and IL-4 and IFN-γ levels 
were determined by means of ELISA. 
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Chapter 6: Photoactivatable α-GalCer analogues 
6.1 Introduction 
In our search towards potent Th1 polarizing iNKT cell antigens, we pursued the hypothesis that the 
stability of the binary (CD1d/glycolipid) and ternary (CD1d/glycolipid/TCR) complex, govern the 
cytokine secretion. However, in literature there is little consensus about the relative importance of 
both complex stabilities. In order to investigate this, we aimed at introducing a covalent bond 
between glycolipid and the CD1d molecule, resulting in a substantial increase of the CD1d/glycolipid 
complex stability. 
A popular strategy to achieve covalency is the use of photoactivatable crosslinkers, which upon 
irradiation with light of the appropriate wavelength convert to highly reactive species, capable of 
introducing covalent bonds between interacting molecules. Since the initial report on photoaffinity 
labeling1 describing the use of a diazoacetyl group to inactivate chymotrypsin, several other 
photophores have emerged. Among them diazirines, benzophenones and arylazides have 
demonstrated a widespread applicability and accordingly, gained increasing interest.2(Figure 6.1) 
 
Figure 6.1 Photocrosslinking groups used in biological systems 
To function in a biological context, the photoaffinity label should meet certain criteria. First off, the 
photoaffinity probe should be stable in the biological environment and must be activated solely upon 
irradiation with light of a specific wavelength. In addition, this wavelength may not harm the 
biological system of interest (λact > 300 nm). Second, to minimize non-specific labeling, the generated 
reactive intermediate needs to have a shorter lifetime than that of the macromolecular interaction of 
interest. Furthermore, the reactive species must be promiscuous and rapidly react with any chemical 
entity in its proximity, regardless of its nature, and form stable covalent adducts. Finally, to avoid 
disturbances in the studied interaction, the size of the photoactivatable group needs to be reduced 
to a minimum. 
In the next section the photochemistry and characteristics of the above mentioned photophores will 





The diazirine group is activated upon irradiation of light with a wavelength of 350-380 nm, which is 
well above the 300 nm limit, hence no significant damage to biological systems is observed. 
Irradiation results in the loss of molecular nitrogen and the generation of a singlet carbene species 
VII. (Scheme 6.1) In tandem, approximately thirty percent of the starting material is isomerized to 
the linear diazo compound III. Upon photoexcitation, the latter can expel molecular nitrogen and 
form the singlet carbene again, however at the wavelengths generally used, this conversion is 
relatively slow.3 Consequently, this diazo compound is proportionately long-lived and can, due to the 
high susceptibility towards nucleophilic attack, result in nonspecific binding or hydrolysis of the 
crosslinking species. To overcome this issue, a strong electron-withdrawing trifluoromethyl group can 
be appended in α-position, this stabilizes the diazo isomer and minimizes undesired side reactions.4 
The singlet carbene VII is highly reactive and displays a very short half-life of approximately 1 
nanosecond. Additionally, due to intersystem crossing, the singlet carbene can transform into triplet 
carbene species XII.  
While triplet carbenes react like diradicals, singlet carbenes react as nucleophile, electrophile, or 
amphiphile, depending on the substitution pattern. Singlet carbene species generally give rapid 
insertion reactions into C-H or heteroatom-H bonds, albeit compared to insertion into alcohols (VIII), 
C-H insertions (X) are generally less efficient.5 In the case where the singlet carbene is inserted into 
primary or secondary N-H bonds (IV), an undesired side reaction can occur. The resulting amine can 
expel HF, forming enamine V, which is in equilibrium with imine VI. Both species can be hydrolyzed 
to the corresponding ketone, losing the captured substrate.5 Whereas C-H insertion of the triplet 
carbene yields the same product X, two side reactions scavenge this reactive intermediate. To 
generate a clean C-H insertion, radical intermediate XIII should react with the formed carbon radical. 
However, when a second hydrogen radical is abstracted from a different C-H bond instead, the 
reactive intermediate is reduced and no longer available for cross-linking. Additionally the triplet 
carbene can be quenched by molecular oxygen resulting in ketone XI.6 Finally, unsubstituted 3-alkyl-
3H-diazirines are best avoided as their carbenes are highly susceptible to hydride shift, resulting in 
olefin formation.7 
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Scheme 6.1 Possible reaction pathways of the reactive intermediates formed after photolysis of 3-
aryl-3H-diazirines. The inset shows the hydride shift of a singlet carbene derivative of unsubstituted 
3-alkyl-3H-diazirines resulting in olefin formation. ISC, intersystem crossing. (Adapted from Geurink 
et al., 2012, Topics in Current Chemistry) 
A great advantage of diazirines is their stability towards strong acidic and basic environments as well 
as various oxidating and reducing agents. In contrast, the bulkiness of aryl diazirines and the 
substantial amount of diazo isomer formation, are inconvenient. Moreover, due to the high reactivity 
of the singlet carbene species, scavenging with O-H bonds in an aqueous environment is rapid, 
leading to low crosslinking efficiency. An additional disadvantage is that the chemical synthesis of 
diazirines is often more challenging than other photoaffinity labels. 
6.3 Benzophenones 
Like diazirines, the exciting wavelength of benzophenones lies around 350-360 nm. Upon absorption 
of a photon, benzophenones reversibly form a triplet state benzhydryl diradical XVI. (Scheme 6.2) 
When an appropriate reaction partner is absent, this diradical exists for an approximate 120 µs 
before relaxing back to the ground state. In the other case, the diradical will abstract a hydrogen 
atom from a nearby X-H bond and insert in the latter. In contrast to diazirines, benzhydryl diradicals 
are more reactive towards C-H bonds as compared to O-H bonds. Additionally, C-H bonds that can 
form stable carbon radicals are highly susceptible to react, such as amino acid α-positions, benzylic 
systems, heteroatom flanked hydrogen atoms and tertiary carbon centers. While all amino acids can 
react, benzophenones exhibit high preference for the ε-H in methionine.8 Hydrogen abstraction at 
the α-center of amino acids results in ketyl formation XVIII and alkyl radical XIX, which rapidly 
recombine to furnish the final benzhydrol adduct XX. If H-abstraction occured from glycine, the 




While the diradical can be quenched by water, forming the corresponding hydrate XXI, dehydration 
to the ketone XV and successive irradiation recycles the diradical species. Consequently, the 
benzophenone features a high crosslinking efficiency but in tandem possesses a greater opportunity 
for non-specific labeling. A second side product occurs after homodimerization of ketyl XVIII yielding 
benzopinacol XXII. Yet, due to the relative big differences in reaction rates between hydrogen 
abstraction and recombination, only trace amounts of pinacol are generally observed.2 
 
Scheme 6.2 Possible reaction pathways of benzophenones after photolysis. (Adapted from Geurink 
et al., 2012, Topics in Current Chemistry) 
A major disadvantage associated with benzophenones is the relative bulkiness, resulting in steric 
hindrance and disturbance of the macromolecular interaction of interest. Furthermore, long 
irradiation times are generally needed to observe reasonable crosslinking efficiency,9 however due to 
the long wavelengths used, the damage to biological systems is minimal.10,11 
6.4 Arylazides 
Similar to diazirines, arylazides expel molecular nitrogen upon irradiation with light of the 
appropriate wavelength, resulting in singlet nitrene species XXVIII. (Scheme 6.3) This nitrene is 
electrophilic in nature and rapidly inserts in nearby C-H bonds to give a covalent adduct XXV. In 
addition, due to its highly energetic and reactive character, the singlet nitrene is readily converted to 
other lower-energy intermediates. Among them are the benzazirine XXXIII 12,13 and the 
corresponding triplet nitrene XXIX, which is a result of intersystem crossing. These triplet nitrenes 
behave like diradicals and react analogous to activated benzophenones (vide supra), abstracting a 
hydrogen radical from a nearby C-H bond and subsequently coupling to the formed carbon radical. 
On the other hand, benzazirine XXXIII can further rearrange into dehydroazepine XXXIV, and as both 
species are long-lived electrophiles, they will react with nearby nucleophiles to form adducts XXXII 
and XXXV, respectively. Due to the long-lived nature of these rearranged intermediates, low 
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crosslinking efficiencies and off-target labeling are generally associated with arylazide photophores.10 
In a biological context, arylazides can be quenched via two side reactions. Whereas thiols reduce the 
azide group to the corresponding amine XXIV,14 oxidation of the triplet nitrene by molecular oxygen 
gives rise to nitro species XXVI.15 
 
Scheme 6.3 Possible reaction pathways of the reactive intermediates formed after photolysis of aryl 
azides. ISC, intersystem crossing; NuH, nucleophile. (Adapted from Geurink et al., 2012, Topics in 
Current Chemistry) 
The small size of the aryl azide moiety together with the ease of preparing aryl azide probes clearly 
offers some advantages. However, the main issue is the small wavelengths at which arylazides get 
activated. The maximum absorption of unsubstituted phenyl azide is approximately 250 nm, well-
below the 300 nm cut-off for biocompatibility. To overcome this disadvantage, several substituted 
aryl azides have been developed. Introducing substituents ortho to the azide group, generally leads 
to undesired cyclizations after photolysis and thus should be avoided.2 In contrast, electron-
withdrawing substituents like nitro, hydroxyl, and acyl groups are beneficial as they increase molar 
absorptivity and red-shift the absorption maximum.6,16 Additionally, (per)fluorinated aryl azides have 
a lower tendency to rearrange to the benzazirine and dehydroazepine intermediates, resulting in 
more efficient insertion reactions.17 Nonetheless, crosslinking yields for aryl azides are often below 
thirty percent, as a consequence of the plethora of different reaction pathways after irradiation, 




6.5 Synthesis of a photoactivatable α-GalCer analogue 
We designed the photoactivatable α-GalCer analogue based on the structure of the potent Th1 
polarizing glycolipid 7DW8-5, which shows strong binding to CD1d.18 Substitution of the fluorine 
atom to an azide functionality generates the corresponding arylazide photoaffinity label. (Figure 6.2) 
While the azide group is bigger in size than the fluorine atom, the electronic effects on the phenyl 
group should be small, as fluoroarenes and arylazides have similar Hammet constant values.19  
 
Figure 6.2 Structures of 7DW8-5 and the envisioned photo-activatable α-GalCer analogue 6.1 
Modifications of the acyl moiety are generally more accessible as compared to alteration of other 
parts of the α-GalCer structure. Thus, the aimed derivative can be obtained upon condensation of 11-
(4-azidophenyl)undecanoic acid with deprotected lyso-galactosylceramide 6.9. The latter is obtained 
via acid hydrolysis of the Boc-group following catalytic hydrogenation of 6.7. In this way the 
hydrogenation step is performed before introduction of the arylazide functionality and undesired 
reduction to the aniline is circumvented. The Boc-protected derivative is swiftly obtained from azide 
6.6, which is a well-known intermediate in α-GalCer chemistry, and is the glycosylation product of 
previously used trichloroacetimidate 4.13 and a suitable protected phytosphingosine derivative 6.5. 
(Scheme 6.4) 
Scheme 6.4 Retrosynthetic scheme for the synthesis of the photocrosslinking α-GalCer derivative 6.1 
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The synthesis of 11-(4-azidophenyl)undecanoic acid (6.4) starts with a Sonogashira reaction between 
commercially available 10-undecynoic acid and 1-iodo-4-nitrobenzene. Next, the obtained alkyne 6.2 
was subjected to a hydrogenation reaction, which saturated the triple bond and concomitantly 
reduced the nitro group to the corresponding aniline. Finally, a Sandmeyer reaction with sodium 
azide as nucleophile, furnished the required carboxylic acid 6.4. (Scheme 6.5) 
Scheme 6.5 Reagents and conditions: a) Pd(PPh3)2Cl2, CuI, Et3N, 1-iodo-4-nitrobenzene, RT, 16h, 
51%; b) Pd/C, AcOH, H2, MeOH, RT, 6h, 86%; c) i) 2 M HCl, NaNO2, 0 °C, 15’, dark; ii) NaN3, RT, 18h, 
dark, 47% (over 2 steps) 
The preparation of 6.1 began with the glycosylation reaction between trichloroacetimidate 4.13 and 
known azidophytosphingosine derivative 6.5.20 The latter is obtained after metal-catalyzed 
diazotransfer, tritylation of the primary alcohol followed by per-benzylation and trityl ether cleavage 
of commercially available D-ribo-phytosphingosine. Notably, the glycosylation reaction proceeded 
with impressive yield (91%) and excellent α-selectivity (α/β ratio: 5.5/1) to furnish galactoside 6.6. 
Next, the azide moiety was reduced under Staudinger conditions and the resulting amine was 
condensed with di-tert-butyl dicarbonate to afford Boc-protected derivative 6.7. Subsequent 
catalytic hydrogenolysis and treatment with HCl, yielded crude amine 6.9, which was acylated with 
the acid chloride of 6.4, leading to the envisioned derivative 6.1. (Scheme 6.6) 
Scheme 6.6 Reagents and conditions: a) 4.13, TMSOTf, THF, -30 °C, 3h, 77% (14% β); b) i) PMe3, H2O, 
THF, RT, 7h; ii) Boc2O, DCM, Et3N, RT, 18h, 81% (over 2 steps); c) Pd black, H2, CHCl3, EtOH, RT, 8h, 
61%; d) 1 M HCl in a 90% aqueous AcOH solution, DCM, RT, 5h; e) acid chloride of 6.4, THF, saturated 




6.6 Crystallographic evaluation of 6.1 
To investigate the formation of a covalent bond between CD1d and the glycolipid, we turned our 
attention to the crystal structure of the CD1d/6.1 complex. CD1d was incubated with a three times 
molar excess of lipid and exposed to UV radiation at 254 nM wavelength for 5 to 60 seconds. Next, 
the protein-lipid complex was subjected to crystallization and structure determination. A control 
experiment included the crystallization of the same protein-lipid complex prior to UV exposure. 
Strikingly, in the UV-irradiated crystals, about 50% of the thiol groups of Cys12 rotate to form a 
covalent adduct with the phenyl moiety of 6.1. This covalent bond formation is clearly associated 
with UV-irradiation, since the untreated control crystal, fails to show the cysteine rotamer. (Figure 
6.4)  
 
Figure 6.4 Crystal structures of the CD1d/6.1 complex, A’ pocket view. Left panel: The UV-irradiated 
crystal shows a covalent adduct with 6.1 formed through rotation of Cys12 (in approximately 50% of 
the crystals). Right panel: In the absence of UV irradiation no covalent bond is formed 
The basis for the relatively low crosslinking efficiency is probably related to the binding mode of 6.1 
in CD1d. While the acyl chain of 6.1 can enter the A’ pocket of CD1d in both clockwise as anti-
clockwise direction, only the anti-clockwise binding results in covalent bond formation. This is nicely 
illustrated in the crystal structures displayed above, where the green electron density represents 
clockwise binding and clearly contours nicely. In contrast the blue electron density, and thus anti-
clockwise binding, allows the arylazide to come close in the proximity of Cys12 and enables covalent 
bond formation. Based on this observation, we reasoned that lengthening the acyl chain by seven 
methylene units, would allow the arylazide moiety to penetrate further down the A’ pocket bringing 
it closer to Cys12 in its conserved position.  
6.7 Second generation photoactivatable α-GalCer analogue 
The previously used synthetic strategy mounts the acyl moiety onto the glycolipid in the final step of 
the synthesis, therefore we could easily modify the strategy to obtain the acyl-elongated derivative 
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6.10. However, we needed to prepare the suitable 18-(4-azidophenyl)octadecanoic acid to proceed 
with the acylation of amine 6.9.  
Since 17-octadecynoic acid is not commercially available, an alternative synthetic scheme was 
developed for the preparation of the desired carboxylic acid. First, a SN2 reaction between 
deprotonated THP-protected propargyl alcohol and 1-bromopentadecane followed by acid hydrolysis 
of the THP-ether, resulted in alkynol 6.11. Next, an alkyne-zipper reaction with ethylene-1,2-diamine 
in the presence of sodium hydride gave access to the corresponding terminal alkyne, which is 
amenable for Sonogashira reaction with 1-iodo-4-nitrobenzene, furnishing alcohol 6.14. Subsequent 
pyridinium dichromate oxidation to the corresponding carboxylic acid and palladium catalyzed 
hydrogenation swiftly yielded aniline 6.16, which after Sandmeyer reaction with sodium azide, gave 
18-(4-azidophenyl)octadecanoic acid (6.17). (Scheme 6.7) 
 
Scheme 6.7 Reagents and conditions: a) n-BuLi, 1-bromopentadecane, THF, DMPU, -78 °C  50 °C, 
16h; b) TsOH.H2O, MeOH, RT, 3h, 74% (over 2 steps); c) ethylene-1,2-diamine, NaH, 0 °C  RT  70 
°C, 2h30’, 61%; d) Pd(PPh3)2Cl2, CuI, Et3N, 1-iodo-4-nitrobenzene, RT, 15h, 81%; e) PDC, DMF, RT, 18h, 
64%; f) Pd/C, AcOH, H2, CHCl3, EtOH, 30 °C, 16h; g) i) 2 M HCl, NaNO2, 0 °C, 15’, dark; ii) NaN3, RT, 18h, 
dark, 56% (over 3 steps) 
With the required 18-(4-azidophenyl)octadecanoic acid in hand, we carried on with the acylation of 
amine 6.9 to yield the envisioned photoaffinity labeled α-GalCer analogue 6.10. (Scheme 6.8) 
 
Scheme 6.8 Reagents and conditions: acid chloride of 6.17, THF, saturated NaOAc solution, dark, RT, 
2h, 47% (over 2 steps) 




6.8 Biological evaluation 
In order to assess whether the introduction of the azide functionality in the 7DW8-5 structure is not 
detrimental for the activity, 1 µg of the prepared glycolipids was administered to Balb/c mice, and at 
various time points blood samples were obtained for IFN-γ and IL-4 quantification by means of ELISA. 
(Figure 6.5) Similar to 7DW8-5, arylazide 6.1 induces a potent Th1 cytokine response characterized by 
high levels of IFN-γ and marginal IL-4 secretion. Noteworthy, the antigenic potency of 6.1 is inferior 
to α-GalCer, which is a reflection of the shorter acyl chain length in the arylazide derivative. Indeed, a 
higher antigenic potency is observed for the acyl-elongated 6.10 but unfortunately, at the same time 
the Th1 behavior of the azidophenyl derivative is lost. 
 
Figure 6.5 IFN-γ and IL-4 levels at different time points after injection of 1µg of the glycolipids in 
Balb/c mice 
 
To our surprise, when 6.1 and 6.10 were evaluated in a human setting, where 1x104 human iNKT cells 
(cell line #630B) were cocultured with 4x104 glycolipid loaded Hela-CD1d cells followed by IFN-γ 
determination after 24h, both compounds showed very potent human iNKT cell activation surpassing 
α-GalCer. (Figure 6.6) In contrast with the data obtained for mice, 6.1 is clearly able to stimulate 
higher IFN-γ titers as compared to the acyl-elongated 6.10. Moreover, 6.1 displays similar activity 
towards human iNKT cells as 7DW8-5.21 The latter should not be unexpected given the analogues 
physicochemical properties of the azido functionality and a fluorine atom. 
  Photoactivatable α-GalCer analogues 
 
  155 
 
Figure 6.6 IFN-γ secretion after coculture of human iNKT cells and Hela CD1d cells with the indicated 
photoaffinity labeled α-GalCer analogues. Bars represent means + SEM. 
It is important to note that all the biological data presented above was obtained under non-
irradiated conditions. Further experiments applying UV-irradiation to induce the covalent linkage 
between glycolipid and CD1d are still ongoing. 
6.9 Conclusion 
We successfully prepared photoactivatable α-GalCer analogues by introducing an arylazide moiety in 
the acyl chain of the glycolipids. Initial biological evaluation revealed that the photoactivatable iNKT 
cell ligands are indeed able to activate mouse iNKT cells, and display promising antigenic activity 
towards human iNKT cells largely outperforming α-GalCer. Furthermore, we nicely showed that upon 
UV-irradiation, 6.1 can form covalent interactions with the CD1d protein. However, a moderately low 
crosslinking efficiency is observed, probably due to the necessity for Cys12 from within the A’ pocket 
to rotate in order to allow covalent bond formation. Hence, a similar lipid with a slightly increased 
acyl chain length might go deeper in the A’ pocket and come close in the proximity of Cys12 in its 
conserved position and lead to a higher degree of crosslinking. Additional experiments will show 
whether 6.10 can indeed accomplish more efficient covalent bond formation and attach to the CD1d 
molecule with minimal conformational effects in the A’ pocket. 
Interestingly, during our investigation of arylazide-modified α-GalCer analogues, the group of Porcelli 
reported iNKT cell ligands bearing a terminal benzophenone moiety in the fatty acid chain.22 Whereas 
no crosslinking efficiency nor data on the nature of the covalent bond were disclosed, biological 
evaluation of these benzophenones showed a clear increase in antigenic properties after UV 




untreated situation. Consequently, we are eager to receive the data for our covalent glycolipids 
under cross-linking conditions. 
6.10 Experimental Part 
11-(4-nitrophenyl)undec-10-ynoic acid (6.2) 
To a solution of 10-undecynoic acid (1.82 g, 10 mmol) and 1-iodo-4-nitrobenzene (3.11 g, 12.5 mmol) 
in degassed Et3N (28 mL) at 0 °C, was added CuI (48 mg, 0.25 mmol) and Pd(PPh3)2Cl2 (176 mg, 0.25 
mmol). The reaction mixture was allowed to reach room temperature and was stirred overnight. 
Upon completion of the reaction, the solvent was removed under reduced pressure and the residue 
was dissolved in EtOAc (50 mL) and washed with 1 M HCl solution (30 mL). The aqueous layer was 
extracted with EtOAc (2 x 30 mL) and the combined organic layer was washed with saturated NaHCO3 
(70 mL) and brine (70 mL). After drying over Na2SO4, filtration and evaporation, the crude residue 
was purified by flash chromatography (DCM/EtOAc: 9/1) to afford carboxylic acid 6.2 (1.54 g, 51%) as 
a yellow solid. 
1H NMR (300 MHz, CDCl3): δ 1.24 – 1.53 (m, 8 H, CH2) 1.56 – 1.72 (m, 4 H, CH2) 2.37 (t, J = 7.8 
Hz, 2 H, CH2) 2.45 (t, J = 6.7 Hz, 2 H, CH2) 7.48 – 7.56 (m, 2 H, arom. H) 8.12 – 8.19 (m, 2 H, arom. H). 
13 C NMR (75 MHz, CDCl3): δ 19.53, 24.60, 28.32, 28.52, 28.81, 28.85, 28.95, 29.07, 33.95, 
79.34, 96.68, 123.47, 131.16, 132.21, 146.56, 179.84. 
Exact mass (ESI-MS) for C17H20NO4 [M-H]
- found,302.1394; calcd, 302.1398. 
11-(4-aminophenyl)undecanoic acid (6.3) 
A solution of 6.2 (1.12 g, 3.69 mmol) in MeOH (10 mL) and AcOH (1 mL) was hydrogenated in the 
presence of Pd/C (200 mg) for 6h under atmospheric pressure. Upon reaction completion, the 
mixture was filtered through a patch of celite. The filter cake was rinsed with MeOH and the filtrate 
was evaporated to dryness. Next, the crude residue was purified by flash column chromatography 
(0%  5% MeOH in DCM) to yield aniline 6.3 (881 mg, 86%) as a yellow solid. 
1H NMR (300 MHz, CDCl3): δ 1.21 – 1.40 (m, 12 H, CH2) 1.50 – 1.71 (m, 4 H, CH2) 2.35 (t, J = 
7.5 Hz, 2 H, CH2) 2.50 (t, J = 7.4 Hz, 2 H, CH2) 5.59 (br. s, 2H, NH2) 6.62 – 6.67 (m, 2 H, arom. H) 6.95 – 
7.01 (m, 2 H, arom. H). 
13C NMR (75 MHz, CDCl3): δ 24.69, 29.04, 29.17, 29.34, 29.42, 29.45, 31.72, 33.97, 35.04, 
115.36, 129.11, 133.28, 143.71, 179.35. 
Exact mass (ESI-MS) for C17H28NO2 [M+H]
+ found, 278.2118; calcd, 278.2115. 
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11-(4-azidophenyl)undecanoic acid (6.4) 
To a suspension of 6.3 (200 mg, 0.69 mmol) in 2 M aqueous HCl solution (5 mL) at 0 °C, was added 
sodium nitrite (1 M aqueous solution, 0.76 mL, 0.76 mmol) and the reaction was stirred for 15 
minutes shed from light. Next, sodium azide (1 M aqueous solution, 0.73 mL, 0.73 mmol) was added 
and the reaction was allowed to reach room temperature and was stirred overnight in the dark. The 
precipitate was filtered and the residue was purified by flash chromatography (0%  7% MeOH in 
DCM) to afford carboxylic acid 6.4 (99 mg, 47%) as a pale solid. 
1H NMR (300 MHz, CDCl3): δ 1.24 – 1.40 (m, 12 H, CH2) 1.52 – 1.69 (m, 4 H, CH2) 2.36 (t, J = 
7.5 Hz, 2 H, CH2) 2.58 (t, J = 7.4 Hz, 2 H, CH2) 6.91 – 6.98 (m, 2 H, arom. H) 7.13 – 7.19 (m, 2 H, arom. 
H). 
13C NMR (75 MHz, CDCl3): δ 24.66, 29.02, 29.16, 29.19, 29.37, 29.42, 29.46, 31.46, 33.91, 
35.30, 118.84, 129.69, 137.27, 139.74, 179.49. 
Exact mass (ESI-MS) for C17H24N3O2 [M-H]
- found, 302.1873; calcd, 302.1874. 
 (2S,3S,4R)-2-azido-3,4-di-O-benzyl-octadecane-1,3,4-triol (6.5) 
Prepared as previously published.20 
1H NMR (300 MHz, CDCl3): δ 0.88 (t, J = 6.8 Hz, 3 H, terminal CH3) 1.58 – 1.23 (m, 26 H, CH2), 
2.49 (dd, J = 6.8 and 6.2 Hz, 1 H, OH) 3.60 – 3.73 (m, 3 H, H-2, H-3 and H-4) 3.79 (ddd, J = 11.7, 6.7 
and 5.1 Hz, 1 H, Ha-1) 3.89 (dd, J = 11.4 and 5.9 Hz, 1 H, Hb-1) 4.57 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.63 (d, 
J = 10.5 Hz, 1 H, CH2Ph) 4.67 (d, J = 10.2 Hz, 1 H, CH2Ph) 4.72 (d, J = 11.1 Hz, 1 H, CH2Ph) 7.27 – 7.39 
(m, 10 H, arom. H). 
13C NMR (75 MHz, CDCl3): δ 14.36, 22.93, 25.72, 29.60, 29.80, 29.84, 29.90, 29.92, 29.94, 
30.47, 32.16, 62.50, 63.31, 72.79, 73.87, 77.45, 79.27, 80.75, 127.49, 128.08, 128.16, 128.23, 128.25, 
128.34, 128.69, 128.76, 137.87, 138.20, 147.10. 
Exact mass (ESI-MS) for C32H50N3O3 [M+H]
+ found, 524.3853; calcd, 524.3847. 
Spectral data are consistent with the literature data.  
(2S,3S,4R)-2-azido-3,4-di-O-benzyl-1-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-
octadecane-1,3,4-triol (6.6) 
To a mixture of trichloroacetimidate 4.13 (8.23 g, 13.88 mmol) in THF (60 mL) under argon 
atmosphere was added a solution of azidophytosphingosine 6.5 (4.87 g, 9.30 mmol) in THF (60 mL). 
The solution was cooled to -30 °C and TMSOTf (0.3 mL, 1.4 mmol) was added. After stirring for 1 




pressure. The resulting residue was purified by column chromatography (hexanes/EtOAc: 9/1) 
affording glycolipid 6.6 (6.848 g, 77 %) as a white solid together with the β-anomer (1.27 g, 14%). 
1H NMR (300 MHz, CDCl3): δ 0.88 (t, J = 6.4 Hz, 3 H, terminal CH3), 1.65 – 1.26 (m, 26 H, CH2) 
3.57 (app. s, 1 H, H-5”) 3.62 (ddd, J = 7.1 and 3.5 Hz, 1 H, H-4) 3.73 – 3.69 (m, 3 H, H-1, H-2 and H-3) 
3.88 (dd, J = 12.6 and 1.3 Hz, 1 H, H-6”) 4.04 – 3.99 (m, 2 H, H-1 and H-3”) 4.14 – 4.07 (m, 2 H, H-2” 
and H-6”) 4.16 (app. d, J = 3.5 Hz, 1 H, H-4”) 4.50 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.58 (d, J = 11.7 Hz, 1 H, 
CH2Ph) 4.60 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.67 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.74 (d, J = 12.3 Hz, 1 H, 
CH2Ph) 4.77 (d, J = 10.4 Hz, 1 H, CH2Ph) 4.81 (d, J = 13.2 Hz, 1 H, CH2Ph) 4.86 (d, J = 12.0 Hz, 1 H, 
CH2Ph) 4.97 (d, J = 3.2 Hz, 1 H, H-1”) 5.45 (s, 1 H, H-8”) 7.41 – 7.21 (m, 23 H, arom. H) 7.53 – 7.51 (m, 
2 H, arom. H). 
13C NMR (75 MHz, CDCl3): δ 14.35, 21.58, 22.92, 25.70, 29.47, 29.60, 29.72, 29.85, 29.88, 
29.90, 29.92, 29.94, 30.01, 30.26, 32.16, 62.04, 63.22, 68.69, 69.56, 72.28, 72.31, 72.44, 73.74, 74.02, 
74.91, 75.69, 76.04, 77.44, 77.90, 79.20, 79.65, 99.38, 101.30, 121.12, 126.58, 127.70, 127.75, 
127.85, 127.91, 127.94, 128.00, 128.04, 128.15, 128.34, 128.47, 128.51, 128.59, 128.62, 129.10, 
129.90, 138.07, 138.26, 138.60, 139.00. 
Exact mass (ESI-MS) for C59H75KN3O8 [M+K]
+ found, 992.5189; calcd, 992.5186. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-2-
tertbutyloxycarbonylamino-octadecane-1,3,4-triol (6.7) 
To a solution of azide 6.6 (800 mg, 0.84 mmol) in THF (30 mL) at room temperature, PMe3 (1 M 
solution of in THF, 12.6 mL, 12.6 mmol) was added dropwise. After stirring for 3h at room 
temperature, H2O (4 mL) was added and the reaction mixture was allowed to stir overnight at room 
temperature. Then the solvent was removed under reduced pressure and the product was dried by 
making an azeotropic mixture with toluene to afford the crude amine. The crude amine was 
subsequently dissolved in DCM (13 mL) and Et3N (3.3 mL) followed by the addition of Boc2O (1.1 g, 
5.03 mmol). The reaction mixture was stirred overnight at room temperature, evaporated under 
reduced pressure and purified by column chromatography (0%  20% EtOAc in hexanes) to yield 6.7 
(703 mg, 81%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 0.90 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.21 – 1.34 (m, 20 H, CH2) 
1.43 (br. s, 9 H, tBu) 1.47 – 1.73 (m, 6 H, CH2) 3.52 – 3.58 (m, 1 H, H-4) 3.59 (br. s, 1 H, H-5”) 3.72 – 
3.81 (m, 2 H, Ha-1 and H-3) 3.82 – 3.96 (m, 3 H, Hb-1, H-2 and Ha-6”) 3.96 – 4.09 (m, 2 H, H-2” and H-
3”) 4.09 – 4.13 (m, 1 H, Hb-6”) 4.15 – 4.21 (m, 1 H, H-4”) 4.42 – 4.56 (m, 2 H, CH2Ph) 4.56 – 4.68 (m, 2 
H, CH2Ph) 4.73 – 4.88 (m, 5 H, CH2Ph and NH(CO)) 4.95 (d, J =3.1 Hz, 1 H, H-1”) 5.47 (s, 1 H, H-8”) 7.18 
– 7.44 (m, 23 H, arom. H) 7.50 – 7.55 (m, 2 H, arom. H). 
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13C NMR (75 MHz, CDCl3): δ 14.11, 22.69, 25.83, 28.01, 28.40, 29.36, 29.65, 29.71, 31.92, 
51.68, 62.82, 68.48, 69.41, 71.83, 73.61, 74.51, 75.60, 76.10, 79.21, 79.43, 79.75, 99.42, 101.01, 
126.31, 127.54, 127.57, 127.79, 127.88, 128.08, 128.26, 128.29, 128.32, 128.35, 128.82, 137.83, 
138.47, 138.55, 138.64, 138.73, 155.34. 
Exact mass (ESI-MS) for C64H86NO10 [M+H]
+ found, 1028.6260; calcd, 1028.6246. 
(2S,3S,4R)-1-O-α-D-galactopyranosyl-2-tertbutyloxycarbonylamino-octadecane-1,3,4-triol (6.8) 
A solution of 6.7 (703 mg, 0.68 mmol) in CHCl3 (6 mL) and EtOH (18 mL) was hydrogenated under 
atmospheric pressure in the presence of palladium black (50 mg). Upon reaction completion, the 
mixture was filtered through celite. The filter cake was rinsed with CHCl3 and EtOH and the filtrate 
was evaporated to dryness. After purification by column chromatography (10%  18% MeOH in 
DCM), compound 6.8 (242 mg, 61%) was obtained as a pale yellowish solid. 
1H NMR (300 MHz, pyridine-d5): δ 0.88 (t, J = 6.4 Hz, 3 H, terminal CH3) 1.15 – 1.34 (m, 21 H, 
CH2) 1.37 – 1.46 (m, 1 H, CH2) 1.51 (s, 9 H, tBu) 1.60 – 1.75 (m, 1 H, CH2) 1.80 – 1.98 (m, 2 H, CH2) 2.22 
– 2.35 (m, 1 H, CH2) 4.24 – 4.35 (m, 3 H, Ha-1, H-3”, H-4) 4.38 – 4.53 (m, 4 H, H-3”, H-4” and CH2-6”) 
4.57 (d, J = 3.0 Hz, 1 H, H-5”) 4.61 – 4.74 (m, 2 H, Hb-1 and H-2”) 4.91 – 5.01 (m, 1 H, H-2) 5.56 (d, J = 
3.8 Hz, 1 H, H-1”) 6.41 (br. s, 6 H, OH) 7.46 (d, J = 9.1 Hz, 1 H, NH). 
13C NMR (75 MHz, pyridine-d5): δ 14.86, 23.50, 27.03, 29.13, 30.17, 30.48, 30.54, 30.58, 
30.68, 30.90, 32.68, 34.87, 53.09, 63.10, 68.94, 70.82, 71.47, 72.16, 72.94, 73.41, 77.24, 79.06, 
101.81, 157.14. 
Exact mass (ESI-MS) for C34H63N2O10 [M+pyridine+H]
+ found, 659.4462; calcd, 659.4477. 
(2S,3S,4R)-1-O-α-D-galactopyranosyl-2-amino-octadecane-1,3,4-triol (6.9) 
Glycolipid 6.8 (118 mg, 0.2 mmol) was dissolved in DCM (20 mL) and 1 M HCl in 90% aqueous AcOH 
solution (100 µL) was added at room temperature. After 35 minutes TLC showed uncomplete 
conversion of the starting material and another amount of the HCl solution (100 µL) was added. This 
process was repeated till TLC (DCM/MeOH: 8/2) showed full disappearance of the starting material. 
In total 600 µL was added during this reaction. Next, the solvents were removed under reduced 
pressure and the residue was co-evaporated with MeOH (3 x 5mL). The resulting crude amine was 
used without further purification in the acylation step. 
An analytical sample was purified by flash reverse phase column chromatography (gradient system of 
HCOOH in H2O (0.1 %, v/v)/HCOOH in CH3CN (0.1 %, v/v)) to characterize the amine intermediate. 
1H NMR (300 MHz, methanol-d4): δ 0.89 (t, J = 6.5 Hz, 3H, terminal CH3) 1.20 – 1.46 (m, 24 H, 




H-3 and Ha-6”) 3.68 – 3.87 (m, 6 H, CH2-1, H-2, H-2”, H-3” and H-5”) 3.89 (d, J = 3.0 Hz, 1 H, H-4”) 4.12 
(dd, J = 10.0 and 2.2 Hz, 1 H, Ha-6”) 4.89 (1 H, H-1” under HOD peak). 
13C NMR (75 MHz, methanol-d4): δ 14.59, 23.86, 26.45, 30.59, 30.88, 30.91, 33.20, 35.61, 
55.03, 61.58, 62.87, 63.06, 65.25, 68.05, 68.90, 70.25, 70.69, 71.16, 71.42, 71.64, 72.61, 73.10, 73.86, 
82.66, 101.00, 101.13. 
Exact mass (ESI-MS) for C24H50NO8 [M+H]
+ found, 480.3537; calcd, 480.3531. 
(2S,3S,4R)-1-O-α-D-galactopyranosyl-2-(11-(4-azidophenyl))undecanoylamino-octadecane-1,3,4-triol 
(6.1) 
The crude amine 6.9 (0.2 mmol) was dissolved in THF (2.5 mL) and saturated aqueous NaOAc (2.5 
mL). In a separate flask 11-(4-azidophenyl)undecanoic acid 6.4 (74 mg, 0.24 mmol) was refluxed for 
2h in oxalylchloride (4 mL) and the crude acid chloride was obtained after evaporation of the solvent 
by a stream of nitrogen and subsequent drying on high-vacuum. The crude acid chloride was 
dissolved in THF (2.5 mL) and added dropwise to the biphasic mixture. The reaction mixture was 
stirred for 2h at room temperature and TLC showed complete conversion of the starting material. 
Next the aqueous layer was extracted with THF (3 x 15 mL) and the combined organic layer was dried 
over Na2SO4, filtered and evaporated. The crude residue was purified by column chromatography 
(10%  16 % MeOH in DCM) furnishing final compound 6.1 (56 mg, 37%) as a pale solid. 
1H NMR (300 MHz, pyridine-d5): δ 0.99 (t, J =6.6 Hz, 3 H, terminal CH3) 1.22 – 1.60 (m, 31 H, 
CH2) 1.60 – 1.84 (m, 4 H, CH2) 1.84 – 2.17 (m, 5 H, CH2) 2.21 – 2.36 (m, 2 H, CH2) 2.66 – 2.77 (m, 4 H, 
CH2) 4.32 – 4.53 (m, 4 H, Ha-1, H-4 and CH2-6”) 4.53 – 4.64 (m, 4 H, H-2”, H-3, H-3” and H-4”) 4.64 – 
4.76 (m, 2 H, Ha-1 and H-5”) 5.14 (dd, J = 10.4 and 4.9 Hz, 1 H, H-2) 5.59 (d, J = 3.7 Hz, 1 H, H-1”) 7.16 
– 7.24 (m, 2 H, arom. H) 7.39 – 7.47 (m, 2 H, arom. H). 
13C NMR (75 MHz, pyridine-d5): δ 13.32, 21.88, 25.42, 25.48, 28.34, 28.52, 28.60, 28.69, 
28.75, 28.83, 28.89, 28.92, 28.98, 29.10, 29.16, 30.70, 31.06, 31.67, 34.35, 35.76, 50.70, 53.98, 61.17, 
67.10, 68.88, 69.43, 70.06, 71.31, 71.49, 73.95, 99.84, 118.37, 129.39, 136.55, 139.27, 173.80. 
Exact mass (ESI-MS) for C41H72N4NaO9 [M+Na]
+ found, 787.5192; calcd, 787.5192; m.p. 142 – 
144 °C. 
octadec-2-yn-1-ol (6.12) 
n-BuLi (1.6 M in hexanes, 11.11 mL, 17.78 mmol) was added dropwise to a stirred solution of 2-(2-
propynyloxy)tetrahydropyran (2.5 mL, 17.78 mmol) in anhydrous THF (20 mL) at -78 °C, and the 
resulting mixture was stirred at this temperature for 30 min. DMPU (2.36 mL) was then added, and 
stirring was continued for 10 min before dropwise addition of 1-Bromopentadecane (4.66 mL, 16.14 
mmol).The resultant mixture was allowed to warm to room temperature and was heated at 50 °C for 
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18 h. Next, the mixture was allowed to cool to room temperature, and saturated aqueous NH4Cl (25 
mL) was added. The layers were separated, and the aqueous layer was extracted with Et2O (2 x 50 
mL). The combined organic layer was concentrated in vacuo to furnish crude alkyne 6.11, which was 
used in the next reaction without further purification. The residue was dissolved in MeOH (35 mL), 
and TsOH.H2O (1.4 g, 7.36 mmol) was added. The resulting mixture was stirred at room temperature 
for 3 h, then poured in ice-cold H2O (100 mL). The aqueous layer was extracted with Et2O (2 x 50 mL) 
and the combined organic layer was dried over MgSO4, filtered and evaporated to dryness. The crude 
residue was purified by flash chromatography (hexanes/EtOAc: 9/1) to afford alcohol 6.12 (3.193 g, 
74%) as a white solid. 
1H NMR (300 MHz, CDCl3): δ 0.88 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.17 – 1.43 (m, 24 H, CH2) 
1.45 – 1.57 (m, 2 H, CH2) 2.15 – 2.26 (m, 2 H, CH2) 4.25 (t, J = 2.1 Hz, 2 H, CH2). 
13C NMR (75 MHz, CDCl3): δ 14.08, 18.70, 22.66, 28.59, 28.85, 29.13, 29.33, 29.50, 29.63, 
29.66, 31.89, 51.37, 78.24, 86.63. 
Spectral data are consistent with the literature data.  
octadec-17-yn-1-ol (6.13) 
In a flame-dried, two-neck, 50-mL flask was placed ethylene-1,2-diamine (15 mL) under N2 
atmosphere at 0 °C, and NaH (60% in mineral oil, 750 mg) was added in one portion. The cooling bath 
was removed and the suspension was allowed to warm to room temperature. During the warm up, 
the color changed to deep blue-violet and bubbling was observed. The mixture was stirred at room 
temperature for 1 h and was subsequently warmed to 60 °C. After being stirred at 60 °C for 1 h, the 
deep blue-black mixture was cooled to 45 °C and alkynyl alcohol 6.12 (1 g, 3.75 mmol) was added in 
one portion. After addition, the mixture was warmed back to 65 °C and was stirred for 1 h. Then, the 
mixture was cooled to 0 °C and H2O (15 mL) and 1 M HCl solution (15 mL) were added. The mixture 
was poured into a separating funnel containing 1 M HCl solution (35 mL) and was extracted with Et2O 
(3 x 35 mL). The combined organic layers were washed with 1 M HCl solution (75 mL) and half-brine 
(75 mL), then were dried over MgSO4, filtered and evaporated to dryness. The crude residue was 
purified by flash chromatography (hexanes/Et2O: 65/35) to afford alcohol 6.13 (609 mg, 61%) as a 
white solid. 
1H NMR (300 MHz, CDCl3): δ 1.17 – 1.46 (m, 20 H, CH2) 1.47 – 1.64 (m, 4 H, CH2) 1.94 (t, J = 
2.6 Hz, 1 H, CHalkyne) 2.18 (td, J = 7.0 and 2.6 Hz, 2 H, CH2) 3.64 (t, J = 6.5 Hz, 2 H, CH2). 
13C NMR (75 MHz, CDCl3): δ 18.38, 25.73, 28.49, 28.76, 29.10, 29.42, 29.50, 29.59, 29.65, 
32.81, 63.06, 67.99, 84.80. 





To a solution of octadec-17-yn-1-ol 6.13 (500 mg, 1,88 mmol) and 1-iodo-4-nitrobenzene (584 mg, 
2.35 mmol) in degassed Et3N (5.5 mL) at 0 °C, was added CuI (9 mg, 47 µmol) and Pd(PPh3)2Cl2 (33 
mg, 47 µmol). The reaction mixture was allowed to reach room temperature and was stirred 
overnight. Upon completion of the reaction, the solvent was removed under reduced pressure and 
the residue was dissolved in EtOAc (50 mL) and subsequently washed with 1 M HCl solution (30 mL). 
The aqueous layer was extracted with EtOAc (2 x 30 mL) and the combined organic layer was washed 
with saturated NaHCO3 (70 mL) and brine (70 mL). After drying over Na2SO4, filtration and 
evaporation, the crude residue was purified by flash chromatography (toluene/Et2O: 9/1) to afford 
alcohol 6.14 (591 mg, 81%) as a yellow solid. 
1H NMR (300 MHz, CDCl3): δ 1.22 – 1.39 (m, 20 H, CH2) 1.39 – 1.68 (m, 8 H, CH2) 2.44 (t, J = 
7.0 Hz, 2 H, CH2) 3.64 (t, J = 6.5 Hz, 2 H, CH2) 7.48 – 7.55 (m, 2 H, arom. H) 8.12 – 8.18 (m, 2 H, arom. 
H). 
13C NMR (75 MHz, CDCl3): δ 19.54, 25.73, 28.38, 28.92, 29.10, 29.42, 29.50, 29.60, 29.65, 
32.79, 63.05, 79.29, 96.83, 123.45, 131.21, 132.20, 146.55. 
Exact mass (ESI-MS) for C24H38NO3 [M+H]
+ found, 388.2848; calcd, 388.2846. 
18-(4-nitrophenyl)octadec-17-ynoic acid (6.15) 
To a solution of alcohol 6.14 (500 mg, 1.29 mmol) in anhydrous DMF (3 mL) was added PDC (1.698 g, 
4.52 mmol) in one portion. The reaction was stirred at room temperature overnight. Upon 
completion, H2O (60 mL) was added to the reaction mixture and the aqueous layer was extracted 
with Et2O (3 x 25 mL). The combined organic layer was subsequently washed with H2O (8 x 15 mL), 
dried over MgSO4, filtered and evaporated. The crude residue was purified by flash chromatography 
(hexanes/Et2O: 8/2) to afford carboxylic acid 6.15 (329 mg, 64%) as a white solid. 
1H NMR (300 MHz, CDCl3): δ 1.19 – 1.33 (m, 18 H, CH2) 1.39 – 1.51 (m, 4 H, CH2) 1.57 – 1.69 
(m, 4 H, CH2) 2.35 (t, J = 7.5 Hz, 2 H, CH2) 2.45 (t, J = 7.0 Hz, 2 H, CH2) 7.48 – 7.55 (m, 2 H, arom. H) 
8.12 – 8.19 (m, 2 H, arom. H). 
13C NMR (75 MHz, CDCl3): δ 19.56, 24.66, 28.40, 28.92, 29.04, 29.10, 29.22, 29.42, 29.50, 
29.62, 34.00, 79.29, 96.81, 123.45, 131.22, 132.20, 146.53, 179.92. 
Exact mass (ESI-MS) for C24H34NO4 [M-H]
- found, 400.2498; calcd, 400.2493. 
18-(4-azidophenyl)octadecanoic acid (6.17) 
A solution of 6.15 (401 mg, 1 mmol) in EtOH (12 mL), CHCl3 (4 mL) and AcOH (1 mL) was 
hydrogenated in the presence of Pd/C (80 mg) for 16h at 30 °C, under atmospheric pressure. Upon 
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reaction completion, the mixture was filtered through a patch of celite. The filtrate was evaporated 
to dryness and co-evaporated twice with toluene, to furnish crude aniline 6.16, which was used 
without further purification in the Sandmeyer reaction. 
The aniline was suspended in 2 M aqueous HCl solution (7.25 mL) at 0 °C, and sodium nitrite (1 M 
aqueous solution, 1.1 mL, 1.1 mmol) was added. The reaction was stirred for 15 minutes shed from 
light followed by addition of sodium azide (1 M aqueous solution, 1.06 mL, 1.06 mmol). The reaction 
mixture was allowed to reach room temperature and was stirred overnight in the dark. The formed 
precipitate was filtered and the residue was purified by flash chromatography (toluene/DCM: 8/2) to 
afford carboxylic acid 6.17 (225 mg, 56%) as a pale solid. 
1H NMR (300 MHz, CDCl3): δ 1.15 – 1.42 (m, 25 H, CH2) 1.53 – 1.70 (m, 5 H, CH2) 2.36 (t, J = 
7.3 Hz, 2 H, CH2) 2.58 (t, J = 7.6 Hz, 2 H, CH2) 6.95 (d, J = 8.2 Hz, 2 H, arom. H) 7.16 (d, J = 8.2 Hz, 2 H, 
arom. H). 
13C NMR (75 MHz, CDCl3): δ 24.67, 29.05, 29.22, 29.42, 29.46, 29.59, 29.65, 31.48, 34.03, 
35.30, 118.81, 129.68, 137.25, 139.75, 179.99. 
Exact mass (ESI-MS) for C24H38N3O2 [M-H]
- found, 400.2970; calcd, 400.2970. 
(2S,3S,4R)-1-O-α-D-galactopyranosyl-2-(18-(4-azidophenyl))octadecanoylamino-octadecane-1,3,4-
triol 
Crude amine 6.9 (0.32 mmol) was dissolved in THF (3.5 mL) and saturated aqueous NaOAc (3.5 mL). 
In a separate flask 18-(4-azidophenyl)octadecanoic acid 6.17 (168 mg, 0.41 mmol) was refluxed for 
2h in oxalylchloride (6 mL) and the crude acid chloride was obtained after evaporation of the solvent 
by a stream of nitrogen and subsequent drying on high-vacuum. The crude acid chloride was 
dissolved in THF (3.5 mL) and dropwise added to the biphasic mixture. The reaction mixture was 
stirred for 2h at room temperature and TLC showed complete conversion of the starting material. 
Next the aqueous layer was extracted with THF (3 x 30 mL) and the combined organic layer was dried 
over Na2SO4, filtered and evaporated. The crude residue was purified by column chromatography 
(6%  14 % MeOH in DCM) furnishing final compound 6.10 (129 mg, 47%) as a pale solid. 
1H NMR (300 MHz, pyridine-d5): δ 0.88 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.15 – 1.51 (m, 45 H, 
CH2) 1.51 – 1.76 (m, 4 H, CH2) 1.76 – 1.99 (m, 5 H, CH2) 2.23 – 2.38 (m, 2 H, CH2) 2.46 (t, J = 7.5 Hz, 2 
H, CH2) 2.58 (t, J = 7.5 Hz, 2 H, CH2) 4.28 – 4.38 (m, 2 H, H-4 and H-3”) 4.38 – 4.49 (m, 4 H, Ha-1, H-3” 
and CH2-6”) 4.50 – 4.58 (m, 2 H, H-4” and H-5”) 4.62 – 4.74 (m, 2 H, Ha-1 and H-2”) 4.96 (br. s, 1 H, 
OH) 5.23 – 5.34 (m, 1 H, H-2) 5.59 (d, J = 3.8 Hz, 1 H, H-1”) 6.09 (br. s, 1 H, OH) 6.32 (br. s, 1 H, OH) 
6.45 (br. s, 1 H, OH) 6.53 (br. s, 1 H, OH) 6.62 (br. s, 1 H, OH) 7.03 – 7.09 (m, 2 H, arom. H) 7.23 – 7.28 




13C NMR (75 MHz, pyridine-d5): δ 14.69, 23.35, 26.80, 26.90, 29.86, 30.02, 30.17, 30.22, 
30.28, 30.34, 30.40, 30.55, 30.77, 32.17, 32.54, 34.78, 35.83, 37.21, 51.85, 63.07, 69.10, 70.71, 71.40, 
72.03, 72.90, 73.46, 77.16, 101.95, 119.77, 130.66, 138.06, 140.55, 173.61. 
Exact mass (ESI-MS) for C48H87N4O9 [M+H]
+ found, 863.6470; calcd, 863.6468; m.p. 168-170 
°C. 
Co-culture of human iNKT cells and Hela-CD1d cells 
1 x 104 Human iNKT cells (cell line #630B) were co-cultured with 4 x 104 HeLa-CD1d cells that are 
incubated overnight in the presence of the indicated glycolipids (1μg/mL, 0.1μg/mL or 0.01μg/mL 
respecyively). After 24h of co-culture at 37 °C, supernatant was collected and IL-4 and IFN-γ levels 
were determined by means of ELISA. 
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Chapter 7: Sulfogalactosylceramides 
7.1 Introduction 
Thus far, the analogues prepared in the previous chapters were aimed at targeting iNKT cells, and 
therefore little attention was attributed to the function and characteristics of type II NKT cells. The 
latter require CD1d for activation, but do not express the Vα14-Jα18 TCR and fail to recognize α-
GalCer. This NKT cell population displays a more heterogeneous TCR repertoire and accordingly 
responds to a wide variety of glycolipid antigens, including endogenous and microbial glycolipids. 
A well-known type II NKT cell antigen is sulfatide, which is a self-glycolipid that is found in many 
organs and is a mixture of multiple isoforms with different lengths and saturations of the fatty acid 
chain. The nervonic acid (C24:1, n-9) sulfatide isoform is a major component of myelin sheets of the 
central nervous system and can activate an important subset of type II NKT cells.1 A different 
sulfatide isoform called lyso-sulfatide, which lacks the fatty acid chain, is also found in the nervous 
system and is the most potent sulfatide isoform described to date.2 (Figure 7.1) 
 
Figure 7.1 Structures of type II NKT cell self-antigens 
Type II NKT cells are known to respond to a wide array of microbial antigens in addition to self-
glycolipids. Among them, glycolipids derived from Mycobacterium tuberculosis, Corynebacterium 
glutamicum3 and Listeria monocytogenes4 were described as potent activators of several subtypes of 
the type II NKT cell population. These observations strongly suggest that type II NKT cells are 
implicated in the immunological response against the aforementioned microorganisms. 
As currently no direct or indirect methods exist to identify the entire type II NKT cell population in 
vivo, relatively little is known about the immunological role and characteristics of type II NKT cells. 
Furthermore, recent reports highlight that the majority of the NKT cells in humans, are type II NKT 
cells, suggesting that they have greater therapeutic potential as compared to their iNKT cell 
counterparts.5 
With the focus of NKT cell biology steadily shifting towards type II NKT cells, novel glycolipid antigens 




Additionally, the currently known commercially available type II NKT cell ligands, frequently suffer 
from poor quality, resulting in unwanted activation of iNKT cells in biological experiments.6  
7.2 Functions of type II NKT cells 
As mentioned in the introduction, unraveling the role and function of type II NKT cells is hampered by 
the inability to efficiently track the cells, together with the lack of proper models to assess their 
function in vivo. Nevertheless, the past two decades certain immunological tasks have been 
elucidated by using CD1d-tetramers loaded with type II NKT cell ligands and comparing immune 
responses of CD1d-/-mice (lacking both invariant and type II NKT cells) with Jα18-/- mice (only lacking 
iNKT cells). Figure 7.2 summarizes several type II NKT cell functions described thus far. The next 
section describes the biological role of type II NKT cells in more detail. 
  
Figure 7.2 Functions of type II NKT cells (Macho-Fernandez et al., 2015, Front Immunol), GR= 
granulocytic marker, HBV = hepatitis B virus, GVHD = graft-versus-host disease, EMCV-D = 
diabetogenic encephalomyocarditis virus-induced pathology, Con-A = concavaline-A 
7.2.1 Anti-tumor immunity 
In contrast to iNKT cells that play a critical role in tumorsurveillance, sulfatide-reactive type II NKT 
cells are generally believed to suppress anti-tumor immunity.7,8 The ability to secrete anti-
inflammatory cytokines like IL-13 together with up-regulation of specific markers on myeloid-derived 
suppressor cells (MDSC), results in attenuated cytotoxic T-cell responses.9 However, recent reports 
highlight the ability of type II NKT-cells to directly kill lymphoma cells10 and to elicit anti-tumor 
immunity in a B16 melanoma model.11 Hence, depending on the situation, type II NKT cells can 
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counteract the anti-tumor activity of iNKT cells but can also fulfill protective roles against tumor 
growth.  
7.2.2 Auto-immunity 
Similar to the dual character in tumor immunity, type II NKT cells provide protective or deleterious 
functions in the context of auto-immune diseases. While sulfatide-mediated activation of type II NKT 
cells suppress autoimmunity in a mouse model for multiple sclerosis termed experimental 
autoimmune encephalitis (EAE)12 and type I diabetes,13 disease is promoted in systemic lupus 
erythematosus (SLE)14 and colitis.15 Protective effector functions have also been demonstrated for 
concanavalin-A-induced hepatitis16, hepatic ischemic reperfusion1, alcoholic liver17 and graft-versus-
host disease.18 Moreover, activation of type II NKT cells induced liver and adipose tissue 
inflammation, resulting in exacerbation of obesity in mice.19  
7.2.3 Microbial infections 
7.2.3.1 Parasitic infections 
Type I and type II NKT cells show distinct, albeit complementary roles in the host defense against 
schistosomiasis, which is a chronic disease caused by Schistosoma parasites. During the acute phase 
of infection, iNKT cells secrete IFN-γ leading to the production of specific immunoglobulins which are 
markers of a Th1 response. On the other hand, a Th2 response is generated by type II NKT cells, as in 
type II depleted mice a marked decrease in Th2 cytokines was observed.20 In contrast, in the context 
of infection with Trypanosoma cruzi, the causative agent of Chagas disease, type II NKT cells 
enhanced deleterious inflammatory anti-parasite responses, while the response is attenuated by 
activated iNKT cells. As a consequence, wild type (WT) and CD1d-/-mice were less sensitive to 
infection with T. cruzi and displayed lesser morbidity and mortality as compared to Jα18-/- mice.21 
7.2.3.2 Bacterial infections 
Since a range of bacterial antigens is able to activate type II NKT cells, it is likely that these cells exert 
important functions during host defense against these pathogens. While comparable mortality rates 
were observed for WT, CD1d-/- and Jα18-/- mice upon induced sepsis after Staphylococcus aureus 
inoculation, concomitant administration of sulfatide, improved survival rates.22 Similar protective 
type II NKT cell functions have also been suggested for Mycobacterium tuberculosis3 and Listeria 
monocytogenes infections.23 
7.2.3.3 Viral infections 
During diabetogenic encephalomyocarditis virus-induced pathology (EMCV-D), type II NKT cells 




show increased disease severity during EMCV-D infection.24 Additionally, sulfatide administration 
resulted in reduced viral replication upon HIV-1 infected SCID mice,25 again suggesting type II NKT 
cells carry out protective immune functions. However, for hepatitis B virus (HBV) infections, a dual 
role is reserved for type II NKT cells, ranging from immune responses that control viral replication to 
immune-mediated induction of tissue damage.26,27 
As the above mentioned examples show, type II NKT cells can either promote protective innate and 
adaptive cell-mediated immune responses, or contribute to infection with various infectious agents 
and counter-act tumorsurveillance. In order to efficiently address type II NKT cells for immune 
therapy, the factors governing this dual character of type II NKT cells need to be determined and will 
be important areas of future research. 
7.3 Synthesis of type II NKT cell ligands 
While several synthetic routes exist for the preparation of sulfatide,28,29 no reports on the synthesis 
of lyso-sulfatide are currently available. As depicted in the retro-analysis (Scheme 7.1) lyso-sulfatide 
7.2 and lyso-sulfatide derivative 7.3, can be accessed through selective sulfation of the C3-hydroxyl 
of the galactose sugar, followed by amine deprotection of intermediates A. The latter are obtained 
after hydrolysis of the ester protecting groups in glycosides B, resulting from β-glycosylation between 
trichloroacetimidate 7.13 and a suitable protected sphingosine derivative C. While D-ribo-
phytosphingosine is readily available, commercial D-erythro-sphingosine is rather expensive and was 
prepared accordingly. Whereas multiple synthetic approaches use phytosphingosine as starting 
material to furnish the C18-sphingosine backbone,30 the requirement to modify the sphingosine in 
derivative 7.3 discarded these routes. Instead, a chiral pool approach was used where glycosyl 
acceptors C were obtained from a common building block 7.8, via olefin cross-metathesis. Dioxane 
7.8 is prepared through conversion of L-serine to Garner’s aldehyde, Grignard addition of vinyl 
lithium and isomerisation from oxazolidine to dioxane. 
 
Scheme 7.1 Retrosynthetic analysis for the synthesis of lyso-sulfatide 7.2 and lyso-sulfatide derivative 
7.3 
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The synthesis of dioxane 7.8 started from commercially available L-Boc-serine. First the carboxylic 
acid was converted to Weinreb amide 7.4, using EDC as a coupling agent. Next, reaction with 2,2-
dimethoxypropane in the presence of BF3.Et2O furnished oxazolidine 7.5, which upon reduction with 
lithium aluminum hydride is readily converted to L-Garner’s aldehyde 7.6. Grignard additions of vinyl 
organometallic reagents to Garner’s aldehyde have been extensively investigated, presenting vinyl 
lithium as the reagent of choice for achieving high anti-selectivity.31 Thus, vinyl lithium was prepared 
through n-BuLi addition to tetravinyl tin,32 and was subsequently reacted with the crude Garners 
aldehyde, furnishing vinylogous alcohol 7.7. At this point separating syn- and anti-alcohols proved 
troublesome. However, when oxazolidine 7.7 was converted to 1,3-dioxane 7.8 by acid hydrolysis 
and successive acetalisation with 2,2-dimethoxypropane. The resulting 1,3-dioxane epimers could 
easily be separated by straightforward column chromatography. (Scheme 7.2) 
 
Scheme 7.2 Reagents and conditions: a) EDC, HN(OMe)Me.HCl, NMM, −15 °C, 1 h; b) 2,2-di-
methoxypropane, BF3·Et2O, acetone, RT, 2h, quantitative yield (over 2 steps); (c) LiAlH4, THF, 0 °C, 45 
min; (d) tetravinyl tin, THF, n-BuLi, −78 °C  RT, 1 h; then addition to Garner’s aldehyde, THF, −78 °C 
 RT, 16h, 68% (over 2 steps); e) i) TsOH·H2O, MeOH, RT, 4h; ii) TsOH·H2O, 2,2-dimethoxy-propane, 
RT, 5h, 43%. 
 
The stereochemistry of anti-1,3-dioxane 7.8 was unambiguously characterized by NMR spectroscopy. 
(Figure 7.3) Since the dioxane ring adopts a stable chair conformation, anti- and syn-configurations 
can be distinguished by defining the coupling constant value between protons H-2 and H-3. As 
illustrated in figure 7.3 the spectrum displays a 3J2,3 = 10.1 Hz which is consistent with a trans-diaxial 
arrangement of these protons and the erythro stereochemistry. Conversely, related dioxanes which 






Figure 7.3 NMR spectrum of 7.7, inset shows an enlargement of the H-3 peak with the respective 
coupling constant values (Spectrum in DMSO at 60 °C) 
With dioxane 7.8 in hand, we went onward with the synthesis towards protected sphingosine 
derivatives 7.12. Olefin cross-metathesis between 7.8 and 1-pentadecene or dodec-11-enylbenzene 
using Grubbs 2nd generation catalyst furnished, after careful separation of the major E-alkene 
product, D-erythro-sphingosines 7.9. Next, the acetonide was cleaved upon treatment with p-
toluenesulfonic acid in methanol and the alcohol functionalities were protected as TBS-ethers using 
TBSCl. Finally, dilute HF.pyridine conditions at low temperature selectively cleaved the primary 
silylether, producing glycosylacceptors 7.12a-b. (Scheme 7.3) 
 
Scheme 7.3 Reagents and conditions: a) Grubbs 2nd generation, pentadecene (dodec-11-
enylbenzene), DCM, reflux, 6h, 57% (69%); b) TsOH, MeOH, RT, 5h, 94% (91%); c) TBSCl, imidazole, 
DCM, RT, 18h, 97% (98%); d) pyridine/HF.pyridine/THF (1,15/1/2,85), THF, 73% (78%). 
Having obtained the appropriate glycosyl acceptors, reaction with galactose trichloroacetimidate 
7.13 in the presence of TMSOTf was expected to furnish the corresponding β-glycosides. Strikingly, 
instead of the envisioned β-glycoside, ortho-ester 7.14bis was obtained in good yield. 
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As mentioned in chapter 3, TMSOTf mediated departure of the leaving group results in the formation 
of an oxacarbenium ion, which is stabilized through neighboring group participation. The resulting 
acyloxonium ion is responsible for the facial selectivity of the nucleophilic attack in β-glycosylation 
protocols, shielding off the bottom face thereby forcing attack from the opposite top face. However, 
the nucleophile can also attack the C2 position of the dioxolane ring, leading to undesired ortho-
ester formation. (Scheme 7.4) 
 
Scheme 7.4 Mechanism of the undesired ortho-ester formation 
In carbohydrate chemistry ortho-ester formation is a known issue.34 To prevent the formation of 
ortho-esters, O-acyl protecting groups with high steric demand or with high electron delocalization 
should be employed.35 In this regard, the advantage of O-pivaloyl glycosyl donors has been 
demonstrated by Kunz and coworkers.36 Indeed, when glycosyl acceptor 7.12a was reacted with per-
O-pivaloyl trichloroacetimidate 7.15, β-galactoside 7.16 was isolated, albeit in low yield. (Scheme 7.5) 
 
Scheme 7.5 Glycosylation with per-O-pivaloylated trichloroacetimidate 7.15. Reagents and 
conditions: TMSOTf, DCM, 4 Å molecular sieves, -20 °C, 2h, 21%. 
A thorough literature study learned that ortho-ester formation is not only dependent on the 
substitution pattern of the glycosyl acceptor. In addition, other parameters like reaction conditions, 
reactivity of the glycosyl acceptor and overall stability of the ortho-ester, have implications in the 
outcome of the glycosylation reaction. When the reactivity of the glycosyl donor and acceptor is 




of (phyto)ceramides suffers from poor reactivity, this complies with our observation. Indeed, it has 
been proposed that an intramolecular hydrogen bond between the lone pair of oxygen and the 
amide (or carbamate) hydrogen, withdraws electron density rendering the oxygen less nucleophilic.37 
(Figure 7.4) 
 
Figure 7.4 An intramolecular hydrogen bond decreases the nucleophilicity of the primary alcohol 
Therefore, to increase the nucleophilicity of the glycosyl acceptor we modified the protecting group 
strategy on the sphingosine intermediate. We chose to protect the C2-amine as an azide 
functionality, as this eliminates the possible intramolecular hydrogen bond. Furthermore, 
azidosphingosine glycosyl acceptors have been used in combination with trichloroacetimidate 7.13 to 
furnish β-glycosides in good yields and without ortho-ester generation.38 We started from olefin 
cross-methatesis products 7.9, which upon treatment with HCl followed by metal-catalyzed 
diazotransfer reaction, furnished diols 7.17 in excellent yield. Next, the primary alcohol was 
protected as tert-butyldiphenylsilyl ether and the remaining hydroxyl was esterified with benzoyl 
chloride. Finally, the glycosyl acceptors 7.19a-b were treated with hydrogen fluoride to avoid benzoyl 
group migration upon silylether cleavage (Scheme 7.6)  
 
Scheme 7.6 Reagents and conditions: a) i) THF, 6 M aq. HCl, 50 °C, 18h; ii) TfN3, MeOH/H2O (1:1), 
CuSO4, Et3N, 0 °C  RT, 16h, quant. yield (quant. yield) (b) i) TBDPSCl, DMAP, DMF, DCM, Et3N, 0 °C 
 RT, 18h; ii) BzCl, DMAP, DCM, Et3N, 0 °C  RT, 18h, 60% (82%) (c) THF, MeCN, 40% aq. HF, RT, 8d, 
74% (57%). 
As anticipated, glycosylation of protected azidosphingosines 7.19 with benzoyl trichloroacetimidate 
7.13 proceeded swiftly and produced β-glycosides 7.20, without the formation of ortho-ester 
isomers. Next, the ester protecting groups were hydrolyzed with sodium methoxide and the sulfate 
group was introduced at position 3 of the galactose sugar. The selective sulfation occurs after 
treatment of the deprotected glycosides with dibutyltin oxide and subsequent reaction of the 
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dibutylstannilene acetal with trimethylamine sulfur trioxide complex. Lastly, Staudinger reduction of 
galactosides 7.22, led to lyso-sulfatides 7.2 and 7.3. (Scheme 7.7) 
 
Scheme 7.7 Reagents and conditions: a) 7.13, TMSOTf, DCM, 4 Å molecular sieves, -30 °C  RT, 1h, 
69% (72%); b) NaOMe, DCM, RT, 18h, 70% (74%); c) i) Bu2SnO, MeOH, 65 °C, 2h; ii) SO3.NMe3, THF, 
RT, 6h, 64% (75%); d) THF, 0,1M NaOH, PMe3, RT, 16h, 80% (91%). 
 
In addition to lyso-sulfatides 7.2 and 7.3, we prepared nervonic acid sulfatide isoform 7.1 according 
to literature procedures.30e,29 
 
7.4 Biological evaluation 
So far, only the antigenic activity of the final compounds was assessed for a single type II NKT cell 
hybridoma by means of a plate-bound assay. In brief, plates were coated with soluble mCD1d and 
were subsequently incubated for 24h with the indicated concentration of glycolipids. Next 5x104 
XV19 cells (a type II NKT cell hybridoma) were added and after 16 hours of coculture, IL-2 was 
determined by ELISA. The data is depicted in figure 7.5 and clearly illustrates that all prepared lyso-
sulfatide derivatives are weaker antigens than sulfatide 7.1, which was prepared according to 





Figure 7.5 IL-2 secretion after coculture with XV19cells (type II NKT cell hybridoma) 
Strikingly, these results are in contrast to previous data showing that lysosulfatide 7.2 induces a 
greater IL-2 secretion from the XV19 type II NKT cell hybridoma, as compared to sulfatide 7.1.17,2 
However, the aforementioned data were generated through a typical NKT cell stimulation assay in 
the presence of APC, while we used the APC-free CD1d-coated plate assay. Previous experiments 
using a similar APC-free approach, confirm our observations that in these assays, lyso-sulfatide is a 
weaker antigen than sulfatide 7.1.39 The decrease in antigenic potency could be a result of the higher 
solubility of the lysosulfatide derivatives. After the incubation step in the plate-bound assay, the 
excess of reagents are removed in three consecutive washing steps before the addition of the type II 
cell NKT cell hybridoma. A substantial amount of the lysosulfatide glycolipids could concomitantly be 
removed during these wash sequences. 
While the glycosphingolipids prepared above, are mainly aimed at targeting type II NKT cells, 
surprising results were observed in a study on the activation of human iNKT cells by components 
from the myelin sheath. The lipid-rich myelin sheath, which is the target of the autoimmune 
response in multiple sclerosis (MS), has long been suspected to contain antigens able to activate iNKT 
cells.40 
When the group of Peter van den Elzen fractionated bovine myelin, they observed human iNKT cell 
activation only for the lipid fraction containing charged lipids, including sulfatides and gangliosides. 
Noteworthy, mouse iNKT cells showed no activation, emphasizing the dissimilarity in antigens 
recognized by human and mouse iNKT cells. Further experiments using commercial sulfatides and 
gangliosides, revealed that only sulfatide elicites iNKT cells responses. 
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Next, to exclude the possibility that the human iNKT cell activation stems from contaminants in the 
purchasable glycosphingolipids, the human iNKT cell response for final compounds 7.1 and 7.2 was 
evaluated alongside with a C26:0 sulfatide and a commercial sulfatide mixture. (Figure 7.6) As 
displayed below, both 7.1 and 7.2 induce significant activation of human iNKT cells, the most potent 
being lysosulfatide 7.2. 
 
Figure 7.6 IFN-γ secretion induced upon overnight incubation of glycolipid-loaded CD1d-transfected 
K562 cells with human iNKT cell line BM2a.3 
In order to gain insights into the distinct recognition of sulfatide by human and mouse iNKT cells, a 
cross-presentation assay was performed. In contrast to α-GalCer, no human iNKT cell activation was 
observed when sulfatide 7.1 was force-presented by mouse CD1d. Moreover, mouse iNKT cells could 
not be stimulated by both mouse and human CD1d loaded with sulfatide, indicating that sulfatide 7.1 
is solely recognized by the human iNKT cell when presented in the context of human CD1d. (Table 
7.1) 
 




A possible explanation for the observed unique binding properties of sulfatide 7.1, arises from the 
difference between mouse and human CD1d. As mentioned in chapter 1, human CD1d features a 
tryptophan residue (Trp153) in the binding groove, while in mouse-CD1d this residue is a much 
smaller glycine unit (Gly155).41 This dissimilarity has previously been shown to affect recognition of 
several microbial antigens, without affecting α-GalCer presentation.42  
The binding models of two possible orientations of 7.1 in the hCD1d/TCR complex are shown below. 
The models suggest that the sugar moiety of 7.1 binds between Trp153 and the CDR1α and CDR3α 
loops of the human iNKT cell receptor. (Figure 7.7) Conversely, due to the absence of Trp153 in mice, 
a substantial conformational change is required to allow recognition by the TCR of mouse iNKT cells. 
The disfavorable energetic cost associated with the aforementioned conformational shift, might be 
the reason for the lack of activity observed for sulfatide in mice. 
 
Figure 7.7 Binding models of two possible orientations of sulfatide 7.1 in the hCD1d/TCR complex 
7.5 Conclusion 
In summary, we developed a synthetic strategy for the preparation of sphingosine-modified 
(lyso)sulfatide derivatives and applied it to the synthesis of synthetic lyso-sulfatide 7.2, which to the 
best our knowledge represents the first total synthesis of this glycolipid. 
In addition we prepared sulfatide 7.1 which is a well-known type II NKT cell antigen together with 
novel lyso-sulfatide derivative 7.3. Future experiments with this panel of type II NKT cell ligands will 
focus on elucidating type II NKT cell functions both in humans and mice. 
The preliminary biological evaluation showed weak stimulatory properties for the lysosulfatide 
derivatives against XV19 type II NKT hybridoma cells. However, as discussed, the low antigenic 
potency could be a result of the assay used to evaluate the IL-2 secretion induced by these 
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compounds. Future experiments will therefore include assays in the presence of APC and will 
evaluate the sulfatides against a broader panel of type II NKT cell hybridomas. 
Sulfatides are generally thought to be type II NKT cell antigens, unable to stimulate iNKT cells, and 
while this is certainly the case in mice, it is not true for humans. In collaboration with Peter van den 
Elzen we have shown that human iNKT cells are activated by sulfatide 7.1 associated with human 
CD1d. This observation immediately identifies sulfatide, which is omnipresent in the human body, as 
endogenous iNKT cell antigen, which most likely plays a crucial role in the physiology of human iNKT 
cells. 
7.6 Experimental part 
tert-butyl (S)-4-(methoxy(methyl)carbamoyl)-2,2-dimethyloxazolidine-3-carboxylate (7.5) 
L-Boc-serine (10.5 g, 51.2 mmol) was dissolved in DCM (160 mL) and cooled to -15 °C followed by the 
addition of N,O-dimethylhydroxyamine hydrochloride (5.25 g, 53.76 mmol) and N-methylmorpholine 
(5.91 mL, 53.76 mmol). Next, EDC (10.31 g, 53.76 mmol) was added portion-wise over the course of 
30 minutes. The reaction mixture was stirred for an additional 30 minutes at -15 °C and then ice cold 
1 M HCl (35 mL) was added. The aqueous layer was extracted with DCM (105 mL) and the combined 
organic layer was washed with saturated NaHCO3 solution (200 mL). The aqueous layer was extracted 
twice with DCM (2 x 50 mL) and the combined organic phases were dried over MgSO4, filtered and 
evaporated under reduced pressure. The resulting crude Weinreb-amide was used without further 
purification in the acetalization reaction. The white solid was dissolved in acetone (135 mL) followed 
by 2,2-dimethoxypropane (200 mL) and BF3.Et2O (0.43 mL) addition. The reaction was stirred for 1,5 
h, subsequently quenched by addition of Et3N (1.1 mL) where after the solvents were evaporated 
under reduced pressure. The resulting residue was purified by column chromatography 
(hexanes/EtOAc: 8/2) affording 7.5 (13.73 g, quant. yield) as a white solid. 
1H-NMR (300 MHz, CDCl3) both rotamers: δ 1.40 (s, 9 H, tBu) 1.48 (s, 9 H, tBu) 1.51 (s, 3 H, 
CH3) 1.55 (s, 3 H, CH3) 1.67 (s, 3 H, CH3) 1.69 (s, 3 H, CH3) 3.20 (s, 6 H, 2 x NCH3) 3.69 (s, 3 H, OCH3) 
3.73 (s, 3 H, OCH3) 3.94 (ddd, J = 12.4, 9.2 and 3.4 Hz, 2 H, CH2) 4.18 (ddd, J = 9.2, 7.3 and 4.7 Hz, 2 H, 
CH2) 4.68 – 4.74 (m, 1 H, CH) 4.77 – 4.82 (m, 1 H, CH). 
13C-NMR (75 MHz, CDCl3): δ 24.51, 24.59, 25.32, 25.58, 28.26, 32.38, 32.52, 57.55, 57.81, 
61.12, 65.78, 66.08, 79.92, 80.45, 94.31, 94.88, 151.24, 152.08, 170.46, 171.23. 
Exact mass (ESI-MS) for C13H24NO4 [M+Na]






Weinreb amide 7.5 (27.8 g, 96.41 mol) was dissolved in anhydrous THF (450 mL) and cooled to 0 °C. 
Lithium aluminum hydride (2.2 g, 57.87 mmol) was added at 0 °C and the mixture was stirred at this 
temperature for 45 minutes. The mixture was then cooled to –20 °C and quenched with saturated 
KHSO4 solution (350 mL). Et2O (900 mL) was added and the reaction was stirred violently for 30 
minutes. The ether layer was then dried by addition of Na2SO4, filtered and the solvents were 
removed under reduced pressure. Co-evaporation with toluene furnished the crude Garners 
aldehyde which was used without further purification. In a separate flask tetravinyltin (7.4 mL, 40.48 
mmol) was dissolved in anhydrous THF (250 mL) under an atmosphere of argon and cooled to −78 °C, 
followed by slow addition of n‐BuLi (1.6 M in hexanes, 96.4 mL, 154.3 mmol). The reaction mixture 
was allowed to reach room temperature and was stirred for 1 hour. The crude Garners aldehyde was 
dissolved in anhydrous THF (195 mL) and cooled to –78 °C, followed by dropwise addition of the 
freshly prepared vinyl lithium solution. The reaction was then stirred overnight, while reaching room 
temperature. Next, the reaction mixture was diluted with EtOAc (500 mL), washed with saturated 
NaHCO3 solution (500 mL) and brine (500 mL). The aqueous layers were washed with EtOAc (500 mL) 
and the combined organics were dried over Na2SO4, filtered and concentrated. The crude reaction 
mixture was then dissolved in acetonitrile (100 mL) and washed with hexanes (2 x 100 mL). The 
hexane layer was extracted with acetonitrile (2 x 100 mL) and the combined acetonitrile layers were 
concentrated under reduced pressure giving a yellow oil. The resulting residue was purified by 
column chromatography (hexanes/EtOAc: 9/1) affording 7.7 (14.36 g, 58%) as a clear oil. 
1H-NMR (300 MHz, CDCl3): δ 1.48 – 1.58 (m, 15 H, tBu and acetonide) 3.89 – 4.01 (m, 2 H, Ha-
1 and OH) 4.15 – 4.29 (m, 2 H, Hb-1 and H-2) 5.19 – 5.23 (m, 1 H, H-3) 5.34 – 5.39 (m, 2 H, CH=CH2) 
5.83 – 5.90 (m, 1 H, CH=CH2). 
13C-NMR (75 MHz, CDCl3): δ 24.81, 26.58, 28.68, 62.31, 65.02, 74.52, 81.51, 94.76, 116.53, 
137.18, 154.51. 
Exact mass (ESI-MS) for C13H24NO4 [M+H]
+ found, 258.1705; calcd, 258.1700.  
tert-butyl ((4R,5S)-2,2-dimethyl-4-vinyl-1,3-dioxan-5-yl)carbamate (7.8) 
Allylic alcohols 7.7 (4.55 g, 17.67 mmol) were dissolved in MeOH (200 mL) and TsOH.H2O (403 mg, 
2.12 mmol) was added. The reaction mixture was stirred for 4h at room temperature. Upon 
completion of the reaction a saturated NaHCO3 solution (150 mL) was added and the aqueous layer 
was extracted with EtOAc (3 x 200 mL). The combined organic phase was washed with brine (250 
mL), dried over Na2SO4, filtered and evaporated under reduced pressure. Next, the crude diol was 
dissolved in 2,2-dimethoxypropane (150 mL) and TsOH.H2O (150 mg, 0.8 mmol) was added and the 
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reaction was allowed to stir 5h at room temperature. The reaction was quenched by addition of a 
saturated NaHCO3 solution (75 mL) and the aqueous layer was extracted with EtOAc (3 x 100 mL). 
The combined organic phase was washed with brine (150 mL), dried over Na2SO4, filtered and 
evaporated under reduced pressure. The resulting residue was purified by flash column 
chromatography (0  15% EtOAc in Toluene) affording pure dioxane 7.8 (1.98 g, 43%) as a white 
solid. 
1H NMR (300 MHz, DMSO-d6, 90 °C) δ 1.29 (s, 3 H, CH3) 1.35 (s, 9 H, tBu) 1.41 (s, 3 H, CH3) 
3.21 – 3.32 (m, 1 H, H-2) 3.56 – 3.68 (m, 2 H, CH2-1) 4.16 (ddt, J = 10.1, 6.1 and 1.1 Hz, 1 H, H-3) 5.11 
(ddd, J = 10.5, 1.9 and 0.9 Hz, 1 H, Ha-5) 5.23 (ddd, J = 17.2, 2.0 and 1.4 Hz, 1 H, Hb-5) 5.73 (ddd, J = 
17.1, 10.7 and 6.2 Hz, 1 H, CH=CH2). 
13C-NMR (75 MHz, DMSO-d6): δ 19.91, 29.10, 29.73, 48.75, 62.91, 74.86, 80.59, 99.68, 120.02, 
136.29, 157.20. 
Exact mass (ESI-MS) for C13H24NO4 [M+H]
+ found, 258.1712; calcd, 258.1700.  
Spectral data are consistent with the literature data.  
tert-butyl ((4R,5S)-2,2-dimethyl-4-((E)-pentadec-1-en-1-yl)-1,3-dioxan-5-yl)carbamate (7.9a) 
To a solution of 7.8 (1 g, 3.89 mmol) in anhydrous DCM (5 mL), pentadec‐1‐ene (1.64 g, 7.78 mmol) 
was added. The flask was flushed with argon before addition of Grubbs catalyst 2nd generation (64 
mg, 0.08 mmol) and the reaction was refluxed under an atmosphere of argon until TLC showed no 
change in reaction composition (6 hours). The reaction mixture was concentrated in vacuo and 
purified by column chromatography (0 25 % Et2O in hexanes) furnishing 7.9a (0.97 g, 57% yield) as 
a clear viscous oil together with a minor amount of the Z-isomer. 
 1H NMR (300 MHz, CDCl3): δ 0.88 (t, J = 6.7 Hz, 3 H, terminal CH3) 1.20 – 1.38 (m, 22 H, CH2) 
1.41 (s, 12 H, CH3 and tBu) 1.47 (s, 3 H, CH3) 2.03 (q, J = 7.0 Hz, 2 H CH=CHCH2) 3.40 – 3.55 (m, 1 H, H-
5) 3.62 (t, J = 10.1 Hz, 1 H, Ha-6) 3.93 – 4.04 (m, 2 H, H-4 and Hb-6) 4.29 (br. s, 1 H, NH) 5.44 (dd, J = 
15.4 and 7.6 Hz, 1 H, CH=CHCH2) 5.76 (dt, J = 15.4 and 6.7 Hz, 1 H, CH=CHCH2). 
 13C NMR (75 MHz, CDCl3) δ 14.09, 19.56, 22.67, 28.30, 28.73, 28.92, 29.27, 29.34, 29.48, 
29.57, 29.63, 29.66, 31.91, 32.35, 48.97, 63.14, 74.66, 77.20, 98.63, 127.18, 136.41, 155.06. 
 Exact mass (ESI-MS) for C26H49KNO4 [M+K]
+ found, 478.3237; Calcd., 478.3252. 
tert-butyl ((4R,5S)-2,2-dimethyl-4-((E)-12-phenyldodec-1-en-1-yl)-1,3-dioxan-5-yl)carbamate (7.9b) 
To a solution of 7.8 (1 g, 3.89 mmol) in anhydrous DCM (5 mL), dodec-11-en-1-ylbenzene (1.9 g, 7.77 




generation (64 mg, 0.08 mmol) and the reaction was refluxed under an atmosphere of argon until 
TLC showed no change in reaction composition (6 hours). The reaction mixture was concentrated in 
vacuo and purified by column chromatography (0  25 % Et2O in hexanes) furnishing 7.9b (1.27 g, 
69% yield) as a clear viscous oil together with a minor amount of the Z-isomer. 
 1H NMR (300 MHz CDCl3) δ 1.21 – 1.39 (m, 14 H, CH2) 1.42 (s, 12 H, CH3 and tBu) 1.48 (s, 3 H, 
CH3) 1.55 – 1.66 (m, 2 H, CH2) 2.04 (q, J = 6.9 Hz, 2 H, CH=CHCH2) 2.60 (t, J = 7.6 Hz, 2 H, CH2Ph) 3.40 – 
3.55 (m, 1 H, H-5) 3.63 (t, J = 10.2 Hz, 1 H, Ha-6) 3.92 – 4.05 (m, 2 H, H-4 and Hb-6) 4.28 (br. s, 1 H, 
NH) 5.43 (dd, J = 15.4 and 7.7 Hz, 1 H, CH=CHCH2) 5.77 (dt, J = 15.2 and 6.7 Hz, 1 H, CH=CHCH2) 7.13 – 
7.20 (m, 3 H, arom. H) 7.23 – 7.31 (m, 2 H, arom. H). 
13C NMR (75 MHz, CDCl3) δ 19.55, 28.10, 28.31, 28.74, 28.90, 29.24, 29.32, 29.45, 29.49, 
29.54, 29.56, 31.51, 32.35, 35.97, 48.92, 63.12, 74.66, 77.20, 79.59, 98.62, 125.51, 127.17, 128.19, 
128.37, 136.38, 142.92, 155.06. 
 Exact mass (ESI-MS) for C29H48NO4 [M+H]
+ found, 474.3574; Calcd., 474.3578. 
tert-butyl ((2S,3R,E)-1,3-dihydroxyoctadec-4-en-2-yl)carbamate (7.10a) 
To a solution of 7.9a (1 g, 2.27 mmol) in MeOH (30 mL), TsOH.H2O (60 mg, 0.32 mmol) was added. 
The reaction mixture was stirred 5h at room temperature and subsequently quenched with saturated 
NaHCO3 solution (10 mL). The aqueous layer was extracted with EtOAc (3 x 25 mL) and the combined 
organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and evaporated to dryness. 
The crude residue was purified by column chromatography (30  40 % EtOAc in hexanes) furnishing 
diol 7.10a (850 mg, 94% yield) as a white solid. 
 1H NMR (300 MHz CDCl3) δ 0.89 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.21 – 1.43 (m, 22 H, CH2) 
1.46 (s, 9 H, tBu) 2.06 (q, J = 6.8 Hz, 2 H, CH=CHCH2) 2.61 (d, J = 4.5 Hz, 2 H, 2 x OH) 3.53 – 3.65 (m, 1 
H, H-2) 3.71 (ddd, J = 12.5, 7.4 and 3.7 Hz, 1 H, Ha-1) 3.94 (dt, J = 13.3 and 3.9 Hz, 1 H, Hb-1) 4.32 (q, J 
= 4.9 Hz, 1 H, H-3) 5.30 (d, J = 6.4 Hz, 1 H, NH) 5.54 (ddt, J = 15.4, 6.5 and 1.3 Hz, 1 H, H-4) 5.79 (dtd, J 
= 15.4, 6.8 and 1.0 Hz, 1 H, H-5). 
13C NMR (75 MHz, CDCl3) δ 14.32, 22.88, 28.55, 29.32, 29.39, 29.61, 29.66, 29.83, 29.88, 
32.12, 32.45, 55.54, 62.89, 75.22, 80.01, 129.13, 134.41, 156.39. 
 Exact mass (ESI-MS) for C23H45KNO4 [M+K]
+ found, 438.2978; Calcd., 438.2975. 
tert-butyl ((2S,3R,E)-1,3-dihydroxy-15-phenylpentadec-4-en-2-yl)carbamate (7.10b) 
To a solution of 7.9b (2.01 g, 4.25 mmol) in MeOH (60 mL), TsOH.H2O (118 mg, 0.62 mmol) was 
added. The reaction mixture was stirred 4h at room temperature and subsequently quenched with 
saturated NaHCO3 solution (20 mL). The aqueous layer was extracted with EtOAc (3 x 50 mL) and the 
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combined organic layer was washed with brine (75 mL), dried over Na2SO4, filtered and evaporated 
to dryness. The crude residue was purified by column chromatography (30  40 % EtOAc in hexanes) 
furnishing diol 7.10b (1.698 g, 91% yield) as a white solid. 
1H NMR (300 MHz CDCl3) δ 1.22 – 1.43 (m, 14 H, CH2) 1.46 (s, 9 H, tBu) 1.55 – 1.68 (m, 2 H, 
CH2) 2.06 (q, J = 7.0 Hz, 2 H, CH=CHCH2) 2.61 (t, J = 7.7 Hz, 2 H, CH2Ph) 2.67 (d, J = 5.1 Hz, 2 H, 2 x OH) 
3.53 – 3.65 (m, 1 H, H-2) 3.71 (ddd, J = 11.3, 7.0 and 3.5 Hz, 1 H, Ha-1) 3.94 (dt, J = 11.5 and 4.0 Hz, 1 
H, Hb-1) 4.32 (q, J = 4.9 Hz, 1 H, H-3) 5.26 – 5.36 (m, 1 H, NH) 5.53 (ddt, J = 15.4, 6.5 and 1.3 Hz, 1 H, 
H-4) 5.79 (dtd, J = 15.4, 6.8 and 1.1 Hz, 1 H, H-5) 7.14 – 7.21 (m, 3 H, arom. H) 7.25 – 7.31 (m, 2 H, 
arom. H). 
13C NMR (75 MHz, CDCl3) δ 27.83, 28.37, 29.08, 29.16, 29.24, 29.31, 29.43, 29.48, 29.56, 
31.51, 32.27, 35.97, 55.38, 62.64, 74.82, 79.79, 125.51, 128.18, 128.37, 128.63, 128.90, 134.12, 
134.44, 142.91, 156.21. 
 Exact mass (ESI-MS) for C26H43NNaO4 [M+Na]
+ found, 456.3080; Calcd., 456.3084. 
tert-butyl ((2S,3R,E)-1,3-di-(tert-butyldimethylsilyloxy)-4-en-2-yl)carbamate (7.11a) 
To a solution of 7.10a (850 mg, 2.13 mmol) in anhydrous DCM (7 mL), imidazole (440 mg, 6.47 mmol) 
and TBSCl (975 mg, 6.47 mmol) were added. The reaction was heated to 40 °C and stirred overnight. 
Next, H2O (5 mL) was added and the aqueous layer was extracted with DCM (3 x 10 mL). The 
combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and evaporated 
to dryness. The crude residue was purified by column chromatography (hexane/toluene: 5/5) 
furnishing 7.11a (1.298 g, 97% yield) as a colorless oil. 
 1H NMR (300 MHz CDCl3) δ 0.00 – 0.06 (m, 12 H, SiCH3) 0.87 – 0.92 (m, 21 H, tBuSi and 
terminal CH3) 1.20 – 1.40 (m, 22 H, CH2) 1.43 (s, 9 H, tBu) 2.01 (q, J = 6.9 Hz, 2 H, CH=CHCH2) 3.51 – 
3.67 (m, 2 H, Ha-1 and H-2) 3.78 (dd, J = 9.9 and 4.5 Hz, 1 H, Hb-1) 4.19 (t, J = 6.4 Hz, 1 H, H-3) 4.62 (d, 
J = 8.4 Hz, 1 H, NH) 5.42 (dd, J = 15.4 and 7.0 Hz, 1 H, H-4) 5.61 (dtd, J = 15.4, 6.8 and 0.6 Hz, 1 H, H-
5). 
13C NMR (75 MHz, CDCl3) δ -5.47, -5.33, -4.92, -4.05, 14.11, 18.12, 18.24, 22.69, 25.86, 25.91, 
28.42, 29.19, 29.26, 29.36, 29.52, 29.62, 29.66, 29.68, 31.93, 32.24, 56.62, 61.43, 73.08, 78.78, 
130.05, 133.13, 155.55. 
 Exact mass (ESI-MS) for C35H73NNaO4Si2 [M+Na]







To a solution of 7.10b (1.68 g, 3.87 mmol) in anhydrous DCM (30 mL), imidazole (790 mg, 11.61 
mmol) and TBSCl (1.75 g, 11.61 mmol) were added. The reaction was heated to 40 °C and stirred 
overnight. Next, H2O (20 mL) was added and the aqueous layer was extracted with DCM (3 x 50 mL). 
The combined organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and 
evaporated to dryness. The crude residue was purified by column chromatography (hexane/EtOAc: 
9/1) furnishing 7.11b (2.507 g, 98% yield) as a colorless oil. 
 1H NMR (300 MHz CDCl3) δ 0.02 – 0.09 (m, 12 H, SiCH3) 0.86 – 0.94 (m, 18 H, tBuSi) 1.22 – 
1.41 (m, 14 H, CH2) 1.44 (s, 9 H, tBu) 1.57 – 1.69 (m, 2 H, CH2) 2.02 (q, J = 6.9 Hz, 2 H, CH=CHCH2) 2.61 
(t, J = 7.5 Hz, 2 H, CH2Ph) 3.51 – 3.67 (m, 2 H, Ha-1 and H-2) 3.79 (dd, J = 10.0 and 4.5 Hz, 1 H, Hb-1) 
4.20 (t, J = 5.7 Hz, 1 H, H-3) 4.63 (d, J = 8.5 Hz, 1 H, NH) 5.42 (dd, J = 15.5 and 7.0 Hz, 1 H, H-4) 5.62 
(dtd, J = 15.5, 6.8 and 0.9 Hz, 1 H, H-5) 7.14 – 7.21 (m, 3 H, arom. H) 7.25 – 7.31 (m, 2 H, arom. H). 
13C NMR (75 MHz, CDCl3) δ -5.48, -5.34, -4.93, -4.07, 18.11, 18.23, 25.86, 25.91, 27.97, 28.41, 
29.17, 29.24, 29.34, 29.51, 29.59, 31.53, 32.23, 35.98, 56.61, 61.43, 73.08, 78.80, 125.51, 128.18, 
128.37, 130.05, 133.11, 142.93, 155.57. 
 Exact mass (ESI-MS) for C38H72NO4Si2 [M+H]
+ found, 662.4999; Calcd., 662.4994. 
tert-butyl ((2S,3R,E)-1-hydroxy-3-(tert-butyldimethylsilyloxy)-4-en-2-yl)carbamate (7.12a) 
In a polyethylene vial, a solution of 7.11a (200 mg, 0.32 mmol) in THF (3.3 mL) was cooled to 0 °C. 
Then 2 mL of a stock solution containing pyridine (3 mL) and HF.pyridine (2.7 mL) in THF (7.5 mL) was 
added. After stirring for 4 h at 0 °C the reaction mixture was quenched with saturated NaHCO3 
solution (5 mL) and the aqueous layer was extracted with EtOAc (3 x 15 mL). The combined organic 
layer was washed with saturated NaHCO3 solution (50 mL) and brine (50 mL), dried over Na2SO4, 
filtered and evaporated to dryness. The crude residue was purified by flash column chromatography 
(0%  20% EtOAc in hexanes) furnishing alcohol 7.12a (120 mg, 73% yield) as a colorless oil. 
 1H NMR (300 MHz CDCl3) δ 0.04 (s, 3 H, SiCH3) 0.08 (s, 3 H, SiCH3) 0.85 – 0.94 (m, 12 
H, tBuSi and terminal CH3) 1.21 – 1.42 (m, 22 H, CH2) 1.46 (s, 9 H, tBu) 2.04 (q, J = 6.6 Hz, 2 H, 
CH=CHCH2) 2.98 (d, J = 10.0 Hz, 1 H, OH) 3.39 – 3.51 (m, 1 H, H-2) 3.58 (td, J = 10.6 and 3.4 Hz, 1 H, 
Ha-1) 4.04 (d, J = 11.5 Hz, 1 H, Hb-1) 4.49 (br. s, 1 H, H-3) 5.35 (d, J = 7.7 Hz, 1 H, NH) 5.46 (ddt, J = 
15.4, 6.1 and 1.3 Hz, 1 H, H-4) 5.61 (dt, J = 15.4 and 6.8, 1 H, H-5). 
13C NMR (75 MHz, CDCl3) δ -5.16, -4.52, 14.11, 18.01, 22.68, 25.80, 28.41, 29.12, 29.14, 29.35, 
29.46, 29.62, 29.65, 29.67, 29.69, 31.92, 32.19, 55.16, 62.33, 76.31, 79.40, 129.27, 133.32, 155.71. 
 Exact mass (ESI-MS) for C29H60NO4Si [M+H]
+ found, 514.4294; Calcd., 514.4286. 
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tert-butyl((2S,3R,E)-1-hydroxy-3-(tert-butyldimethylsilyloxy)-15-phenylpentadec-4-en-2-yl)carbamate 
(7.12b) 
In a polyethylene vial, a solution of 7.11b (530 mg, 0.8 mmol) in THF (8.5 mL) was cooled to 0 °C. 
Then 5 mL of a stock solution containing pyridine (3 mL) and HF.pyridine (2.7 mL) in THF (7.5 mL) was 
added. After stirring for 4 h at 0 °C the reaction mixture was quenched with saturated NaHCO3 
solution (10 mL) and the aqueous layer was extracted with EtOAc (3 x 30 mL). The combined organic 
layer was washed with saturated NaHCO3 solution (75 mL) and brine (75 mL), dried over Na2SO4, 
filtered and evaporated to dryness. The crude residue was purified by flash column chromatography 
(0%  25% Et2O in hexanes) furnishing alcohol 7.12b (343 mg, 78% yield) as a colorless oil. 
 1H NMR (300 MHz CDCl3) δ 0.13 (s, 3 H, SiCH3) 0.17 (s, 3 H, SiCH3) 1.00 (m, 9 H, tBuSi) 1.28 – 
1.51 (m, 14 H, CH2) 1.55 (s, 9 H, tBu) 1.64 – 1.76 (m, 2 H, CH2) 2.13 (q, J = 7.2 Hz, 2 H, CH=CHCH2) 2.69 
(t, J = 7.8 Hz, 2 H, CH2Ph) 3.09 (d, J = 9.0 Hz, 1 H, OH) 3.47 – 3.60 (m, 1 H, H-2) 3.66 (td, J = 11.4 and 
3.5 Hz, 1 H, Ha-1) 4.11 (d, J = 11.3 Hz, 1 H, Hb-1) 4.56 (br. s, 1 H, H-3) 5.43 (d, J = 7.7 Hz, 1 H, NH) 5.54 
(ddt, J = 15.4, 6.2 and 1.3 Hz, 1 H, H-4) 5.80 (dt, J = 15.4 and 6.6, 1 H, H-5) 7.21 – 7.28 (m, 3 H, arom. 
H) 7.32 – 7.38 (m, 2 H, arom. H). 
13C NMR (75 MHz, CDCl3) δ -5.19, -4.56, 17.97, 25.77, 28.38, 29.07, 29.30, 29.39, 29.46, 29.53, 
29.56, 31.48, 32.15, 35.95, 55.17, 62.22, 76.18, 79.32, 125.48, 128.14, 128.32, 129.28, 133.22, 
142.87, 155.68. 
 Exact mass (ESI-MS) for C32H58NO4Si [M+H]
+ found, 548.4127; Calcd., 548.4130. 
1,2,3,4,6-penta-O-benzoyl-α-D-galactopyranose  
D-Galactose (20,11 g, 110 mmol) was dissolved in pyridine (240 mL), cooled to 0 °C and benzoyl 
chloride (80 mL, 670 mmol) was added dropwise. Next, the reaction mixture was heated to 65 °C and 
stirred for 1h. The resulting suspension was quenched with H2O (10 mL) and allowed to reach room 
temperature before addition of extra H2O (100 mL). The resulting mixture was poured into ice water 
(2 L) and after 1h, the water layer was decanted and the residue was dried under reduced pressure. 
Column chromatography (Toluene/EtOAc: 95/5) gave pure 1,2,3,4,6-penta-O-benzoyl-α-D-
galactopyranose (54.6 g, 71%) as a white foam.  
1H NMR (300 MHz, CDCl3): δ 4.44 (dd, J = 11.3 and 7.0 Hz, 1 H, Ha-6) 4.65 (dd, J = 11.3 and 6.5 
Hz, 1 H, Hb-6) 4.85 (dt, J = 7.0, 6.5 and 1.2 Hz, 1 H, H-5) 6.05 (dd, J = 10.6 and 3.6 Hz, 1 H, H-2) 6.15 
(dd, J = 10.6 and 3.2 Hz, 1 H, H-3) 6.21 (dd, J = 3.2 and 1.2 Hz, 1 H, H-4) 6.97 (d, J = 3.6 Hz, 1 H, H-1) 




13C NMR (75 MHz, CDCl3): δ 61.83, 67.71, 68.42, 68.46, 69.43, 90.62, 128.28, 128.38, 128.42, 
128.71, 128.74, 128.81, 128.88, 129.02, 129.27, 129.53, 129.72, 129.89, 129.91, 133.22, 133.32, 
133.36, 133.73, 133.88, 164.48, 165.42, 165.48, 165.73, 165.92.  
Exact mass (ESI-MS) for C34H28KO10 [M+K]
+ found, 635.1320; calcd, 635.1320. 
2,3,4,6-Tetra-O-benzoylgalactopyranose 
1,2,3,4,6-penta-O-benzoyl-α-D-galactopyranose (5 g, 7.14 mmol) was dissolved in DCM (12.5 mL), 
cooled to 0 °C and HBr (30% in AcOH, 2.5 mL) was added dropwise. The reaction mixture was allowed 
to warm to room temperature and was stirred for 2h. Upon consumption of the starting material, the 
reaction mixture was diluted with DCM (75 mL) and the organic layer was washed with saturated 
NaHCO3 solution (50 mL), brine (50 mL) and H2O (50 mL). The organic layer was filtered and 
evaporated under reduced pressure. The resulting white solid was dissolved in acetone (22 mL) and 
H2O (1 mL) before addition of Ag2CO3 (1 g, 3.63 mmol). The resulting mixture was stirred for 2h at 
room temperature, filtered through a patch of celite and evaporated under reduced pressure. The 
resulting residue was purified by column chromatography (hexane/ EtOAc: 7/3) affording pure 
2,3,4,6-Tetra-O-benzoylgalactopyranose (4.07 g, 96%) as a white solid. 
1H NMR (CDCl3, 300 MHz, anomeric mixture): δ 4.35 – 4.49 (m, 1 H, Ha-6) 4.58 – 4.72 (m, 1 H, 
Hb-6) 4.88 (t, J = 6.5 Hz, 1/2 H, H-5) 5.05 (t, J = 7.3 Hz, 1/2 H, H-5) 5.58 – 5.65 (m, 1 H, H-2) 5.67 – 5.76 
(m, 1 H, H-1) 5.83 – 5.88 (m, 1/2 H, H-3) 5.99 – 6.02 (m, 1/2 H, H-3) 6.04 – 6.11 (m, 1 H, H-4) 7.20 – 
7.28 (m, 3 H, arom. H) 7.52 – 7.66 (m, 9 H, arom. H) 7.76 – 7.82 (m, 2 H, arom. H) 7.95 – 8.04 (m, 4 H, 
arom. H) 8.07 – 8.12 (m, 2 H, arom. H).  
13C NMR (CDCl3, 75 MHz): δ 62.41, 67.03, 67.98, 69.32, 69.47, 91.13, 128.21, 128.27, 128.36, 
128.49, 128.63, 129.66, 129.83, 129.89, 133.01, 133.07, 133.23, 133.39, 133.54, 165.45, 165.71, 
166.02, 166.14.  
Exact mass (ESI-MS) for C34H28NaO10 [M+Na]
+ found, 619.1578; calcd, 619.1575. 
2,3,4,6-Tetra-O-benzoyl-1-(2,2,2-trichloroethanimidate)-α-D-galactopyranoside (7.13) 
To a solution of 2,3,4,6-Tetra-O-benzoylgalactopyranose (900 mg, 1.51 mmol) in anhydrous DCM (12 
mL) at 0 °C, DBU (0.11 mL, 0.75 mmol) and trichloroacetonitrile (1.51 mL, 15.1 mmol) were added. 
The reaction mixture was stirred for 4 hours at 0 °C. Upon completion, the reaction was diluted with 
DCM and celite was added. The solvent was removed under reduced pressure and the residue was 
purified by column chromatography (hexanes/EtOAc: 8/2 + 1 V% Et3N) yielding 7.13 (797 mg, 71 %) 
as a white foam.  
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1H NMR (CDCl3, 300 MHz): δ 4.45 (dd, J = 11.5 and 6.5 Hz, 1 H, Ha-6) 4.62 (dd, J = 11.5 and 6.5 
Hz, 1 H, Hb-6) 4.88 (t, J = 6.5 Hz, 1 H, H-5) 5.98 (dd, J = 10.7 and 3.6 Hz, 1 H, H-2) 6.09 (dd, J = 10.7 
and 3.3 Hz, 1 H, H-3) 6.93 (d, J = 3.6 Hz, 1 H, H-1) 7.23 – 7.67 (m, 12 H, arom. H) 7.78 – 7.84 (m, 3 H, 
arom. H) 7.93 – 8.01 (m, 3 H, arom. H) 8.13 – 8.07 (m, 3 H, arom. H) 8.64 (s, 1 H, NH). 
13C NMR (CDCl3, 75 MHz): δ 63.29, 63.63, 70.24, 80.98, 84.09, 84.80, 103.13, 105.54, 126.67, 
128.41, 128.56, 128.62, 128.69, 129.00, 129.52, 129.93, 130.13, 130.25, 133.31, 133.52, 133.78, 
133.91, 160.54, 165.73, 165.94, 166.23. 
3’,4’,6’-tri-O-benzoyl-1’,2’-O-(2-phenyl-2-O-(tert-butyl ((2S,3R,E)-3-((tert-butyldimethylsilyl)oxy)-4-en-
2-yl)carbamate)-1,3-dioxolane)-α-D-galactopyranoside (7.14bis) 
Glycosylacceptor 7.12a (519 mg, 1.01 mmol) and 7.13 (960 mg, 1.3 mmol) were dissolved in 
anhydrous THF (15 mL). The solution was stirred in the presence of molecular sieves (4 Å , 100 mg) 
for 30 minutes at -20 °C. TMSOTf (0.04 mL, 0.2 mmol) was added dropwise and the resulting mixture 
was stirred for 2 h at -20 °C. The reaction was quenched by adding Et3N (1 mL) followed by filtration 
over a patch of celite and evaporation of the solvents. Flash column chromatography (2%  20% 
EtOAc in hexanes) furnished ortho-ester 7.14bis (921 mg, 84%) as a pale oil. 
1H NMR (CDCl3, 300 MHz): δ -0.03 (s, 3 H, SiCH3) 0.00 (s, 3 H, SiCH3) 0.82 (s, 9 H, tbuSi) 0.89 (t, 
J = 6.7 Hz, 3 H, terminal CH3) 1.16 – 1.36 (m, 22 H, CH2) 1.42 (s, 9 H, tBu) 1.95 (q, J = 6.7 Hz, 2 H, 
CH=CHCH2) 3.50 (dd, J = 10.1 and 4.4 Hz, 1 H, Ha-1) 3.55 – 3.64 (m, 1 H, Hb-1) 3.64 – 3.76 (m, 1 H, H-
2) 4.16 (t, J = 6.2 Hz, 1 H, H-3) 4.37 (dd, J = 11.1 and 5.6 Hz, 1 H, Ha-6) 4.47 – 4.54 (m, 1 H, H-4’) 4.59 
(dd, J = 10.9 and 6.6 Hz, 1 H, Hb-6) 4.65 (d, J = 8.7 Hz, 1 H, NH) 4.80 (t, J = 5.6 Hz, 1 H, H-2’) 5.31 (dd, J 
= 15.4 and 7.2 Hz, 1 H, H-4) 5.50 (dd, J = 6.3 and 4.2 Hz, 1 H, H-3’) 5.47 – 5.63 (m, 1 H, H-5) 5.80 (dd, J 
= 4.1 and 2.5 Hz, 1 H, H-5’) 6.21 (d, J = 5.1 Hz, 1 H, H-1’) 7.34 – 7.44 (m, 10 H, arom. H) 7.51 – 7.68 (m, 
5 H, arom. H) 7.91 – 8.00 (m, 5 H, arom. H). 
13C NMR (CDCl3, 75 MHz): δ -5.02, -4.10, 14.12, 18.03, 22.69, 25.80, 28.40, 29.10, 29.21, 
29.36, 29.46, 29.60, 29.68, 31.92, 32.17, 54.97, 62.16, 62.35, 66.53, 68.96, 70.24, 73.57, 73.60, 79.01, 
98.31, 120.46, 126.03, 128.34, 128.43, 128.50, 128.95, 129.15, 129.44, 129.54, 129.62, 129.77, 
129.83, 133.13, 133.33, 133.50, 136.72, 155.45, 165.19, 165.96. 
Exact mass (ESI-MS) for C63H86NO13Si [M+H]
+ found, 1092.5856; calcd, 1092.5863. 
1,2,3,4,6-penta-O-pivaloyl-β-D-galactopyranose  
To a solution of D-Galactose (9,08 g, 50 mmol) in pyridine (38 mL) and DCM (63 mL), pivaloyl chloride 
(38.7 mL, 312.5 mmol) was added dropwise. The reaction mixture was heated to reflux temperature 




taken in Et2O (250 mL) and washed with 1 M aqueous H2SO4 (100 mL), saturated NaHCO3 solution 
(100 mL) and H2O (100 mL).Then the organic phase was dried over Na2SO4, filtered and evaporated to 
dryness. The resulting residue was crystallized from boiling ethanol and yielded protected sugar 
1,2,3,4,6-penta-O-pivaloyl-β-D-galactopyranose (30.04 g, quantitative yield) as a white solid. 
1H NMR (300 MHz, CDCl3): δ 1.13 (s, 9 H, tBu) 1.17 (s, 9 H, tBu) 1.18 (s, 9 H, tBu) 1.20 (s, 9 H, 
tBu) 1.25 (s, 9 H, tBu) 3.99 (dd, J = 10.0 and 6.5 Hz, 1 H, Ha-6) 4.09 (ddd, J = 6.5 and 1.0 Hz, 1 H, H-5) 
4.17 (dd, J = 10.0 and 6.5 Hz, 1 H, Hb-6) 5.17 (dd, J = 10.0 and 3.5 Hz, 1 H, H-3) 5.43 (dd, J = 3.5 and 
1.0 Hz, 1 H, H-4) 5.58 (dd, J = 10.0 and 8.0 Hz, 1 H, H-2) 5.72 (d, J = 8.0 Hz, 1 H, H-1). 
Exact mass (ESI-MS) for C31H52NaO11 [M+Na]
+ found, 623.3400; calcd, 623.3402. 
Spectral data are consistent with the literature data.43 
2,3,4,6-Tetra-O-pivaloyl-galactopyranose 
To a solution of 1,2,3,4,6-penta-O-pivaloyl-β-D-galactopyranose (3 g, 5 mmol) in DMF (10 mL), 
hydrazine acetate (0.55 g, 6.25 mmol) was added. The reaction mixture was heated to 60 °C and was 
stirred overnight. Next, the reaction mixture was diluted with EtOAc (75 mL) and the organic layer 
was washed with brine (3 x 50 mL). The organic layer was evaporated under reduced pressure and 
the resulting residue was purified by column chromatography (hexane/EtOAc: 85/25) affording pure 
galactoside 2,3,4,6-Tetra-O-pivaloyl-galactopyranose (899 mg, 35%) as a white solid together with 
recovered starting material (2.3 g). 
1H NMR (CDCl3, 300 MHz, anomeric mixture): δ 1.11 – 1.15 (m, 9 H, tBu) 1.16 – 1.24 (m, 18 H, 
2 x tBu) 1.24 – 1.30 (m, 9 H, tBu) 2.97 (br. s, 1/2 H, OH) 3.54 (br. s, 1/2 H, OH) 3.92 – 4.22 (m, 2 H, 
CH2-6) 4.50 (t, J = 7.1 Hz, 1 H, H-4) 4.69 – 4.76 (m, 1 H, H-1) 5.02 – 5.23 (m, 1 H, H-5) 5.38 – 5.56 (m, 2 
H, H-2 and H-3).  
Exact mass (ESI-MS) for C26H44NaO10 [M+Na]
+ found, 539.2827; calcd, 539.2827. 
2,3,4,6-Tetra-O-pivaloyl-1-(2,2,2-trichloroethanimidate)-α-D-galactopyranoside (7.15) 
To a solution of 2,3,4,6-Tetra-O-pivaloyl-galactopyranose (500 mg, 0.97 mmol) in anhydrous DCM (9 
mL) at 0 °C, DBU (72 µL, 0.48 mmol) and trichloroacetonitrile (1.0 mL, 9.7 mmol) were added. The 
reaction mixture was stirred for 5 hours at 0 °C. Upon completion the reaction mixture was diluted 
with DCM and celite was added. The solvent was removed under reduced pressure and the residue 
was purified by column chromatography (hexanes/EtOAc: 9/1 + 1 V% Et3N) yielding 7.15 (465 mg, 73 
%) as a white foam.  
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1H NMR (CDCl3, 300 MHz): δ 1.11 – 1.22 (m, 27 H, 3 x tBu) 1.29 (s, 9 H, tBu) 4.00 – 4.18 (m, 2 
H, CH2-6) 4.49 (t, J = 6.6 Hz, 1 H, H-5) 5.43 (dd, J = 10.4 and 3.6 Hz, 1 H, H-2) 5.53 – 5.62 (m, 2 H, H-3 
and H-4) 6.63 (d, J = 3.6 Hz, 1 H, H-1) 8.67 (s, 1 H, NH). 
Exact mass (ESI-MS) for C28H44Cl3NNaO10 [M+Na]
+ found, 682.1913; calcd, 682.1923. 
Spectral data are consistent with the literature data.44 
tert-butyl-((2S,3R,E)-1-(2,3,4,6-tetra-O-pivaloyl-β-D-galactopyranosyloxy)-3-(tert-
butyldimethylsilyloxy)-4-en-2-yl)carbamate (7.16) 
Glycosylacceptor 7.12a (150 mg, 0.29 mmol) and 7.15 (292 mg, 0.44 mmol) were dissolved in dry 
DCM (8 mL). The solution was stirred in the presence of molecular sieves (4 Å , 100 mg) at room 
temperature for 30 minutes. The mixture was cooled to -20 °C before addition of TMSOTf (11.6 µL, 
58 µmol) and stirring was continued for 2h at this temperature. The reaction was quenched by 
adding Et3N (1 mL) followed by filtration over a patch of celite and evaporation of the solvents. Flash 
column chromatography (0  10% EtOAc in hexanes) furnished galactoside 7.16 (61 mg, 21%) as a 
colorless oil. 
1H NMR (CDCl3, 300 MHz): δ 0.02 (s, 3 H, SiCH3) 0.08 (s, 3 H, SiCH3) 0.84 – 0.93 (m, 12 H, tBuSi 
and terminal CH3) 1.11 – 1.16 (m, 9 H, tBu) 1.16 – 1.23 (m, 9 H, tBu) 1.23 – 1.36 (m, 40 H, tBu and 
CH2) 1.39 (s, 9 H, tBu) 1.99 (q, J = 6.5 Hz, 2 H, CH=CHCH2) 3.42 (dd, J = 9.2 and 3.4 Hz, 1 H, Ha-1) 3.56 
– 3.76 (m, 1 H, H-2) 3.92 – 4.26 (m, 5 H, Hb-1, H-4, H-4’ and CH2-6’) 4.49 (d, J = 7.7 Hz, 1 H, H-1’) 4.62 
(d, J = 9.5 Hz, 1 H, NH) 5.09 – 5.25 (m, 2 H, H-2’ and H-5’) 5.32 – 5.47 (m, 2 H, H-3’ and H-4) 5.61 (dt, J 
= 15.3 and 6.6 Hz, 1 H, H-5). 
13C NMR (CDCl3, 75 MHz): δ -4.91, -4.19, 14.08, 18.00, 22.66, 25.91, 27.05, 27.11, 28.37, 
29.13, 29.28, 29.33, 29.50, 29.65, 30.17, 31.40, 31.89, 32.17, 38.72, 38.81, 39.02, 54.51, 60.97, 66.62, 
67.92, 69.03, 70.82, 73.23, 78.94, 101.12, 119.07, 123.92, 124.41, 130.47, 133.63, 155.23, 176.79, 
176.91, 177.21, 177.81. 
Exact mass (ESI-MS) for C55H102NO13Si [M+H]
+ found, 1012.7141; calcd, 1021.7115. 
(2S,3R,E)-2-azidooctadec-4-ene-1,3-diol (7.17a) 
To a solution of compound 7.9a (1.54 g, 3.5 mmol) in THF (70 ml) was added a 6 M aqueous HCl 
solution (14 ml). The reaction mixture was allowed to stir overnight at 50 °C. Next, the mixture was 
neutralized with 10% aqueous NaOH and extracted with DCM (5 x 50 ml), dried over Na2SO4, filtered 




In a separate flask, a solution of NaN3 (1.14 g, 17.5 mmol) in H2O (3 mL) and DCM (3 mL) was cooled 
to 0 °C in an ice bath. To this mixture Tf2O (1.97 g, 7 mmol) was added dropwise over a period of 10 
min. The reaction was stirred for 2 h at 0 °C, the organic phase was separated and the aqueous layer 
was extracted with DCM (2 x 7.5 mL). Next, the combined organic phase was washed with saturated 
Na2CO3 solution (20 mL) and used without further purification.  
The crude amine was dissolved in a MeOH/H2O mixture (1/1, 70 ml) before addition of Et3N (7 mmol, 
0.98 ml) and CuSO4 (0.18 mmol, 28 mg). The reaction mixture was cooled to 0 °C and the above 
prepared TfN3 solution was added. The mixture was allowed to reach room temperature and was 
stirred overnight. The solvent evaporated under reduced pressure and the residue purified by 
column chromatography (hexane/EtOAc: 7/3) to afford 7.17a (1.14 g, quant. yield) as a white solid. 
 1H NMR (300 MHz CDCl3) δ 0.89 (t, J = 6.5 Hz, 3 H, terminal CH3) 1.20 – 1.46 (m, 22 H, CH2) 
2.00 – 2.17 (m, 4 H, CH2 and 2 x OH) 3.52 (app. q, J = 5.6 Hz, 1 H, H-2) 3.73 – 3.86 (m, 2 H, CH2-1) 4.26 
(t, J = 6.2 Hz, 1 H, H-3) 5.55 (ddt, J = 15.3, 7.3 and 1.5 Hz, 1 H, H-4) 5.83 (dtd, J = 15.4, 6.7 and 0.9 Hz, 
1 H, H-5). 
 13C NMR (75 MHz, CDCl3) δ 14.02, 22.59, 28.93, 29.22, 29.28, 29.44, 29.55, 29.59, 29.61, 
31.92, 32.29, 62.34, 66.69, 73.37, 128.03, 135.82. 
 Exact mass (ESI-MS) for C18H36N3O2 [M+H]
+ found, 326.2805; Calcd., 326.2802. 
Spectral data are consistent with the literature data.  
 (2S,3R,E)-2-azido-15-phenylpentadec-4-ene-1,3-diol (7.17b) 
To a solution of compound 7.9b (1.07 g, 1.96 mmol) in THF (40 ml) was added a 6 M aqueous  HCl 
solution (7.8 ml). The reaction mixture was allowed to stir overnight at 50 °C. Next, the mixture was 
neutralized with 10% aqueous NaOH and extracted with DCM (5 x 30 ml), dried over Na2SO4, filtered 
and evaporated to dryness.  
In a separate flask a solution of NaN3 (638 mg, 9.8 mmol) in H2O (2 mL) and DCM (2 mL) was cooled 
to 0 °C in an ice bath. To this mixture Tf2O (1.1 g, 3.29 mmol) was added dropwise over a period of 10 
min. The reaction was then stirred for 2 h at 0 °C, the organic phase was separated and the aqueous 
layer was extracted with DCM (2 x 5 mL). Then the combined organics were washed with saturated 
Na2CO3 solution and used without further purification.  
Next, the crude amine was dissolved in a MeOH/H2O mixture (1/1, 40 ml) before addition of Et3N 
(3.29 mmol, 0.46 ml) and CuSO4 (0.1 mmol, 16 mg). The reaction mixture was cooled to 0 °C and the 
above prepared TfN3 solution was added. The mixture was allowed to reach room temperature and 
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was stirred overnight. The mixture was evaporated under reduced pressure and purified by column 
chromatography (hexane/EtOAc: 7/3) to afford 7.17b (766 mg, quant. yield) as a white solid. 
 1H NMR (300 MHz CDCl3) δ 1.23 – 1.45 (m, 16 H, CH2) 1.56 – 1.68 (m, 2 H, CH2) 2.00 – 2.13 (m, 
4 H, CH2 and 2 x OH) 2.61 (t, J = 7.6 Hz, 2 H, CH=CHCH2) 3.52 (q, J = 5.5 Hz, 1 H, H-2) 3.73 – 3.85 (m, 2 
H, CH2-1) 4.22 – 4.30 (m, 1 H, H-3) 5.55 (ddt, J =15.5, 7.3 and 1.4 Hz, 1 H, H-4) 5.83 (dtd, J = 15.4, 6.7 
and 0.9 Hz, 1 H, H-5) 7.15 – 7.21 (m, 3 H, arom. H) 7.25 - 7.32 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 28.88, 29.14, 29.33, 29.42, 29.50, 29.54, 31.51, 32.29, 35.98, 
62.62, 66.76, 73.82, 77.21, 125.53, 128.02, 128.20, 128.38, 136.04, 142.93. 
 Exact mass (ESI-MS) for C21H33N3NaO2 [M+Na]
+ found, 382.2461; Calcd., 382.2465. 
(2S,3R,E)-2-azido-1-((tert-butyldiphenylsilyl)oxy)octadec-4-en-3-yl benzoate (7.18a) 
To a solution of compound 7.17a (1.25 g, 3.85 mmol) in anhydrous DCM (30 ml) and DMF (10 ml) at 0 
°C, Et3N (0.81 ml, 5.79 mmol), DMAP (48 mg, 0.39 mmol) and TBDPSCl (1.45 ml, 5.58 mmol) were 
added. The reaction mixture was allowed to warm to room temperature and was stirred for 24 h. 
Next, the mixture was diluted with EtOAc (50 mL), washed with brine (3 x 20 mL), dried with Na2SO4 
and the solvent removed under reduced pressure. The crude alcohol was dissolved in dry DCM (45 
ml) and Et3N (2.7 ml) and cooled to 0 °C before the addition of DMAP (46 mg, 0.38 mmol) and 
benzoyl chloride (0.9 ml, 7.75 mmol). The reaction mixture was allowed to warm to room 
temperature and was stirred overnight. After reaction completion, the mixture was diluted with DCM 
(50 mL), washed with 1 M HCl solution (3 x 20 mL), saturated NaHCO3 (3 x 20 mL) and brine (3 x 20 
mL). The organic layer was dried with Na2SO4, filtered and the solvent was removed under reduced 
pressure. Flash chromatography (0%  10% EtOAc in hexanes) afforded title compound 7.18a (1.56 
g, 61 %) as pale oil. 
 1H NMR (300 MHz CDCl3) δ 0.88 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.07 (s, 9 H, tBu) 1.19 – 1.39 
(m, 22 H, CH2) 2.02 (q, J =7.0 Hz, 2 H, CH=CHCH2) 3.72 – 3.76 (m, 2 H, CH2-1) 3.79 – 3.86 (m, 1 H, H-2) 
5.55 (ddt, J =15.5, 7.9 and 1.4 Hz, 1 H, H-4) 5.68 (dd, J = 8.2 and 4.7 Hz, 1 H, H-3) 5.90 (dt, J =15.2 and 
6.7 Hz, 1 H, H-5) 7.29 – 7.47 (m, 8 H, arom. H) 7.54 – 7.69 (m, 5 H, arom. H) 7.98 – 8.03 (m, 2 H, arom. 
H). 
 13C NMR (75 MHz, CDCl3) δ 14.11, 19.12, 22.69, 26.67, 28.70, 29.11, 29.34, 29.42, 29.56, 
29.65, 31.92, 32.33, 63.34, 65.76, 74.30, 77.20, 123.19, 127.74, 127.79, 128.38, 129.71, 129.80, 
129.85, 130.06, 132.69, 132.82, 133.05, 135.54, 138.47, 165.17. 
 Exact mass (ESI-MS) for C41H57KN3O3Si [M+K]




(2S,3R,E)-2-azido-1-((tert-butyldiphenylsilyl)oxy)-15-phenylpentadec-4-en-3-yl benzoate (7.18b) 
To a solution of compound 7.17b (705 mg, 1.96 mmol) in anhydrous DCM (15 mL) and DMF (5 mL) at 
0 °C, Et3N (0.41 ml, 2.92 mmol), DMAP (24 mg, 0.2 mmol) and TBDPSCl (0.74 ml, 2.85 mmol) were 
added. The reaction mixture was allowed to warm to room temperature and was stirred for 24 h. 
Next, the mixture was diluted with EtOAc (25 mL), washed with brine (3 x 10 mL), dried with Na2SO4 
and the solvent removed under reduced pressure. The crude alcohol was dissolved in anhydrous 
DCM (27 ml) and Et3N (1.9 ml) and cooled to 0 °C before the addition of DMAP (28 mg, 0.23 mmol) 
and benzoyl chloride (0.54 ml, 4.65 mmol). The reaction mixture was allowed to warm to room 
temperature and was stirred overnight. After reaction completion, the mixture was diluted with DCM 
(30 mL), washed with 1 M HCl solution (3 x 15 mL), saturated NaHCO3 (3 x 15 mL) and brine (3 x 15 
mL). The organic layer was dried with Na2SO4, filtered and the solvent was removed under reduced 
pressure. Flash chromatography (0%  10% EtOAc in hexanes) afforded title compound 7.18b (1.31 
g, 82 %) as a colorless oil. 
 1H NMR (300 MHz CDCl3) δ 1.07 (s, 9 H, tBu) 1.18 – 1.39 (m, 14 H, CH2) 1.54 – 1.66 (m, 2 H, 
CH2) 2.03 (q, J = 6.8 Hz, 2 H, CH=CHCH2) 2.59 (t, J = 7.7 Hz, 2 H, CH2Ph) 3.72 – 3.76 (m, 2 H, CH2-1) 3.79 
– 3.86 (m, 1 H, H-2) 5.55 (ddt, J = 15.4, 8.0 and 1.4 Hz, 1 H, H-4) 5.68 (dd, J = 8.2 and 5.0 Hz, 1 H, H-3) 
5.90 (dt, J = 15.0 and 6.9 Hz, 1 H, H-5) 7.13 – 7.20 (m, 2 H, arom. H) 7.24 – 7.70 (m, 12 H, arom. H) 
7.73  – 7.78 (m, 2 H, arom. H) 7.98 – 8.03 (m, 2 H, arom. H) 8.14 – 8.18 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 19.12, 19.36, 26.69, 27.01, 28.69, 29.10, 29.33, 29.39, 29.50, 
29.56, 31.53, 32.33, 35.98, 63.35, 65.76, 74.30, 77.20, 123.22, 125.53, 127.76, 127.80, 128.20, 
128.38, 128.44, 129.73, 129.80, 129.85, 130.09, 130.38, 131.22, 131.82, 132.69, 132.82, 133.07, 
133.16, 135.34, 135.54, 138.46, 142.94, 165.17. 
 Exact mass (ESI-MS) for C44H55N3NaO3Si [M+Na]
+ found, 724.3887; Calcd., 724.3905. 
(2S,3R,E)-2-azido-1-hydroxyoctadec-4-en-3-yl benzoate (7.19a) 
In a polyethylene vial, a solution of azide 7.18a (878 mg, 1.31 mmol) in THF (5 ml) and acetonitrile 
(25 ml) was cooled to 0 °C before addition of a 40% aqueous HF solution (2.1 ml). The mixture was 
allowed to reach room temperature and was stirred for 12 days until TLC (hexanes/EtOAc: 8/2) 
showed total disappearance of the starting material. The reaction mixture was carefully neutralized 
with a saturated NaHCO3 solution and extracted with EtOAc (3 x 50 mL). The organic layer was 
washed with saturated NaHCO3 (75 mL), dried with Na2SO4, filtered and the solvent removed under 
reduced pressure. Column chromatography (hexane/EtOAc: 8/2) afforded the title compound 7.19a 
(419 mg, 74 %) as a colorless oil. 
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 1H NMR (300 MHz CDCl3) δ 0.89 (t, J = 6.5 Hz, 3 H, terminal CH3) 1.19 – 1.33 (m, 20 H, CH2) 
1.33 – 1.47 (m, 2 H, CH2) 1.94 – 2.02 (m, 1 H, OH) 2.09 (q, J = 7.0 Hz, 2 H, CH=CHCH2) 3.59 – 3.70 (m, 1 
H, Ha-1) 3.72 – 3.86 (m, 2 H, Hb-1 and H-2) 5.56 – 5.67 (m, 2 H, H-3 and H-4) 5.90 – 6.02 (m, 1 H, H-5) 
7.43 – 7.50 (m, 2 H, arom. H) 7.56 – 7.63 (m, 1 H, arom. H) 8.05 – 8.09 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 14.11, 22.67, 28.67, 29.11, 29.34, 29.40, 29.56, 29.65, 31.91, 
32.37, 61.99, 66.19, 74.57, 77.20, 123.27, 128.49, 129.73, 129.79, 133.33, 138.82, 165.48. 
 Exact mass (ESI-MS) for C25H39KN3O3 [M+K]
+ found, 468.2629; Calcd., 468.2623. 
(2S,3R,E)-2-azido-1-hydroxy-15-phenylpentadec-4-en-3-yl benzoate (7.19b) 
In a polyethylene vial, a solution of azide 7.18b (1.31g, 1.87 mmol) in THF (7 ml) and acetonitrile (36 
ml) was cooled to 0 °C before addition of a 40% aqueous HF solution (3 ml). The mixture was allowed 
to reach room temperature and was stirred for 8 days until TLC (hexanes/EtOAc: 8/2) showed total 
disappearance of the starting material. The reaction mixture was carefully neutralized with a 
saturated NaHCO3 solution and extracted with EtOAc (3 x 50 mL). The organic layer was washed with 
saturated NaHCO3 (75 mL), dried with Na2SO4, filtered and the solvent removed under reduced 
pressure. Column chromatography (hexane/EtOAc: 8/2) afforded the title compound 7.19b (486 mg, 
56 %) as a colorless oil. 
 1H NMR (300 MHz CDCl3) δ 1.19 – 1.44 (m, 13 H, CH2) 1.51 – 1.66 (m, 3 H, CH2) 1.90 – 1.97 (m, 
1 H, OH) 2.08 (q, J = 6.9 Hz, 2 H, CH=CHCH2) 2.59 (t, J = 7.8 Hz, 2 H, CH2Ph) 3.57 – 3.67 (m, 1 H, Ha-1) 
3.71 – 3.85 (m, 2 H, Hb-1 and H-2) 5.55 – 5.66 (m, 2 H, H-3 and H-4) 5.89 – 6.02 (m, 1 H, H-5) 7.12 – 
7.20 (m, 3 H, arom. H) 7.23 – 7.30 (m, 2 H, arom. H) 7.41 – 7.49 (m, 2 H, arom. H) 7.54 – 7.61 (m, 1 H, 
arom. H) 8.02 – 8.09 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 28.67, 29.10, 29.31, 29.37, 29.48, 29.53, 31.51, 32.37, 35.98, 
61.99, 66.19, 74.57, 77.20, 123.30, 125.53, 128.20, 128.38, 128.49, 129.80, 133.34, 138.79, 142.94, 
165.48. 
 Exact mass (ESI-MS) for C28H37N3NaO3 [M +Na]
+ found, 486.2730; Calcd., 486.2727. 
(2S, 3R, 4E) -2-Azido-3-benzoyloxy-1- (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyloxy)-4-octadecene 
(7.20a) 
Azide 7.19a (100 mg, 0.23 mmol) and 7.13 (222 mg, 0.3 mmol) were dissolved in dry DCM (4 mL). The 
solution was stirred in the presence of molecular sieves (4 Å , 100 mg) at -30 °C for 30 minutes. 
TMSOTf (8.3 µL, 46 µmol) was added dropwise and the resulting mixture was stirred at -30 °C for 30 




30 minutes until TLC showed complete consumption of the glycosyldonor. The reaction was 
quenched by adding Et3N (1 mL) followed by filtration over a patch of celite and evaporation of the 
solvents. Flash column chromatography (0  2% EtOAc in Toluene) furnished galactoside 7.20a (165 
mg, 71%) as a white solid. 
 1H NMR (300 MHz CDCl3) δ 0.87 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.14 – 1.36 (m, 22 H, CH2) 
1.93 (q, J = 6.7 Hz, 2 H, CH=CHCH2) 3.69 (q, J = 4.7 Hz, 1 H, Ha-1) 3.95 – 4.07 (m, 2 H, Hb-1 and H-2) 
4.28 – 4.41(m, 2 H, H-5’ and H-6’) 4.63 (dd, J = 10.4 and 6.0 Hz, 1 H, Hb-6’) 4.86 (d, J = 7.8 Hz, 1 H, H-
1”) 5.43 – 5.53 (m, 1 H, H-4) 5.57 – 5.64 (m, 2 H, H-3 and H-3’) 5.68 – 5.86 (m, 2 H, H-2’ and H-5), 5.99 
(d, J = 3.6 Hz, 1 H, H-4’) 7.21 – 7.28 (m, 3 H, arom. H) 7.33 – 7.66 (m, 12 H, arom. H) 7.76 – 7.81 (m, 2 
H, arom. H) 7.95 – 8.05 (m, 6 H, arom. H) 8.08 – 8.19 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3) δ 14.31, 22.92, 28.78, 29.43, 29.45, 29.59, 29.82, 29.94, 32.08, 
32.53, 62.07, 64.45, 68.22, 69.41, 69.78, 71.62,71.81, 74.76, 102.12, 123.13, 128.47, 128.59, 128.66, 
128.82, 128.89, 129.23, 129.44, 129.58, 129.94, 130.02, 130.24, 133.35, 133.48, 133.84, 138.81, 
165.27, 165.45, 165.71, 165.84, 166.18. 
 Exact mass (ESI-MS) for C59H65N3NaO12 [M+Na]
+ found, 1030.4485; Calcd., 1030.4460. 
(2S,3R,4E)-2-Azido-3-benzoyloxy-1-(2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyloxy)-15-
phenylpentadecene (7.20b) 
Azide 7.19b (386 mg, 0.83 mmol) and 7.13 (800 mg, 1.08 mmol) were dissolved in anhydrous DCM 
(14 mL). The solution was stirred in the presence of molecular sieves (4 Å , 400 mg) at -30 °C for 30 
minutes. TMSOTf (30 µL, 0.17 mmol) was added dropwise and the resulting mixture was stirred at -
30 °C for 30 minutes. Next, the solution was allowed to reach room temperature and was stirred for 
an additional 30 minutes until TLC showed complete consumption of the glycosyldonor. The reaction 
was quenched by adding Et3N (1 mL) followed by filtration over a patch of celite and evaporation of 
the solvents. Flash column chromatography (0  2% EtOAc in Toluene) furnished galactoside 7.20b 
(760 mg, 88%) as a white solid. 
 1H NMR (300 MHz, CDCl3) δ 1.14 – 1.37 (m, 14 H, CH2) 1.59 (quin., J = 7.0 Hz, 2 H, CH2) 1.93 (q, 
J = 6.2 Hz, 2 H, CH=CHCH2) 2.59 (t, J = 8.2 Hz, 2 H, CH2Ph) 3.69 (dd, J = 9.1 and 4.7 Hz, 1H, Ha-1) 3.94 – 
4.07 (m, 2 H, Hb-1 and H-2) 4.28 – 4.42 (m, 2 H, H-5’ and Ha-6’) 4.62 (dd, J = 10.5 and 6.1 Hz, 1H, Hb-
6’) 4.87 (d, J = 7.9 Hz, 1 H, H-1’) 5.43 – 5.53 (m, 1 H, H-4) 5.57 – 5.64 (m, 2 H, H-3, H-3’), 5.68 – 5.86 
(m, 2 H, H-2’, H-5) 6.00 (d, J = 2.9 Hz, 1 H, H-4’) 7.12 – 7.66 (m, 21 H, arom. H) 7.76 – 7.81 (m, 2 H, 
arom. H) 7.94 – 8.14 (m, 7 H, arom. H). 
  Sulfogalactosylceramides 
 
  197 
 13C NMR (75 MHz, CDCl3) δ 28.59, 29.11, 29.31, 29.34, 29.48, 29.54, 31.50, 32.27, 35.97, 
61.84, 63.46, 67.92, 68.16, 69.58, 71.40, 71.58, 74.68, 77.20, 101.23, 122.57, 125.51, 128.18, 128.27, 
128.37, 128.46, 128.66, 128.93, 129.27, 129.33, 129.73, 129.77, 129.95, 130.05, 130.23, 133.10, 
133.22, 133.30, 133.60, 138.93, 142.91, 164.96, 165.05, 165.52, 165.98. 
 Exact mass (ESI-MS) for C62H64N3O12 [M+H]
+ found, 1042.4496; Calcd., 1042.4485. 
(2S,3R,4E)-2-Azido-1-(β-D-galactopyranosyloxy)-3-hydroxy- 4-octadecene (7.21a) 
Glycoside 7.20a (636 mg, 0.63 mmol) was dissolved in DCM (10 mL) and NaOMe (0.05 M solution in 
MeOH, 3.4 mL) was added. After stirring overnight, Amberlyst 120R (H+ form) was added to 
neutralize the reaction mixture. The exchange resin was filtered off and evaporation of the filtrate 
yielded a crude solid that was purified by column chromatography (2%  12% MeOH in DCM) to 
afford 7.21a (210 mg, 68% yield) as a white solid. 
 1H NMR (300 MHz, CDCl3/CD3OD, 1:1, referenced on CDCl3) δ 0.65 (t, J = 6.3 Hz, 3 H, terminal 
CH3) 0.96 – 1.24 (m, 22 H, CH2) 1.84 (dd, J = 13.8 and 6.6 Hz, 2 H, CH=CHCH2) 3.23 – 3.39 (m, 4 H, H-2, 
H-2’, H-3’ and H-5’) 3.47 – 3.62 (m, 3 H, Ha-1 and CH2-6’) 3.62 – 3.68 (m, 1 H, H-4’) 3.73 – 3.81 (m, 1 
H, Hb-1) 3.98 (t, J = 7.0 Hz, 1 H, H-3) 4.03 (d, J = 7.5 Hz, 1 H, H-1’) 5.28 (dd, J = 15.4 and 7.6 Hz, 1 H, H-
4) 5.56 (dt, J = 15.4 and 7.0 Hz, 1 H, H-5). 
 13C NMR (75 MHz, CDCl3) δ 13.83, 22.61, 29.01, 29.19, 29.31, 29.45, 29.57, 29.63, 31.88, 
32.37, 61.37, 65.67, 68.71, 68.94, 71.20, 71.89, 73.53, 75.14, 77.63, 103.55, 128.12, 135.25. 
 Exact mass (ESI-MS) for C24H45KN3O7 [M+K]
+ found, 526.2880; Calcd., 526.2889. 
(2S, 3R, 4E) -2-Azido-1-(β-D-galactopyranosyloxy)-3-hydroxy- 15-phenylpentadecene (7.21b) 
Glycoside 7.20b (848 mg, 0.81 mmol) was dissolved in DCM (10 mL) and NaOMe (0.05 M solution in 
MeOH, 3.6 mL) was added. After stirring for 72h, Amberlyst 120R (H+ form) was added to neutralize 
the reaction mixture. The exchange resin was filtered off and evaporation of the filtrate yielded a 
crude solid that was purified by column chromatography (2%  12% MeOH in DCM) to afford 7.21b 
(313 mg, 74% yield) as a white solid. 
 1H NMR (300 MHz, CDCl3/CD3OD, 1:1, referenced on CDCl3) δ 0.90 – 1.15 (m, 14 H, CH2) 1.30 
(quin., J = 7.1 Hz, 2 H, CH2) 1.76 (q, J = 7.1 Hz, 2 H, CH=CHCH2) 2.29 (t, J = 7.4 Hz, 2H, CH2Ph) 3.17 – 
3.31 (m, 4 H, H-2, H-2’, H-3’ and H-5’) 3.40 – 3.55 (m, 3 H, Ha-1 and CH2-6’) 3.59 (dd, J = 3.2 and 1.0 
Hz, 1 H, H-4’) 3.67 (dd, J = 10.7 and 6.4 Hz, 1 H, Hb-1) 3.90 (t, J = 6.9 Hz, 1 H, H-3) 3.95 (d, J = 7.3 Hz, 1 
H, H-1’) 5.21 (ddt, J = 15.4, 7.5 and 1.4 Hz, 1 H, H-4) 5.48 (dtd, J = 15.0, 6.6 and 0.7 Hz, 1 H, H-5) 6.80 – 




 13C NMR (75 MHz, CDCl3/CD3OD, 1:1) δ 28.43, 28.58, 28.64, 28.84, 28.95, 30.96, 31.77, 35.31, 
60.74, 65.18, 68.22, 68.44, 70.60, 71.46, 73.00, 74.53, 95.33, 103.04, 124.87, 127.34, 127.54, 127.57, 
127.73, 128.75, 134.56, 142.29, 165.51. 
 Exact mass (ESI-MS) for C27H43N3NaO7 [M+Na]
+ found, 544.2991; Calcd., 544.2993. 
(2S,3R,4E)-2-Azido-1-(3-O-(Sodiumoxysulfonyl)-β-D-galactopyranosyloxy)-3-hydroxy-4-octadecene 
(7.22a) 
Compound 7.21a (75 mg, 0.15 mmol) and Bu2SnO (58 mg, 0.23 mmol) were stirred in MeOH (4 mL) at 
65 °C, under argon atmosphere for 2 h. The solvent was evaporated under reduce pressure and the 
dibutylstannylene complex was treated with Me3N·SO3 (42 mg, 0.3 mmol) in THF (6 mL) at room 
temperature for 5 h. The solvent was removed under reduced pressure, then the residue was 
dissolved in CHCl3/MeOH 1:1 (5 mL) and cation exchange resin (Amberlyte IR120 Na
+ form) was 
added for 45 minutes without stirring. The resin was filtered and the filtrate concentrated in vacuo 
and subjected to flash chromatography (8%  16% MeOH in DCM) to give compound 7.22a (58 mg, 
68%) as a white solid. 
 1H NMR (300 MHz, CDCl3/CD3OD, 1:1, referenced on CDCl3) δ 0.48 (t, J = 6.8 Hz, 3 H, terminal 
CH3) 0.79 – 1.05 (m, 22 H, CH2) 1.67 (q, J = 6.5 Hz, 2 H, CH=CHCH2) 3.14 – 3.24 (m, 2 H, H-2 and H-5’) 
3.31 – 3.45 (m, 4 H, Ha-1, H-2’ and CH2-6’) 3.55 (dd, J = 10.9 and 6.9 Hz, 1 H, Hb-1) 3.80 (t, J = 6.4 Hz, 
1 H, H-3) 3.83 – 3.89 (m, 2 H, H-3’ and H-4’) 3.96 (d, J = 8.0 Hz, 1 H, H-1’) 5.11 (ddt, J = 15.4, 7.6 and 
1.0 Hz, 1 H, H-4) 5.38 (dt, J = 15.4, 6.7 Hz, 1 H, H-5). 
 13C NMR (75 MHz, CDCl3/CD3OD, 1:1) δ 12.89, 21.86, 28.29, 28.43, 28.56, 28.72, 28.85, 28.89, 
31.16, 31.60, 60.48, 65.11, 66.60, 68.21, 68.63, 71.41, 74.18, 79.99, 102.74, 127.45, 134.26. 
 Exact mass (ESI-MS) for C24H44N3O10S [M-H]
- found, 566.2753; Calcd., 566.2753. 
(2S,3R,4E)-2-Azido-1-(3-O-(Sodiumoxysulfonyl)-β-D-galactopyranosyloxy)-3-hydroxy-15-
phenylpentadecene (7.22b) 
Compound 7.21b (86 mg, 0.16 mmol) and Bu2SnO (62 mg, 0.25 mmol) were stirred in MeOH (4 mL) 
at 65 °C, under argon atmosphere for 2 h. The solvent was evaporated under reduce pressure and 
the dibutylstannylene complex was treated with Me3N·SO3 (46 mg, 0.33 mmol) in THF (6 mL) at room 
temperature for 5 h. The solvent was removed under reduced pressure, then the residue was 
dissolved in CHCl3/MeOH 1:1 (5 mL) and cation exchange resin (Amberlyte IR120 Na
+ form) was 
added for 45 minutes without stirring. The resin was filtered and the filtrate concentrated in vacuo 
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and subjected to flash chromatography (8%  16% MeOH in DCM) to give compound 7.22b (83 mg, 
78%) as a white solid. 
 1H NMR (300 MHz, CDCl3/CD3OD, 1:1, referenced on CDCl3) δ 0.50 – 0.61 (m, 2 H, CH2) 0.92 – 
1.14 (m, 12 H, CH2) 1.29 (quin., J = 7.6 Hz, 2 H, CH2) 1.75 (dd, J = 13.4 and 6.5 Hz, 2 H, CH=CHCH2) 2.28 
(t, J = 7.6 Hz, 2 H, CH2Ph) 3.23 – 3.31 (m, 2 H, H-2 and H-5’) 3.41 – 3.55 (m, 4 H, Ha-1, H-2’ and CH2-6’) 
3.65 (dd, J = 10.6 and 6.6 Hz, 1 H, Hb-1) 3.88 (t, J = 6.6 Hz, 1 H, H-3) 3.93 – 3.98 (m, 2 H, H-3’ and H-4’) 
4.06 (d, J = 7.6 Hz, 1 H, H-1’) 5.20 (ddt, J = 15.4, 7.5 and 1.2 Hz, 1 H, H-4) 5.47 (dtd, J = 15.1, 6.6 and 
0.7 Hz, 1 H, H-5) 6.79 – 6.87 (m, 3 H, arom. H) 6.89 – 6.97 (m, 2 H, arom. H). 
 13C NMR (75 MHz, CDCl3/CD3OD, 1:1) δ 28.41, 28.58, 28.63, 28.82, 28.93, 30.95, 31.75, 35.30, 
54.03, 60.64, 65.12, 66.79, 68.30, 68.71, 71.47, 74.11, 79.95, 102.74, 124.86, 127.53, 127.71, 134.53, 
142.27. 
 Exact mass (ESI-MS) for C27H42N3O10S
- [M-H]- found, 600.2602; Calcd., 600.2596. 
(2S,3R,4E)-2-amino-1-(3-O-(Sodiumoxysulfonyl)-β-D-galactopyranosyloxy)-3-hydroxy-4-octadecene 
(7.2) 
Azide 7.22a (45 mg, 0.08 mmol) was dissolved in THF (7 mL) and 0.1 M NaOH solution (0.8 mL). PMe3 
(1M in THF, 0.16 mL, 0.16 mmol) was added dropwise to the mixture and the reaction was stirred for 
7h at room temperature. The solution was neutralized with a 0.1 M HCl solution and the solvents 
were evaporated in vacuo. Purification of the crude reaction mixture by column chromatography 
(14%  22% MeOH in DCM) furnished compound 7.2 (34 mg, 80%) as a white solid. 
 1H NMR (300 MHz, CDCl3/CD3OD, 1:1, referenced on CDCl3) δ 0.56 (t, J = 6.5 Hz, 3 H, terminal 
CH3) 0.89 – 1.14 (m, 22 H, CH2) 1.76 (q, J = 6.9 Hz, 2H, CH=CHCH2) 3.03 – 3.10 (m, 1 H, H-2) 3.29 (dd, J 
= 7.5 and 4.2 Hz, 1 H, H-3’) 3.39 – 3.53 (m, 3 H, H-2’ and CH2-6’) 3.65 (d, J = 6.3 Hz, 2 H, CH2-1) 3.97 – 
3.93 (m, 2 H, H-4’ and H-5’) 4.00 (t, J = 5.3 Hz, 1 H, H-3) 4.06 (d, J =7.7 Hz, 1 H, H-1’) 5.11 (ddt, J = 
15.4, 6.7 and 1.3 Hz, 1 H, H-4) 5.54 (dtd, J = 15.3, 6.6 and 0.9 Hz, 1 H, H-5). 
 13C NMR (75 MHz, CDCl3/CD3OD, 1:1) δ 13.10, 21.99, 28.38, 28.69, 28.85, 28.98, 29.02, 31.27, 
31.68, 55.06, 60.91, 65.23, 66.83, 68.88, 69.03, 74.57, 79.60, 102.14, 125.97, 135.27. 
 Exact mass (ESI-MS) for C24H46NO10S
- [M-H]- found, 540.2844; Calcd., 540.2848. m.p. 








Azide 7.22b (100 mg, 0.16 mmol) was dissolved in THF (14 mL) and 0.1 M NaOH solution (1.6 mL). 
PMe3 (1M in THF, 0.32 mL, 0.32 mmol) was added dropwise to the mixture and the reaction was 
stirred for 7h at room temperature. The solution was neutralized with a 0.1 M HCl solution and the 
solvents were evaporated in vacuo. Purification of the crude reaction mixture by column 
chromatography (14%  22% MeOH in DCM) furnished compound 7.3 (87 mg, 91%) as a white solid. 
 1H NMR (300 MHz, CDCl3/CD3OD, 1:1, referenced on CDCl3) δ 0.45 – 0.59 (m, 2 H, CH2) 0.86 – 
1.12 (m, 12 H, CH2) 1.27 (quin., J = 7.3 Hz, 2 H, CH2) 1.75 (dd, J = 13.6 and 6.4 Hz, 2 H, CH=CHCH2) 2.25 
(t, J = 7.6 Hz, 2 H, CH2Ph) 3.02 – 3.10 (m, 1 H, H-2) 3.28 (dd, J = 7.4 and 4.3 Hz, 1 H, H-5’) 3.37 – 3.52 
(m, 3 H, H-2’ and CH2-6’) 3.64 (d, J = 6.2 Hz, 2 H, CH2-1) 3.89 – 3.96 (m, 2 H, H-3’ and H-4’) 3.99 (t, J = 
5.6 Hz, 1 H, H-3) 4.06 (d, J = 7.7 Hz, 1 H, H-1’) 5.11 (ddt, J = 15.4, 6.8 and 1.3 Hz, 1 H, H-4) 5.53 (dtd, J 
= 15.4, 6.7 and 0.9 Hz, 1 H, H-5) 6.77 – 6.85 (m, 2 H, arom. H) 6.87 – 6.95 (m, 3 H, arom. H). 
 13C NMR (75 MHz, CDCl3/CD3OD, 1:1) δ 28.38, 28.61, 28.67, 28.84, 28.93, 30.93, 31.68, 35.27, 
55.06, 60.88, 65.25, 66.83, 68.86, 69.02, 74.54, 79.56, 102.14, 124.86, 125.97, 127.51, 127.68, 
135.25, 142.23. 
 Exact mass (ESI-MS) for C27H44NO10S
- [M-H]- found, 574.2667; Calcd., 574.2691; m.p. 
decomposes at 195 °C. 
Cell free plate assay 
hCD1d-Fc β2-microglobulin single-chain protein was generated as described previously.45 Briefly, 
CD1d-Fc (0.5 mg/ml) and anti–LFA-1 (50 ng/ml; Serotec) were coated on 96-well flat-bottom plates, 
pulsed with sonicated lipids, and cultured with BM2a.3 (50,000 cells per well) overnight. 
Cross-presentation assay 
Mouse (DN32 and 24.7) or human (BM2a.3 and M0) iNKT cells were cultured with K562-hCD1d 
(human APCs) or RMAS-mCD1d (mouse APCs) and aGalCer (1 mg/ml) or sulfatide (6 mg/ml). Mouse 
IL-2 or human IFN-g production by iNKT was measured in the supernatant by ELISA, as determined in 
independent experiments performed a minimum of three times. The plus sign (+) indicates 
statistically significant responses (p < 0.01, ANOVA). 
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Chapter 8: General conclusion 
First, a versatile synthetic methodology was developed for the preparation of phytosphingosine-
modified α-GalCer derivatives. Hitherto, the phytosphingosine moiety has been poorly investigated 
due to the challenging chemistry required to access the envisioned derivatives. Our novel approach 
allows variations in the later stages of the synthesis via amide coupling and was employed for the 
synthesis of a series of analogues, which were named α-galactosylsphingamides. (Figure 8.1) 
 
Figure 8.1 General α-galactosylsphingamide structure 
The introduction of an amide bond in the phytosphingosine chain unfortunately results in poor iNKT 
cell activation. However, at the molecular level, the affinity for the TCR of iNKT cells for the CD1d/α-
galactosylsphingamide complex is not compromised to such degree that would suggest poor 
antigenic properties. Consequently, these compounds might be iNKT cell antagonists and could find 
application in the treatment of certain autoimmune diseases. Hence, effort to evaluate the 
antagonist activity of the α-galactosylsphingamides are ongoing. In addition, while absent in the 
binary complex, an unprecedented hydrogen bond between Tyr73 within CD1d and the amide 
moiety has been observed in the ternary complex. Future efforts to design strong binding CD1d 
agonists could target this novel H-bond. 
Subsequently, we successfully completed the challenging synthesis of C6”-modified α-C-GalCer 
analogues. The pursued reaction sequence allows the construction of the corresponding E-alkene 
and saturated C-glycosides from the majority of known α-GalCer analogues, demonstrating the 
versatile character of the methodology. Regarding the biological activity of the initially prepared C-
glycoside series, we demonstrated in two separate experiments that both C6”-naphthylurea and 
pyridinecarbamate C-glycolipids are able to stimulate human iNKT cells. Hence, these compounds 
show more promise as compared to their parent α-C-GalCer, which is inactive in a human setting. 
Even more encouraging, E-alkene C6”-pyridinecarbamate 5.3 exhibits comparable to superior IFN-γ 
secretion compared to α-GalCer in the Hela-CD1d/human iNKT cell coculture. 
In addition, the incorporation of an arylazide species in the acyl chain of α-galactosylceramide 
furnished photoactivatable iNKT cell ligands that form covalent bonds with CD1d upon irradiation 
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with light of a specific wavelength. Noteworthy, compared to α-GalCer, the photoactivatable 
glycosphingolipids 6.1 and 6.10 showed superior IFN-γ secretion in the Hela-CD1d/human iNKT cell 
assay when no UV irradiation was applied. Further experiments, this time under irradiation 
conditions, are highly awaited.  
Lastly, we prepared endogenous sulfatide displaying greater purity compared to commercial samples 
originating from natural extracts. In addition, we disclosed the first synthetic scheme for the 
manufacturing of endogenous lysosulfatide. These two sulfatide derivatives were employed to 
demonstrate that sulfatide is recognized by human iNKT cells and that it most likely plays an 
important role in human iNKT cell function. This observation will drastically impact NKT cell research, 
as up to now, sulfatide compounds were only thought to stimulate type II NKT cells. Finally, the 
developed lysosulfatide scheme allowed the construction of sphingosine-modified β-
galactosylsphingosines, including an analogue with a terminal phenyl ring. The type II NKT cell 
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Chapter 9: Broader International Context, Relevance, and Future Perspectives 
9.1 Context: Cancer immunotherapy 
In oncology, we are currently experiencing a burst in immunotherapeutic therapies, where the host’s 
immune system is trained to target malignant cells. In 2013, cancer immunotherapy was deemed 
breakthrough of the year by Science magazine, after results from several clinical trials demonstrated 
its therapeutic power. To date, most success has been obtained with antibody strategies that block 
inhibitory immune pathways. Accordingly, during the past five years, monoclonal antibodies like 
Nivolumab, Ipilimumab and Pembrolizumab have gained FDA approval and display impressive 
curative potential. In addition, the first chimeric antigen receptor (CAR)-T cell therapies have been 
recently approved by the FDA.1 Unfortunatly, the response rate of these novel therapies is still 
relatively low as only 15 to 20 percent of the patients benefit from treatment. Moreover, removing 
the brakes of our immune system can result in severe adverse effects like inflammation of the colon 
and pituitary gland and worsening of auto-immune conditions. Therefore, new approaches in the 
immunotherapeutic field exhibiting a broader scope and improved safety profile are highly awaited. 
The characterization of iNKT cells as a pivotal T cell population that orchestrates a wide variety of 
immune responses, identified these cells as interesting immunotherapeutic targets with broad 
clinical applicability. In contrast to conventional T cells that recognize peptide fragments associated 
with MHC-molecules, iNKT cells recognize lipid and glycolipid antigens in the context of CD1d. These 
special lymphocytes seem to have the unique ability to bridge innate and adaptive immunity since 
upon activation, they rapidly secrete large amounts of cytokines, triggering the trans-activation of 
other immune-cells and unfurls the complete immune arsenal. Conversely, iNKT cell activation has 
demonstrated potent antiviral, antibacterial and anti-tumor effects and can prevent the 
development of auto-immune diseases like type I diabetes and atherosclerosis. 
The discovery of α-GalCer, which is the prototypical antigen for iNKT cell activation, greatly 
accelerated advances in the field of NKT-cell biology. Besides being invaluable for research purposes, 
α-GalCer was evaluated in several clinical trials in patients with solid tumors. In general, the toxicity 
of α-GalCer administration is minimal and limits to a single case of grade 3 adverse effects, during all 
performed clinical trials. Unfortunately, while immunological, biochemical and even clinical 
responses have been observed in patients treated with α-GalCer, results are not consistent and do 
not offer the anticipated benefit. It is generally believed that the lack in efficacy stems from the 
concomitant release of copious amounts of both pro-inflammatory Th1- and anti-inflammatory Th2-




effect, hence, depending on the situation, a more biased response towards either Th1 or Th2 would 
be more desirable. 
Indeed, modification of the α-GalCer structure yielded several glycolipid antigens that are able to 
skew the cytokine profile of iNKT cells and display superior biological activity compared to the parent 
molecule. Among them, OCH and the C-glycoside of α-GalCer are regarded as model Th2- and Th1-
biasing glycolipids, respectively. OCH offers enhanced protection against collagen-induced arthritis 
and diabetes, and displays a significant increased suppression of EAE as compared to α-GalCer. On 
the other hand, the potent Th1-polarizer α-C-GalCer is 100 times more potent than α-GalCer against 
lung metastases and even 1000 times more effective against malaria. While these glycolipid antigens 
are clearly superior to α-GalCer in mice, human data is scarce and indicates that these effects not 
necessarily translate to humans, as it is known that α-C-GalCer is unable to activate human iNKT cells 
in vitro. Moreover, the mechanism governing the overall cytokine profile induced by structural 
related compounds is still unknown and hampers rational design of promising glycolipid antigens. 
Another possible explanation for the discrepancy in α-GalCer therapy between humans and mice, 
may lie in the lower frequency of iNKT cells in humans. While in mice, iNKT cells represent 0.2-0.5 % 
of the blood lymphocytes and up to 30% in the liver, the numbers in humans range from 0.01-1% in 
the blood and float around 1% in the liver.2 Accordingly, α-GalCer therapy might be less efficient in 
humans as compared to mice. Moreover, given the high degree of variability in the iNKT cell numbers 
for humans, individuals with a higher iNKT cell number should be favored for iNKT cell therapy. 
Finally, recent reports indicate that the majority of the NKT cells in humans are type II NKT cells, 
suggesting that the latter have greater therapeutic potential as compared to their iNKT cell 
counterparts in a human setting. 3 Unfortunately, the current understanding of the biology of type II 
NKT cells in humans is very limited. 
It is clear that iNKT cell therapy holds tremendous opportunities for immunotherapeutic purposes, 
but several scientific hurdles still have to be overcome to make iNKT cell therapy a clinical success. 
9.2 Relevance 
While iNKT cell therapy can boost the immune system and potentiate antitumor responses, the most 
promising results to date make use of glycolipid derivatives as adjuvant in various vaccination 
platforms. 
Anderson et al. reported vaccines consisting of allergen-derived peptide fragments conjugated with 
the α-GalCer structure by means of an in vivo degradable linker moiety. Consequently, splenic DCs 
effectively cross-presented the peptide fragment of the vaccine to CD8+ T cells and concomitantly 
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activated the helper function of NKT cells by displaying CD1d/α-GalCer complexes on their cell 
surface. As a result, greater peptide-specific CD8+ T cell numbers were observed as compared to 
vaccine mixtures containing a molar equivalent of both α-GalCer and the peptide of interest.4 (Figure 
9.1) Furthermore, the enhanced induction of CTL responses does not require CD4+ T cell help and 
conversely does not exacerbate IgE responses, rendering this vaccination strategy particularly useful 
in the context of allergic diseases. 
A similar strategy was employed by Cavallari et al. for the vaccination against Staphylococcus 
pneumoniae, the causative agent of pneumococcal diseases including severe meningitis, bacteremia 
and pneumonia. An antigenic polysaccharide from the cell-wall of the Gram-positive bacterium was 
conjugated to the primary hydroxyl function of the galactose unit in α-GalCer. Again, the 
glycoconjugate vaccine induced specific humoral immunity against the linked polysaccharide and led 
to superior antibody titers as compared to a mixture of unconjugated α-GalCer and antigen.5 An 
alternative strategy that enables the concomitant delivery of both antigen and α-GalCer to the same 
immune cell consists of encapsulating both components in a nanoparticle. Upon administration of 
such nanoparticles, higher specific antibody titers were observed as compared to a combination of 
free antigen and α-GalCer.6 
 
Figure 9.1 Left: Chemical structure of 9.1 and 9.2: α-GalCer conjugated with a OVA257 peptide 
fragment or a LCMVgp33 peptide, respectively. Right: Assessment of the endogenous cytotoxic 
response 7 d after administration of 9.1 (left) or 9.2 (right) compared to animals administered with 
unconjugated components. (adapted from Anderson et al., 2014, Nat. Chem. Biol.), LCMV = 
lymphocytic choriomeningitis virus, OVA = ovalbumine 
In addition to the conjugate-vaccine strategies described above, the superior adjuvant activity of Th1 
polarizing iNKT cell ligands compared to α-GalCer, was demonstrated in several studies. Huang et al. 
evaluated the immunological response after vaccination with Globo H (GH) combined with a set of 
glycolipid antigens as adjuvant. The Globo H hexasaccharide is overexpressed on a variety of cancer 




clinical trials. Compared to the phase III clinical trial vaccine containing a saponin-based adjuvant, the 
combination of GH-epitope and glycolipid adjuvant elicited more anti-GH IgG antibodies. The most 
promising combination combined the antigen with the Th1 polarizing glycolipid C34, displaying a p-
fluorophenyl phenyl ether in its acyl chain, while the use of α-GalCer as adjuvant proved less 
efficient.7 
Similarly, compared to α-GalCer, the glycolipid 7DW8-5 enhanced significantly greater CD8+ T cell and 
humoral responses during a malaria vaccination protocol.8 (Figure 9.2) The follow-up study in non-
human primates indicated that the glycolipid antigen is well-tolerated and provides significant 
enhancement in malaria-specific CD8+ T cell responses after immunization.9 These results are truly 
encouraging as to date there is no single adjuvant that can potently induce a vaccine induced CTL 
response or enhance the immunogenicity of a viral-vector based vaccine. 
 
Figure 9.2 Adjuvant effect of 7DW8-5 on a malaria vaccine in mice. Left pane: antigen-specific anti-
body titers after immunization with the indicated vaccination protocol. Right pane: amount of 
parasite-specific rRNA in the liver 42h after challenge with 104 infective malaria sporozoites (adapted 
from Li et al., 2010, PNAS) 
We recently evaluated the adjuvant effect of our C6”-modified α-GalCer analogues, PyrC-α-GalCer 
and NU-α-GalCer in the context of the aforementioned malaria vaccination strategy (Collaboration 
with Prof. M. Tsuji). Interestingly, both Th1 polarizing glycolipids induced a similar reduction of 
parasite-specific rRNA in the liver of immunized mice, as the glycolipid 7DW8-5.10 
9.3 Recommendations and Contributions 
In order to rationally design new glycolipid antigens which are able to bias the cytokine secretion of 
iNKT cells, the involved mechanisms that govern Th1 or Th2-responses should be identified. 
Consequently, the glycolipid derivatives synthesized during this thesis contain modifications aimed at 
gathering clues to unravel of the polarization process.  
First, we developed a synthetic strategy allowing the late-stage diversification of phytosphingosine-
modified α-GalCer analogues. Synthetically more challenging alteration of the phytosphingosine 
chain is ill explored in literature, but had previously led to interesting observations. While the 
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implemented modifications were aimed at reinforcing the CD1d/glycolipid-complex stability by 
means of extra hydrophobic interactions, all α-galactosylsphingamide derivatives, including the acyl-
elongated derivatives, proved less potent than α-GalCer and exhibited lower loading levels in CD1d. 
Thus, we were unable to produce stabilized binary complexes and the main reason probably lies in 
the less well ordered presentation of the galactose sugar of the galactosylsphingamides in the binary 
complex. Interestingly, upon TCR engagement the galactose is pushed back in the conserved position 
and an unprecedented hydrogen bond is formed between the carbonyl of the amide functionality 
and Tyr73 from within the F’ pocket of CD1d. 
The crystal structure of the CD1d/ galactosylsphingamide complex nicely confirms that although both 
the acyl chain and phytosphingosine chain contribute to the stability of the CD1d/glycolipid complex, 
it is the phytosphingosine chain that controls the CD1d/glycolipid footprint.11 
Second, we were the first to tackle the challenging task of synthesizing C-glycoside derivatives of 
previously identified Th1-polarizing compounds. While many times suggested in literature, prior to 
the presented work, no synthetic protocols were developed for the preparation of both saturated 
and E-alkene C-glycosides of C6”-modified α-GalCer analogues. Due to the high versatility of the 
designed strategy, the C-glycoside equivalent of most α-GalCer analogues described to date can be 
accessed. 
Additionally, we contributed to the enrichment of the toolbox of NKT cell biologists with the 
synthesis of a photoactivatable α-GalCer analogue that covalently binds CD1d. Evaluation of these 
compounds under irradiation of light with the appropriate wavelength is highly awaited.  
Finally, we prepared both established and novel type II NKT cell antigens. These glycolipids should 
allow NKT cell biologists to learn more about the function of type II NKT cells. 
9.4 Future perspectives 
We expect that future iNKT cell research will further focus on the development of strong antigens 
that potently skew the cytokine response and offer additional benefit in tumor immunotherapy and 
as vaccine-adjuvant. Therefore, unraveling the polarization mechanisms will continue to be a key 
priority and will guide the design of new glycolipid antigens. Additionally, since iNKT cell activation is 
deleterious in a variety of disease conditions including allergic responses and atherosclerosis, the 
search for glycolipids that can antagonize the CD1d/NKT cell immune branch is gaining attention. 
Finally, the focal-point of NKT cell biology continues to shift from iNKT to type II NKT cells and will 




following subsections alternative suggestions for the design of new glycolipids are discussed in more 
detail. 
9.4.1 iNKT cell antagonists 
The biological evaluation of the galactosylsphingamide compounds identified the latter as possible 
iNKT cell antagonists. The inability to activate iNKT cells while still displaying affinity for the TCR could 
hold the iNKT cell away from competing CD1d/antigen complexes and result in an additional 
antagonistic effect. The current issue however, is that the sphingamide compounds are unable to 
compete with glycolipids like OCH to occupy the CD1d binding groove. Therefore, combining the 
sphingamides with known CD1d-affinity enhancing modifications might be beneficial. (Figure 9.3) The 
synthetic methodology allows swift access to acyl chains bearing aromatic moieties which have been 
shown to increase hydrophobic interactions in the A’ pocket and result in greater CD1d/glycolipid 
complex stability. In addition, the benzylidene protecting group strategy offers the possibility to 
modify the C6”-position as reductive cleavage with borane.THF under cupper catalysis selectively 
liberates the primary alcohol.12 Both CD1d or TCR affinity can be enhanced by installing a 
naphthylurea or pyridinecarbamate functionality, respectively. 
 
Figure 9.3 Alternative suggestions to optimize the antagonistic properties of the sphingamide series 
9.4.2 C-glycosides 
The biological evaluation of the C6”-modified α-C-GalCer analogues will be further investigated in a 
B16 melanoma model to assess the tumor suppressive potential. We expect that the greater in vivo 
stability will give rise to long-lived CD1d/C-glycoside complexes and will result in superior tumor 
protection as compared to α-GalCer. To the best of our knowledge we currently possess the most 
antigenic α-GalCer C-glycoside analogue, but we plan on expanding our C-glycoside series even more. 
Other C6”-modifications will be explored and will be combined with the acyl-chain like the one from 
glycolipid 7DW8-5, in an attempt to further enhance the biological response of these novel 
compounds. (Figure 9.4) Furthermore, we envisage the evaluation of the new C6”-modified α-C-
GalCer derivatives in a vaccine setting. 
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Figure 9.4 Planned elaboration of the C-glycoside panel 
9.4.3 Covalent linker 
We are currently in the process of optimizing our α-GalCer photo-crosslinker. We’ll start with the 
identification of the optimal spacer-length for the azidophenyl moiety and will strive towards better 
crosslinking efficiency. In addition, other photoactivatable functionalities will be explored as to 
increase the excitation wavelength and enhance the biocompatibility of the covalent α-GalCer 
analogue. Concomitantly, incorporating the photoactivatable group in various parts of the α-GalCer 
structure will be investigated. (Figure 9.5) 
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